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1HEMATOPOIESIS
Hematopoiesis (from ancient Greek: αιμα, ‘blood’ and ποιεω ‘to make’) is the process 
that generates new blood cells. This complex process takes place in the bone marrow 
and is carefully organized and strictly regulated by growth factors and transcription 
factors (Figure 1). Hematopoietic stem cells (HSCs) are responsible for the continuous 
generation and maintenance of diverse types of mature blood cells (or lineages) that 
exert distinct important functions1. Red blood cells or erythrocytes (from: ερυθρος, 
‘red’, κυτος, ‘vessel/cell’) are required for the transportation of oxygen from the lungs 
throughout the body. Platelets or thrombocytes (from: θρομβος, ‘clot’) are, together 
with coagulation factors, responsible for the process of blood clotting. White blood 
cells or leukocytes (from: λευκος, ‘white’) play a critical role in the host defense 
mechanism against pathogens. To warrant these pivotal processes, approximately 
200 billion erythrocytes, 100 billion leukocytes and 100 billion thrombocytes are 
produced in adults every day2. Since mature blood cells are predominantly short-lived, 
HSCs are required to replenish this system. Therefore, HSCs produce multilineage 
progenitors that, in turn, produce lineage-committed precursors3,4 (Figure 1). Rare 
long-term HSCs (LT-HSC) reside at the top of this hierarchy. These cells give rise to 
the more frequent short-term HSC (ST-HSC)5. Both types of HSCs have the unique 
capacity to maintain themselves through self-renewal and at the same time generate 
more mature progeny through differentiation, a process called asymmetrical cell 
division3,5,6. LT-HSCs are mainly quiescent and are capable of securing hematopoiesis 
throughout life. ST-HSCs are the drivers of daily hematopoietic replenishment and 
have a more restricted ability to self-renew (less than 8 weeks)3. ST-HSC can undergo 
differentiation into a multipotent progenitor (MPP) that, in turn, gives rise to the 
progenitors of the two main lineages of hematopoiesis: the common lymphoid 
progenitor (CLP)7 and the common myeloid progenitor (CMP)8. The CLP generates 
lymphoid precursors that produce B cells, T cells and Natural Killer (NK) cells. 
The CMP can differentiate toward a granulocyte-macrophage progenitor (GMP), 
giving rise to precursors of monocytes/macrophages, neutrophils, eosinophils and 
basophils, and a megakaryocyte-erythroid progenitor (MEP), giving rise to precursors 
of erythrocytes and megakaryocytes. This continuous process of self-renewal and 
differentiation is activated or accelerated if the demand for blood cells increases (e.g. 
during infection or after blood loss), and is tightly controlled by lineage-specific 
hematopoietic cytokines and intracellular activation of lineage-specific transcription 
factors (Figure 1).
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ACUTE LEUKEMIA AND LEUKEMOGENESIS
Leukemia (from: λευκος, ‘white’ and αιμα ‘blood’) is a type of cancer that is 
characterized by an accumulation of immature, abnormal hematopoietic progenitors 
in the bone marrow. In contrast to healthy progenitors, these leukemic progenitors 
are highly proliferative and proliferate independently of the demand of blood 
cells. Further, the diff erentiation capacity of leukemic cells is impaired, while 
self-renewal capacity is still present. The initiation and development of leukemia, 
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Figure 1. Schematic representation of hematopoiesis. 
Blood cell development is a strictly orchestrated  process progressing from the hematopoietic stem cell toward 
diff erentiated blood cells. This fi gure shows a schematic representation of this process. It includes the cytokines 
that support survival, proliferation and diff erentiation at several stages during hematopoiesis (red text in gray 
background) and depicts at which stage of hematopoiesis transcription factor are essential for further diff erentia-
tion (determined by conditional knockout models)2,4. Abbreviations: LT-HSC, long-term hematopoietic stem cell; 
ST-HSC, short-term hematopoietic stem cell; MPP, multipotent progenitor; CMP, common myeloid progenitor; 
CLP, common lymphoid progenitor; MEP, megakaryocyte-erythroid progenitor; GMP, granulocyte-macrophage 
progenitor; TNK, T cell and NK cell progenitor; BCP, B cell progenitor; EP, erythroid progenitor; MkP, megakaryo-
cyte progenitor; MP, monocyte progenitor; GP, granulocyte progenitor; NKP, NK cell progenitor; TCP,  T cell 
progenitor; SCF, stem cell factor; TPO, thrombopoietin; IL, interleukin; GM-CSF, granulocyte macrophage colony 
stimulating factor; EPO, erythropoietin; M-CSF; macrophage colony stimulating factor; G-CSF, granulocyte colony 
stimulating factor.
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or leukemogenesis, is an ‘evolutionary’ process in which multiple independent 
aberrations accumulate in a pre-leukemic cell. These aberrations affect genetic or 
epigenetic regulators of important cellular processes. Genetic alterations are mostly 
caused by chromosomal aberrations and gene mutations. Epigenetic modifications 
are driven by regulators of DNA methylation, histone modification, and by 
microRNAs9. The multitude of genetic and epigenetic hits driving leukemia makes 
this disease very heterogeneous. 
Leukemia is classified based on the speed of disease progression (acute 
versus chronic) and the affected lineage of hematopoiesis (myeloid or lymphoid). 
Acute leukemia is characterized by the accumulation of highly proliferative 
leukemic progenitor cells that have completely lost their capacity to differentiate. 
In contrast, chronic leukemia has a slow onset and progression, and is defined by 
the accumulation of more mature progenitors that still have partial differentiation 
capacity. Since leukemia can originate from both myeloid and lymphoid progenitors, 
acute leukemia is classified as either acute myeloid leukemia (AML)10,11 or acute 
lymphoblastic leukemia (ALL)12-14. These types of acute leukemia comprise multiple 
heterogeneous malignancies driven by distinct pathogenic mechanisms. Despite the 
genetic heterogeneity of acute leukemia, the clinical features at diagnosis are highly 
similar. Due to the proliferation of immature progenitors in the bone marrow, patients 
with acute leukemia develop pancytopenia (from: παν, ‘all’ and κυτος, ‘vessel/cell’ 
and πενια, ‘deficiency’). These patients have a shortage of functional erythrocytes 
(anemia), leukocytes (leukopenia), and thrombocytes (thrombocytopenia). 
These deficiencies result in weakness, fatigue and paleness (anemia), induced 
vulnerability for infections (leukopenia), and bleeding tendency shown by easy 
bruising, formation of hemorrhages and/or the presence of petechiae or ecchymoses 
(thrombocytopenia). Furthermore, patients can suffer from bone pains, anorexia, 
headaches, and abdominal discomfort. The prevalence and prognosis of patients 
with acute leukemia differ between subtypes. AML is the most common subtype of 
acute leukemia in adults, with a prevalence of 3.8 cases per 100.000 and a median 
age of onset of approximately 70 years11. ALL is the most common form of cancer in 
children with an incidence rate of 1 per 20.000 children. In the Netherlands, every 
year ~150 children are newly diagnosed with leukemia, of which 125 children with 
ALL and 25 children with AML. Sixty percent of all patients with ALL are children 
with an average age of onset between 2-5 years12-14. The prognosis of patients with 
acute leukemia is affected by multiple factors, including age at diagnosis, white 
blood cell count at diagnosis, initial response to chemotherapy, the type of acute 
leukemia (AML versus ALL), and the genetic abnormalities that characterize the 
leukemia10-14. This thesis focuses on the most common pediatric malignancy: acute 
lymphoblastic leukemia.
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PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
Overall survival rates of pediatric acute lymphoblastic leukemia (ALL) have increased 
steadily over the last five decades12-18. While chances of survival in the early sixties 
were approximately 10%, currently most children (more than 85%) with ALL are 
cured12-19. This remarkable increase is mostly due to optimization of multi-agent 
chemotherapeutic drug regimens combined with risk-directed therapy protocols, 
and increased standards of supportive care17-19. An essential step in this progress 
was the cytogenetic and molecular characterization of common abnormalities 
in pediatric ALL subtypes and the subsequent assessment of the risk of relapse 
for these subgroups. This characterization also facilitated better minimal residual 
disease monitoring, which is essential for risk stratification and the early detection 
of relapsed disease.
Genetic subclassification and prognostic significance
Pediatric ALL can be subdivided in leukemia originating from a B cell progenitor 
(B-cell precursor ALL, or BCP-ALL) and leukemia originating from the T cell lineage 
(T-ALL). BCP-ALL is the most frequent pediatric ALL, representing approximately 
85% of pediatric ALL cases. During the last decades, pediatric ALL has been 
investigated extensively, resulting in the discovery of major BCP-ALL and T-ALL 
subtypes with distinct molecular drivers and associated prognoses (Figure 2).
Good prognostic BCP-ALL subgroups
The most recurrent alterations in pediatric BCP-ALL are translocation t(12;21)
(p13;q22) and hyperdiploidy20. These alterations are believed to be initial events in 
leukemogenesis that occur years before leukemia initiation and are even occurring 
in utero, since their presence has been shown in neonatal blood spots on Guthrie 
cards21. Both subgroups have an excellent prognosis. Hyperdiploidy, the presence 
of more than 50 chromosomes per leukemic cell, is present in approximately 25% of 
pediatric patients with BCP-ALL. The overall event-free survival of children within 
this subgroup is almost 90%12,22,23. Among patients with hyperdiploidy, the presence 
of extra copies of chromosome 4, 10 or 17 has been associated with an even more 
favorable prognosis, while trisomy of chromosome 5 confers poorer outcome22. 
Translocation t(12;21)(p13;q22), resulting in the ETV6-RUNX1 fusion gene, is 
present in approximately 25% of pediatric BCP-ALL patients and is therewith the 
most common fusion gene in childhood cancer24-26. ETV6-RUNX1 positive BCP-ALL 
is a subgroup with overall good prognostic features (event-free survival rates of 
85%-95%)23,27. In this group, a wide variety of additional genetic aberrations further 
affect prognosis, including deletion of the second ETV6 gene, duplication of RUNX1, 
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and an extra der(21)t(12;21). Both ETV6-RUNX1 positive ALL without an additional 
genetic aberration and ETV6-RUNX1 positive ALL with der(21)t(12;21) duplication 
confer poorer outcome (5 year disease-free survival of less than 80%)27. Another 
good prognostic BCP-ALL subgroup includes patients with a t(1;19)(q23;p13.3) 
induced TCF3-PBX1 (or E2A-PBX1) fusion gene. This subgroup comprises 2-5% of 
Hyperdiploidy
>50 chromosomes
ETV6-RUNX1
t(12;21)
TCF3-PBX1
t(1;19)
B lineage - Other
BCR-ABL1 - like
MLL rearrangements
BCR-ABL
t(9;22)
TAL/LMO rearrangements
B-cell lineage
85%
T cell lineage
15%
HOXA-activating rearrangements
TLX rearrangements
Proliferative cluster
Immature cluster
~21%
~35%
~21%
~15%
~4%
~7%
A
B
Figure 2. Major BCP-ALL and T-ALL subtypes have distinct molecular drivers and associated 
prognoses. 
(A) BCP-ALL can be subdivided in 7 clusters comprising 85% of all pediatric ALL patients. T-ALL can be subdi-
vided in 5 clusters comprising 15% of all pediatric ALL patients. (B) Prognosis of diff erent subtypes BCP-ALL and 
T-ALL diff ers signifi cantly. Figure 2B is adapted from Pui et al. 13.
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BCP-ALL patients and has excellent prognostic features ( >95% event free survival)23. 
Together, these three subtypes of BCP-ALL have more than 90% 5 years event-free 
survival. This excellent prognosis is mainly due to a good response to commonly 
used chemotherapeutics23,28,29.
Poor prognostic BCP-ALL subgroups
BCP-ALL patients with the BCR-ABL1 fusion gene (2% of BCP-ALL), BCR-ABL1 like 
gene expression profiles (15-20%), MLL-rearrangements (2%), and hypodiploidy 
(1%) have a poor prognosis, exhibiting average event-free survival rates lower than 
50%. The incidence of translocation t(9;22)(q34;q11), resulting in the BCR-ABL1 
fusion gene, increases with age: while this fusion is present in only 2% of pediatric 
ALL patients, this percentage increases to 25% in adult ALL patients. This subgroup 
is characterized by a high frequency of RAG-mediated deletions of Ikaros (IKZF1), 
a transcription factor that plays an important role in normal B cell development 
(see Figure 1)30,31. Recently, the introduction of targeted therapy directed against 
the fusion protein (tyrosine kinase inhibitors, such as Imatinib) has improved the 
prognosis of this subgroup dramatically18,32-36. Addition of Imatinib to treatment 
protocols has resulted in an increase of the event-free survival rates of pediatric 
BCR-ABL1 positive ALL from ~35% to > 70%35,37. 
The MLL-rearranged BCP-ALL subgroup comprises translocations involving 
the MLL gene on chromosome 11q23, and more than 50 different fusion partners. The 
most frequent MLL translocations are: t(4;11), resulting in MLL-AF4, t(11;19), resulting 
in MLL-ENL, and t(9;11), resulting in MLL-AF9. These MLL-rearrangements mainly 
occur in infants (present in 80% of infants with ALL) and induce the development of 
an ALL subtype with less favorable prognosis due to therapy resistance38. 
Extensive gene expression profiling of BCP-ALL patients recently revealed 
a new BCP-ALL subtype with unfavorable outcome that has a gene expression 
profile similar to BCR-ABL1 positive patients: BCR-ABL-like ALL39-41. More than 
80% of patients with such a BCR-ABL1-like signature display abnormalities in genes 
that are important for B-cell differentiation, including IKZF1, PAX5 and EBF1 (see 
Figure 1)40,41. Both the BCR-ABL1-like signature and IKZF1 deletion are independent 
prognostic factors predicting poor outcome of pediatric ALL.
T-ALL
T-ALL represents approximately 15% of pediatric ALL cases and can be subdivided 
in five distinct subgroups based on the most recurrent genetic abnormalities, namely 
the TAL/LMO subgroup (comprised of oncogenic rearrangements of TAL or LMO 
genes), the HOXA subgroup (comprised of HOXA-activating rearrangements), the 
TLX subgroup (comprised of oncogenic rearrangement of TLX1 or TLX3), the early/
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immature subgroup (comprised of e.g. MEF2C-activating rearrangements), and the 
proliferative subgroup (comprised of e.g. NKX2-activating rearrangements)42. The 
prognosis for children with T-ALL remains inferior compared to BCP-ALL. In recent 
treatment protocols, the 5-year event free survival rate of T-ALL patients is around 
80% 19,20,23. The early/immature subgroup, also known as early T-cell precursor (ETP) 
leukemia, is a T-ALL subgroup associated with a poor prognosis43-45. The prognostic 
relevance of the other distinct subgroups is still largely unknown, and varies per 
treatment protocol20. 
Targeting leukemia-specific aberrations
Treatment of ALL has been optimized by using the above-described prognostic 
information in the risk stratification and subsequent therapy schedules of patients. 
This approach has led to significant increase in survival of pediatric ALL patients. 
However, the functional role of the subtype-specific aberrations is largely unknown. A 
better understanding of the cellular processes affected by these genetic abnormalities 
will provide insight into the prognostic features of a specific subgroup and might 
enable targeting of the molecular drivers of ALL. In the first part of this thesis, we 
attempt to identify the molecular effectors of ETV6-RUNX1 positive BCP-ALL.
ETV6-RUNX1 POSITIVE ACUTE LYMPHOBLASTIC 
LEUKEMIA
The t(12;21)(p13;q22) rearrangement fuses the 5’ non-DNA binding region of the 
ETS family transcription factor ETV6 (TEL) to almost the entire RUNX1 (AML1) 
locus46, resulting in the formation of the ETV6-RUNX1 fusion protein (also known as 
TEL-AML1)24,25. Both fusion partners (ETV6 and RUNX1) are important regulators 
of hematopoiesis.
ETV6
The ETV6 gene is a member of a large family of ETS-domain transcription factors 
that are important regulators of proliferation, differentiation and apoptosis47,48. ETV6 
is a ubiquitously expressed protein that is comprised of 3 major domains (Figure 3). 
The pointed domain (PD) is important for nuclear export of ETV649, transcriptional 
repression50,51, heterodimerization52, and oligo-homodimerization53. The repression 
domain is essential for sequence-specific transcriptional repression of target 
genes54. The ETS domain is involved in DNA binding and is important for protein-
protein interactions48. Genetic mutations in ETV6 have frequently been observed in 
leukemia, suggesting an important role for ETV6 in regulation of hematopoiesis55. 
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Indeed, analysis of mouse chimeras with ETV6-/- embryonic stem cells revealed that 
ETV6 function is essential for both normal hematopoiesis in the bone marrow and 
survival of HSCs56. Therefore, it is not surprising that in addition to ETV6-RUNX1, 
other ETV6 related fusion proteins (including ETV6-PDGFRβ57, ETV6-ABL58, and 
ETV6-JAK259) have been identified in hematological malignancies.
1 38 125 340 420 452
PD REPRESSION ETS DBD
1 52 204 479
Runt DBD p300ID ACTIVATION 
Runt DBD p300ID ACTIVATION PD REPRESSION
1 38 125 336 368 512 796
ETV6
RUNX1
ETV6-RUNX1
mSin3A ID
mSin3A ID
t(12;21)(p13;q22) breakpoint
GR RD
GR RD
Figure 3. Schematic representation of ETV6, RUNX1 and the ETV6-RUNX1 fusion protein.  
Translocation (12;21) fuses the 5’ non-DNA binding region of ETV6 to almost the entire RUNX1 locus. Numbers 
represent amino acids flanking the major domains of the proteins. Abbreviations: PD, oligomerization pointed 
domain; DBD, DNA binding domain; p300ID, histone acetyl transferase p300 interaction domain; mSin3A ID, 
corepressor mSin3a interaction domain; GR RD, Groucho-related corepressor domain. Adapted from Zelent et al.46.
RUNX1
The transcription factor RUNX1 (Runt-related protein 1), also known as AML1 
(acute myeloid leukemia 1) and CBFα (Core binding factor α), is considered to 
be a key regulator of hematopoiesis. It has, for example, been demonstrated that 
RUNX1 plays a critical role in regulation of definitive hematopoiesis during 
embryogenesis60. In addition, conditional deletion of RUNX1 in adult mice revealed 
that RUNX1 also plays an important role in regulation of adult hematopoiesis. These 
mice exhibit reduced megakaryocyte differentiation and a block in lymphocyte 
development61. Furthermore, RUNX1 also negatively regulates the number of 
quiescent HSCs, suggesting that RUNX1 plays an important role in regulation of 
HSC maintenance62. RUNX1 regulates hematopoiesis via transcriptional inhibition 
of, for example, p21WAF/CIP and induction of a large number of specific target genes, 
including Myeloperoxidase, M-CSFR, IL-3R, Neutrophil elastase, Granzyme B, T-cell 
receptors, and B-cell receptors63. The transcriptional activity of RUNX1 depends on 
the association with CBFβ. CBFβ itself does not bind to the DNA but enhances the 
DNA-binding ability of RUNX1 and protects it from ubiquitin-mediated proteolysis64. 
It has been demonstrated that mice expressing mutated CBFβ exhibit a phenotype 
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similar to RUNX1 deficient mice, indicating that CBFβ is essential for RUNX1 
function in vivo65. Taken together, the observed hematopoietic defects in RUNX1 and 
CBFβ deficient mice demonstrate the importance of correct regulation of RUNX1 
transcriptional activity in healthy hematopoietic cells. Chromosomal translocations 
involving RUNX1 have been identified in a large proportion of pediatric leukemias. 
In addition to the ETV6-RUNX1 fusion protein, more than a dozen chromosomal 
translocations have been found that involve RUNX1. For example, the t(8;21)
(q22;q22) translocation, resulting in expression of the RUNX1-RUNX1T1 fusion 
protein, occurs in 12–30% of pediatric AML patients66,67. 
ETV6-RUNX1
The ETV6-RUNX1 fusion product combines the pointed domain of ETV6 with 
all functional domains of RUNX1 (Figure 3)46. Similar to RUNX1, ETV6-RUNX1 
transcriptional activity depends on binding to CBFβ68. ETV6-RUNX1 can act as a 
dominant-negative protein. ETV6-RUNX1 can form an inhibitory complex through 
recruitment of histone deacetylases (HDAC) by ETV6 and mSin3a by RUNX146,69. Like 
RUNX1-RUNX1T1, ETV6-RUNX1 is thought to have higher affinity for multiple AML 
binding sites, resulting in abrogation of the transcriptional activity of endogenous 
RUNX146,69. However, experiments performed with transgenic mice expressing 
ETV6-RUNX1 under its endogenous promoter revealed different phenotypes 
compared to RUNX1 deficient mice. Whereas expression of ETV6-RUNX1 induced 
the number of LT-HSCs, RUNX1 deficiency resulted in reduced LT-HSC levels61,62,70. 
Further, chromatin immunoprecipitation in a murine cell line model revealed that, 
although ETV6-RUNX1 predominantly binds DNA through the Runt DNA binding 
domain, it also binds multiple ETV6-RUNX1 specific promoter regions71. This 
suggests that ETV6-RUNX1 not only functions as a dominant-negative protein for 
RUNX1 transcriptional activity, but also regulates ETV6-RUNX1 specific target genes 
(Figure 4). The molecular mechanisms underlying the emergence and maintenance 
of ETV6-RUNX1 positive BCP-ALL remain to be investigated, although previous 
research has unraveled drivers of this ALL subtype. Previous reports revealed 
that enhanced levels of STAT3, heat-shock proteins, Survivin, Has-mir-125b-2, the 
erythropoietin receptor, and cytoskeleton regulatory genes as well as aberrant 
regulation of the TGFβ pathway or the interferon α/β pathway are important for 
ETV6-RUNX1 positive BCP-ALL68,72-80.
The ETV6-RUNX1 fusion protein induces a silent pre-leukemic clone that 
requires additional genetic hits for the transition to leukemia70,81-85. These pre-leukemic 
ETV6-RUNX1 positive HSCs have a high proliferation rate, still possess self-renewal 
properties, and are capable of contributing to hematopoiesis. However, they fail to 
outcompete normal HSCs70,84,86. In case of leukemia development, this early genetic 
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lesion is followed by a small number of ‘driver’ copy number alterations, which are 
predominantly directed to genes regulating normal B cell differentiation87,88. These 
alterations are acquired independently and without preferential order, thereby 
generating a dynamic clonal architecture87. This genetic variation implies that 
targeted therapy in ETV6-RUNX1 positive ALL should be directed to (targets of) 
initial lesions that are present in all subclones, such as ETV6-RUNX1. This concept 
is further supported by the observation that ETV6-RUNX1 positive cell lines are 
highly dependent on the expression of the fusion protein for their survival75,89. To 
date, ETV6-RUNX1 positive cells cannot be selectively targeted or sensitized to 
conventional chemotherapy. For the development of novel targeted therapies with 
less short-term and long-term side effects, it is therefore important to identify the 
molecular pathways induced by the ETV6-RUNX1 fusion protein. Chapter 3 and 4 
of this thesis are dedicated to find such targets.
ETV6-RUNX1ETV6-RUNX1
RUNX1 TG
TGT/CGGT
RUNX1
CBF β
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Figure 4. Model for the transcriptional mechanisms by which ETV6-RUNX changes gene expres-
sion in pre-leukemic cells. 
(A) RUNX1 is known to start transcription of target genes by reversing mSin3a/histone deacetylase (HDAC) 
binding and subsequent association with an activating complex including the histone acetyl transferases p300 
and CREB-binding protein (CBP). (B) ETV6-RUNX1 functions as a dominant-negative protein repressing native 
RUNX1 protein targets through strong binding of a repressor complex consisting of corepressor mSin3a, nuclear 
receptor corepressor 1 (N-CoR) and histone deacetylase (HDAC) (left). However, recent data suggests that ETV6-
RUNX1 also binds ETV6-RUNX1 specific promoter regions and can activate transcription of these genes important 
for ETV6-RUNX1 function.
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1HEALTHY AND LEUKEMIC BONE MARROW MICROENVIRONMENT
In addition to molecular events that drive leukemogenesis and are intrinsically 
important for the leukemic cell, increasing evidence suggests that also the 
microenvironment plays an essential role in leukemogenesis and maintenance of 
leukemia. 
The healthy bone-marrow microenvironment
Hematopoietic stem and progenitor cells (HSPCs) reside in the bone marrow 
microenvironment, a complex ecosystem comprised of several specialized cell 
types. This microenvironment, or niche, regulates HSCs in line with the need 
for specific blood cells, offers relative hypoxia and is important for stemness of 
HSCs90. Bone marrow niche cells, including mesenchymal stromal cells (MSCs), 
endothelial cells (ECs), megakaryocytes (MKs) and osteoblasts (OBs) directly or 
indirectly regulate HSC function by either secreting soluble supportive factors, or 
expressing cell-bound signaling molecules91-93. Bone marrow niche cells produce 
numerous growth factors, including stem cell factor (SCF), transforming growth 
factor β (TGFβ), thrombopoietin (TPO), Interleukin-7 (IL-7), and erythropoietin 
(EPO). These factors are either important regulators of HSC quiescence or drive the 
proliferation and differentiation of HSCs toward a certain hematopoietic lineage. 
Furthermore, niche cells produce chemokines essential for homing toward and 
anchoring in the niche, including stromal cell-derived factor 1 (SDF1 or CXCL12). 
Recently, analysis of conditional knock-out mouse models has provided a better 
understanding of the role of different stromal compartments in regulation of 
HSC function and the production of the above-mentioned factors. Vascular ECs, 
which form the blood vessels of the bone marrow, express factors regulating HSC 
function including SCF and CXCL12, both important for HSC maintenance94-96, 
NOTCH ligands, important for HSC self-renewal97, and E-selectin, important for 
HSC proliferation98, indicating that these cells are important instructors of HSCs. 
In addition, mature megakaryocytes are often found in close proximity to HSCs 
within the bone marrow niche99,100. These blood platelet progenitors secrete growth 
factors important for HSC quiescence (e.g. TPO101, CXCL4100, and TGFβ99) and, in 
stress conditions, produce growth factors for HSC proliferation (e.g. FGF199). By far 
the best-studied bone marrow niche cells are MSCs, multipotent adult stromal cells 
for the mesenchymal lineage. These cells can differentiate toward the osteogenic 
(bone), chondrogenic (cartilage) and adipocytic (fat) lineages102. Bone marrow MSCs 
surround the ECs of the arterioles and sinusoid vessels. In murine bone marrow, it 
has become evident that various MSC populations exist that all are important for 
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HSC function. Important markers for murine MSC populations are Nestin103, NG2104, 
Leptin receptor (LEP-R)105, PDGFRA, CD150, and Sca-1106,107. While these populations 
all have MSC characteristics and express HSC-supportive factors, including 
SCF and CXCL12, they are localized at diff erent regions of the bone marrow and 
diff erentially aff ect HSCs93. While, NG2 positive MSCs are mainly located around 
arterioles and co-localize with quiescent HSCs, LEP-R positive MSCs are located 
peri-sinusoidal and co-localize with proliferating HSCs104. Another specifi c subset 
of MSCs highly expresses CXCL12 (CXCL12-abundant reticular (CAR) cells) and is 
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Figure 5. Model for the healthy bone marrow microenvironment. 
Hematopoietic stem cells reside in the bone marrow microenvironment, where they are maintained by several spe-
cialized supporting cells93. This model shows a selection of cellular subsets that have been shown to be important 
for murine hematopoiesis91. The cytokines and growth factors that are produced by these cells are color-coded. See 
main text for more details (paragraph 5.1). Abbreviations: HSC, hematopoietic stem cell; MSC, mesenchymal stro-
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shown to be important in regulation of HSC proliferation108. A substantial fraction of 
CAR cells are osteoblastic progenitor cells, a more differentiated subset of MSCs109. 
These cells also express important factors for HSCs, including CXCL12, SCF and 
ANGPT1106,109, and are important for the proliferation of lymphoid and common 
myeloid progenitors110. Furthermore, mature osteoblasts have been shown to secrete 
IL-7 and to be essential for maintenance and proliferation of B cell progenitors95,96,111. 
This suggests that specialized compartments exist within the bone marrow niche, 
differentially regulating quiescence, proliferation and differentiation of HSPCs. 
In contrast to our understanding of the functional role of these stromal subsets 
on murine HSPCs, the role of human stromal subsets within the bone marrow is 
poorly understood. Human HSPCs are localized within the trabecular region of the 
bone and mainly co-localize with MSCs expressing HSC-supportive factors107,112-114. 
In addition, MSCs, ECs, and osteoblastic progenitors all can support the maintenance 
and proliferation of HSPCs in vitro115, suggesting that also in the human bone marrow 
these cells play an essential role in HSPC regulation.
The leukemic bone marrow microenvironment
Like healthy HSPCs, leukemic cells reside in the local microenvironment of the bone 
marrow. By using similar homing and anchoring signals, including E-selectin and 
CXCL12,  leukemic cells create a leukemic niche that interferes with normal HSPC 
function116-118. Furthermore, in comparison to healthy HSPCs, leukemic cells are less 
dependent on niche signals for their survival and proliferation, making them strong 
invaders119-121. The invasion of leukemic cells was shown to remodel the human bone 
marrow niche by impairing angiogenesis and inducing bone loss122. Several mouse 
models have provided further insight into the changes in bone marrow stromal 
cells after leukemogenesis. For example, BCR-ABL1 positive CML cells have been 
shown to down-regulate CXCL12 production in bone marrow stromal cells, which 
directly impaired normal HSC maintenance109,123, and to up-regulate platelet growth 
factor (PLGF) secretion by stroma, directly inducing CML cell proliferation124. In 
addition, Jak2V617F myelodysplastic syndrome (MDS) cells and MLL-AF9 AML cells 
were shown to induce neuropathy in bone marrow, thereby affecting the activity 
and maintenance of normal MSC subsets, which in turn led to accelerated disease 
development125,126. Human MDS cells have also been shown to up-regulate important 
regulators of fibrosis (e.g. LIF and VEGF) in bone marrow stromal cells, which were 
in turn important for MDS cell survival in a xenograft mouse model127. 
Leukemia-induced changes of the microenvironment appear to be important for 
initiation, maintenance and progression of disease. In addition, healthy hematopoietic 
cells could be transformed to MDS cells in a deficient microenvironment128-132. 
Similarly, activation of an oncogene or oncogenic pathway, e.g. activation of 
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β-catenin, in stromal cells could initiate leukemogenesis131-133. To date, it is not clear 
whether such mutations also occur in human disease. 
The leukemic microenvironment not only induces leukemogenesis as described 
above, it also protects leukemic cells from elimination by immune responses and 
chemotherapeutic agents, and can facilitate the development of drug resistance134-137. 
Several studies report the induction of resistance to both classical chemotherapeutic 
agents and newly developed targeted therapies (such as tyrosine kinase inhibitors) 
by the tumor microenvironment137-143. The disruption of the leukemic niche is 
therefore considered a promising new therapeutic strategy95,117,144-151.
Approaches to disrupt the leukemic niche
Targeting the leukemic niche can be approached in several ways. The most explored 
option is the reduction of leukemic cell homing to and anchoring in the niche. Pioneer 
studies using granulocyte colony stimulating factor (G-CSF) showed that addition 
of growth factors to conventional chemotherapy can enhance therapy efficiency152. 
G-CSF was later shown to decrease CXCL12 levels in the bone marrow, resulting 
in mobilization of stem cells153. More recently, several pre-clinical studies used 
CXCR4 inhibition as a means to disrupt the leukemic niche. Stromal-derived factor-1 
(SDF-1/CXCL12) is a chemoattractant that is actively produced by MSCs, ECs and 
osteoblasts in the bone marrow. CXCL12 binds to the CXCR4 receptor, which is 
highly expressed on HSCs and leukemic cells. Blocking CXCR4/CXCL12 interaction 
with CXCR4 antagonists leads to mobilization of leukemic cells, increased sensitivity 
to therapeutic agents, and prolonged survival in mouse models146,147,150,151,154-159. Phase 
1/2 clinical trials have shown the feasibility of using CXCR4 antagonists during 
chemotherapeutic treatment160-164. However, growth factor priming (with G-CSF/
GM-CSF) in more than 4000 AML patients has not resulted in overall improved 
survival rates165. In addition, recent data argues that leukemic stem cells are not 
mobilized by CXCR4 inhibition166, suggesting that CXCR4 inhibition is not sufficient 
to completely disrupt leukemic niches. Furthermore, CXCR4 inhibition does not 
only interrupt the leukemic, but also the healthy hematopoietic niche167,168. 
An alternative approach to disrupt the leukemic niche, is the inhibition of 
communication between leukemic cells and their stromal counterparts. Several 
communication mechanisms between leukemic cells and stromal niche cells are 
known to be important for their interaction, including integrin signaling, cytokine 
and chemokine signaling, and extracellular vesicle signaling141. However, the 
mechanisms underlying the crosstalk within the leukemic niche and consequently 
how this communication drives leukemic cell survival and chemotherapy resistance 
remains poorly understood. Recently, tunneling nanotubes (TNTs), or membrane 
nanotubes, have been described as a novel mode of communication between 
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eukaryotic cells169-173. These intercellular membrane conduits have been observed in 
several cell types, complex tissues, and organisms172,174-176 and facilitate the transport 
of several types of cargo171,172,177-179. The pathophysiological importance of TNTs has 
been well established in the field of immunology, since it has been shown that prions 
and HIV-1 particles use TNTs to promote disease spread173,180. TNTs have also been 
observed between cancer cells173,179,181,182. However, the presence of TNTs within 
the leukemic niche and hence their role in crosstalk within this niche has not been 
addressed.  Importantly, the functional role of TNTs in leukemic cell survival and 
drug resistance is currently unknown. 
SCOPE AND OUTLINE OF THIS THESIS
New treatment regimens increasingly aim to target specific intrinsic characteristics 
and extrinsic signals important for leukemia. This approach has for example led to 
the successful development of targeted inhibitors, such as imatinib and dasatinib, 
that drastically improved the outcome of BCR-ABL1 positive leukemia patients19,31-35. 
However, the majority of pediatric patients with leukemia are still treated with 
non-specific classic chemotherapy regimens. Twenty percent of pediatric ALL cases 
relapse due to resistance to this therapy183,184, while long-term side effects of treatment 
remain considerable97,185,186. This thesis aims to identify leukemia-specific processes 
that can be used to target leukemic cells or the leukemic microenvironment. 
The first part of this thesis focuses on cellular processes that are driven by 
initial mutations present in (pre-) leukemic cells in order to better understand 
leukemogenesis and leukemia. Further, we aim to inhibit these biological processes 
in order to selectively target leukemic cells. 
In chapter 2, we focus on one of the most important intracellular signaling 
programs in human cells: the PI3K/PKB signaling pathway. We review the role of 
this signaling pathway in normal and malignant hematopoiesis and summarize the 
efforts to target this pathway in order to improve therapy of leukemia patients. 
In chapter 3 and 4, we focus on the cellular processes that are affected by 
the ETV6-RUNX1 fusion protein. We studied the effects of ectopic expression of 
ETV6-RUNX1 in healthy hematopoietic progenitor cells and found that ETV6-RUNX1 
induces pro-proliferative, pro-survival, and pro-migratory signaling pathways. In 
chapter 3, we describe the enhanced expression of the class-III phosphoinositide 
3-kinase Vps34 in ETV6-RUNX1 positive ALL. Vps34 is an important regulator 
of autophagy, and was found to be important for proliferation and survival of 
ETV6-RUNX1 positive ALL cells. This chapter further describes the pre-clinical 
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evaluation of autophagy inhibition as targeted therapy for ETV6-RUNX1 positive 
leukemia. In chapter 4, we describe the importance of Leukemia-Associated Rho 
guanine exchange factor (LARG) and RhoA in the pro-migratory phenotype 
induced by ETV6-RUNX1. This chapter aims to target these cell-intrinsic mediators 
of ETV6-RUNX1 positive leukemic cell migration in order to develop strategies 
that target leukemic cell migration without affecting the migration of healthy 
hematopoietic cells.
The leukemic microenvironment protects leukemic cells from elimination by classic 
and targeted therapy. The second part of this thesis aims to better understand the 
dynamic crosstalk between leukemic cells and human bone marrow-derived stromal 
cells in order to find novel ways to disrupt this leukemic niche. 
Chapter 5 describes the discovery of tunneling nanotube signaling as 
communication mechanism between leukemic cells and mesenchymal stromal cells. 
We investigate the functional consequence of the inhibition of TNT signaling on cell 
survival and drug resistance of leukemic cells. In chapter 6, we evaluate whether 
leukemic cells modify MSC-mediated production of chemokines to create a leukemic 
niche. We investigate how this modified MSC secretome affects migration of leukemic 
cells, healthy hematopoietic progenitors, and MSCs. Furthermore, we aim to identify 
alternative candidate factors for leukemic niche disruption. 
Finally, the results outlined in this thesis are discussed in chapter 7 and summarized 
in chapter 9. 
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ABSTRACT
An important mediator of cytokine signaling implicated in regulation of hematopoiesis 
is the PI3K/protein kinase B (PKB/c-Akt) signaling module. Constitutive activation 
of this signaling module has been observed in a large group of leukemias. Because 
activation of this signaling pathway has been demonstrated to be sufficient to induce 
hematologic malignancies and is thought to correlate with poor prognosis and 
enhanced drug resistance, it is considered to be a promising target for therapy. A high 
number of pharmacologic inhibitors directed against either individual or multiple 
components of this pathway have already been developed to improve therapy. In 
this review, the safety and efficacy of both single and dual-specificity inhibitors will 
be discussed as well as the potential of combination therapy with either inhibitors 
directed against other signal transduction molecules or classic chemotherapy.
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PI3K plays a critical role in both HSC maintenance and lineage development
The PI3K family consists of 3 distinct subclasses of which, to date, only the class I 
isoforms have been implicated in regulation of hematopoiesis. Three distinct catalytic 
class IA isoforms have been identified: p110α, p110β, and p110δ1. These isoforms are 
predominantly activated by protein tyrosine kinases and form heterodimers with 
a group a regulatory adapter molecules, including p85α, p85β, p50α, p55α, and 
p55γ1. In addition, a single-class 1B isoform termed p110γ has been described, which 
can be specifically activated by G-protein coupled receptors and associates with a 
p101 regulatory molecule1. The most important substrate for these class I PI3Ks is 
phosphatidylinositol 4,5 bisphosphate [PI(4,5)P2] which can be phosphorylated at the 
D3 position of the inositol ring on extracellular stimulation, resulting in the formation 
of phosphatidylinositol 3,4,5 trisphosphate [PI(3,4,5)P3]1 (Figure 1). The activity of 
PI3K can be inhibited by phosphate and tensin homologue (PTEN), a ubiquitously 
expressed tumor suppressor protein that can dephosphorylate PIP3, resulting in the 
formation of PI(4,5)P21,2. Similarly, SH2-containing inositol-5′-phosphatase 1 (SHIP1), 
a protein predominantly expressed in hematopoietic cells, can hydrolyze PIP3 to 
generate PI(3,4)P21,2. Although both PTEN and SHIP1 act on the main product of 
PI3K, PI(3,4,5)P3, the generated products PI(3,4)P2 and PI(4,5)P2 both act as discrete 
second messengers activating distinct downstream events2. Recently, pleckstrin 
homology (PH) domain leucine-rich repeat protein phosphatase (PHLPP) was found 
to terminate PKB signaling by directly dephosphorylating and inactivating PKB3. 
However, a role for PHLPP in regulation of hematopoiesis remains to be determined. 
Inositol 1,3,4,5-tetrakiphosphate [Ins(1,3,4,5)P4], which is generated from inositol 
1,4,5-triphosphate [Ins(1,4,5)P3] by inositol triphosphate 3-kinase B (InsP3KB), is 
considered to be a fourth negative regulator of the PI3K/PKB signaling module. The 
activity of downstream effectors of PI3K, including PKB, can be abrogated because 
of binding of PI(3,4,5)P3-specific pleckstrin homology (PH) domains to Ins(1,3,4,5)
P44. Since the identification of PI3K, it has become evident that it plays an essential 
role in proliferation, survival, and differentiation of many different cell types. 
Correct regulation of the activity of PI3K has been demonstrated to be essential 
for maintenance of hematopoietic stem cells using PTEN- and SHIP1-deficient 
mice that displayed constitutive activation of PI3K activity. In those mice, an initial 
expansion of HSCs could be observed that was followed by a depletion of long-term 
repopulating HSCs5. The role of class I PI3K isoforms in lineage development has 
been investigated in more detail. Combined deletion of p85α, p55α, and p50α has, 
for example, resulted in a complete block in B lymphocyte development6. Similarly, 
introduction of a mutated, catalytically inactive p110δ (p110δD910A) in the normal 
p110δ locus also resulted in a block in early B lymphocyte development, whereas 
T-cell development was unaffected7. These results indicate that PI3K activity is 
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essential for normal B lymphocyte development. In addition, conditional deletion 
of either PTEN or SHIP1 in adult HSCs, resulting in activation of the PI3K pathway, 
not only reduced the level of B-lymphocytes but also enhanced the level of myeloid 
cells8,9. Furthermore, enhanced levels of megakaryocyte progenitors have been 
observed in SHIP1-deficient mice10. In time, both PTEN- and SHIP1-deficient mice 
developed a myeloproliferative disorder that progressed to leukemia8,9. In PTEN 
heterozygote (+/−) SHIP null (−/−) mice, a more severe myeloproliferative phenotype, 
displayed by reduced erythrocyte and platelet numbers and enhanced white blood 
cell counts including elevated levels of neutrophils and monocytes in the peripheral 
blood, could be observed11. Recently, a shorter SHIP1 isoform (s-SHIP1), which is 
transcribed from an internal promoter in the SHIP1 gene, has also been implicated 
in positive regulation of lymphocyte development during hematopoiesis12. 
Pharmacologic inhibition of PI3K activity in human umbilical cord blood-derived 
CD34+ HSCs and progenitor cells revealed that inhibition of the activity of PI3K is 
sufficient to completely abrogate both proliferation and differentiation of eosinophil 
and neutrophil progenitors eventually leading to cell death13. Finally, mice deficient 
for InsP3KB, resulting in an induction of PKB activity, display higher levels of 
granulocyte-macrophage progenitors and mature neutrophils in the bone marrow14 
and dramatically reduced levels of mature CD4+ and CD8+ T lymphocytes15. Together, 
these studies suggest that correct temporal regulation of PI3K activity is critical for 
both HSC maintenance and regulation of lineage development.
PKB is an important mediator of PI3K in regulation of hematopoiesis
An important mediator of PI3K signaling is protein kinase B (PKB/c-akt). Whereas 
PKB is cytosolic in unstimulated cells, PI3K-mediated activation of PKB requires 
translocation of PKB to the membrane. PI(3,4,5)P3, which is generated by PI3K, serves 
as an anchor for PH domain–containing proteins in the membrane, including PKB16. 
Activation of PKB requires phosphorylation on both Thr308 in the activation loop, 
by phosphoinositide-dependent kinase 1 (PDK1) and Ser473, within the carboxyl-
terminal hydrophobic motif, by the MTORC2 complex that consists of multiple 
proteins, including mTOR, Rictor, mLST8, DEPTOR, Sin1, and PROTOR17 (Figure 1).
Three highly homologous PKB isoforms have been described to be expressed in 
mammalian cells: PKBα, PKBβ, and PKBγ. PKB has been demonstrated to play an 
important role in regulation of cell survival and proliferation in a large variety of cell 
types18. Analysis of HSCs derived from PKBα/PKBβ double-knockout mice revealed 
that PKB plays an important role in maintenance of long-term repopulating HSCs. 
These PKBα/PKBβ double-deficient HSCs were found to persist in the G0 phase of the 
cell cycle, suggesting that the functional defects observed in these mice with regard 
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to long-term hematopoiesis were caused by enhanced quiescence19. In contrast, loss 
of only one of the isoforms only minimally affected HSCs19. In addition, ectopic 
expression of constitutively active PKB in mouse HSCs conversely resulted in transient 
expansion and increased cycling of HSCs, followed by apoptosis and expansion of 
immature progenitors in BM and spleen, which was also associated with impaired 
engraftment20. In addition to HSC maintenance, PKB also plays a critical role in the 
regulation of cell fate decisions during hematopoietic lineage development. High 
PKB activity in human umbilical cord blood-derived hematopoietic progenitors 
was, for example, found to promote neutrophil and monocyte differentiation and 
to inhibit B lymphocyte development, whereas reduction of PKB activity has been 
demonstrated to be required for optimal eosinophil maturation13. In addition, PKB 
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Figure 1. Schematic representation of the PI3K/PKB signaling module. 
Activation of PI3K by receptor stimulation results in the production of PtdIns(3,4,5)P3 at the plasma membrane. 
PKB subsequently translocates to the plasma membrane where it is phosphorylated by PDK1 and the mTORC2 
complex. On phosphorylation, PKB is released into the cytoplasm where it can both inhibitory phosphorylate mul-
tiple substrates, including FoxO transcription factors and GSK-3, and induce the activity of other substrates, such 
as mTOR as part of the mTORC1 complex. Negative regulators of the PI3K/PKB signaling module include PTEN, 
SHIP1, Ins(1,3,4,5)P4, and PHLPP1/2.
42 Chapter 2
plays an important role in regulation of proliferation and survival, but not maturation, 
of human dendritic cell (DC) progenitors21. The development of a myeloproliferative 
disease, characterized by extramedullary hematopoiesis in liver and spleen, and 
lymphoblastic thymic T-cell lymphoma in the majority of mice transplanted with 
mouse bone marrow cells ectopically expressing constitutively active PKB further 
demonstrates the importance for correct regulation of PKB activity in HSCs and 
progenitor cells20. In addition, recent findings suggest that constitutive activation of 
PKBβ is sufficient to accelerate MYC-induced T-cell acute lymphoblastic leukemia 
(T-ALL) in zebrafish22. Furthermore, analysis of mice deficient for both PKBα and 
PKBβ, but not single knockout mice, revealed that the generation of marginal zone 
and B1 B cells and the survival of mature follicular B cells also depend on correct 
regulation of PKB activity23.
Downstream effectors of PKB differentially regulate hematopoiesis
Multiple PKB substrates have been identified, including members of the FoxO 
subfamily of forkhead transcription factors FoxO1, FoxO3, and FoxO4, the serine/
threonine kinase glycogen synthase kinase-3 (GSK-3), and the serine/threonine kinase 
mammalian target of rapamycin (mTOR) as part of the MTORC1 complex, which 
also includes the regulatory associated protein of mTOR (Raptor; Figure 1)18. FoxO 
transcription factors, which are inhibitory phosphorylated by PKB18, are known to 
play an important role in regulation of proliferation and survival of various cell types. 
In addition, these transcription factors play an important role in HSC maintenance, 
which has been demonstrated by conditional deletion of FoxO1, FoxO3, and FoxO4 
in the adult hematopoietic system24. An initial expansion of HSCs has been observed 
in those mice, which correlated with an HSC-specific up-regulation of cyclin D2 and 
down-regulation of cyclin G2, p130/Rb, p27, and p2124. After this initial expansion, 
a reduction in HSC numbers was observed, resulting in a defective long-term 
repopulating capacity24. Similarly, competitive repopulation experiments revealed 
that deletion of FoxO3 alone is also sufficient to impair long-term reconstitution25. 
In addition, in aging mice deficient for FoxO3, the frequency of HSCs was increased 
compared with wild-type littermate controls25. Both mouse models have also been 
used to examine the role of FoxO transcription factors in lineage development. 
Conditional deletion of FoxO1, FoxO3, and FoxO4 resulted in enhanced levels of 
myeloid cells and decreased numbers of peripheral blood lymphocytes under normal 
conditions. In time, these mice developed leukocytosis characterized by a relative 
neutrophilia and lymphopenia24. In contrast, in FoxO3-deficient mice, neutrophilia 
only developed during aging and under myelosuppressive stress conditions26. 
Although deletion of FoxO3 alone was not sufficient to induce neutrophilia, ectopic 
expression of a constitutively active, nonphosphorylatable, FoxO3 mutant in mouse 
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hematopoietic progenitors did result in a decrease in the formation of both myeloid 
and erythroid colonies27, suggesting that FoxO3 does play an important role in lineage 
development. Modulation of the activity of either PKB or FoxO transcription factors 
has been observed to alter the level of reactive oxygen species (ROS). Although ROS 
levels are reduced in PKBα/β-deficient mice19, increased levels have been observed 
in mice deficient for FoxO25. Increasing the ROS levels in PKBα/β-deficient mice was 
sufficient to rescue differentiation defects, but not impair long-term hematopoiesis19. 
Reducing the ROS levels in FoxO-deficient mice with N-acetyl-L-cysteine, an 
antioxidative agent, was sufficient to abrogate the enhanced levels of proliferation 
and apoptosis in FoxO-deficient HSCs and to restore the reduced colony-forming 
ability of these cells24. These studies demonstrate that correct regulation of ROS by 
FoxO transcription factors is essential for normal hematopoiesis.
Recent findings have demonstrated that correct regulation of the activity 
of GSK-3, which is inhibitory phosphorylated by PKB18, is also essential for HSC 
maintenance. A reduction in long-term, but not short-term, repopulating HSCs has, 
for example, been observed in GSK3-deficient mice28. In addition, disruption of 
GSK-3 activity in mice with a pharmacologic inhibitor or shRNAs has been shown 
to transiently induce expansion of both HSCs and progenitor cells followed by 
exhaustion of long-term repopulation HSCs28,29. An acceleration of neutrophil and 
megakaryocyte recovery could be observed after transplantation of mice treated with 
a GSK-3 inhibitor, suggesting a role for GSK-3 in lineage development29. Indeed, ex 
vivo experiments with human hematopoietic progenitors revealed that GSK-3 can 
enhance eosinophil differentiation and inhibit neutrophil development at least in 
part via regulation of C/EBPα, a key regulator of hematopoiesis13. 
A third, important mediator of PI3K/PKB signaling is mTOR18. In contrast 
to GSK-3 and FoxO transcription factors, which are inhibitory phosphorylated by 
PKB, the activity of mTOR is positively regulated by PKB. Inhibition of the GTPase 
activating protein Tuberous sclerosis protein 2 (TSC2)/TSC1 complex by PKB results 
in accumulation of GTP-bound Rheb and subsequent activation of mTOR30. In 
addition, because rapamycin was sufficient to revert the HSC phenotype of mice 
in which GSK-3 was depleted, it is probable that mTOR is an important effector 
of GSK-328. Conditional deletion of TSC1 in mice, resulting in activation of mTOR, 
has been demonstrated to enhance the percentage of cycling HSCs and to reduce 
the self-renewal capacity of HSCs in serial transplantation assays31. In addition, 
treatment of PTEN-deficient mice with rapamycin appears to be sufficient to revert 
the HSC phenotype in those mice, indicating that mTORC1 is an important mediator 
of PI3K in regulation of HSC proliferation32. In addition, deletion of TSC1 has been 
demonstrated to induce ROS levels in HSCs. In vivo treatment of TSC1-deficient 
mice with an ROS antagonist restored HSC numbers and function31, suggesting that 
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TSC1, similar to FoxO transcription factors, regulates HSC numbers at least in part 
via ROS. Although mice deficient of TSC1 also display reduced granulocyte and 
lymphocyte numbers, this is probably because of reduced progenitor proliferation. 
In contrast to PKB, which regulates both proliferation and differentiation of myeloid 
progenitors13, mTOR primarily regulates expansion of hematopoietic progenitors, 
as was demonstrated for, for example, granulocyte progenitors33 and progenitors 
for interstitial DCs and Langerhans cells21. Although the molecular mechanisms 
underlying mTOR-mediated regulation of lineage development are largely unknown, 
it has recently been demonstrated that mTOR decreases the ratio of wild-type C/
EBPα (C/EBPαp42) and truncated C/EBPαp30, which is generated by alternative 
translation initiation, resulting in high levels of the smaller p30 C/EBPα isoform34, 
which inhibits trans-activation of C/EBPα target genes in a dominant-negative 
manner and binds to the promoters of a unique set of target genes to suppress their 
transcription.
Together, these studies show that FoxO transcription factors GSK-3 and mTOR 
are all important mediators of PI3K in terms of HSC maintenance and lineage 
development.
Deregulated PI3K/PKB signaling in malignant hematopoiesis
The studies described in the first three sections of this review clearly demonstrate that 
deregulation of the PI3K/PKB signaling module dramatically affects hematopoiesis 
resulting in the development of hematologic malignancies. To investigate whether, 
in patients, the development of leukemia can be caused by aberrant regulation of 
this signaling module, research has focused on identifying mutations in PI3K and 
upstream and downstream regulators of this molecule (Figure 2). Constitutive 
activation of class I PI3K isoforms has been observed in a high percentage of patients 
with acute35,36 and chronic leukemia37. In contrast to the expression of p110α, β, and 
γ, which is only up-regulated in leukemic blasts of some patients, p110δ expression 
appears to be consistently up-regulated in cells from patients with either acute 
myeloid leukemia (AML) or acute promyelocytic leukemia36,38. Activating mutations 
in the kinase domain (H1047R) and helical domain (E545A) of p110α have been 
detected in a wide variety of human solid tumors39. The latter has also been detected 
in acute leukemia, albeit in a very low percentage (1 of 88)39. In addition, another 
activating helical domain mutation (E545G) has recently been detected in a chronic 
myeloid leukemia (CML) cell line40. Furthermore, both activating mutations in p110α 
(PIK3CA) and in-frame insertions/deletions in the PI3K regulatory subunit p85α 
(PIK3R1) have been observed in a low number of pediatric T-ALL patients (both 2 of 
44)41. In a small group of myelodysplastic syndrome (MDS) patients, however, the 
above described mutations could not be detected42. 
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Importantly, ectopic expression of mutated p110α has been demonstrated to 
be sufficient to induce leukemia in a mouse transplantation model43. Alternatively, 
constitutive activation of PI3K may also be caused by either aberrant expression or 
activation of PTEN. Reduced expression of PTEN has, for example, been observed 
in different types of leukemia. Although analysis of both myeloid leukemic cell 
lines and primary AML blasts indicates that PTEN mutations are rare in AML44,45, 
both homozygous and heterozygous deletion of PTEN as well as nonsynonymous 
sequence alterations in exon 7 have been detected in approximately 15% and 25% 
of T-ALL patients, respectively41. In addition, analysis of primary T-ALL cells 
revealed that, as a result of mutation-induced alternative splicing, full-length SHIP1 
p85 BD Ras BD C2 Helical domain Catalytic domainPI3K p110α
 E545A 
(AML & ALL)
E542K * H1047R *
p85α
PIP2-BR Phosphatase domain C2 Domain PESTPTEN
   Activation
          (ALL)
SH2 Inositol 5-phosphataseSHIP1
PH domain S/T Kinase domain Regulatory domainPKB
PEST
   Sequence alterations (exon 7) (ALL)
NPXY
PxxP motifs
   Deactivation (AML)
   Deletion #
        (ALL)
E17K (ALL)
   Deletion/loss (ALL)
SH3 BHD SH2 iSH2 SH2
 E545G 
(CML)
Figure 2. Schematic representation of the known mutations in the PI3K/PKB signaling module 
in leukemia. 
Aberrant regulation of the PI3K/PKB signaling module has been found in a large group of patients with leukemia. 
However, only few mutations are known to directly affect hematopoiesis. Mutations indentified in leukemic cells 
are indicated above the linear (unscaled) representations of PI3K, SHIP, PTEN, and PKB. Grey arrows/lines indi-
cate activating mutations; black arrows, inactivating mutations/deletions. *Mutations found in AML and ALL cell 
lines. **Mutation found in CML cell line. #Mutations inducing leukemia in mouse model. BD indicates binding do-
main; C2, C2 domain (putative membrane binding domain); SH2, Src homology 2 region (tyrosine-phosphorylated 
residue binding region); BHD, Bcr homology domain; SH3, Src homology 3 region (proline-rich protein-protein 
interaction region); and BR, binding region.
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expression is often low or undetectable46. In addition, an inactivating mutation in 
the phosphatase domain of SHIP1 has also been detected in primary AML blasts47.
Although constitutive activation of PKB, resulting in enhanced survival 
signals48-50, has been demonstrated in a significant fraction of AML51,52 and chronic 
lymphoid leukemia (CLL) patients50,53,54, until recently, no PKB mutations were 
found in patients with leukemia. However, an activating mutation in the pleckstrin 
homology domain of PKB (E17K) has recently been detected in various solid 
tumors55 and one pediatric T-ALL patient41. In contrast, this mutation could not be 
detected in a several cohorts of CLL56,57, CML58, and AML patients57,59, suggesting 
that this particular mutation is very rare. However, transplantation of mice with 
bone marrow cells ectopically expressing this E17K mutation was sufficient to 
induce leukemia55. Although mutations in mTOR have thus far not been described 
in hematologic malignancies, a recent study has identified several mTOR mutations 
in solid tumors60. Interestingly, 2 single amino acid mutations, S2215Y and R2505P, 
identified in large intestine adenocarcinoma and renal cell carcinoma, respectively, 
appear to induce constitutive activation of mTOR, even under nutrient starvation 
conditions60.
In addition to mutations in the PI3K signaling module itself, mutations in 
cytokine receptors, including constitutive activation of FMS-like tyrosine kinase 3 
(FLT3) by internal tandem duplication (Flt3-ITD)61 and mutation in c-Kit43,62 have 
been described to affect PI3K signaling in hematologic malignancies. In addition 
to these tyrosine kinase receptors, the activity of the PI3K/PKB pathway can also 
be enhanced by several fusion proteins, including Bcr-Abl63, which can be detected 
in virtually all patients with CML and in a subset of patients with ALL64. The 
mechanisms underlying Bcr-Abl–mediated activation of the PI3K/PKB signaling 
pathway have been investigated extensively. Coimmunoprecipitation experiments 
revealed that Bcr-Abl associates with Shc65, which subsequently binds to the p85α 
subunit of PI3K66 resulting in activation. In addition, expression of Bcr-Abl has been 
shown to reduce the levels of PHLPP1 and PHLPP2, which are negative regulators 
of PKB phosphorylation67, and to up-regulate the level of p110γ68. Bcr-Abl has also 
been shown to indirectly induce the activity of the PI3K/PKB signaling module by, 
for example, increasing the level of Nox-4–generated ROS resulting in inhibition of 
PP1a, a negative regulator of PI3K/PKB69.
Other potential regulators of PI3K often mutated or aberrantly expressed in 
leukemia include Ras1, Evi170, PP2A52, and casein kinase 2 (CK2)35. Inhibition of 
CK2 has been shown to reduce the activity of the PI3K/PKB signaling module by 
dephosphorylation and activation of PTEN, resulting in induction of apoptosis 
in primary CLL cells in vitro71,72. Interestingly, in a subset of MDS patients, it 
was demonstrated that deletion of glutathione S-transferase θ can result in the 
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generation of a DNA sequence homologous to mTOR, thereby inducing the activity 
of downstream effectors of mTOR in a PI3K/PKB-independent manner. Inhibition of 
mTOR in these cells was sufficient to induce apoptosis73,74. 
It is evident that the activity of the PI3K/PKB signaling module is regulated 
by various extracellular factors, suggesting that deregulation of the production of 
those factors by components of the microenvironment could also result in aberrant 
hematopoiesis. Several studies have revealed that the microenvironment of CLL 
patients constitutively activates PI3K in leukemic cells, induces proliferation and 
survival of CLL cells, and contributes to the resistance of leukemic cells to cytotoxic 
agents75-80. Inhibition of the PI3K/PKB signaling pathway was shown to be sufficient 
to induce apoptosis in CLL cells75,76. In addition, the migratory capacity of primary 
CLL cells has been demonstrated to be enhanced by CX3CL1 in an autocrine 
manner78. Constitutive release of soluble CX3CL1 by CLL cells results in a PKB-
dependent up-regulation of CXCR4, a chemokine receptor that is important for CLL 
cell migration78.
Although the studies described in this section clearly demonstrate that 
constitutive activation of the PI3K/PKB signaling module can result in the 
development of leukemia, enhanced FoxO activity has also been observed in 40% of 
the AML patients81. Similarly, enhanced FoxO activity could also be observed in MLL-
AF9–induced AML in a mouse model81. Activation of PKB or deletion of FoxO1/3/4 
was sufficient to reduce leukemic cell growth, suggesting that inactivation of the 
PI3K/PKB signaling module contributes to the development of MLL-AF9–induced 
leukemia81. Together, these studies demonstrate that, in addition to constitutive 
activation of the PI3K/PKB signaling pathway, inactivation of this module can also 
result in the development of leukemia.
Prognosis of leukemia with activated PI3K/PKB signaling
Because the PI3K/PKB signaling module is aberrantly regulated in many patients 
with leukemia, the question was raised whether the level of PI3K/PKB activation in 
leukemic blasts could be used as a prognostic marker. Mouse transplantation studies 
with blasts from pediatric de novo B-ALL patients revealed that a rapid induction of 
leukemia correlates with enhanced mTOR activity in the leukemic blasts82. In addition, 
comparison of pediatric T-ALL patients revealed that the survival rate of patients 
positively correlates with the level of PTEN83. Similar observations were made in 
a different cohort of pediatric T-ALL patients, in which PTEN deletions correlated 
with early treatment failure in T-ALL41. Furthermore, constitutive activation of the 
PI3K pathway, as measured by enhanced FoxO3 expression84 or phosphorylation85, 
enhanced levels of phosphorylated, and therefore inactive, PTEN86 or enhanced 
levels of phosphorylated PKB52,87 is also considered to be an independent adverse 
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prognostic factor in AML patients. Similarly, in MDS, activation of the PI3K/
PKB pathway has only been detected in high-risk MDS, but not in low-risk MDS 
patients88,89, suggesting that high PKB activity may also be an adverse prognostic 
factor for MDS.
In contrast, Tamburini et al suggest that enhanced PKB phosphorylation 
positively correlates with the survival of AML patients90. Although the short-
term survival rate (within 12 months) appeared to be slightly lower in the group 
displaying high PKB phosphorylation compared with the group with low levels of 
phosphorylated PKB, both the long-term survival and relapse-free survival were 
significantly enhanced90. Except for this last study, all other studies suggest that 
enhanced PI3K/PKB activity correlates with reduced survival rate in both ALL and 
AML patients.
The molecular mechanisms underlying this reduced prognosis are, thus 
far, incompletely understood. However, a reduced apoptotic response has been 
observed in AML blasts displaying enhanced PI3K/PKB activation91. In addition, 
PI3K has been demonstrated to induce expression of the multidrug resistance-
associated protein 1, a member of the ATP-binding cassette membrane transporters 
that functions as a drug efflux pump92, suggesting that high PI3K activity induces 
drug resistance. The observation that high levels of multidrug resistance-associated 
protein 1 correlate with enhanced drug resistance in AML cells and poor prognosis 
supports that hypothesis93.
PI3K/PKB signaling as a therapeutic target in leukemia
Because aberrant regulation of the PI3K signaling module has frequently been 
observed in leukemic cells, PI3K and its downstream effectors are considered to be 
promising targets for therapy (Figure 3; Table 1). The functionality of LY294002 and 
wortmannin, 2 well-known PI3K inhibitors that prevent ATP to bind to and activate 
PI3K, has for example been investigated extensively. Preclinical experiments indicate 
that both LY294002 and wortmannin induce apoptosis in leukemic cells and rescue 
drug sensitivity. However, it has also been demonstrated that both inhibitors are 
detrimental for normal cells13,94. In addition, both inhibitors exhibit little specificity 
within the PI3K family and inhibit the activity of other kinases, including CK2 and 
smMLCK, respectively95. Recently, several novel PI3K inhibitors, including S1416196, 
the p110α-selective inhibitor AS70263097, the p110β-selective inhibitor TGX-11536, 
and the p110δ inhibitors IC8711436,38 and CAL-10180,98-100 have been discovered that 
also appear to affect proliferation and survival of leukemic blasts. It has, for example, 
been demonstrated that IC87114 reduces proliferation and survival of both AML 
blasts38 and acute promyelocytic leukemia cells36 without affecting the proliferation 
of normal hematopoietic progenitors38. For CAL-101, a dual mechanism of action 
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has been revealed in patients with CLL. CAL-101 both decreases the survival of 
CLL cells directly and abrogates cellular interactions between CLL cells components 
of the tissue microenvironment98,100. Phase 1 or 2 clinical trials (NCT00710528 and 
NCT01090414) have therefore been initiated to examine the efficacy of CAL-101 as a 
therapeutic agent in CLL.
Research has also focused on the development of pharmacologic compounds 
that inhibit PKB. One such compound is perifosine, a synthetic alkylphosphocholine 
with oral bioavailability that inhibits PKB phosphorylation by competitive interaction 
with its PH domain and promotes degradation of PKB, mTOR, Raptor, Rictor, p70S6K, 
and 4E-BP1101. It has been demonstrated that this compound induces apoptosis in 
multidrug-resistant human T-ALL cells and primary AML cells102,103 but does not 
affect normal CD34+ hematopoietic progenitor cells103. The efficacy of perifosine in 
treatment of different types of leukemia is currently examined in several phase 2 
clinical trials (NCT00391560 and NCT00873457). Phosphatidylinositol ether lipid 
analogs inhibit PKB activity in a similar manner compared with perifosine. Treatment 
of HL60 cells with phosphatidylinositol ether lipid analogs resulted in inhibition of 
proliferation and sensitization to chemotherapeutic agents in concentrations that did 
not affect proliferation of normal hematopoietic progenitors104. Another specific PKB 
inhibitor (AKT-I-1/2 inhibitor) has been demonstrated to efficiently reduce colony 
formation in high-risk AML samples52 and induces apoptosis in primary CLL cells105. 
The PKB inhibitor triciribine (API-2), a purine analog, has been demonstrated to 
interact with the PH domain of PKB and can thus prevent association of PKB with 
PI(3,4,5)P3. In T-ALL cell lines, API-2 has been demonstrated to induce cell cycle 
arrest and apoptosis106. The safety of this inhibitor is currently examined in a phase 
1 clinical trial in patients with advanced hematologic malignancies (NCT00363454). 
Recently, a novel specific PKB inhibitor termed AiX has been demonstrated to 
preferentially induce apoptosis in CLL cells with a normal immunoglobulin status 
that correlates with poor clinical outcome107. 
Rapamycin and its analogs RAD001 (everolimus), CCI-779 (temsirolimus), 
AP23573 (deforolimus), and RAD001108,109 inhibit the mTORC1 complex by 
association with FKBP-12, which abrogates the association of Raptor with mTOR110. 
The efficacy of these compounds as therapeutic drugs has been examined in various 
preclinical and clinical studies for a wide range of malignancies. Although both 
rapamycin and its analog CCI-779 exhibit strong anti–tumor capacities in vitro82,111,112, 
only a partial response was observed in clinical trials with rapamycin112 or its analog 
AP23573 in hematologic malignancies113. The observed induction of PKB activity in 
AML blasts treated with rapamycin or AP23573 may explain the limited therapeutic 
effects of these compounds114. Furthermore, experiments with PTEN-deficient mice 
revealed that withdrawal of rapamycin results in a rapid reinduction of leukemia 
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and death in the majority of mice, which is probably because of failure to eliminate 
the leukemic stem cell population115. In a subset of CLL patients, RAD-001 displays 
a modest antitumor activity116. In addition, treatment of CLL patients with RAD-
001 results in mobilization of malignant cells from the protective nodal masses into 
the peripheral blood116. As an alternative, ATP-competitive mTOR inhibitors have 
recently been generated that inhibit the activity of both mTORC1 and mTORC2117. 
Compared with rapamycin, the mTORC 1/2 inhibitor PP242 more efficiently reduced 
the development of leukemia in mice transplanted with primary ALL blasts or 
preleukemic thymocytes overexpressing PKB117, while inducing less adverse effects 
on proliferation and function of normal lymphocytes117,118. Similarly, OSI-027, another 
mTORC1/2 inhibitor118, has been demonstrated to exhibit anti–leukemic effects 
in both Ph+ ALL and CML cells119,  and, compared with rapamycin, to efficiently 
suppress proliferation of AML cell lines120. 
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Figure 3. Schematic representation of the PI3K/PKB signaling module and the available inhibi-
tors inhibiting this pathway. 
Several inhibitors have been developed to inhibit aberrant regulation of the PI3K/PKB signaling module in leu-
kemia. These inhibitors target single or multiple proteins in the pathway. Black boxes represent groups of similar 
inhibitors; and black arrows, the specific target of the inhibitors.
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Table 1. Inhibitors of the PI3K/PKB signaling pathway.
Target Compound Effect Leukemia Clinical Trials (phase) Reference(s)
In vitro   In vivo
PI3K
 
 
Wortmannin + -  147,148
LY294002 + -  37,148-150
AS702630 + - 105
S14161 + +  96
p110β TGX-115 + -  36,105
p110δ
 
IC87114 + -  36,38,105,145
AMG 319 - - CLL and ALL NCT01300026 (I)
CAL-101 +
+
+
+
CLL and AML
CLL and AML
NCT01090414 (I)
NCT00710528 (I)
80,99,100
80,99,100
PDK1 UCN-01 + -  122
PKB
 
 
 
 
 
 
 
 
 
 
Perifosine
 
+
-
-
-
RRL
CLL
NCT00391560 (II)
NCT00873457 (II)
101-103
PIA + -  104
A-443654 + - 53
AiX + - 107
AKT-I-1/2 + - 52,53
Triciribine 
(API-2)
+ - NCT00363454 (I) 106
GSK690693 + - NCT00493818 (I) 151
MK2206
 
- - RRL
AML
NCT01231919 (I)
NCT01253447 (II)
SR13668 - - NCT00896207 (I)
GSK2141795 - - NCT00920257 (I)
GSK21110183 - - RRL NCT00881946 (I/II)
mTOR
 
 
 
 
 
 
 
 
Rapamycin
 
+
+
+
+
+
+
ALL
ALL and AML
CML
NCT00795886 (II)
 NCT00068302 (I)
(II)
112,152,153
112,152,153
154,155
RAD001 +
+
+
+
+
+
AML and MDS
B-CLL
CLL
NCT00636922 (I/II)
(II)
(II)
138
109
116
CCI-779 +
+
+
+
+
+
+
+
ALL
CLL
RRL
CLL
(II) 
NCT00290472 (II)
NCT00084916 (II)
NCT00084474 (II)
156
AP23573 
 
- - AML
RRL
(II)
NCT00086125 (II)
113
PP242 + + 117,118,157
OSI-027 + - 118-120
AZD-8050 + - 118
PI3K/mTOR PI-103 + + 76,126,127,158
PI3K/mTOR NVP-BEZ235 + + 123-125
PI3K/PDK1 BAG956 + + 121
PKB/PDK1/Flt3 KP372-1 + - 128
RRL indicates relapsed and refractory leukemia. 
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Dual inhibition of the PI3K/PKB pathway
Although the single-specificity inhibitors do affect the survival of leukemic cells, their 
effect in patients appears to be modest. The efficacy of combination therapy using 
multiple inhibitors directed against different intermediates of the PI3K signaling 
module is therefore also under investigation. Combined inhibition of mTOR and 
p110δ with RAD001 and IC87114, respectively, has for example been demonstrated 
to synergistically reduce proliferation of AML blasts114. Similarly, combining the 
PI3K/PDK1 inhibitor BAG956 with RAD001 also resulted in a synergistic reduction 
in tumor volume in a mouse model transplanted with BCR-ABL–expressing cells121. 
Finally, the efficacy of a novel combination regimen, including both perifosine and 
UCN-01 (NCT00301938), a PDK1 inhibitor that is known to induce apoptosis in AML 
cells in vitro122, is currently examined in a phase 1 trial.
To further optimize inhibition of the PI3K signaling module, dual-specificity 
inhibitors have also been generated (Table 1). Recently, NVP-BEZ235, an orally 
bioavailable imidazoquinoline derivative that inhibits the activity of both PI3K 
and mTOR by binding to their ATP-binding pocket, has been identified123. This 
compound significantly reduced proliferation and survival in both primary T-ALL124 
and AML cells125 as well as leukemic cell lines124,125 without affecting the clonogenic 
capacity of normal hematopoietic progenitors125. Another potent dual inhibitor for 
both class I PI3K isoforms and mTORC1 is PI-103, a synthetic small molecule of the 
pyridofuropyrimidine class. PI-103 has been demonstrated to reduce proliferation 
and survival of cells from T-ALL126, AML127, and CLL patients76 and appears to 
exhibit a stronger anti–leukemic activity compared with both rapamycin126 and 
the combination of RAD001 and IC87114127. Importantly, although PI-103 reduces 
proliferation of normal hematopoietic progenitors, survival is not affected127. A dual 
PI3K/PDK1 inhibitor called BAG956 has also recently been described. Although this 
compound can inhibit proliferation of BCR-ABL and FLT3-ITD–expressing cells, its 
anti–leukemic capacity is reduced compared with RAD001121. In addition to these 3 
dual-specificity inhibitors, KP372-1, a multiple kinase inhibitor capable of inhibiting 
PKB, PDK1, and FLT3, has been generated128. It has been demonstrated that KP372-1 
can induce apoptosis in primary AML cells and leukemic cell lines without affecting 
the survival of normal hematopoietic progenitors128. 
Optimization of treatment strategies with combination therapy
Leukemogenesis involves aberrant regulation of various signal transduction 
pathways, including, but not limited to, the PI3K signaling module. Simultaneous 
targeting of multiple aberrantly regulated signal transduction pathways is therefore 
considered to be a promising therapeutic strategy (Tables 2 and 3). Histone 
deacetylase inhibitors have, for example, emerged as a promising class of anti–tumor 
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agents. Although, in mouse models, the histone deacetylase inhibitor MS-275 only 
partially inhibited leukemic cells, combined administration of MS-275 and RAD001 
potentiated the effect of both inhibitors individually both in vitro and in vivo129. 
Synergistic negative effects on proliferation and survival of leukemic cell lines have 
also been observed after coadministration of histone deacetylase inhibitors and 
perisofine130. Although proteosome inhibitors are considered to be a new class of 
therapeutic agents, treatment of pediatric and adult B-ALL patients with such an 
inhibitor (bortezomib) was not sufficient to induce a robust anti–tumor response131. 
Experiments in leukemic cell lines and primary cells from B-ALL patients revealed 
that, whereas MG132, a proteosome inhibitor, and RAD001 alone only modestly 
reduce cell viability, combined inhibition of proteosomes and mTOR significantly 
enhanced cell death132. In addition to proteosome inhibitors, the efficacy of specific 
tyrosine kinase inhibitors, including inhibitors of Flt3, Abl, and c-Kit, has been 
investigated in preclinical and clinical models. Combined inhibition of tyrosine 
kinases and the PI3K/PKB pathway resulted in a synergistically enhanced anti–
leukemia effect in ALL and AML cells121 compared with the individual inhibitors. 
Phase 1 or 2 clinical trials have therefore been initiated to investigate the synergistic 
effects of combined inhibition of PI3K/PKB and Flt3 (NCT00819546) or c-Kit 
(NCT00762632). The occurrence of clinical resistance to STI-571 is a major problem 
Table 2. Combination regimens with single specificity inhibitors.
Target Compound Combination regimens Effects Leukemia Clinical trials 
(phase)
Reference(s)
In vitro In vivo
 PI3K
 
 
 Wortmannin ATRA (DA)
Imatinib (Bcr-Abl TKI)
+
+
-
-
 159
141
 LY294002
 
Apigenin (CK2 I)
ATRA (DA)
Imatinib (Bcr-Abl TKI)
Arsenic trioxide
+
+
+
+
-
-
-
-
 
 
160
159
141
161
 p110δ  IC87114 VP16 (CT) + -  145
CAL-101 Lenalidomide
CT & mAb CD20
Rituximab
+
+
+
-
-
-
CLL
CLL
NCT01088048 (I)
NCT01203930 (II)
99
PDK1
 
 
UCN-01
 
 
Ara-C (CT)
Cytarabine (CT)
Fludarabine (CT)
+
-
-
-
-
-
AML
AML and MDS
RRL
(II) 
NCT00004263 (I)
NCT00019838 (I)
146
OSU-03012 Imatinib (Bcr-Abl TKI) + - 140
PP2A Forskolin Idarubicine/Ara-C + -  162
PKB
 
 
 
 
 
Perifosine
 
 
 
UCN-01
HDAC I
TRAIL (AI)
Etoposide (CT
-
+
+
+
-
-
-
-
RRL
 
 
 
NCT00301938 (I)
130
163
103
 PIA CT + -  104
Triciribine Cytarabine (CT) + -  106
MK2206 Rituximab (mAb CD20)
Arsenic trioxide
-
+
-
-
CLL NCT01369849 (I/II)
161
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Table 2. Combination regimens with single specificity inhibitors. (continued)
Target Compound Combination regimens Effects Leukemia Clinical trials 
(phase)
Reference(s)
In vitro In vivo
mTOR
 
 
 
 
 
 
 
 
 
 
 
 
 
Rapamycin
 
 
 
 
 
 
 
 
 
UCN-01
3-BrOP (glycolysis I)
Imatinib (Bcr-Abl TKI)
Notch I
Erlotinib (EGFR-TKI)
Curcumin
Dexamethason
Etoposide (CT)
Decatibine (CT)
Aracytin (CT)
Methotrexate (CT)
Anthracyclin (CT)
Daunorubicine (CT)
CT
 
+
+
+
+
+
+
+
+
-
-
+
+
+
+
+
+
-
-
-
-
-
-
-
+
-
-
+
-
-
-
-
-
 
 
AML
AML
ALL and CLL
ALL and CML
AML
AML and CML
NCT00861874 (I)
NCT00235560 (II)
NCT01162551 (II)
NCT00776373 (I/II)
NCT01184898 (I/II)
NCT00780104 ( I/II)
122
164
139
165
166
167
168,169
144
111
170
171
152
152
152
 RAD001
 
 
 
 
 
 
 
 
IC87114
BAG956
Bortezomib (PI)
MS-275 (HDAC I)
PKC412 (Flt3 TKI)
Imatinib (Bcr-Abl TKI)
Nilotinib (c-Kit-TKI)
Alemtuzumab (mAb 
CD52)
ATRA (DA)
Ara-C (CT)
Vincristine (CT)
CT
+
+
+
+
-
+
+
-
-
+
+
+
-
-
-
+
-
+
-
-
-
-
-
+
-
+
-
-
 
 
 
 
AML and MDS
CML
CML
 AML
 CLL
AML
AML
NCT00819546 (I)
NCT00093639 (I/II)
NCT01188889 (I/II)
NCT00762632 (I/II)
NCT00935792 (I/II)
NCT00544999 (I)
NCT01154439 (I)
114
121
132
129
139
139
172
132,149
173
 CCI-779 Methotrexate (CT)
Clofarabine (CT)
STI-571 (Bcr-Abl TKI)
+
-
-
+
-
-
 
AML
CML
NCT00775593 (II)
NCT00101088 (I)
111
PP242 Vincristine (CT) + -   118
OSI-027 STI-571 (Bcr-Abl TKI) + - 119
GILZ STI-571 (Bcr-Abl TKI) + - 137
DA indicates differentiating agents; TKI, tyrosine kinase inhibitor; I, inhibitor; CT, chemotherapy; AI, apoptosis 
inducer; RRL, relapsed and refractory leukemia; and PI, proteasome inhibitor.
Table 3. Combination regimens with dual specificity inhibitors.
Target Compound Combination regimens Effects Clinical trials 
(phase)
Reference(s)
In vitro In vivo
PI3K/mTOR
 
 
PI-103
 
 
Nutlin-3 (MDM2-I)
STI-571 (Bcr-Abl-TKI)
Arsenic disulfide
Vincristine (CT)
Fludarabine (CT)
+
+
+
+
+
-
-
-
-
-
158
142
174
126
76
PI3K/mTOR NVP-BEZ235 CT + - 124
PI3K/PDK1
 
BAG956
 
STI-571 (Bcr-Abl-TKI)
Rapamycin / RAD-001
PKC412 (Flt3 TKI)
+
+
+
+
-
+
121
121
121
I indicates inhibitor; TKI, tyrosine kinase inhibitor; and CT, chemotherapy
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for CML patients. Although the most common mechanisms of induction of resistance 
are mutations or alterations in the Bcr-Abl gene133, a STI-571–induced compensatory 
PKB/mTor activation has also been described as a potential mechanism for the 
persistence of Bcr-Abl-positive cells in STI-571–treated patients134-136. A combination 
of pharmacologic compounds inhibiting the PI3K/PKB pathway and STI-571 has 
been shown to be effective in cells from STI-571–resistant CML patients119,121,137-142. 
Several phase 1 or 2 clinical trials have therefore been initiated to determine the 
effectiveness of such a combination therapy in STI-571–resistant CML patients 
(NCT01188889, NCT00093639, and NCT00101088).
Chemotherapy has been shown to be effective in a subset of patients. However, 
incomplete remission and the development of a refractory disease have been observed 
in many patients with acute leukemia143. To optimize treatment, chemotherapy 
could potentially be combined with specific pharmacologic inhibitors (Table 2). 
Coadministration of mTOR inhibitors with different types of chemotherapeutic 
drugs, including etoposide, Ara-C, cytarabine, and dexamethasone, has, for 
example, been demonstrated to induce synergistic anti–leukemia effects in cells 
from AML patients144 and ALL patients111,132. Several phase 1 or 2 clinical trials have 
therefore been initiated to investigate and optimize the synergistic effect of mTOR 
inhibitors and chemotherapeutic drugs in patients (NCT00544999, NCT01184898, 
NCT00780104, NCT01162551, and NCT00776373, NCT00861874, NCT00235560, 
and NCT01154439). In addition, synergistic effects have been observed in AML 
cells after coadministration of chemotherapeutic agents with IC87114145, UCN-01146, 
or triciribine106. Similar results were obtained in T-ALL cells when combining the 
dual-specificity inhibitors PI-103 and NVP-BEZ235 with chemotherapy124,126. Finally, 
inhibition of the activity of p110δ with CAL-101 was shown to be sufficient to 
abrogate lenalidomide-induced activation of primary CCL cells99. In addition to the 
clinical trials focusing on CAL-101 alone, the efficacy of a combination regimen with 
both CAL-101 and lenalidomide is therefore also under investigation in phase 1 or 2 
clinical trials (NCT01203930 and NCT0108848).
Future perspectives
During the last 2 decades, it has become clear that the PI3K/PKB signal transduction 
pathway plays an important role in both normal and malignant hematopoiesis. 
As discussed in “Derequlated P13K/PKB signaling in malignant hematopoiesis”, 
aberrant regulation of this signaling module has been observed in a large group 
of acute leukemias. Although mutations in PI3K, PKB, or the upstream regulators 
PTEN and SHIP1 have been detected in cells from patients with leukemia, these 
mutations appear to be rare. These mutations can therefore not account for the large 
incidence of constitutive activation of PI3K in patients with leukemia. In contrast, 
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several oncogenic fusion proteins and mutated tyrosine kinase receptors have been 
demonstrated to induce hematologic malignancies by constitutive activation of the 
PI3K/PKB signaling module. Because PI3K is frequently activated in leukemia and 
activation of this molecule is thought to correlate with poor prognosis and drug 
resistance, it is considered to be a promising target for therapy. A high number of 
pharmacologic inhibitors directed against both individual and multiple components 
of this pathway have already been developed to improve therapy. Although the 
single-specificity inhibitors do affect the survival of leukemic cells, their effect in 
patients appears to be modest. This can be explained by both inhibitor-induced 
abrogation of negative feedback loops and alternative mechanisms of activation 
of downstream effectors of PI3K/PKB. Although further research is required to 
examine the safety and efficacy of the dual-specificity inhibitors, these compounds 
appear to possess more promising anti–leukemic activities compared with single-
specificity inhibitors. In addition, to further optimize therapeutic regimens, research 
has focused on coadministration of inhibitors of the PI3K signaling module with 
either classic chemotherapy or inhibitors directed against other signal transduction 
molecules. The in vitro studies and mouse transplantation experiments described 
herein strongly suggest that both strategies could indeed be used to improve current 
therapeutic regimens in specific patient groups.
Inhibition of aberrantly regulated intracellular signal transduction pathways 
provides an important means to improve therapeutic regimens for patients with 
leukemia. Because the PI3K/PKB signaling pathway appears to be highly deregulated 
in a large number of patients with leukemia, this pathway is considered to be a 
promising target for therapy. Compared with targeting individual components of 
the PI3K/PKB signaling module alone, either abrogating this pathway at multiple 
levels using dual-specificity inhibitors or combining pathway specific inhibitors with 
classic regimens appears to be a more effective therapeutic strategy for patients with 
leukemia. Further research is therefore warranted to examine the safety and efficacy 
of these regimens in leukemia patients.
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ABSTRACT
Translocation t(12;21), resulting in the ETV6-RUNX1 (or TEL-AML1) fusion protein, 
is present in 25% of pediatric patients with B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) and is considered a first hit in leukemogenesis. A targeted 
therapy approach is not available for children with this subtype of leukemia. Here, 
we report an important role for autophagy in ETV6-RUNX1 positive BCP-ALL. To 
identify the molecular mechanisms underlying ETV6-RUNX1 driven leukemia, 
we performed gene expression profiling of healthy hematopoietic progenitors in 
which we ectopically expressed ETV6-RUNX1. We reveal an ETV6-RUNX1 driven 
transcriptional network that positively regulates proliferation, survival and cellular 
homeostasis. In addition, Vps34, an important regulator of autophagy, was found 
to be up-regulated in ETV6-RUNX1 positive BCP-ALL patient cells. We show that 
induction of Vps34 was transcriptionally regulated by ETV6-RUNX1 and correlated 
with high levels of autophagy. Knockdown of Vps34 in ETV6-RUNX1 positive 
cell lines severely reduced proliferation and survival. Inhibition of autophagy by 
hydroxychloroquine, a well-tolerated autophagy inhibitor, reduced cell viability in 
both BCP-ALL cell lines and primary patient-derived BCP-ALL cells and selectively 
sensitized primary ETV6-RUNX1 positive leukemic cells to L-asparaginase. These 
findings reveal a causal relationship between ETV6-RUNX1 and autophagy, and 
provide the first pre-clinical evidence for the efficacy of autophagy inhibitors in 
ETV6-RUNX1 driven leukemia.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. 
During the last decades, the overall survival rates of pediatric ALL have improved 
significantly1. This is primarily due to optimization of conventional chemotherapeutic 
drug regimens combined with risk-directed therapies1. However, to date, still 20% 
of pediatric ALL cases relapse because of resistance to therapy2,3. In addition, long-
term treatment-induced side effects remain considerable4,5. New treatment regimens 
increasingly aim to target specific intrinsic characteristics of leukemia. This approach 
has, for example, led to the successful development of BCR-ABL1 inhibitors6,7. 
Regrettably, such a targeted approach is not available for the majority of children 
suffering from leukemia.
Translocation t(12;21)(p13;q22), resulting in the ETV6-RUNX1 fusion protein 
(also known as TEL-AML1), is present in 25% of pediatric patients with B-cell 
precursor acute lymphoblastic leukemia (BCP-ALL) and is therewith the most 
common fusion protein in childhood cancer8-10. The t(12;21)(p13;q22) rearrangement 
fuses the 5’ non-DNA binding region of the ETS family transcription factor ETV6 
(TEL) to almost the entire RUNX1 (AML1) locus11. Despite the favorable prognosis 
associated with this cytogenetic type of BCP-ALL9,12,13, resistance to chemotherapeutic 
drugs and relapse occur in 10-20% of these patients13-18.
The ETV6-RUNX1 fusion protein induces a silent pre-leukemic clone that 
requires additional genetic hits for the transition to leukemia15,16,19-22. Although these 
pre-leukemic ETV6-RUNX1 positive hematopoietic stem cells (HSCs) still possess 
self-renewal properties and are capable of contributing to hematopoiesis, they fail to 
outcompete normal HSCs20,21,23. In ETV6-RUNX1 positive leukemia, this early genetic 
lesion is followed by a small number of ‘driver’ copy number alterations, which are 
predominantly directed to genes regulating normal B cell differentiation24,25. These 
alterations are acquired independently without preferential order, thereby generating 
a dynamic clonal architecture24. This genetic variation implies that targeted therapy 
in ETV6-RUNX1 driven ALL should be directed to targets of initial lesions that 
are present in all subclones. This concept is further supported by the observation 
that ETV6-RUNX1 positive cell lines are highly dependent on the expression of the 
fusion protein for their survival26,27. For the development of novel targeted therapies, 
it is important to identify the molecular pathways induced by expression of the 
ETV6-RUNX1 fusion protein. Previous reports revealed that enhanced levels of 
STAT3, heat-shock proteins, survivin, has-mir-125b-2, the erythropoietin receptor, 
and cytoskeleton regulatory genes and aberrant regulation of the TGFβ pathway 
are important for ETV6-RUNX1 positive BCP-ALL26,28-35. However, the complete 
molecular network underlying the persistence and maintenance of ETV6-RUNX1 
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BCP-ALL remains to be investigated. Additionally, to date, ETV6-RUNX1 positive 
cells cannot be selectively targeted or sensitized to conventional chemotherapy. 
In this study, we elucidate the transcriptional network regulated by the ETV6-
RUNX1 fusion protein and show that induction of autophagy is important for the 
survival and proliferation of ETV6-RUNX1 positive leukemic cells. Pharmacological 
inhibition of autophagy sensitized primary ETV6-RUNX1 positive cells to 
L-Asparaginase, one of the key chemotherapeutic drugs used in the treatment of 
childhood BCP-ALL. Herewith, we propose autophagy inhibition as a promising 
novel means to improve treatment for ETV6-RUNX1 positive ALL.
METHODS
Details are provided in the supplementary methods section.
Transduction and gene expression profiling of primary cells
CD34-positive hematopoietic progenitor cells (CB-CD34+ cells) were derived from 
cord blood and transduced with retrovirus expressing ETV6-RUNX1 and eGFP. 
DAPI- CD34+ GFP+ CB-CD34+ cells were sorted using a BD ARIA II sorter. After 
sorting, cells were lysed and RNA was extracted and subsequently linearly amplified. 
Bone marrow aspirates were obtained from children with newly diagnosed 
BCP-ALL prior to treatment. Leukemic blasts were collected and processed as 
previously described. 
Affymetrix GeneChip HG-U133-Plus-2.0 microarrays were used for all samples. 
Microarray data of CB-CD34+ cells are available in the ArrayExpress database under 
accession number E-MTAB-3466. Microarray data of BCP-ALL blasts are available in 
the Gene Expression Omnibus database.
Functional assays
For protein quantification, both western blot analysis as reverse phase protein arrays 
were used. Vps34 promoter activity was studied using a reporter construct consisting 
of a 1.4 kB region of the Vps34 promoter upstream of the Gaussia luciferase gene. 
Cell viability was quantified using MTT cytotoxicity assays or flow cytometry-
based Annexin V - Propidium Iodide assays. Silencing of genes was achieved using 
transfection of specific siRNAs or a lentiviral knockdown approach using the pLKO.1 
Mission vector containing a puromycin selection marker. Autophagy levels (number 
and volume of LC3B positive vesicles) were quantified using confocal scanning 
microscopy (Leica SP5). 
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Statistical analysis
Statistical analysis of microarray data of paired CB-CD34+ cells was performed 
using a linear mixed model. Microarray data of primary cells from ALL patients 
were analyzed using LIMMA. Functional analysis of differential gene expression 
was performed using QIAGEN’s Ingenuity Pathway Analysis. Both the Student’s 
t-test and the Student’s paired t-test were used as statistical test when applicable. 
Bar graphs represent the mean of biological replicates. Error bars represent standard 
error of the mean (S.E.M.).
RESULTS
Ectopic expression of ETV6-RUNX1 in healthy CD34+ progenitors activates 
pro-proliferative and pro-survival transcriptional networks  
In order to elucidate the molecular mechanisms underlying ETV6-RUNX1 driven 
BCP-ALL, we performed gene expression profiling on healthy, umbilical cord blood-
derived, CD34-positive hematopoietic progenitors (CB-CD34+) ectopically expressing 
the ETV6-RUNX1 fusion gene. To generate retrovirus, bicistronic retroviral DNA 
constructs were used co-expressing ETV6-RUNX1 and eGFP. CB-CD34+ cells were 
retrovirally transduced with ETV6-RUNX1-eGFP or an eGFP expressing control 
vector. Forty hours after transduction, eGFP-positive cells were sorted from the 
non-transduced cells by fluorescent activated cell sorting (n = 5, Figure 1A). RT-
PCR confirmed that the ETV6-RUNX1 fusion transcript was only expressed in the 
CB-CD34+ cells transduced with ETV6-RUNX1 (p ≤ 0.001; supplementary Figure 1C). 
Gene expression analysis revealed that 196 genes were differentially expressed in 
ETV6-RUNX1 transduced CB-CD34+ cells in comparison to empty vector controls (2 – 
40 fold; p ≤ 0.05; Figure 1B). Ingenuity Pathway Analysis on these 196 genes predicted 
an interacting gene network of 36 genes with direct or indirect relationships (Figure 
1C). One of these genes was CDKN1A (p21), a previously described ETV6-RUNX1 
target gene36. Other genes that were strongly upregulated are the transcription factors 
GATA1, GATA2, HEY1 and EGR1, and the growth factors IL8 and CSF1 (Figure 1C). 
Analysis of gene ontology (GO) functional categories indicated that ETV6-RUNX1 
induces a pro-survival and pro-proliferative phenotype (Figure 1D, E; supplementary 
Figure 2A, B). In addition, both an increase in cellular homeostasis (supplementary 
Figure 2B), and regulation of the cytoskeleton was predicted (data not shown). These 
data provide a better insight into the effects of the ETV6-RUNX1 fusion protein in 
healthy progenitors, and reveal a transcriptional network that activates proliferation 
and inhibits apoptosis. 
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Figure 1. Ectopic expression of ETV6-RUNX1 in healthy CD34+ progenitors activates pro-prolifer-
ative and pro-survival transcriptional networks.
CD34-positive hematopoietic progenitors (CB-CD34+ cells) were isolated from cord blood, upon which cells were 
divided in two fractions. One fraction was transduced with ETV6-RUNX1-IRES-eGFP, while the other fraction was 
transduced with control EV-IRES-eGFP (n = 5 biological replicates). Forty hours after transduction, CD34+ DAPI- 
eGFP+ hematopoietic progenitors were sorted from non-transduced cells (for gating strategy see supplementary 
Figure 1). After sorting, RNA was extracted, checked for quality and linearly amplifi ed. Gene expression analysis 
was subsequently performed using Aff ymetrix Genechip microarrays.
(A) Flowchart of the experimental approach.
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Vps34 is up-regulated in ETV6-RUNX1 positive BCP-ALL and is driven by the 
ETV6-RUNX1 fusion protein
To identify novel ETV6-RUNX1 target genes, the above-described ETV6-RUNX1 
induced gene expression profiles in CB-CD34+ cells were compared with gene 
expression profiles of primary ALL cells. For this analysis, we used data from cohorts 
in which ETV6-RUNX1 positive BCP-ALL patients were included36-40 and data from 
an ETV6-RUNX1 knockdown study performed in a leukemic cell line41 (Figure 2A). 
Pathway analysis on differentially expressed genes (top 500, see supplementary 
Table 1) in the largest patient cohort (Erasmus MC cohort, 654 ALL patients including 
172 ETV6-RUNX1 positive BCP-ALL patients and 401 ETV6-RUNX1 negative 
BCP-ALL patients42) revealed a pro-survival and pro-proliferative phenotype in 
ETV6-RUNX1-positive patient cells, similar to the phenotype predicted in CB-CD34+ 
cells ectopically expressing ETV6-RUNX1 (Figure 2F). The class III PI3-kinase Vps34 
(PIK3C3) was found to be recurrently upregulated in ETV6-RUNX1 positive ALL 
patient cells (Figure 2A-C; 2.7-fold higher expression in Erasmus MC cohort, FDR-
adjusted p = 7.24E-39). 
To determine the direct effect of the ETV6-RUNX1 fusion protein on Vps34 
expression, ETV6-RUNX1 was ectopically expressed in CB-CD34+ cells. Forty hours 
after transduction, Vps34 mRNA expression was significantly up-regulated by 
1.3-fold (Figure 2D; p = 0.03), confirming the induction of Vps34 by the ETV6-RUNX1 
fusion protein. Reciprocal experiments were performed in ETV6-RUNX1 positive 
cells (REH cell line and ETV6-RUNX1 transduced CB-CD34+ cells) using siRNAs 
directed to the ETV6-RUNX1 breakpoint. Although the ETV6-RUNX1 mRNA levels 
could only be reduced by 30-35% (supplementary Figure 3B; p ≤ 0.05), this reduction 
was sufficient to significantly reduce the levels of Vps34 mRNA and protein both by 
approximately 40% (Figure 2E; p ≤ 0.05). 
Figure 1. Ectopic expression of ETV6-RUNX1 in healthy CD34+ progenitors activates pro-prolifer-
ative and pro-survival transcriptional networks. (continued)
(B) Heat map displaying gene probe sets that were either over-expressed (in red) or under-expressed (in blue) 
in comparison to the mean expression of all probe sets. Forty hours after transduction, 196 gene probe sets were 
significantly (p ≤ 0.05; FDR-adjusted) over-expressed or under-expressed in ETV6-RUNX1 positive CB-CD34+ cells 
in comparison to control CB-CD34+ cells. Data were analyzed using a linear mixed model. Genes were consid-
ered differentially expressed when p ≤ 0.05 after multiple testing correction using false discovery rate (FDR). (C) 
Ingenuity pathway analysis of the differentially expressed genes was performed to elucidate the interconnected 
transcriptional network present within this gene set. The level of up- (red) and down-regulation (blue) of genes 
was visualized by the intensity of the colors. Direct relationships were marked with undotted arrows. Indirect rela-
tionships were marked with dotted arrows. (D/E) Ingenuity pathway analysis was used to analyze gene ontology 
(GO) functional categories and activation of disease/function annotation based on current literature. Functional 
categories inducing a pro-survival (D) or a pro-proliferative (E) state in ETV6-RUNX1 positive HPCs and the dif-
ferentially regulated genes responsible for this prediction are shown.
See also supplementary Figure 1 and 2.
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Figure 2. Vps34 is recurrently up-regulated in ETV6-RUNX1 positive BCP-ALL and is driven by 
the ETV6-RUNX1 fusion protein.
(A) We compared gene expression levels in ETV6-RUNX1 positive ALL cells with gene expression levels in ETV6-
RUNX1 negative ALL cells. We used 5 cohorts in which ETV6-RUNX1 positive BCP-ALL patients were included 
and gene expression data were publically available. In addition, we analyzed differential gene expression in an 
ETV6-RUNX1 knockdown study performed in an ETV6-RUNX1 positive leukemic cell line. (B) 2log expression 
levels of the gene probe set mapped to Vps34 were analyzed in a cohort of 132 pediatric ALL patients published by 
Yeoh et al.36. Gene expression of ETV6-RUNX1 positive patients (green bar) was compared to gene expression of 
all other B-ALL patients (excluding T-ALL): *** FDR-adjusted p = 3.45*10-15. (C) 2log expression levels of the gene 
probe set mapped to Vps34 were analyzed in a cohort of 653 pediatric ALL patients published by Van der Veer et 
al.42. Gene expression of ETV6-RUNX1 positive patients (green bar) was compared to gene expression of all other 
B-ALL patients (excluding T-ALL). Grey dashed line represents mean expression of all patients: *** FDR-adjusted 
p = 7.24*10-39.
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ETV6-RUNX1 and ETV6-RUNX1 target genes enhance Vps34 promoter activity
The up-regulation of Vps34 expression in ETV6-RUNX1 positive BCP-ALL patients 
and ETV6-RUNX1 transduced CB-CD34+ cells, suggests that the Vps34 promoter is 
activated directly or indirectly by ETV6-RUNX1. Analysis of the Vps34 promoter, 
using publically available ChIP-seq data, revealed that transcription factors known 
to play an important role in regulation of hematopoiesis, including GATA1, GATA2, 
EGR1 and HEY143-47, can interact with the Vps34 promoter (Figure 3A). Four of these 
transcription factors, namely GATA1, GATA2, EGR1 and HEY1, were also found to 
be upregulated in ETV6-RUNX1 transduced CB-CD34+ cells (Figure 1C, Figure 3B). 
The mRNA expression levels of these four genes were modestly increased in ETV6-
RUNX1 transduced CB-CD34+ cells 20 hours after transduction and significantly 
up-regulated after 40 hours: GATA1, GATA2, EGR1, and HEY1 were up-regulated 
3.8-fold (p = 0.046) 2.2-fold (p = 0.019), 5.0-fold (p = 0.004), and 24.9-fold (p = 0.015), 
respectively (Figure 3B). 
To investigate the role of ETV6-RUNX1 and the transcription factors GATA1, 
GATA2, EGR1, and HEY1 in regulation of the activity of the Vps34 promoter, 
luciferase reporter assays were performed using a reporter construct consisting of 
the Gaussia luciferase gene downstream of a 1.4 kB region (-1383 to +58) of the Vps34 
promoter (Figure 3C). Although RUNX1 expression alone was sufficient to induce 
Vps34 promoter activity (2.4-fold compared to control, p ≤ 0.01), co-expression of 
its cofactor CBFβ further enhanced Vps34 promoter activity (4.5-fold compared to 
control, p ≤ 0.05). Similarly, expression of ETV6-RUNX1 was sufficient to induce 
Vps34 promoter activity (4.2-fold compared to control, p ≤ 0.05), and luciferase 
expression was further enhanced by co-expression of CBFβ (13-fold compared to 
control, p ≤ 0.05). These results demonstrate that, although both RUNX1 and ETV6-
Figure 2. Vps34 is recurrently up-regulated in ETV6-RUNX1 positive BCP-ALL and is driven by 
the ETV6-RUNX1 fusion protein. (continued)
(D) CB-CD34+ cells were transduced with ETV6-RUNX1-IRES-eGFP or with control EV-IRES-eGFP after which 
eGFP+ cells were sorted and Vps34 mRNA levels were determined by Q-PCR and normalized to HPRT. Grey bars 
represent the mean of 5 biological replicates. Gene expression of Vps34 was compared between ETV6-RUNX1+ CB-
CD34+ cells and EV-control CB-CD34+ cells (n = 5; p = 0.03). (E) ETV6-RUNX1 positive cells were transfected with 
siRNAs directed to the ETV6-RUNX1 breakpoint or scrambled control siRNAs. Vps34 mRNA levels were deter-
mined in ETV6-RUNX1+ cells (REH (n=2) and ETV6-RUNX1 transduced CB-CD34+ cells (n=2)) by Q-PCR, normal-
ized to HPRT, and compared to the average expression of cells transfected with scrambled control siRNAs (n = 3, p 
≤ 0.001). Vps34 protein expression was quantified in REH cells by western blot and compared to protein expression 
of REH cells transfected with scrambled control siRNAs (n = 2, p ≤ 0.05 and p ≤ 0.01 for siRNA#1 and siRNA#5 
respectively). Bars represent mean. Error bars represent S.E.M. (F) Ingenuity pathway analysis was used to analyze 
gene ontology (GO) functional categories and activation of disease/function annotation based on current literature. 
Table shows annotations that were similarly activated in ETV6-RUNX1 positive BCP-ALL patients and ETV6-
RUNX1 positive CB-CD34+ cells (40 hours after transduction). The top 500 differentially expressed genes between 
ETV6-RUNX1 positive and EVT6-RUNX1 negative patients in the Erasmus MC cohort were used for this analysis.
See also supplementary Figure 3.
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Figure 3. ETV6-RUNX1 and ETV6-RUNX1 target genes enhance Vps34 promoter activity.
(A) The UCSC genome browser (GRCh37/hg19) was used to analyze the transcription factors that bind to the Vps34 
promoter. Several transcription factors known to play an important role in regulation of hematopoiesis were found 
to be interacting with this promoter region. Using publically available ChIP-seq data, the interaction of the tran-
scription factors RUNX1, GATA1, GATA2, EGR1 and HEY1 with the Vps34 promoter is shown. (B) Umbilical cord 
blood-derived CD34+ cells were retrovirally transduced to ectopically express the ETV6-RUNX1 fusion protein. 
Gene expression analysis was performed 20 and 40 hours after transduction. 
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RUNX1 function as transcriptional activators of Vps34, ETV6-RUNX1 induces Vps34 
promoter activity more efficiently (Figure 3C). In addition, these results demonstrate 
that CBFβ acts as a co-activator for both RUNX1 and ETV6-RUNX1 in inducing 
Vps34 promoter activity. 
Additional luciferase reporter assays revealed that the ETV6-RUNX1 target 
genes HEY1, EGR1 and GATA1 induce Vps34 promoter activity in a dose-dependent 
manner. HEY1, EGR1, and GATA1 induced Vps34 promoter activity up to 13-fold 
(p ≤ 0.05), 5.0-fold (p ≤ 0.001), and 10-fold (p ≤ 0.05), respectively (Figure 3C). GATA2 
expression did not induce luciferase expression, which was in concordance with the 
absence of a GATA2 DNA binding domain in the -1338/+58 promoter region used for 
the reported assays (Figure 3A and 3C). Together, these results demonstrate that the 
Vps34 promoter is not only positively regulated by the ETV6-RUNX1 fusion protein 
itself, but also by its target genes HEY1, EGR1 and GATA1 (Figure 3D). 
Autophagy levels are high in ETV6-RUNX1 positive BCP-ALL and regulated by 
ETV6-RUNX1 and Vps34
The class III PI3-kinase Vps34 is known to be a key player in regulation of autophagy 
48-51.  We hypothesized that ETV6-RUNX1-mediated up-regulation of Vps34 induces 
autophagy in BCP-ALL cells. To investigate this, autophagy levels were determined 
in ALL cell lines and BCP-ALL primary patient cells by western blot analysis and 
Reverse Phase Protein Arrays (RPPA). Western blot analysis in a panel of ALL cell 
lines, revealed that Vps34 protein levels are the highest in the ETV6-RUNX1 positive 
cell line REH (Figure 4A). In comparison to ETV6-RUNX1 negative ALL cell lines, 
lower levels of p62 (SQSTM1) and LC3B, both specifically degraded by autophagy, 
were observed in REH cells. These results are in concordance with high levels of 
autophagy in REH cells (Figure 4A). RPPA on samples from a large cohort of newly 
diagnosed BCP-ALL patients revealed that the level of Vps34 was 9.6-fold higher 
in BCP-ALL cells compared to healthy bone marrow derived mononuclear cells 
(59 BCP-ALL patients versus 10 healthy controls, p ≤ 0.001). Vps34 levels were also 
Figure 3. ETV6-RUNX1 and ETV6-RUNX1 target genes enhance Vps34 promoter activity. (con-
tinued)
For flow chart; see left panel. The gene expression levels of GATA1, GATA2, EGR1 and HEY1 are shown. P-values 
represent the differences between ETV6-RUNX1 positive (green bars) compared to ETV6-RUNX1 negative (white 
bars) CB-CD34+ cells (FDR-adjusted). (C) Upper panel: schematic representation of the -1383 to +58 region of the 
Vps34 promoter cloned upstream of the Gaussia luciferase gene. Bar graphs: HEK293T cells were co-transfect-
ed with a Vps34 promoter construct, RUNX1 and/or CBFβ (left panel), increasing concentrations of GATA1 and 
GATA2 (middle panel) or HEY1 and EGR1 (right panel) expression constructs. Luciferase activity was determined 
48 hours after transfection. eGFP expression was quantified in each sample by flow cytometric analysis and used 
to normalize luciferase activity. Data were depicted as fold induction compared to empty vector controls. Error 
bars represent SEM. * p ≤  0.05, ** p ≤ 0.01, *** p ≤ 0.001. (D) Proposed model for activation of the Vps34 promoter 
by ETV6-RUNX1 and its downstream targets.
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signifi cantly higher in ETV6-RUNX1 positive patient cells in comparison to ETV6-
RUNX1 negative BCP-ALL (B-Other) patient cells (1.2-fold, p ≤ 0.05). In line with 
this, lower p62 protein levels were observed in ETV6-RUNX1 positive in comparison 
to ETV6-RUNX1 negative BCP-ALL patient cells (1.4-fold, p ≤ 0.01; Figure 4B). These 
RPPA data were confi rmed by western blot in a smaller set of patients (supplementary 
Figure 4A, B)
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Figure 4. Autophagy levels are high in ETV6-RUNX1 positive BCP-ALL and regulated by 
ETV6-RUNX1 and Vps34.
(A) Western blot analysis was performed to determine the expression levels Vps34, p62 (sequestosome 1), and LC3B 
in ALL cell lines. PIK3R4 was used as a loading control.
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An siRNA approach was used to investigate whether ETV6-RUNX1 regulates 
autophagy. To quantify the level of autophagy, the number and volume of LC3B-
positive vesicles were calculated per cell with a 3D object analyzer using Huygens 
Professional software (Figure 4C). Knockdown of ETV6-RUNX1 resulted in a 45% 
reduction in the number of LC3B-positive vesicles and 50% reduction in the volume 
of LC3B-positive vesicles per cell (p ≤ 0.001 and p ≤ 0.05, respectively; Figure 4D-F). 
In addition, knockdown of Vps34 reduced the number of LC3B-positive vesicles 
and the volume of LC3B-positive vesicles with 79% (p ≤ 0.001) and 84% (p ≤ 0.05), 
respectively (Figure 4D-4F). These results show that autophagy levels are high in 
ETV6-RUNX1 positive BCP-ALL cells. In addition, both ETV6-RUNX1 and Vps34 
are essential for maintaining high levels of autophagy in ETV6-RUNX1-positive 
leukemic cells. 
Vps34 is essential for the survival of ETV6-RUNX1 positive leukemic cells
To determine the functional role of Vps34 in ETV6-RUNX1 positive leukemic cells, 
lentiviral knockdown studies were performed in two ETV6-RUNX1 positive cell lines 
(REH and REHS1). For these studies, four independent short hairpin RNAs were 
used. Short hairpins shVps34#1 and shVps34#2 were directed against the main Vps34 
transcript variants, whereas shVps34#3 and shVps34#4 were directed against the two 
full length transcript variants only (Figure 5A and supplementary Figure 5A). Vps34 
knockdown of at least 80% was achieved with all four individual shRNAs (Figure 
5B, C and supplementary Figure 5B). Knockdown of only the full-length Vps34 
transcript variants with shVps34#3 and shVps34#4 significantly reduced proliferation 
of the ETV6-RUNX1-positive cell lines REH and REHS1 (p ≤ 0.01, supplementary 
Figure 5C, D). Knockdown of all main Vps34 transcript variants with shVps34#1 
and shVps34#2 resulted in a complete growth arrest of these ETV6-RUNX1 positive 
Figure 4. Autophagy levels are high in ETV6-RUNX1 positive BCP-ALL and regulated by 
ETV6-RUNX1 and Vps34. (continued)
(B) Quantification of protein levels of Vps34 and p62 measured by reverse phase protein array (RPPA) in 10 normal 
bone marrow samples (nBM), 30 ETV6-RUNX1 positive primary BCP-ALL patient samples (ETV6-RUNX1+), and 
29 B-Other primary BCP-ALL patient samples (BO). Data are means ± S.E.M.; * p ≤  0.05, ** p ≤ 0.01, *** p ≤ 0.001.
(C) Representative confocal images of REH cells after permeabilization and staining with DAPI and LC3B an-
tibody. Z-stacks were deconvolved using Huygens Professional software, after which number and volume of 
LC3B-positive vesicles could be quantified. (D) Representative confocal images showing LC3B-positive vesicles 
in ETV6-RUNX1 positive BCP-ALL cell line REH. Left panels show an overlay of LC3B expression and DAPI 
staining (nuclear staining). Middle panels show only LC3B expression. Right panel shows 3D representations after 
deconvolution of the 488nm signal representing the LC3B expression. For the quantification of number and volume 
of LC3B-positive vesicles, we excluded cells with atypical nuclei. Upper panels represent control conditions after 
transfection with scrambled siRNAs. Lower 6 panels represent conditions after transfection with siRNAs against 
ETV6-RUNX1 or Vps34.  (E) Quantification of the number of LC3B-positive vesicles after 3D deconvolution of im-
ages (n = 3, *** p ≤ 0.001). (F) Quantification of the number of LC3B-positive vesicles multiplied by the volume of 
these vesicles after 3D deconvolution of images (n = 3, * p ≤ 0.05).
See also supplementary Figure 4.
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Figure 5. Vps34 is essential for the survival of ETV6-RUNX1 positive leukemic cells.
(A) Schematic representation of the known transcript variants of Vps34 (Ensembl Genome Browser; 
ENSG00000078142) and the shVps34#1 and shVps34#2 recognitions sites. (B) ETV6-RUNX1 positive (REH) BCP-
ALL cells were lentivirally transduced with scrambled shRNA control, or two distinct shRNA constructs to silence 
Vps34 expression. 
Autophagy drives ETV6-RUNX1 positive leukemia 81
3
cell lines (p ≤ 0.001; Figure 5D, E). In contrast, knockdown of either all main Vps34 
transcript variants or the full-length Vps34 transcripts in ETV6-RUNX1 negative 
NALM6 cells decreased proliferation to a lesser extent (p ≤ 0.001; Figure 5D, E).
To investigate whether the observed growth arrest in ETV6-RUNX1 positive 
cells was due to a block in cell cycle progression or enhanced apoptosis, flow 
cytometric analysis was performed using DyeCycle and Annexin V. Cell cycle 
analysis revealed that knockdown of Vps34 modestly reduces the percentage of 
cycling ETV6-RUNX1 positive cells (Figure 5F, G and supplementary Figure 5E). In 
contrast, a remarkable reduction in survival was observed upon Vps34 knockdown. 
While shRNA mediated knockdown of the full length Vps34 transcript variants 
in ETV6-RUNX1 positive cells (shRNA#3 & shRNA#4) already resulted in 40-50% 
apoptotic cells (supplementary Figure 5F), targeting of all main Vps34 transcript 
variants resulted in even higher levels of apoptosis (80-90%, p<0.01; Figure 5F, H).
In conclusion, knockdown of Vps34 completely arrests cell growth of ETV6-
RUNX1 positive cells by modestly reducing cell cycle progression and strongly 
inducing apoptosis. Although Vps34 knockdown also affects cell cycle progression 
and survival in ETV6-RUNX1 negative cells (data not shown), these cells were still 
able to proliferate.
ETV6-RUNX1 positive ALL cells are relatively sensitive to hydroxychloroquine
To date, no agents are clinically available that specifically inhibit Vps34 activity. 
However, the efficacy of autophagy inhibitors is currently examined in clinical cancer 
treatment trials. To investigate the effect of autophagy inhibition on ETV6-RUNX1 
positive leukemia, we exposed leukemic cells to hydroxychloroquine (HCQ). This 
agent has favorable pharmacological properties and is safely used for decades in 
Figure 5. Vps34 is essential for the survival of ETV6-RUNX1 positive leukemic cells. (continued)
Western blot analysis was performed with an antibody against Vps34 or β-actin to visualize the knockdown of 
Vps34 in REH cells. A representative experiment is shown in which increasing concentrations of virus were used 
to emphasize the specificity of Vps34 knockdown. (C) Data were quantified and depicted as the relative Vps34 
expression in comparison to the expression in cells transduced with scrambled (non-silencing) controls. (D-E) 
ETV6-RUNX1 positive (REH and REHS1) and ETV6-RUNX1 negative (NALM6) BCP-ALL cells were lentivirally 
transduced with scrambled shRNA control (NSC) or two distinct Vps34 shRNA constructs. NI represents non-
infected cells. Cells were cultured for 18 days. To determine the effect on proliferation, cell counts were performed 
every 2-3 days. Representative graphs are shown in (D). The average increase in cell numbers per day is shown in 
(E). T-test was performed to compare control conditions (NSC) with Vps34 knockdown conditions (n = 3, ** p ≤ 0.01, 
*** p ≤ 0.001). Error bars represent S.E.M. (F-H) ETV6-RUNX1 positive (REH) BCP-ALL cells were lentivirally trans-
duced with scrambled shRNA control (NSC) or two distinct shRNA constructs to silence Vps34 expression. After 7 
days of culture, flow cytometrical analysis was performed to determine the effect of Vps34 knockdown on survival 
and cell cycle progression. Representative FACS plots are shown (n = 3).  (G) The percentage of viable (AnnexinV 
positive, Propidium Iodide negative), actively cycling cells was determined using DyeCycle. Data were depicted as 
the percentage of cells in S, G2 M phase (n = 2, * p ≤ 0.05). Error bars represent S.E.M. (H) The percentages of early 
apoptotic (AnnexinV positive, Propidium Iodide negative) and late apoptotic (Propidium Iodide positive) cells 
were determined 7 days after transduction (n = 2, ** p ≤ 0.01, *** p ≤ 0.001). Error bars represent S.E.M.
See also supplementary Figure 5.
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the treatment of malaria and rheumatoid arthritis42. HCQ accumulates within and 
de-acidifi es the lysosome, resulting in increased LC3B-II levels, which is indicative of 
impaired autophagy (Figure 6A). MTT assays were performed to determine the eff ect 
of HCQ on cell viability of ETV6-RUNX1 positive and ETV6-RUNX1 negative ALL 
cell lines (Figure 6B, C and supplementary Figure 6A, B).  While treatment with 20 
μg/ml HCQ resulted in 82% and 95% reduced cell viability of ETV6-RUNX1 positive 
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Figure 6. ETV6-RUNX1 positive ALL cells are relatively sensitive to treatment with hydroxychlo-
roquine.
(A) ETV6-RUNX1 positive (REH and REHS1) and ETV6-RUNX1 negative (NALM6) BCP-ALL cells were cultured 
in absence or presence of HCQ (6.25 μg/ml) for 48 hours. Western blot analysis was performed using an antibody 
against LC3B to determine the eff ectivity of HCQ treatment. (B) ETV6-RUNX1 positive BCP-ALL, ETV6-RUNX1 
negative BCP-ALL, and T-ALL cell lines were cultured in absence or presence of HCQ (20 μg/ml) for 4 days. 
An MTT assay was performed to determine the eff ect of HCQ treatment on the viability of the cells. Data were 
depicted as the percentage of viable cells compared to untreated control. Error bars represent S.E.M. (n=3). (C) 
ETV6-RUNX1 positive BCP-ALL, ETV6-RUNX1 negative BCP-ALL, and T-ALL cell lines were cultured in absence 
or presence of increasing concentrations of HCQ for 4 days. An MTT assay was performed to determine the eff ect 
of HCQ treatment on the viability of the cells. A representative experiment is shown in which data were depicted 
as the percentage of viable cells. (D) Primary ETV6-RUNX1 positive BCP-ALL cells were cultured in absence or 
presence of 5 or 10 μg/ml HCQ for 5 days. Flow cytometric analysis was performed to determine the percentage of 
non-apoptotic (Annexin V negative, Propidium Iodide negative, CD19 positive) cells. Representative FACS plots 
are shown (n = 5). (E) Co-culture experiments were performed with primary ETV6-RUNX1 positive BCP-ALL cells 
and mesenchymal stromal cells (MSCs). Cells were cultured in absence or presence of increasing concentrations 
of HCQ for 5 days. Flow cytometrical analysis was performed to determine the percentage of non-apoptotic (An-
nexin V negative, Propidium Iodide negative, CD19 positive) cells. Data were depicted as the relative reduction in 
survival compared to untreated cells (n = 6 for HCQ 5 μg/ml and HCQ 10 μg/ml; n = 4 for HCQ 20 μg/ml). Error 
bars represent S.E.M. * p ≤ 0.05, ** p ≤ 0.01.
See also supplementary Figure 6.
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BCP-ALL cell lines (REH and REHS1), the viability of ETV6-RUNX1 negative cell 
lines was reduced to a lesser extent (NALM6: 43%, TOM1: 50%, Loucy: 40%, Jurkat: 
0%; Figure 6B). The IC50 of HCQ was significantly lower in ETV6-RUNX1 positive 
ALL cell lines compared to ETV6-RUNX1 negative cell lines (p ≤ 0.001; Figure 6C 
and supplementary Figure 6B). In addition, the effect of HCQ on the survival of 
primary BCP-ALL cells was determined. Primary BCP-ALL cells were cultured for 
5 days upon which flow cytometric analysis was performed (for flow cytometric 
gating strategy see supplementary Figure 6C). Survival of primary ETV6-RUNX1 
positive BCP-ALL cells was significantly reduced after treatment with 10 μg/ml HCQ 
(26%, p ≤ 0.05; Figure 6D, E). In contrast, this treatment did not affect cell viability 
of primary ETV6-RUNX1 negative BCP-ALL cells (supplementary Figure 6D). The 
survival of primary ETV6-RUNX1 positive ALL cells was even further reduced after 
treatment with 20 μg/ml HCQ (79%, p ≤ 0.01; Figure 6E). Co-culture of these ALL 
cells in the presence of primary bone marrow-derived mesenchymal stromal cells 
(MSCs) significantly rescued the HCQ-mediated induction of apoptosis in primary 
ETV6-RUNX1 positive ALL cells (p ≤ 0.05; Figure 6E). These results demonstrate 
that although ETV6-RUNX1 positive BCP-ALL cells are relatively sensitive to HCQ 
treatment, this sensitivity is abrogated by primary MSCs.
Autophagy inhibition sensitizes ETV6-RUNX1 positive ALL cells to 
L-Asparaginase
As our results indicate that inhibition of autophagy reduces survival of ETV6-RUNX1 
positive ALL cells, we investigated whether HCQ-mediated inhibition of autophagy 
could sensitize primary BCP-ALL cells to commonly used chemotherapeutics. To 
investigate the potential of HCQ treatment in sensitization to chemotherapeutics, the 
percentage of apoptotic cells was determined by flow cytometry after 5-days of culture 
either in absence or presence of IC50 values of the chemotherapeutic drug. Our results 
indicate that HCQ treatment (in clinically relevant concentrations52,53) selectively 
sensitizes ETV6-RUNX1 positive leukemic cells to L-Asparaginase treatment (Figure 
7A, B and supplementary Figure 7A). Treatment of primary ETV6-RUNX1 positive 
ALL patient cells with 5 μg/mL or 10 μg/mL HCQ resulted in a 48% and 71% reduction 
in cell survival during L-Asparaginase exposure, respectively (n = 5, p ≤ 0.01 and p ≤ 
0.001; Figure 7B), while ETV6-RUNX1 negative BCP-ALL cells were not sensitized to 
L-Asparaginase (n = 3; Figure 7B, supplementary Figure 7D). Co-culture of primary 
BCP-ALL cells with primary MSCs significantly reversed the HCQ-mediated 
sensitization to L-Asparaginase (p ≤ 0.01, Figure 7C). To investigate whether these 
primary cells could still be sensitized, similar experiments were performed with a 
higher dose of HCQ (20 μg/mL). Inhibition of autophagy with 20 μg/mL HCQ was 
indeed sufficient to significantly sensitize primary ETV6-RUNX1 positive BCP-ALL 
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Figure 7. Autophagy inhibition sensitizes ETV6-RUNX1 positive ALL cells to L-Asparaginase.
(A) Primary ETV6-RUNX1 positive BCP-ALL cells were cultured in absence or presence of IC-50 concentrations 
of L-Asparaginase and increasing concentrations of HCQ. Flow cytometric analysis was performed to determine 
the percentage of non-apoptotic (Annexin V negative, Propidium Iodide negative, CD19 positive) cells (for gating 
strategy see supplementary Fig. 6C). The survival of primary leukemic blasts in presence of L-Asparaginase was 
compared to their survival in absence of L-Asparaginase. White bars represent the relative survival in absence of 
HCQ. Grey bars represent the relative survival in presence of HCQ (5 μg/ml HCQ (light grey) and 10 μg/ml HCQ 
(grey)). (B) Averages of data presented in (a), representing sensitization of primary leukemic blasts by HCQ to L-
Asparaginase (n = 5 for ETV6-RUNX1 positive; n = 3 for ETV6-RUNX1 negative primary patient cells, * p ≤ 0.05, ** 
p ≤ 0.01). Error bars represent S.E.M. (C-D) Co-culture experiments were performed with primary ETV6-RUNX1 
positive BCP-ALL cells and MSCs. Cells were cultured in presence or absence of L-Asparaginase and increasing 
concentrations of HCQ. Flow cytometric analysis was performed to determine the percentage of non-apoptotic 
(Annexin V negative, Propidium Iodide negative, CD19 positive) cells. First, the survival of primary leukemic 
blasts in presence of L-Asparaginase was compared to their survival in absence of L-Asparaginase. Next, data was 
depicted as fold reduction compared to HCQ-untreated controls (n = 5 for conditions in absence of MSCs, n = 7 for 
conditions in presence of MSCs for (C), n = 3 for conditions in absence of MSCs, n = 4 for conditions in presence of 
MSCs for (D)). Error bars represent S.E.M.
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cells to L-Asparaginase both in absence or presence of primary MSCs (80% reduced 
survival, p ≤ 0.05 and p ≤ 0.01 respectively; Figure 7D and supplementary Figure 
7B, C). In contrast to L-Asparaginase, HCQ did not significantly induce apoptosis 
of primary BCP-ALL cells upon treatment with prednisolone or 6-mercaptopurine 
(Figure 7E, F).
These data show that HCQ-mediated inhibition of autophagy results in 
sensitization of ETV6-RUNX1 positive BCP-ALL cells, but not ETV6-RUNX1 
negative BCP-ALL cells, to L-Asparaginase.
DISCUSSION
In this study, we show that the ETV6-RUNX1 fusion gene induces a transcriptional 
network regulating pre-leukemic features in hematopoietic progenitors. We show 
that this network facilitates the induction of autophagy by up-regulating Vps34 
expression in ETV6-RUNX1 positive BCP-ALL (Figure 8). Additionally, our data 
show for the first time that inhibition of autophagy is a promising strategy for 
sensitization of ETV6-RUNX1 positive BCP-ALL cells to the important anti-leukemic 
agent L-Asparaginase. 
The importance of the ETV6-RUNX1 fusion protein for modulation of 
proliferation, survival and cell cycle distribution has already been shown in 
cell lines27,29,41 and mouse models19,54. Similarly, expression of the ETV6-RUNX1 
fusion gene induces survival properties in human cord blood-derived progenitors 
transplanted in NOD/SCID mice or co-cultured in presence of murine MS-5 stromal 
cells20,34,55. However, to date, the downstream effectors of this pro-survival and 
pro-proliferative phenotype have not been elucidated. In this study, we uncovered 
the transcriptional network regulating these phenotypes in a human progenitor 
population by analyzing the gene expression profile after ectopic expression of 
ETV6-RUNX1. This approach allowed us to examine early effects of ETV6-RUNX1 
expression in human hematopoietic progenitors. These data therefore provide a 
comprehensive and functional list of ETV6-RUNX1 target genes (supplementary 
Figure 7. Autophagy inhibition sensitizes ETV6-RUNX1 positive ALL cells to L-Asparaginase. 
(continue)
(E-F) Co-culture experiments were performed with primary ETV6-RUNX1 positive BCP-ALL cells and MSCs. Cells 
were cultured in presence or absence of Prednisolone (E) or 6-Mercaptopurine (F) and increasing concentrations of 
HCQ. Flow cytometric analysis was performed to determine the percentage of non-apoptotic (Annexin V negative, 
Propidium Iodide negative, CD19 positive) cells. The survival of primary leukemic blasts in presence of Predniso-
lone (E) of 6-Mercaptopurine (F) was compared to their survival in absence of these drugs. Next, data was depicted 
as fold reduction compared to HCQ-untreated controls (n = 5 for conditions in absence of MSCs, n = 7 for condi-
tions in presence of MSCs for (E), n = 4 for conditions in absence of MSCs, n = 4 for conditions in presence of MSCs 
for (F)). Error bars represent S.E.M.
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Table 2). In addition to a pro-survival and pro-proliferative phenotype, genes involved 
in cytoskeleton rearrangements and cellular homeostasis were found to be regulated 
by the ETV6-RUNX1 fusion protein (Figure 1). Furthermore, our results reveal that 
autophagy is induced in ETV6-RUNX1 positive cells because of transcriptional 
activation of Vps34, a member of the core (macro)autophagy-regulating complex51 
(Figure 2 – 4). 
Autophagy is a cellular recycling system in which unwanted or damaged 
cellular components are degraded and recycled. All mammalian cells harbor low 
basal levels of autophagy that are used to maintain cellular homeostasis. These levels 
can be rapidly induced upon cellular stress. Autophagy is regulated by components 
of the core autophagy-regulating complex, including Vps34, Beclin-1, and Vps15 
(reviewed in e.g.51). Although autophagy can sustain cell survival during stress 
conditions, it can also result in cell death because of progressive cellular consumption 
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Figure 8. Proposed model for the induction of the Vps34-autophagy pathway in ETV6-RUNX1 
positive BCP-ALL cells.
The ETV6-RUNX1 fusion protein can transcriptionally induce the expression of various transcription factors, in-
cluding GATA1, GATA2, HEY1, and EGR1. ETV6-RUNX1 and its co-factor CBFβ, together with GATA1, HEY1 and 
EGR1 can activate the Vps34 promoter, resulting in enhanced Vps34 expression in ETV6-RUNX1 positive leukemic 
cells. Vps34, in turn, can initiate autophagy by forming a core autophagy-regulating complex with Beclin 1 and 
Vps15. This complex plays an important role in (1) the early initiation (in complex with Atg14L) and (2) the vesicle 
elongation phase (together with UVRAG) of autophagosome formation. Induction of autophagy allows ETV6-
RUNX1 positive cells to maintain homeostasis by degrading and recycling damaged proteins and organelles. In 
addition, activation of the autophagy program in ETV6-RUNX1 positive cells results in enhanced proliferation, 
survival and drug resistance. Inhibition of autophagy in ETV6-RUNX1 positive cells, by treatment with hydroxy-
chloroquine (HCQ) or knockdown of Vps34, is sufficient to reduce proliferation and survival of leukemic blasts and 
to induce sensitization to L-Asparaginase.
Autophagy drives ETV6-RUNX1 positive leukemia 87
3
(reviewed in e.g. 56,57). Whether autophagy plays an initiating or suppressive role in 
cancer is still under debate and is most likely dependent on the oncogenic context 
(reviewed in e.g. 58-62). This potential dual role of autophagy in cancer highlights the 
importance of studies on the context-specific role and the functional importance of 
autophagy in neoplastic processes before the start of autophagy-based therapeutic 
interventions. In the present study, we show that the oncogenic ETV6-RUNX1 fusion 
gene can directly up-regulate the level of autophagy in leukemic cells in absence 
of cellular stress. Our results demonstrate that these enhanced levels of autophagy 
are important to maintain proliferation and survival of ETV6-RUNX1 positive 
leukemic cells (Figure 5 - 7). Knockdown of Vps34 and inhibition of autophagy with 
HCQ reduced the proliferation and survival of ETV6-RUNX1 positive BCP-ALL 
cells, confirming the importance of induced autophagy in these cells (Figure 5, 6). 
Importantly, ETV6-RUNX1 negative primary BCP-ALL cells were not affected by 
autophagy inhibition. 
Autophagy might play an important role in protecting leukemic cells during 
chemotherapeutic treatment with nutrient-modulating drugs like L-Asparaginase 
that actively inhibits protein biosynthesis by asparagine depletion, which leads to 
nutritional deprivation and effective killing of leukemic cells63-65. Here, we show 
that autophagy selectively protects ETV6-RUNX1 positive leukemic cells against 
L-Asparaginase treatment, whereas this effect is absent in ETV6-RUNX1 negative 
leukemic cells (Figure 7). HCQ-mediated inhibition of autophagy did not sensitize 
cells to prednisolone or 6-mercaptopurine, two other often used chemotherapeutics 
in treatment of BCP-ALL. These results highlight the importance of the cellular 
and molecular context in which autophagy inhibition is embedded and show that 
caution is warranted before the general introduction of autophagy inhibitors in the 
treatment of leukemia.
The leukemic microenvironment or niche has been shown to protect leukemic 
cells from elimination by immune responses and chemotherapeutic agents66,67, and 
facilitates the development of drug resistance to classic and targeted chemotherapy68. 
Here, we show that MSCs can abrogate the effects of autophagy inhibition in ETV6-
RUNX1 positive BCP-ALL cells. This highlights that the leukemic niche plays 
a crucial role in induction of resistance to chemotherapy, including autophagy 
inhibition. However, MSC-induced resistance of ETV6-RUNX1 positive cells could 
still be overcome when adequate concentrations of the autophagy inhibitor HCQ 
were used (Figure 7). 
The efficacy of autophagy inhibitors during cancer treatment is currently 
examined in clinical trials (reviewed in e.g. 61,69). Initial results indicate that HCQ 
treatment is safe and tolerated at high concentrations and might be effective in a 
subset of patients (e.g. 70-72). In addition, autophagy-independent “off-target” 
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effects of chloroquines, resulting in enhanced response to chemotherapy have been 
reported73,74. This strengthens the point to use HCQ in clinical practice. However, 
more specific and potent autophagy inhibitors are currently developed and 
preclinical studies with these novel inhibitors (e.g. Lys05) show promising results75. 
In addition, the recent determination of the crystal structure of Vps3450 enables 
the development of clinically available Vps34 inhibitors in the near future76-78. Our 
observation that the ETV6-RUNX1 fusion protein induces Vps34 expression and 
subsequently autophagy, strongly indicates that Vps34/autophagy inhibitors should 
be considered in future protocols of ETV6-RUNX1 positive BCP-ALL.
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SUPPLEMENTARY DATA
SUPPLEMENTARY METHODS
Cell lines
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cell lines NALM6 
(B-Other), REH (ETV6-RUNX1), and 697 (TCF3-PBX1), T-ALL cell lines JURKAT 
(hypotetraploid) and LOUCY (del(5); t(16;20)) and human embryonic kidney cell 
line HEK293T were obtained from DSMZ (Braunschweig, Germany) and used only 
at low passages. REHS1 (REH subclone #1; ETV6-RUNX1) is a ETV6-RUNX1 positive 
cell line with identical genetic background as REH, but with different phenotypic 
characteristics (proliferation and drug resistance profiles). DNA fingerprinting 
was performed routinely on these cell lines to verify their genetic status. ALL cell 
lines were cultured in RPMI-1640 medium (Gibco, Life Technologies, Bleiswijk, 
the Netherlands) supplemented with 10% fetal calf serum (FCS) and 1% penicillin-
streptomycin at 37 °C and 5% CO2. HEK293T cells were cultured in high glucose 
Dulbecco’s Modified Eagle’s Medium with Glutamax (Gibco) supplemented with 
10% FCS and 1% penicillin-streptomycin at 37 °C and 5% CO2.
Isolation of CD34-positive hematopoietic cells from cord blood
Mononuclear cells were isolated from umbilical cord blood (UCB) using 
Lymphoprep sucrose-gradient centrifugation (1.077 g/ml, Nycomed Pharma, Oslo, 
Norway). Immunomagnetic cell separation, using magnetic beads coated with 
CD34 antibodies (Miltenyi Biotec, Gladbach, Germany), was performed to isolate 
CD34-positive hematopoietic progenitor cells (CB-CD34+ cells). Cells were cultured 
in Iscove’s Modified Dulbecco’s Medium (Gibco) supplemented with 10% FCS, 
50μM β-mercaptoethanol, 1% penicillin-streptomycin, 2mM glutamine, stem cell 
factor (SCF; 50ng/mL; Peprotech) and fms-like tyrosine kinase-3 ligand (Flt3L; 50 ng/
mL; Peprotech) at 37°C and 5% CO2. UCB was obtained after informed consent was 
provided according to the Declaration of Helsinki. Protocols were approved by the 
ethics committee of the Erasmus University Medical Centre in Rotterdam.
Isolation of primary BCP-ALL leukemic blasts from patients
Bone marrow aspirates were obtained from children with newly diagnosed BCP-
ALL prior to treatment. Immunophenotype and genetic subtype were determined by 
local hospital procedures and monitored by the central diagnostic laboratory of the 
Dutch Childhood Oncology Group (DCOG) in The Hague. Primary BCP-ALL cells 
were subsequently isolated as previously described1. We included 654 ALL patients 
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including 172 ETV6-RUNX1 positive BCP-ALL patients and 401 ETV6-RUNX1 
negative BCP-ALL patients. In short, mononuclear cells were collected using 
Lymphoprep sucrose-gradient centrifugation (1.077 g/ml, Nycomed Pharma, Oslo, 
Norway). To determine the percentage of leukemic cells in the mononuclear cell 
fraction, May-Grünwald-Giemsa staining was performed on cytospin preparations. 
If necessary, the samples were further enriched, to obtain at least 95% leukemic 
blasts, by depletion of normal hematopoietic cells using anti-CD lineage marker 
coated magnetic beads (Dynal, Oslo, Norway). Cells were cultured in RPMI Dutch-
modified medium (Gibco) supplemented with 20% FCS, Insulin transferrin sodium 
selenite (ITS), glutamin and gentamycin at 37 °C and 5% CO2. Bone marrow aspirates 
were obtained after informed consent was provided according to the Declaration of 
Helsinki. Protocols were approved by the ethics committee of the Erasmus University 
Medical Centre in Rotterdam.
Isolation and characterization of primary MSCs
Mesenchymal stromal cells (MSCs) were isolated, as previously described2, from bone 
marrow aspirates collected during diagnostic procedures. In short, colony-forming 
MSCs were selected by culturing bone marrow aspirates in low glucose DMEM 
(Gibco) supplemented with 15% FCS, 1% penicillin-streptomycin, vitamin C, and 
fibroblast growth factor (FGF) at 37°C and 5% CO2. A panel of positive (CD44/ CD90/ 
CD105/ CD54/ CD73/ CD146/ CD166/ STRO-1) and negative surface markers (CD19/ 
CD45/ CD34) was used to characterize primary MSCs. Flow cytometric analysis was 
performed using the human mesenchymal stem cell marker antibody panel (R&D 
Systems, Minneapolis, MN, USA) and the monoclonal antibodies CD54-PE, CD73-
PE, CD34-PE, and IgG1-PE (BD Biosciences, San Jose, CA, USA). The multilineage 
potential of the selected MSCs was confirmed by allowing the cells to differentiate 
towards adipocytes (Oil Red O staining), osteocytes (Alizarin Red S staining), and 
chondrocytes (Col2a/Thionine/Alcian Blue staining).
Production of bicistronic retrovirus and retroviral transduction of CB-CD34+ 
cells
To generate retrovirus, bicistronic retroviral DNA constructs were used expressing 
the ETV6-RUNX1 fusion gene and enhanced Green Fluorescent Protein (eGFP). 
As a control, a construct expressing only eGFP was used. Both vectors consisted 
of a pMSCV promoter region, an internal ribosomal entry site and an ampicillin 
resistance cassette. HEK293T cells were co-transfected with these constructs and 
second-generation retroviral packaging vectors using XtremeGENE 9 tranfection 
reagents (Roche, Basel, Switzerland). Viral particles were collected in IMDM 48 hours 
after transfection. CD34+ hematopoietic progenitors were pre-cultured overnight as 
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described above, upon which cells were divided in two fractions. One fraction was 
transduced with ETV6-RUNX1-IRES-eGFP, while the other fraction was transduced 
with control EV-IRES-eGFP. Transductions were performed with fresh retrovirus in 
retronectin (Takara, Otsu, Japan) coated wells. 
Fluorescence activated cell sorting of transduced CB-CD34+ cells 
Transduced CB-CD34+ cells were sorted using a BD ARIA II sorter (BD Biosciences) 
after staining with DAPI (Sigma) and PeCy7-conjugated CD34 antibody (BD 
Biosciences). The DAPI negative, CD34 positive and GFP positive population (see 
Fig. S6C for gating strategy) was used for further experiments. The purity of the 
sorts, as determined by flowcytometric analysis of the sorted cells, was in all cases at 
least 95% (see Fig. S1B for a representative post-sort analysis of purity).
Linear RNA amplification and gene expression profiling of CB-CD34+ cells
After sorting, DAPI- CD34+ GFP+ CB-CD34+ cells were lysed and RNA was extracted 
using Nucleospin RNA XS extraction columns according to manufacturer’s protocol 
(Macherey-Nagel, Düren, Germany). Quality of RNA was determined by on-chip-
electrophoresis using a RNA Pico Chip according to manufacturer’s protocol (Agilent 
Technologies, Santa Clara, CA, USA). RNA Integrity scores (RIN) were higher than 
8 for all samples. RNA was subsequently linearly amplified using the Nugen WT-
Amplification™ pico system (Nugen, San Carlos, CA, USA). This system is based on 
RNA-dependent DNA polymerase activity and was previously reported to be most 
suitable for amplification and gene expression of picograms of input RNA3. Samples 
were run on Affymetrix GeneChip Human Genome U133 Plus 2.0 microarrays (Santa 
Clara, CA, USA). Data were normalized using vsnRMA4 and analyzed using a linear 
mixed model5. The model was fitted to ETV6-RUNX1, RUNX1-RUNX1T1 and EV 
data derived for each respective umbilical cord blood donor. Data derived from the 
RUNX1-RUNX1T1 transduced umbilical cord blood donors were omitted for further 
analyses in this manuscript and singularly used for estimating the within umbilical 
cord blood variance. Genes were considered differentially expressed when p ≤ 0.05 
after multiple testing correction using false discovery rate (FDR). Differential gene 
expression was visualized using TIBCO Spotfire software (Perkin Elmer, Waltham, 
MA, USA). Microarray data are available in the ArrayExpress database (http://www.
ebi.ac.uk/arrayexpress) under accession number E-MTAB-3466.
Gene expression profiling of primary BCP-ALL leukemic blasts from patients
Sample preparation and gene expression profiling of leukemic blasts derived 
from bone marrow aspirates was performed as earlier described6. In short, DNA 
and total RNA were isolated using TRIzol reagents (Invitrogen Life Technologies, 
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Breda, the Netherlands) or using the QIAamp DNA Blood mini kit (Qiagen, Venlo, 
the Netherlands) in accordance with the manufacturer’s protocol and subsequently 
RNA quality was determined using a Bioanalyzer 2100 (Agilent, Amstelveen, the 
Netherlands). Only samples with an RNA integrity value >7 were processed further. 
cDNA and cRNA were synthesized using an in vitro transcription one-cycle kit 
(Affymetrix, Santa Clara, CA). Affymetrix U133 plus 2.0 gene-expression microarrays 
were processed, and data were extracted, as described previously1. Microarray data 
are available in the Gene Expression Omnibus database (http://www.ncbi.nlm.nih.
gov/geo/).
Ingenuity Pathway Analysis
Gene networks were generated and functional analysis of differential gene expression 
was performed using QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN, 
Redwood City, USA). The expected increase or decrease of biological functions, 
based on the observed change in gene expression, was defined as a regulation Z 
score and was considered significant when larger than 2 or smaller than -2. P-values 
represent results of a right-tailed Fisher’s Exact Test after Benjamini-Hochberg 
multiple testing correction.
Western blot
For protein analysis, cells were lysed using a cold lysis buffer containing 25 mM Tris 
pH 7.4, 150 mM NaCl, 5mM EDTA pH 8.0, 1% Triton X-100, 10% Glycerol, 10 mM 
Sodium-pyrophosphate, 1 mM Sodium-orthovanadate, 10 mM Glycerolphosphate, 
Dithiothreitol, Phenylmethylsulfonyl Fluoride, Aprotinin and Sodium-Fluoride. 
Equal amounts of protein were separated on a 10% acrylamide gel and subsequently 
blotted on a nitrocellulose membrane using the Trans-Blot Turbo Transfer System 
(Bio-rad, Hercules, CA, USA). Primary antibodies used were: β-actin (ab6276, 
Abcam, Cambridge, UK), LC3B (#2775, Cell Signaling, Danvers, MA, USA), SQSTM1/
p62 (#8025, Cell Signaling), Vps34 (#3358, Cell Signaling) and Vps34 (#4263, Cell 
Signaling). Fluorescently labeled secondary IRDye antibodies were purchased from 
LI-COR Biosciences (Lincoln, NE, USA) and blots were scanned using an Odyssey 
Infrared Imaging System (LI-COR Biosciences).
Reverse Phase Protein Array
Reverse phase protein arrays were performed in collaboration with prof. dr. E. 
Petricoin (George Mason University, Manassas, VA, USA) as previously described 
7. In short, normal bone-marrow samples and pediatric BCP-ALL patient cells 
were lysed in Tissue Protein extraction reagent (T-PER; Pierce, Thermo Scientific, 
Waltham, MA, USA), containing 300mM NaCl, 1 mM orthovanadate and protease 
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inhibitors. Lysates were spotted twice in triplicate on glass-backed nitrocellulose-
coated array slides. Reverse-phase protein arrays were performed according to 
manufacturer’s protocol. Data were normalized for total protein levels and was 
corrected for background staining. Primary antibodies used were: Vps34 (#3358 and 
#4263, Cell Signaling), and SQSTM1/p62 (#8025, Cell Signaling).
siRNA knockdown
Silencing of ETV6-RUNX1 and Vps34 in REH cells or ETV6-RUNX1 transduced 
CB-CD34+ cells was achieved by transfection of siRNAs with Dharmafect 4 (Thermo 
Scientific). 72 hours after transfection, cells were transfected again. Twenty-four 
hours after the second hit, cells were analyzed.
siRNAs used to silence ETV6-RUNX1 have been described previously8. 
siETV6-RUNX1 #1: CCAUUGGGAGAAUAGCAGAAUGCAU; siETV6-RUNX1 
#5: UGGGAGAAUAGCAGAAUGCAUACUU. Vps34 targeting siRNAs were 
purchased from Origene (Rockville, MD, USA). 
Real-time PCR
RNA was extracted using Nucleospin RNA XS extraction columns according 
to manufacturer’s protocol (Macherey-Nagel, Düren, Germany), upon which 
cDNA was synthesized. mRNA levels were quantified by incorporation of SYBR 
green (Thermo Scientific) during quantitative real-time PCR (Applied Biosystems 
7900HT). Primers for ETV6-RUNX1 were 5’-TCGGGAAGACCTGGCTTACA-3’ 
(forward) and 5’-TGGCATCGTGGACGTCTCTA-3’ (reverse). Primers for 
PIK3C3 (Vps34) were 5’-CCTGGAAGACCCAATGTTGAAG-3’ (forward) and 
5’-CGGGACCATACACATCCCAT-3’ (reverse) or 5’-AGTTCCCGGTGTAGGTGGTA-3’ 
(forward) and 5’-ACATTGGGTCTTCCAGGACA-3’ (reverse). To 
normalize data, HPRT or RPS20 were used as reference genes. Primers 
used were: HPRT 5’-TGACACTGGCAAAACAATGCA-3’ (forward) and 
5’-GGTCCTTTTCACCAGCAAGCT (reverse); RPS20: 5′-AAGGGCTGAGGATTTTTG-3′ 
(forward) and 5′-CGTTGCGGCTTGTTAG-3′ (reverse). 
Luciferase reporter assays
To study Vps34 promoter activity, a pEZX reporter construct consisting of a 1.4 kB 
region (-1383 to +58) of the Vps34 promoter upstream of the Gaussia luciferase gene 
(Genecopoeia, Rockville, MD, USA; HPRM12127) was used. The reporter construct 
was transfected in HEK293T cells together with the constructs of interest. In all 
experimental conditions, the amount of transfected DNA was equalized per backbone. 
At the end of the experiment, GFP expression was quantified in each sample by flow 
cytometric analysis and used to normalize luciferase activity. Constructs used were: 
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pCMV5-RUNX1 (Addgene; plasmid 124269); pCMV5-CBFβ (Addgene; plasmid 
124279), pMSCV-ETV6-RUNX1 (a kind gift from Dr. Owen Williams, London, UK) 
, pCMV6-XL5-HEY1 (Origene; plasmid SC115467), pcDNA3-EGR1 (Addgene; 
plasmid 1172910), pMT2-GATA1 (Addgene; plasmid 1362611), pFLAG-CMV2-GATA2 
(Addgene; plasmid 141812).
MTT cytotoxicity assay
The sensitivity of ALL cell lines to hydroxychloroquine was analyzed using 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as 
described before1,13. Cell survival was determined after 4 days of hydroxychloroquine 
exposure. Background signal was subtracted and experimental conditions are 
depicted as the percentage of signal compared to the untreated control. 
Lentiviral knockdown of Vps34
Lentivirus was produced by transfecting HEK293T cells with second generation 
lentiviral helper vectors pPax2 (Addgene plasmid 12260) and VSV-G envelope 
(pMD2G; Addgene plasmid 12259) together with pLKO.1 Mission vector (Sigma) 
targeting PIK3C3 (Vps34). Transfection was performed using XtremeGENE transfection 
reagent according to manufacturer’s protocol (Promega, Madison, WI, USA). 
Target sequences used to silence PIK3C3 were: GCTGCACAACAGACATTTGTA 
(shVps34#1; TRCN0000037798); GAGGCAAATATCCAGTTATAT (shVps34#2; 
TRCN0000196290); CCACGAGAGATCAGTTAAATA (shVps34#3; 
TRCN0000037794); GAGATGTACTTGAACGTAATG (shVps34#4; 
TRCN0000196840). Target sequence for used non-mammalian shRNA control vector 
was CAACAAGATGAAGAGCACCAA (NSC; SHC002). Virus was collected and 
concentrated by ultracentrifugation. For every experiment and every cell line, virus 
was titrated to obtain a transduction efficiency of 90%. This condition was equal 
to an MOI of 2.5. Cell lines were transduced using a spin-infection protocol. Cells 
were subsequently selected using the puromycin selection marker. A MACSQuant 
Analyzer (Miltenyi Biotec, Germany) was used to determine the number of viable, 
Propidium Iodide negative, cells. 
Confocal laser scanning microscopy 
Autophagy levels were visualized by the number and volume of LC3B positive 
vesicles. To quantify autophagy levels, confocal scanning microscopy was performed. 
REH cells were allowed to attach to a glass slide coated with 10 μg/mL fibronectin 
(Sigma) for 30 minutes. Cells were subsequently fixated using 3% formaldehyde in 
PBS for 10 minutes at room temperature. After fixation, slides were blocked with 
10% FCS and 0.2% goat serum in PBS and subsequently incubated overnight at 4°C 
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with LC3B antibody (#2775, Cell Signaling). Slides were subsequently washed twice 
with PBS and stained with goat-anti-rabbit-Alexa 488 secondary antibody for 1 hour. 
After three PBS washes, slides were stained with DAPI (Sigma) for 5 minutes and 
mounted with ProLong Gold antifade reagent (Life Technologies). Images were 
acquired using a confocal laser scanning microscope (Leica SP5). Sequential scanning 
of different channels was performed at a resolution of 1024 x 1024 pixels in the x y 
plane and 0.15 μm steps in z-direction. 
The system was equipped with a 63× plan-apochromat oil 1.4 NA DIC objective. 
The pinhole diameter was set to 1 airy unit (95.5 μm). DAPI and LC3B-anti-rabbit-
Alexa 488 were excited with a 488-nm Argon laser and a 405-nm Diode-Pumped 
Solid-State laser, respectively. Fiji software was used for imaging processing. 
Brightness and contrast were optimized and applied to the entire image. Z-project 
using all slides and maximum intensity projection was used to show the number 
of LC3B-positive vesicles in Figure 4. For quantification of LC3B-positive vesicles, 
Z-stacks of images were deconvolved and processed using Huygens Professional 
software. Both the number and the average volume of vesicles were analyzed. For 
the quantification of number and volume of LC3B-positive vesicles, we excluded cells 
with atypical nuclei. For each experiment, LC3B-positive vesicles were quantified in 
at least 6 cells. 3D-deconvolved images shown in Fig. 4 were created using the same 
software. 
Cell viability assays
Primary patient cells (1 x 106 cells) were co-cultured with or without primary 
mesenchymal stromal cells (5 x 104) for five days in a 24-well plate at 37 °C and 5% CO2. 
Stromal cells were allowed to attach prior to the start of the experiment. Before the 
start of each experiment, leukemic cells were screened for CD19 positivity (Brilliant 
Violet 421 anti-human CD19 antibody). After five days of culture the percentage 
of viable leukemic cells was determined by flow cytometic analysis after staining 
with Brilliant Violet 421 anti-human CD19 antibody (Biolegend), FITC Annexin V 
(Biolegend), and Propidium Iodide (PI; Sigma) Primary leukemic cells were exposed 
to L-Asparaginase, Prednisolone or 6-Mercaptopurine in a concentration that was 
lethal to 50% of the patient derived leukemic cells (IC50) as determined upfront by a 
4-day MTT assay1.
Statistical analysis
Statistical analysis of microarray data of paired (EV-eGFP+ versus ETV6-RUNX1-
eGFP+) CB-CD34+ was performed using a linear mixed model in which multiple 
testing correction was applied by FDR (see also Material and Methods section 
on linear RNA amplification and gene expression profiling of CB-CD34+ cells). 
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Microarray data of primary cells from ALL patients was normalized using vsnrma4, 
batch effects were removed using the empirical Bayes method14, and data were 
analyzed using LIMMA15 and FDR multiple testing correction.  
Both the Student’s t-test and the Student’s paired t-test were used as statistical 
test when applicable. Bar graphs represent the mean of biological replicates. Error 
bars represent standard error of the mean (S.E.M.).
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Supplementary Figure 1. Early eff ects of ETV6-RUNX1 expression in CB-CD34+ cells.
(A) Flow chart used to study the early eff ects of ETV6-RUNX1 fusion protein expression in cord blood-derived 
CD34-positive hematopoietic progenitors (CB-CD34+ cells). CB-CD34+ cells were isolated from cord blood. Per 
cord blood donor, cells were divided in two fractions of which one was transduced with ETV6-RUNX1-IRES-GFP 
and the other fraction with control EV-IRES-GFP. Viable transduced HPCs were sorted after 20 hours based on 
DAPI negativity and CD34 and GFP positivity. RNA was extracted from sorted CB-CD34+ cells, controlled for 
quality and linearly amplifi ed after which gene expression analysis was performed with Aff ymetrix GeneChip 
Human Genome U133 Plus 2.0 microarrays.
(B) Graphs showing the gating strategy used to sort alive, CD34-positive, transduced cord blood cells. First liv-
ing cells were gated based on FSC, SSC and the absence of DAPI incorporation. CD34-positive cells were selected 
based on the positive expression compared to an isotype control. Finally, CD34-positive transduced cells were 
sorted based on eGFP expression. Post-sort purity was more than 95%. (C) Graph showing gene expression lev-
els of ETV6-RUNX1 relative to housekeeping gene RPS20 quantifi ed with Q-PCR (n = 5). EV represents levels 
in CB-CD34+ cells transduced with the empty vector control. ETV6-RUNX1 represents levels in CB-CD34+ cells 
transduced with the ETV6-RUNX1 vector. Data are means ± SEM; *** p ≤ 0.001. (D) Heat map showing which 
gene probe sets are relatively over-expressed (in red) and which gene probe sets are relatively under-expressed 
(in blue) compared to the mean expression of all diff erentially regulated gene probe sets. 203 gene probe sets were 
signifi cantly (p ≤ 0.05; FDR-adjusted) over-expressed or under-expressed when ETV6-RUNX1 positive HPCs were 
compared to control HPCs 20 hours after transduction.
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Supplementary Figure 2. Pathway analysis of ETV6-RUNX1 positive CB-CD34+ cells.
(A) Ingenuity pathway analysis was used to analyze gene ontology (GO) functional categories and activation of 
disease/ function annotation based on current literature. Signifi cantly regulated functional categories are listed 
with their p-value (right-tailed Fisher Exact Test after Benjamini-Hochberg multiple testing correction) and regula-
tion Z-score. This analysis refl ect the pathways induced in CB-CD34+ cells by ETV6-RUNX1 40 hours after trans-
duction. (B) Schematic representation of diff erentially regulated genes predicted to induce cellular homeostasis.
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Supplementary Figure 3. Vps34 expression in ETV6-RUNX1 positive cells.
(A) Graph showing the 2log expression (at initial diagnosis) of the gene probe set mapped to Vps34 in a cohort of 
98 pediatric ALL patients that eventually relapsed after treatment (relapsed patients in the Erasmus MC cohort). 
Grey dashed line represents mean expression of all patients. Gene expression of ETV6-RUNX1 positive patients 
was compared to gene expression of all other B-ALL patients (excluding T-ALL): *** FDR-adjusted p = 5.11*10-6. 
(B) Graph showing gene expression of ETV6-RUNX1 after knockdown of the ETV6-RUNX1 fusion protein. mRNA 
levels were determined in REH (n=2) and ETV6-RUNX1 transduced CB-CD34+ cells (n=1) by Q-PCR, normalized to 
HPRT, and compared to the average expression of cells transfected with scrambled control siRNAs (n = 3, p ≤ 0.05). 
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Supplementary Figure 4. Autophagy levels are high in ETV6-RUNX1 positive BCP-ALL cells.
(A) Western blot analysis of proteins important in the autophagy pathway, namely Vps34, p62 (sequestosome 1), 
and LC3B in primary patient BCP-ALL cells (n=5 for ETV6-RUNX1 positive BCP-ALL patients; n=6 for ETV6-
RUNX1 negative BCP-ALL patients). (B) Quantification of experiment performed in (a). Protein expression of 
Vps34 and p62 is relative to actin expression. 
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Supplementary Figure 5. Vps34 is essential for the survival of ETV6-RUNX1 positive leukemic 
cells.
(A) Schematic representation of the diff erent transcript variants of Vps34, based on currently available literature 
(Ensembl Genome Browser; ENSG00000078142) and the binding locations of shVps34#1-shVps34#4. (B) Represen-
tative western blot showing the knockdown of Vps34 in REH cells.
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Supplementary Figure 5. Vps34 is essential for the survival of ETV6-RUNX1 positive leukemic 
cells. (continued)
(C-D) ETV6-RUNX1 positive (REH and REHS1) and ETV6-RUNX1 negative (NALM6) BCP-ALL cells were len-
tivirally transduced with scrambled shRNA control (NSC, black) or two distinct Vps34 shRNA constructs (grey; 
shVps34 #3 and shVps34#4). NI represents non-infected cells. Cells were cultured for 18 days. To determine the 
effect on proliferation, cell counts were performed every 2-3 days. Representative graphs are shown in (C). Repre-
sentative average increase in cell numbers per day is shown in (D). White bars represent control conditions (NI and 
NSC). Grey bars represent conditions in which Vps34 was knocked down. T-test was performed to compare control 
conditions (NSC) with Vps34 knockdown conditions (n = 3, ** p ≤ 0.01, *** p ≤ 0.001). Error bars represent S.E.M.
(E-F) ETV6-RUNX1 positive (REH) BCP-ALL cells were lentivirally transduced with scrambled shRNA control 
(NSC) or two distinct shRNA constructs to silence Vps34 expression. After 7 days of culture, flow cytometrical 
analysis was performed to determine the effect of Vps34 knockdown on survival and cell cycle progression. (E) 
The percentage of viable (AnnexinV positive, Propidium Iodide negative), actively cycling cells was determined 
using DyeCycle. Data were depicted as the percentage of cells in active cell cycle (S, G2, M stage) at day 7 after 
transduction (n = 2, * p ≤ 0.05). Error bars represent S.E.M. (F) The percentages of early apoptotic (AnnexinV posi-
tive, Propidium Iodide negative) and late apoptotic (Propidium Iodide positive) cells were determined 7 days after 
transduction (n = 2, * p ≤ 0.05, *** p ≤ 0.001). Error bars represent S.E.M.
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Supplementary Figure 6. ETV6-RUNX1 negative ALL cells are not sensitive to treatment with 
hydroxychloroquine.
(A) Bar graph showing the cell viability of HCQ-treated conditions (10 μg/ml) compared to HCQ-untreated con-
ditions after 4 days (MTT). Green bars represent ETV6-RUNX1 positive BCP-ALL cell lines. Black bars represent 
ETV6-RUNX1 negative BCP-ALL cell lines. Dark grey bars represent T-ALL cell lines. (B) Calculation of IC50 con-
centrations of two ETV6-RUNX1 positive ALL cell lines (green), and two ETV6-RUNX1 negative ALL cell lines 
(black and gray). n = 4, *** p ≤ 0.001. IC50 values for Jurkat cells were not reached during treatment with 40 μg/ml 
HCQ (the highest concentration used in this assay). (C) Flow cytometrical gating strategy used to analyze survival 
after HCQ treatment of primary BCP-ALL patient samples in co-culture. First, forward and sideward scatt er were 
used to gate living and apoptotic events. Second, primary mesenchymal stromal cells (MSCs) were gated out based 
on CD19-expression and autofl uorescence in the Amcyan channel (events in red gate were excluded from analy-
sis). Then, viable cells were gated based on Annexin-V and Propidium Iodide staining and subsequently based on 
CD19-expression. Percentage of living cells was calculated by dividing the number of AnnexinV negative, PI nega-
tive, CD19 positive events by the number of events after gating out the MSCs. (D) Graph showing relative survival 
of primary ETV6-RUNX1 negative BCP-ALL cells after treatment with increasing concentrations of HCQ com-
pared to untreated controls. Light grey bars represent treatment with 5 μg/ml HCQ. Grey bars represent treatment 
with 10 μg/ml HCQ. Experiment was performed in absence and presence of primary MSCs (n=3 for conditions in 
absence of MSCs, n = 5 for conditions in presence of MSCs). 
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Supplementary Figure 7. Autophagy inhibition sensitizes ETV6-RUNX1 positive BCP-ALL.
(A) Primary ETV6-RUNX1 positive BCP-ALL cells were cultured in absence or presence of IC-50 concentrations 
of L-Asparaginase and increasing concentrations of HCQ. Flow cytometric analysis was performed to determine 
the percentage of non-apoptotic (Annexin V negative, Propidium Iodide negative, CD19 positive) cells (for gating 
strategy see supplementary Figure 6d). First, the survival of primary leukemic blasts in presence of L-Asparaginase 
was compared to their survival in absence of L-Asparaginase (see Figure 7A for the effect of asparaginase in the 
absence of treatment with other effectors). Next, data was depicted as fold reduction compared to HCQ-untreated 
controls. (B) Primary ETV6-RUNX1 positive BCP-ALL cells were co-cultured with primary MSCs in absence or 
presence of IC-50 concentrations of L-Asparaginase and increasing concentrations of HCQ. Flow cytometric analy-
sis was performed to determine the percentage of non-apoptotic cells. The survival of primary leukemic blasts 
in presence of L-Asparaginase was compared to their survival in absence of L-Asparaginase. Next, data from 
individual patients was depicted as fold reduction compared to HCQ-untreated controls. Light grey bars repre-
sent treatment with 5 μg/ml HCQ. Grey bars represent treatment with 10 μg/ml HCQ. Dark grey bars represent 
treatment with 20 μg/ml HCQ. Experiment was performed twice with cells of patients #1 and #2. (C) Co-culture 
experiments were performed with primary ETV6-RUNX1 positive BCP-ALL cells and MSCs. Cells were cultured 
in presence or absence of L-Asparaginase and increasing concentrations of HCQ. Flow cytometric analysis was 
performed to determine the percentage of non-apoptotic cells. The survival of primary leukemic blasts in presence 
of L-Asparaginase was compared to their survival in absence of L-Asparaginase. Next, data from individual pa-
tients was depicted as fold reduction compared to HCQ-untreated controls. Data were depicted as fold reduction 
compared to HCQ-untreated controls (n=4 for HCQ 2.5 μg/ml; n = 5 for HCQ 5 μg/ml and 10 μg/ml; n=3 for HCQ 
20 μg/ml). Error bars represent S.E.M.
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ABSTRACT
Leukemic cells reside in the bone marrow microenvironment, where they are 
nurtured and protected against chemotherapy. In this study, we aimed to find novel 
ways to disrupt the leukemic niche by targeting intracellular signaling pathways 
that are essential for migration of leukemic cells. We focused on pediatric B-cell 
precursor acute lymphoblastic leukemia harboring t(12;21)(p13;q22), resulting in the 
ETV6-RUNX1 (or TEL-AML1) fusion protein. 
We show that Leukemia Associated Rho Guanine nucleotide exchange 
factor (LARG or ARHGEF12) is selectively up-regulated in ETV6-RUNX1 positive 
leukemic cells, and induced by ectopic expression of ETV6-RUNX1 in healthy 
hematopoietic progenitors. LARG is a RhoA-selective RhoGEF, switching RhoA 
to an active state. Pharmacological small molecule inhibition of LARG/RhoA 
significantly inhibited the migration of ETV6-RUNX1 positive cell lines and primary 
cells toward mesenchymal stromal cells (MSCs) and CXCL12.  This reduction was 
not caused by toxicity, since proliferation and drug resistance were unaffected. In 
contrast, migration of ETV6-RUNX1 negative cells was not altered by LARG/RhoA 
inhibition. These data suggest that enhanced LARG/RhoA signaling is important for 
migration of ETV6-RUNX1 positive leukemic cells toward their microenvironment. 
The specificity of this process for ETV6-RUNX1 positive leukemic cells might enable 
selective targeting of the leukemic niche with small molecule inhibitors.
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INTRODUCTION
The bone marrow microenvironment is shown to be essential in facilitating and 
initiating leukemogenesis1-4. This leukemic niche protects leukemic and pre-leukemic 
cells from elimination by immune responses and chemotherapeutic agents, and can 
facilitate the development of drug resistance5-8. Since close proximity to the niche 
is essential for this protection, disruption of the leukemic niche is an important 
consideration for new therapeutic strategies9-13. Several studies have used G-CSF or 
small molecule inhibitors targeting the CXCR4/CXCL12 axis to inhibit migration of 
leukemic cells toward the niche and show promising pre-clinical results, mainly in 
patients with acute myeloid leukemia11-21. Another approach to disrupt the leukemic 
niche is to target intracellular signaling pathways that are intrinsically important for 
migration of leukemic cells. This approach may lead to a more specific inhibition of 
the leukemic niche, without interfering with healthy hematopoietic niches. However, 
the molecular mechanisms driving leukemic migration are largely unknown. 
This study intends to find the molecular drivers of migration in pediatric 
B-cell precursor acute lymphoblastic leukemia harboring t(12;21)(p13;q22). This 
rearrangement fuses the 5’ non-DNA binding region of the ETS family transcription 
factor ETV6 (TEL) to almost the entire RUNX1 (AML1) locus22, resulting in the 
ETV6-RUNX1 fusion protein (also known as TEL-AML1). ETV6-RUNX1 is present 
in 25% of pediatric patients with B-cell precursor acute lymphoblastic leukemia 
(BCP-ALL) and is therewith the most common fusion gene in childhood cancer23,24. 
Despite the favorable prognosis associated with this cytogenetic subtype of BCP-
ALL24-26, resistance to chemotherapeutic drugs and occurrence of relapse occurs 
in ~10% of these patients25-29. In this study, we show that ETV6-RUNX1 drives the 
expression of genes regulating cytoskeleton organization and migration, including 
the G-protein-regulated Rho Guanine Exchange Factor 12 (ARHGEF12), otherwise 
known as Leukemia Associated Rho GEF (LARG). LARG is a RhoA-selective 
RhoGEF, switching RhoA from a GDP-bound/inactive to a GTP-bound/active 
state30-32. Activation of LARG/RhoA signaling has been implicated in transformation 
to leukemia, regulation of migration, and regulation of cell division32-39. With the 
development of small molecule inhibitors of LARG and RhoA40-42, it becomes feasible 
to target these processes. In the present paper, we demonstrate that ETV6-RUNX1 
positive cells are sensitive for small molecule inhibitors of LARG/RhoA.
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METHODS
Details are provided in the supplementary methods section.
Transduction and gene expression profiling of primary cells
CD34-positive hematopoietic progenitor cells (CB-CD34+ cells) were derived from 
human cord blood and transduced with retrovirus expressing ETV6-RUNX1 and 
eGFP. DAPI- CD34+ GFP+ CB-CD34+ cells were sorted using a BD ARIA II sorter. 
After sorting, cells were lysed and RNA was extracted and subsequently linearly 
amplified. 
Bone marrow aspirates were obtained from children with newly diagnosed 
BCP-ALL prior to treatment. Leukemic blasts were collected and processed as 
previously described. 
Affymetrix GeneChip HG-U133-Plus-2.0 microarrays were used for all samples. 
Microarray data of CB-CD34+ cells are available in the ArrayExpress database under 
accession number E-MTAB-3466. Microarray data of BCP-ALL blasts are available in 
the Gene Expression Omnibus database.
Functional assays
Migration and chemotaxis was quantified using a 6.5 mm diameter transwell system 
(Corning, NY, USA) with a pore size of 5 μm. Prior to the start of the experiment, we 
cultured 5 x 104 primary MSCs in the lower compartment of a transwell system for 
48 hours (bottom compartment) and leukemic cells in absence or presence of LARG 
inhibitors (Y16+G04) or AMD3100 for 16 hours. Next, leukemic cells were added to 
the upper compartment and allowed to migrate for 6 hours. At the end of experiment, 
all cells in the bottom compartment were harvested and stained with DAPI (Life 
Technologies) and antibodies against human CD19 (Brilliant Violet 421 anti-human 
CD19 antibody, Biolegend, San Diego, CA, USA). A MACSQuant analyzer (Miltenyi 
Biotec, Gladbach, Germany) was used to determine the number/percentage of 
migrated DAPI-/CD19+ cells. Silencing of genes was achieved using a lentiviral 
knockdown approach using the pLKO.1 Mission vector containing a puromycin 
selection marker. Protein phosphorylation was analyzed using a multiplex cell 
signaling assay according to manufacturer’s protocol (MILLIPLEX MAP Multi-
pathway Magnetic Bead 9-Plex; Merck Millipore). Cell viability of primary leukemic 
cells was quantified using flow cytometry-based Annexin V - Propidium Iodide 
assays in presence or in absence of the small molecules G04 and Y16. 
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Statistical analysis
Statistical analysis of microarray data of paired CB-CD34+ cells was performed 
using a linear mixed model. Microarray data of primary cells from ALL patients 
were analyzed using LIMMA. Functional analysis of differential gene expression 
was performed using QIAGEN’s Ingenuity Pathway Analysis. Both the Student’s 
t-test and the Student’s paired t-test were used as statistical test when applicable. 
Bar graphs represent the mean of biological replicates. Error bars represent standard 
error of the mean (S.E.M.).
RESULTS
Stromal support induces survival and drug resistance of BCP-ALL cells
In order to visualize the beneficial effects of the stromal microenvironment on BCP-
ALL cell survival, we co-cultured BCP-ALL cells from 10 different patients with or 
without primary MSCs. We observed a consistent increase in BCP-ALL cell survival 
in co-culture conditions (average 2 fold induction compared to mono-culture, p 
≥ 0.001, Figure 1A). In addition, we performed similar experiments in absence or 
presence of prednisolone or l-asparaginase, two spearhead drugs in ALL treatment. 
MSCs significantly induced prednisolone and l-asparaginase resistance (84% vs 
17% and 81% vs 30% reduced viability during prednisolone and l-asparaginase 
treatment, respectively; p ≥ 0.001; Figure 1B and 1C). In correspondence with this 
finding, we previously showed that drug resistance is induced due to direct binding 
of leukemic cells to MSCs via so-called tunneling nanotubes8. These data underline 
the importance of hampering leukemic cell migration toward the leukemic niche.
ETV6-RUNX1 drives a pro-migratory signature in CD34+ progenitors and BCP-
ALL
In order to elucidate the molecular mechanisms driven by the ETV6-RUNX1 
fusion protein, we performed gene expression profiling on healthy, umbilical cord 
blood-derived, CD34 positive hematopoietic progenitors (CB-CD34+) ectopically 
expressing the ETV6-RUNX1 fusion gene and compared their gene expression to 
CB-CD34+ cells expressing a control vector. Ingenuity pathway analysis on the 196 
differentially expressed genes showed significant enrichment of genes involved in 
regulation of cellular movement, migration of cells, and cell morphology (p = 3.92E-06, 
p = 2.44E-04, and p = 1.14E-06 respectively; Figure 1D). These genes were predicted to 
activate the recruitment of leukocytes, leukocyte migration, and cellular movement 
of leukocytes, and to affect morphology of blood cells and activation of leukocytes 
(supplementary Figure 1A). Furthermore, we observed differential regulation of 
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Figure 1. ETV6-RUNX1 induces a pro-migration gene expression signature including LARG.
(A) Primary blasts were isolated from 10 pediatric BCP-ALL patients and subsequently cultured for 5 days in 
absence or presence of primary bone marrow-derived MSCs. Black bars represent the percentage of CD19-pos-
itive, annexin-PI-negative cells in mono-culture. White bars represent the percentage of CD19-positive, annexin-
PI-negative cells in co-culture with MSCs. Error bars represent SEM (n = 10). *** p < 0.001. (B-C) Primary blasts 
were isolated from 10 pediatric BCP-ALL patients and subsequently cultured for 5 days in absence or presence of 
primary MSCs during exposure to prednisolone (B) or l-asparaginase (C). Black bars represent the percentage of 
CD19-positive, annexin-PI-negative cells in mono-culture. White bars represent the percentage of CD19-positive, 
annexin-PI-negative cells in co-culture with MSCs. (D) Gene expression profi ling was performed on healthy, um-
bilical cord blood-derived, CD34-positive hematopoietic progenitors (CB-CD34+) ectopically expressing the ETV6-
RUNX1 fusion gene and CB-CD34+ cells expressing a control vector. Ingenuity pathway analysis of the diff erential-
ly expressed genes (n = 196) was performed to analyze gene ontology (GO) functional categories that are predicted 
to be aff ected by the ectopic expression of ETV6-RUNX1 in CB-CD34+ cells. A right-tailed Fisher’s Exact Test after 
Benjamini-Hochberg multiple testing correction was used in all analyses to identify signifi cantly regulated func-
tional categories (>-log2 are depicted). (E) Gene expression profi les of ETV6-RUNX1 positive BCP-ALL (n = 172) 
and ETV6-RUNX1 negative BCP-ALL patients (n = 401; excluding T-ALL) were compared. 
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genes important in regulation of cytoskeletal organization (supplementary Figure 
1C). Similar pathways were found to be enriched in leukemic cells of ETV6-RUNX1 
positive BCP-ALL patients. We performed pathway analysis on differential gene 
expression between ETV6-RUNX1 positive (n = 172) and ETV6-RUNX1 negative (n 
= 481) patient-derived BCP-ALL cells. ETV6-RUNX1 positive BCP-ALL cells showed 
significant enrichment of genes involved in regulation of cellular movement and cell 
morphology (p = 1.10E-04 and p = 1.96E-03 respectively; Figure 1E). 
LARG is up-regulated in ETV6-RUNX1 positive CB-CD34+ cells and ETV6-
RUNX1 positive BCP-ALL
To identify ETV6-RUNX1 target genes that are responsible for the observed pro-
migratory gene expression signature, we compared and ranked differentially 
expressed genes in ETV6-RUNX1 positive CB-CD34+ cells and ETV6-RUNX1 positive 
BCP-ALL cells. In this analysis, LARG (ARHGEF12) showed to be significantly induced 
in both cell types (rank 1 for combined differential expression, supplementary Figure 
1B). LARG was 5.4-fold up-regulated in CB-CD34+ cells expressing ETV6-RUNX1 (p 
= 0.03; Figure 1F). In addition, LARG was 5.7-fold higher expressed in ETV6-RUNX1 
positive primary ALL cells in comparison to ETV6-RUNX1 negative BCP-ALL cells 
(p = 1.02E-61; Figure 1G). 
Small molecule inhibition of LARG blocks chemotaxis and migration of ETV6-
RUNX1 positive BCP-ALL cells
Since LARG and RhoA play an important role in regulation of cytoskeletal 
rearrangement and migration, we hypothesized that the induction of the LARG/
RhoA signaling pathway contributes to the ETV6-RUNX1 induced migratory 
phenotype. Recently, Shang et al.40,41 identified and validated two specific small 
molecules inhibiting the LARG/RhoA pathway: Y16, a specific LARG inhibitor, and 
G04 (Rhosin), a specific RhoA inhibitor. Combined, these small molecules exhibited 
Figure 1. ETV6-RUNX1 induces a pro-migration gene expression signature including LARG.
(Continued)
The top 500 most differentially regulated genes were subsequently used for pathway analysis. Ingenuity pathway 
analysis of the differentially expressed genes was used to analyze gene ontology (GO) functional categories that 
are predicted to be affected by this differential gene expression. (F) CB-CD34+ cells were isolated from umbilical 
cord blood upon which the cells were divided in two fractions. One fraction was transduced with ETV6-RUNX1-
IRES-eGFP, while the other fraction was transduced with control EV-IRES-eGFP. Forty hours after transduction, 
CD34+eGFP+ cells were sorted after which gene expression profiling was performed using Affymetrix GeneChip 
Human Genome U133 Plus 2.0 microarrays. Left panel represents the gene expression (linear) of LARG (ARH-
GEF12) in 5 different cord blood donors. Right panel represents mean and SD of LARG expression (10log) in all 
donors (n = 5, p = 0.03) (G) Gene expression of LARG in ETV6-RUNX1 positive patients was compared to LARG 
expression in ETV6-RUNX1 negative patients. Graph shows the 2log expression of the gene probe set mapped to 
LARG (201334_s_at).
See also Supplementary Figure 1.
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optimal functional inhibition41. To evaluate the effect of disruption of the LARG/
RhoA axis on migration of BCP-ALL cells, we performed migration assays with 
ETV6-RUNX1 positive (REH and REHS1) and ETV6-RUNX1 negative cell lines 
(NALM6 and 697). Leukemic cells were allowed to migrate for 5 hours toward 
CXCL12 (SDF1) or primary mesenchymal stromal cells (MSCs) of three different 
donors, either in absence or presence of LARG/RhoA inhibitors. Blocking CXCR4 
activity with AMD3100 (Plerixafor) resulted in 80-95% reduction in migration 
toward CXCL12 in all BCP-ALL cell lines, irrespective of the cytogenetic subtype 
(supplementary Figure 2A). In contrast, LARG/RhoA inhibition reduced migration 
of ETV6-RUNX1 positive cell lines toward CXCL12 by 75-80%, but did not affect 
chemotaxis of ETV6-RUNX1 negative BCP-ALL cell lines (p ≤ 0.05; supplementary 
Figure 2B). In correspondence, migration of ETV6-RUNX1 positive BCP-ALL cell 
lines toward primary bone marrow derived MSCs was reduced by 75-90% after 
treatment with LARG/RhoA inhibitors (p ≤ 0.01; Figure 2A). In contrast, migration of 
ETV6-RUNX1 negative BCP-ALL cells toward MSCs was either not affected or even 
induced by LARG/RhoA inhibition (p ≤ 0.05; Figure 2B). Additionally, migration 
of ETV6-RUNX1 positive REH cells toward conditioned MSC medium was 70% 
reduced upon inhibition of LARG/RhoA (p ≤ 0.001; Figure 2C). Next, we used bone 
marrow-derived primary leukemic cells of ETV6-RUNX1 positive BCP-ALL patients 
to confirm these findings. LARG/RhoA inhibition significantly reduced migration 
of primary ETV6-RUNX1 positive BCP-ALL cells toward CXCL12 by 25-45% (n = 2, 
p ≤ 0.05; Figure 2D). Blocking CXCR4 activity with AMD3100 was more effective in 
inhibiting migration toward CXCL12 (n = 2, 65-70%, p ≤ 0.01; Figure 2D) compared to 
LARG/RhoA inhibition, however combined inhibition of CXCR4 and LARG/RhoA 
almost completely abrogated migration of cells from patient #1 toward CXCL12 
(95% reduction, p ≤ 0.001; Figure 2E). Migration of cells from patient #2 was also 
significantly reduced by combined inhibition (80% reduction, p ≤ 0.001; Figure 2E). 
The above described experiments were also performed with solely small 
molecule inhibition of LARG (Y16), since we found LARG to be upregulated 
in ETV6-RUNX1 positive cells. A similar significant reduction in migration of 
ETV6-RUNX1 positive cell line and primary cells during LARG inhibition was 
observed (supplementary Figure 2C -2F). 
LARG inhibition does not affect survival and drug resistance of primary BCP-
ALL cells
Since RhoA activation has been implicated in regulation of cell division and the 
induction of drug resistance43, we studied whether the observed reduced migration 
capacity was not caused by toxicity of the inhibitors. To investigate this, we performed 
survival analysis in an ex vivo co-culture model using primary BCP-ALL blasts and 
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Figure 2. Small molecule inhibition of LARG / RhoA reduces migration of ETV6-RUNX1 positive 
BCP-ALL cells.
(A-B) Transwell migration assays were performed to analyze the effects of small molecule inhibition of LARG/
RhoA on the migration of ETV6-RUNX1 positive (A) or ETV6-RUNX1 negative (B) BCP-ALL cells toward bone 
marrow-derived MSCs of three distinct donors. BCP-ALL cells were treated overnight with LARG and RhoA in-
hibitors (Y16 + G04) to inhibit the LARG/RhoA axis. Graphs represent the number of BCP-ALL cells that migrated 
toward primary MSCs (n = 4 for REH/REHS1/NALM6, n = 2 for 697; * p ≤  0.05, ** p ≤ 0.01, *** p ≤ 0.001). Error bars 
represent SEM. (C) REH cells were allowed to migrate toward conditioned medium of primary MSCs in a transwell 
migration assay in absence of presence of LARG/RhoA inhibitors. REH cells were treated overnight with Y16 and 
G04 (n = 7, *** p < 0.001).
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primary bone-marrow derived MSCs (supplementary Figure 3). Inhibition of LARG/
RhoA signaling did not affect cell survival of primary ETV6-RUNX1 positive BCP-
ALL cells in co-culture (Figure 2F). Similar results were obtained in experiments 
using only LARG inhibitor Y16 (supplementary Figure 2G). 
Additionally, the effect of complete disruption of LARG/RhoA signaling on 
the proliferation and survival of BCP-ALL cell lines was investigated by silencing 
LARG expression using lentiviral short hairpin RNAs (supplementary Figure 4A). 
Knockdown of LARG mildly affected the proliferation of the ETV6-RUNX1 positive 
cell lines REH and REHS1 and the ETV6-RUNX1 negative cell line NALM6 (p<0.05; 
supplementary Figure 4B). However, all cell lines were still able to proliferate 
exponentially. The reduced proliferation was due to a moderate induction of 
apoptosis, but not to altered cell cycle progression (REH; supplementary Figure 
4C and 4D). Also, phosphorylation of key signaling proteins in the PI3K/PKB/
mTOR pathway (PKB/Akt and P70S6K), the MAPK/ERK pathway (ERK and p38), 
the SAPK/JNK pathway (JNK), NFκB signaling (NFκB) or JAK/STAT signaling 
(STAT3 and STAT5A/B) were not affected by LARG knockdown (supplementary 
Figure 5). Only the level of phosphorylated CREB (S133) was significantly reduced 
in LARG-knockdown BCP-ALL cells (p < 0.05; supplementary Figure 4E). This 
suggests a causal interaction between the activation of the LARG/RhoA axis and the 
activation of CREB, which is in line with earlier findings44,45. 
These results show that the strong inhibitory effect of LARG/RhoA inhibitors 
on the migratory phenotype of ETV6-RUNX1 positive leukemic cells cannot be 
attributed to reduced proliferation and/or apoptosis.
Figure 2. Small molecule inhibition of LARG / RhoA reduces migration of ETV6-RUNX1 positive 
BCP-ALL cells. (continued)
(D-E) Primary leukemic cells of two patients with ETV6-RUNX1 positive BCP-ALL (Patient #1 and Patient #2) were 
allowed to migrate toward CXCL12 in a transwell migration assay in absence of presence of LARG/RhoA inhibi-
tors and/or CXCR4 antagonist AMD3100/Plerixafor. BCP-ALL cells were treated overnight with LARG (Y16) and 
RhoA inhibitors (G04). AMD3100 was added 2 hours before the start of the experiment. (D) Bars represent num-
ber of migrated primary leukemic cells in presence of Y16 and G04 (dark grey bars), or in presence of AMD3100 
(black bars). Error bars represent SEM of technical duplicates. * p ≤  0.05, ** p ≤ 0.01. (E) Bars represent number of 
migrated primary leukemic cells in presence of Y16, G04 and AMD3100 (dark grey/black striped bars). Error bars 
represent SEM of technical duplicates. ** p ≤ 0.01, *** p ≤ 0.001. (F) Primary ETV6-RUNX1 positive BCP-ALL cells 
were co-cultured together with primary MSCs for 5 days in absence or presence of the LARG inhibitor Y16 and 
the RhoA inhibitor G04. Graph shows the relative survival (Annexin- , Propidium Iodide- , CD19+ cells) of treated 
ETV6-RUNX1 positive BCP-ALL cells compared to the untreated control cells (n = 4). Error bars represent SEM.
See also Supplementary Figure 2 - 5.
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Figure 3. Proposed model for the induction of migration by LARG in ETV6-RUNX1 positive 
BCP-ALL cells. 
ETV6-RUNX1 induces a pro-migration gene expression signature by inducing gene expression of LARG. The 
RhoA-sekective RhoGEF LARG subsequently switches RhoA from a GDP-bound/inactive to a GTP-bound/active 
state. This switch induces the migratory phenotype of the leukemic cells. Small molecule inhibition of LARG (Y16) 
and RhoA (G04) signaling selectively reduces migration of ETV6-RUNX1 positive leukemic cells. This observed 
reduction was not caused by toxicity of the inhibitors. Due to LARG/RhoA inhibition, ETV6-RUNX1 positive cells 
stop migrating toward the leukemic niche. Consequently, the leukemic niche, that normally facilitates leukemic 
cell survival and induces drug resistance, is disrupted. Hence, LARG/RhoA signaling may be a promising new 
approach to optimize treatment of ETV6-RUNX1 positive leukemia.
DISCUSSION
Disruption of the interaction between leukemic cells and their microenvironment 
remains a major challenge in leukemia treatment. Since CXCR4/CXCL12 signalling 
represents the most important chemokine axis regulating migration of hematopoietic 
stem cells46,47 and lymphocytes48, several studies have used growth factors disrupting 
the CXCR4/CXCL12 axis (e.g. G-CSF)21,49 or small molecule inhibitors targeting 
the CXCR4/CXCL12 axis to inhibit migration of leukemic cells toward the niche. 
The promising pre-clinical results in these studies were mainly found in models 
representing acute myeloid leukemia11-21. In addition, phase 1/2 clinical trials 
have shown the feasibility of using CXCR4 antagonists during chemotherapeutic 
treatment of AML patients19,50-52. However, growth factor priming (with G-CSF/
GM-CSF) of AML in more than 4000 AML patients has not resulted in an improved 
overall survival53. Moreover, recent data argues that leukemia stem cells are not 
mobilized by CXCR4 inhibition54, suggesting that CXCR4 inhibition is not suffi  cient 
to completely disrupt leukemic niches. Furthermore, CXCR4 inhibition does not 
only interrupt the leukemic, but also the healthy hematopoietic niche46,47. 
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Here, we show that the ETV6-RUNX1 fusion protein drives a pro-migratory 
gene expression signature in both healthy CD34+ hematopoietic progenitors and 
leukemic cells. These findings are in concordance with a recent study showing that 
ETV6-RUNX1 induces expression of genes involved in cytoskeletal regulation and 
enhances the migratory capacity of mouse B cells55, and with gene expression studies 
in ETV6-RUNX1 positive BCP-ALL cells showing significant enrichment of genes 
involved in the regulation of migration56,57. This study aimed to find the molecular 
drivers of migration in ETV6-RUNX1 positive leukemic cells. The discovery of the 
importance of the LARG/RhoA signaling pathway in migration of ETV6-RUNX1 
positive leukemic cells makes selective inhibition of migration possible. Since our 
data indicate that migration of ETV6-RUNX1 positive ALL cells was significantly 
reduced by LARG/RhoA inhibitors, while migration of ETV6-RUNX1 negative cells 
was unaffected, we speculate that healthy hematopoietic niches are not affected by 
inhibiting LARG/RhoA signaling. In addition, our data suggest that LARG/RhoA 
inhibitors can work synergistically with CXCR4 antagonists, possibly boosting the 
potential of such agents in ETV6-RUNX1 positive BCP-ALL. For future clinical 
application of these findings, it is important to study the effects of small molecule 
inhibition of LARG/RhoA on both the healthy niche and the ETV6-RUNX1 positive 
leukemic niche in vivo. In addition, these experiments may reveal whether inhibiting 
migration of ETV6-RUNX1 positive cells is sufficient to enhance treatment efficiency.
In conclusion, we demonstrate that ETV6-RUNX1 induces a pro-migration 
gene expression signature and identify LARG as an important regulator of this 
phenotype. Small molecule inhibition of LARG/RhoA signaling selectively reduced 
migration of ETV6-RUNX1 positive leukemic cells. The observed reduced migration 
capacity was not caused by toxicity of the inhibitors. Therefore, small molecule 
inhibition of LARG/RhoA signaling may be a promising new approach to disrupt 
the ETV6-RUNX1 positive leukemic niche.
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SUPPLEMENTARY DATA
SUPPLEMENTARY METHODS
Cell lines and reagents
BCP-ALL cell lines NALM6 (B-Other), REH (ETV6-RUNX1), 697 (TCF3-PBX1), 
and human embryonic kidney cell line HEK293T were obtained from DSMZ 
(Braunschweig, Germany) and used only at low passages. REHS1 (REH subclone 
#1; ETV6-RUNX1) is an ETV6-RUNX1 positive cell line with an identical genetic 
background as REH, but with different phenotypic characteristics (proliferation and 
drug resistance profiles). DNA fingerprinting was performed routinely to verify 
authenticity of cell lines. ALL cell lines were cultured in RPMI-1640 medium (Gibco, 
Life Technologies, Bleiswijk, the Netherlands) supplemented with 10% fetal calf 
serum (FCS) and 1% penicillin-streptomycin at 37 °C and 5% CO2. HEK293T cells 
were cultured in high glucose Dulbecco’s Modified Eagle’s Medium with Glutamax 
(Gibco) supplemented with 10% FCS and 1% penicillin-streptomycin at 37 °C and 5% 
CO2. LARG inhibitor Y16, and RhoA inhibitor G04 were obtained from Calbiochem 
(Calbiochem, Merck Millipore, Billerica, MA, USA). AMD3100 was obtained from 
Sigma (Sigma-Aldrich, St. Louis, MO, USA).
Isolation of CD34 positive hematopoietic cells from cord blood
Mononuclear cells were isolated from human umbilical cord blood (UCB) using 
Lymphoprep sucrose-gradient centrifugation (1.077 g/ml, Nycomed Pharma, Oslo, 
Norway). Immunomagnetic cell separation, using magnetic beads coated with CD34 
antibodies (Miltenyi Biotec, Gladbach, Germany), was performed to isolate CD34 
positive hematopoietic progenitor cells (CB-CD34+ cells). Cells were cultured in 
Iscove’s Modified Dulbecco’s Medium (Gibco) supplemented with 10% FCS, 50μM 
β-mercaptoethanol, 1% penicillin-streptomycin, 2mM glutamine, stem cell factor 
(SCF; 50ng/mL; Peprotech) and fms-like tyrosine kinase-3 ligand (Flt3L; 50 ng/mL; 
Peprotech) at 37°C and 5% CO2. UCB was obtained after informed consent was 
provided according to the Declaration of Helsinki. Protocols were approved by the 
ethics committee of the Erasmus University Medical Centre in Rotterdam.
Isolation of primary BCP-ALL leukemic blasts from patients
Bone marrow aspirates were obtained from children with newly diagnosed BCP-
ALL prior to treatment. Immunophenotype and genetic subtype were determined 
according to local hospital procedures and monitored by the central diagnostic 
laboratory of the Dutch Childhood Oncology Group (DCOG) in The Hague. Primary 
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BCP-ALL cells were isolated as described previously1. Primary ALL samples used 
in this study contained more than 95% leukemic cells. Cells were cultured in RPMI 
Dutch-modified medium (Gibco) supplemented with 20% FCS, Insulin transferrin 
sodium selenite (ITS), glutamin and gentamycin at 37 °C and 5% CO2. Bone marrow 
aspirates were obtained after informed consent of patients and/or parents/guardians 
was provided according to the Declaration of Helsinki. Protocols were approved by 
the ethics committee of the Erasmus University Medical Centre in Rotterdam.
Isolation and characterization of primary MSCs
Mesenchymal stromal cells (MSCs) were isolated, as described previously2, from 
bone marrow aspirates collected during diagnostic procedures. A panel of positive 
(CD44/ CD90/ CD105/ CD54/ CD73/ CD146/ CD166/ STRO-1) and negative surface 
markers (CD19/ CD45/ CD34) was used to characterize the MSCs (the human 
mesenchymal stem cell marker antibody panel, R&D Systems, Minneapolis, MN, 
USA, and the monoclonal antibodies CD54-PE, CD73-PE, CD34-PE, and IgG1-PE, 
BD Biosciences, San Jose, CA, USA). The multilineage potential of the selected MSCs 
was confirmed by allowing the cells to differentiate toward adipocytes (Oil Red O 
staining), osteocytes (Alizarin Red S staining), and chondrocytes (Col2a/Thionine/
Alcian Blue staining).
Retroviral transduction of CB-CD34+ cells, cell sorting and gene expression 
profiling.
Retroviral transduction, cell sorting and gene expression profiling was performed. 
In short, to generate retrovirus, bicistronic retroviral DNA constructs were used 
co-expressing the ETV6-RUNX1 fusion gene and enhanced Green Fluorescent Protein 
(eGFP). As a control, a construct expressing eGFP alone was used. HEK293T cells were 
co-transfected with these constructs and second-generation retroviral packaging 
vectors using XtremeGENE 9 transfection reagents (Roche, Basel, Switzerland). Viral 
particles were filtered and collected in IMDM. CD34+ hematopoietic progenitors, 
pre-cultured overnight as described above, were subsequently transduced with fresh 
retrovirus in retronectin (Takara, Otsu, Japan) coated wells. Transduced CB-CD34+ 
cells were sorted using a BD ARIA II sorter (BD Biosciences) after staining with DAPI 
(Sigma) and incubation with a PeCy7-conjugated CD34 antibody (BD Biosciences). 
The DAPI negative, CD34 positive and eGFP positive population was used for 
further experiments. After lysis, RNA was extracted using Nucleospin RNA XS 
extraction columns according to manufacturer’s protocol (Macherey-Nagel, Düren, 
Germany). Quality of RNA was determined by on-chip-electrophoresis using a RNA 
Pico Chip according to manufacturer’s protocol (Agilent Technologies, Santa Clara, 
CA, USA). RNA Integrity scores (RIN) were higher than 8 for all samples. RNA was 
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subsequently amplified in a linear manner using the Nugen WT-Amplification™ 
pico system (Nugen, San Carlos, CA, USA). Samples were run on Affymetrix gene 
expression arrays (Santa Clara, CA, USA). Data was normalized using vsnRMA 
and analyzed using a linear mixed model3. Genes were considered differentially 
expressed when p ≤ 0.05 after multiple testing using FDR.
Ingenuity Pathway Analysis
Network and functional analyses of differential gene expression were generated 
by QIAGEN’s Ingenuity Pathway Analysis (IPA, QIAGEN, Redwood City, USA). 
The expected change in biological functions, based on the observed change in 
gene expression, was tested using right-tailed Fisher’s Exact Test after Benjamini-
Hochberg multiple testing correction. 
BCP-ALL chemotaxis and migration assays
All experiments were performed using RPMI without FCS at 37°C and 5% CO2. 5 
x 104 primary MSCs cells were cultured in the lower compartment of a transwell 
in a volume of 750 μL for 48 hours prior to the start of the experiment (bottom 
compartment). Leukemic cells were cultured overnight in absence or presence 
of LARG inhibitors (Y16, or Y16+G04) or AMD3100 in RPMI without FCS. At the 
start of experiment, 5 x 105 cells, in a volume of 250 μL, were added to the upper 
compartment of a 6.5 mm diameter transwell system (Corning, NY, USA) with a pore 
size of 5 μm. Cells were allowed to migrate for 6 hours. At the end of experiment, 
all cells in the bottom compartment were harvested and stained with DAPI (Life 
Technologies) and antibodies against human CD19 (Brilliant Violet 421 anti-human 
CD19 antibody, Biolegend, San Diego, CA, USA). A MACSQuant analyzer (Miltenyi 
Biotec, Gladbach, Germany) was used to determine the number/percentage of 
migrated DAPI-/CD19+ cells.
Lentiviral knockdown of LARG
Lentivirus was produced by transfecting HEK293T cells with second generation 
lentiviral helper vectors pPax2 (Addgene plasmid 12260) and VSV-G envelope 
(pMD2G; Addgene plasmid 12259) together with pLKO.1 Mission vector (Sigma) 
targeting LARG (ARHGEF12). Transfection was performed using XtremeGENE 
transfection reagent according to manufacturer’s protocol (Promega, Madison, WI, 
USA). Target sequences used to silence LARG were: GCGTTGCGTAATCATCCAGAA 
(LARG#1; TRCN0000047480); CGTCGCATCTTCCTTGAGTTT (LARG#2; 
TRCN0000047478); CCAGAAGTTCAAAGGCACTTA (LARG#3; TRCN0000047481); 
GCGAGTATCCAGAGAAGGAAT (LARG#4; TRCN0000047482); 
CCACTCAAATGCAAAGGCTTA (LARG #5; TRCN0000047479). Efficient reduction 
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of LARG protein levels was achieved using constructs LARG#1, LARG#4, and 
LARG#5. However, LARG#4 was predicted to partially bind three other human RNAs 
(LYRM1, DHRS7C, and LOC101927461). Therefore, only LARG#1 and LARG#5 were 
used for further experiments. Target sequence used for non-mammalian shRNA 
control vector was CAACAAGATGAAGAGCACCAA (NSC; SHC002). Virus was 
collected and concentrated by ultracentrifugation for 2 hours at 13.000 rpm. For each 
experiment and cell line, virus was titrated to obtain a transduction efficiency of 
~90%. This condition was equal to a MOI of 2.5. Cell lines were transduced using 
a spin-infection protocol. Cells were subsequently selected using the puromycin 
selection marker. A MACSQuant Analyzer (Miltenyi Biotec, Germany) was used to 
determine the number of viable, Propidium Iodide negative, cells. 
Analysis of protein phosphorylation.
To analyze protein phosphorylation, we used a multiplex cell signaling assay 
according to manufacturer’s protocol (MILLIPLEX MAP Multi-pathway Magnetic 
Bead 9-Plex; Merck Millipore). In short, equal amount of cells were lysed with 
MILLIPLEX MAP Lysis Buffer containing freshly prepared protease inhibitors. 
Next, we added β-tubulin control beads as a loading control and performed protein 
expression quantification using the Luminex system (Luminex Corp., Austin, TX, 
USA). This assay was used to quantify the level of phosphorylation of the following 
proteins: CREB (pS133), ERK (pT185/pY187), NFκB (pS536), JNK (pT183/pY185), p38 
(pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B (pY694/699), PKB/Akt 
(pS473). 
Cell viability assays on primary patient cells
Primary patient cells (1 x 106 cells) were co-cultured in absence or presence of primary 
MSCs (5 x 104) for five days in a 24-well plate at 37 °C and 5% CO2 in presence or in 
absence of the small molecules G04 and/or Y16. Stromal cells were allowed to attach 
prior to the start of the experiment. Before the start of each experiment, leukemic cells 
were screened for CD19 positivity (anti-human CD19 Brilliant Violet 421 antibody). 
After five days of culture the percentage of viable leukemic cells was determined 
by flow cytometric analysis after staining with anti-human CD19 Brilliant Violet 
421 antibody (Biolegend), Annexin V FITC (Biolegend), and Propidium Iodide (PI; 
Sigma). Primary leukemic cells were exposed to L-Asparaginase, Prednisolone or 
6-Mercaptopurine in a concentration that was lethal to 50% of the patient derived 
leukemic cells (LC50) as determined upfront by a 4-day MTT assay1.
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Statistical analysis
Statistical analysis of microarray data of paired (EV-eGFP+ versus ETV6-RUNX1-
eGFP+) CB-CD34+ was performed using a linear mixed model in which multiple 
testing correction was applied by FDR. Microarray data of primary cells from ALL 
patients were analyzed using ANOVA and FDR multiple testing.  
Both the Student’s t-test and the Student’s paired t-test were used as statistical 
test when applicable (indicated in figure legends). Bar graphs represent the mean of 
biological replicates. Error bars represent standard error of the mean (SEM).
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SUPPLEMENTARY FIGURES
B CB-CD34+BCP-ALL
Gene name p-value p-value Fold Change Rank
LARG 1.02E-61 0.0298 5.38 1
HOPX 2.24E-16 0.0464 7.37 2
FAM171A1 6.14E-17 0.0108 7.087 3
KCNK6 4.08E-11 0.0350 9.427 4
SPINK2 1.78E-19 0.0317 4.537 5
TIMP3 3.10E-16 0.0415 3.84 6
TRIB2 2.00E-11 0.0328 5.72 7
LMO4 1.31E-23 0.00148 2.95 8
CDKN1A 8.24E-12 0.0355 4.74 9
GATA2 2.16E-21 0.0449 2.61 10
STXBP5 1.34E-13 0.0240 3.76 11
DLC1 5.83E-11 0.0383 4.46 12
RUNX1 0.0177 0.00764 9.36 13
DLC1 0.000414 0.0367 3.83 14
PLAG1 5.56E-34 0.00230 2.12 15
CATSPER2 1.15E-15 0.0222 2.62 16
AP1S1 3.06E-11 0.0244 2.85 17
KIAA1274 1.24E-13 0.0289 2.77 18
NHEDC2 4.28E-22 0.00638 2.18 19
CMIP 1.04E-07 0.0320 2.61 20
MTSS1 0.00103 0.0317 4.67 21
PROS1 3.60E-05 0.0317 9.64 22
TNFRSF10A 5.24E-08 0.0355 3.41 23
CMIP 4.37E-13 0.0317 2.49 24
BHLHE40 1.96E-08 0.00350 3.07 25 
Fold Change
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Supplementary Figure 1. ETV6-RUNX1 drives a pro-migratory signature in hematopoietic pro-
genitors.
(A) Ingenuity pathway analysis was used to visualize genes inducing the migratory phenotype of ETV6-RUNX1 
positive cells. This overview shows the predicted effect of differentially expressed genes in ETV6-RUNX1 positive 
CB-CD34+ cells on cellular processes involved in cell morphology and cellular movement (recruitment of leuko-
cytes, leukocyte migration, cell movement of leukocytes, morphology of blood cells, and activation of leukocytes). 
Dashed lines indicate indirect regulation. Solid lines indicate direct regulation. 
LARG/RhoA signaling blocks migration of ETV6-RUNX1 positive leukemia 131
4
Supplementary Figure 1. ETV6-RUNX1 drives a pro-migratory signature in hematopoietic pro-
genitors. (Continued)
(B) Differentially expressed genes in ETV6-RUNX1 positive CB-CD34+ cells and ETV6-RUNX1 positive BCP-ALL 
cells were ranked (the top 500 most differentially regulated genes in BCP-ALL by p-value, and the differentially 
regulated genes in CB-CD34+ cells by fold change of expression). The sum of ranks was calculated and genes were 
ordered based on the lowest sum of ranks, which correlated with the highest differential expression in this com-
bined analyses. This table provides a toplist of this analysis. (C) Ingenuity pathway analysis was used to visualize 
genes important for the predicted change in cytoskeletal regulation. This overview shows the predicted effect of 
differentially expressed genes in ETV6-RUNX1 positive CB-CD34+ cells on cellular processes involved in organiza-
tion of cytoskeleton and cytoplasm. Dashed lines indicate indirect regulation. Solid lines indicate direct regulation. 
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Supplementary Figure 2. Small molecule inhibition of LARG reduces migration of ETV6-RUNX1 
positive BCP-ALL. 
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Supplementary Figure 2. Small molecule inhibition of LARG reduces migration of ETV6-RUNX1 
positive BCP-ALL. (Continued)
(A-B) Transwell migration assays were performed to analyze the eff ects of small molecule inhibition of LARG/
RhoA on the migration of BCP-ALL cells toward CXCL12. (A) shows the relative migration of the ETV6-RUNX1 
positive cell lines REH and REHS1 toward CXCL12 in absence or presence of inhibitors. (B) shows the relative mi-
gration of ETV6-RUNX1 negative cell lines NALM6 and 697 toward CXCL12 in absence of presence of inhibitors. 
We used Y16 (LARG inhibitor) and G04 (RhoA inhibitor) to disrupt the LARG/RhoA signaling axis (n = 2, * p < 
0.05; ** p < 0.01). As a positive control we used AMD3100, a CXCR4 antagonist (n = 1). BCP-ALL cells were treated 
overnight with Y16 and G04. AMD3100 was added 2 hours before the start of the experiment. (C-D) Transwell 
migration assays were performed to analyze the eff ects of small molecule inhibition of LARG on the migration of 
ETV6-RUNX1 positive (C) or ETV6-RUNX1 negative (D) BCP-ALL cells toward bone marrow-derived MSCs of 
three distinct donors. BCP-ALL cells were treated overnight with LARG inhibitors. Graphs represent the number 
of BCP-ALL cells that migrated toward primary MSCs (n = 4 for REH /NALM6, n = 2 for 697, n = 1 for REHS1). 
Error bars represent SEM. *** p ≤ 0.001. (E-F) Primary leukemic cells of two patients with ETV6-RUNX1 positive 
BCP-ALL (Patient #1 and Patient #2) were allowed to migrate toward CXCL12 in a transwell migration assay in 
absence of presence of LARG  inhibitors and/or CXCR4 antagonist AMD3100. BCP-ALL cells were treated over-
night with LARG (Y16). AMD3100 was added 2 hours before the start of the experiment. (E) Bars represent number 
of migrated primary leukemic cells in presence of Y16 (grey bars), or in presence of AMD3100 (black bars). Error 
bars represent SEM of technical duplicates. * p ≤  0.05, ** p ≤ 0.01. (F) Bars represent number of migrated primary 
leukemic cells in presence of Y16 and AMD3100 (grey/black striped bars). Error bars represent SEM of technical 
duplicates. ** p ≤ 0.01, *** p ≤ 0.001. (G) Primary ETV6-RUNX1 BCP-ALL cells were cultured for 5 days in absence 
of presence of the LARG inhibitor Y16. Graph shows the relative survival (Annexin- , Propidium Iodide- , CD19+ 
cells) of treated ETV6-RUNX1 BCP-ALL cells compared to the untreated control cells (n = 4).
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Supplementary Figure 3. Gating strategy used to quantify the number of living primary BCP-ALL 
cells in co-culture.
Primary ETV6-RUNX1 BCP-ALL cells were co-cultured together with primary MSCs for 5 days after which we 
analyzed survival using Annexin V, Propidium Iodide and CD19. Flow cytometrical analysis was performed as 
depicted here. The red gate in the second panel shows the mesenchymal stromal cells. MSCs were excluded in 
further survival analyses.
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Supplementary Figure 4. LARG knockdown reduces cell proliferation by a modest induction of 
apoptosis.
(A) To analyze the long-term eff ect of abrogation of the LARG/RhoA axis in BCP-ALL cells, we performed lentivi-
ral RNA knockdown studies with short hairpins targeting LARG. Left panel shows a schematic representation of 
the known transcript variants of LARG and the LARG#1, LARG#4 and LARG#5 recognition sites. LARG knock-
down was visualized by western blot analysis using antibodies against LARG or β-Tubulin (right panel). A rep-
resentative experiment is shown (n = 4). Effi  cient reduction of LARG protein levels was achieved using constructs 
LARG#1, LARG#4, and LARG#5. Since LARG#4 was predicted to partially bind three other human RNAs (LYRM1, 
DHRS7C, and LOC101927461) we performed functional experiments with LARG#1 and LARG#5 only. (B) ETV6-
RUNX1 positive (REH and REHS1) and ETV6-RUNX1 negative (NALM6) cells were lentivirally transduced with 
scrambled shRNA control (NSC) or two distinct LARG shRNA constructs (LARG#1 and LARG#5). Cells were cul-
tured for 18 days. To determine the eff ect on proliferation, cells were counted every 2-3 days using a MAQSQuant 
Analyzer. Proliferation of leukemic cells transduced with a shRNA targeting LARG was compared to leukemic 
cells transduced with a NSC control vector (n = ≥ 3 ; * p ≤ 0.05; ** p ≤ 0.01).
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Supplementary Figure 4. LARG knockdown reduces cell proliferation by a modest induction of 
apoptosis. (continued)
(C-D) ETV6-RUNX1 positive REH cells were lentivirally transduced with scrambled shRNA control or two distinct 
LARG shRNA constructs. After seven days of culture, flow cytometrical analysis was performed to determine the 
effect of LARG knockdown on survival and cell cycle progression. The percentage of apoptotic cells (Annexin V 
and/or Propidium Iodide positive; C) and actively cycling cells (determined using DyeCycle; D) is depicted (n = 
3; * p ≤ 0.05). (E) To quantify protein phosphorylation after LARG knockdown in REH cells, we used a multiplex 
cell signaling assay quantifying phosphorylation of the following proteins: CREB (pS133), ERK (pT185/pY187), 
NFκB (pS536), JNK (pT183/pY185), p38 (pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B (pY694/699), 
PKB/Akt (pS473). Protein levels of phospho-CREB were first normalized to β-tubulin protein levels. Graph shows 
the relative levels of phosphorylated CREB in REH cells transduced with two distinct LARG shRNA constructs 
compared to REH cells transduced with scrambled shRNA control construct. Data of the other tested proteins can 
be found in Supplementary Figure 5. Experiment was performed at three different time points post-transduction. 
* p ≤  0.05, ** p ≤ 0.01, *** p ≤ 0.001. 
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Supplementary Figure 5. Analysis of protein expression after LARG knockdown in REH cells.
(A-C) To quantify protein phosphorylation after LARG knockdown in REH cells, we used a multiplex cell signaling 
assay in which we quantified phosphorylation of the following proteins: ERK (pT185/pY187), NFκB (pS536), JNK 
(pT183/pY185), p38 (pT180/pY182), p70 S6K (pT412), STAT3 (pS727), STAT5A/B (pY694/699), PKB/Akt (pS473). 
Graph shows the relative levels of phosphorylated protein in REH cells compared to the protein level of tubulin. 
Bars represent REH cells transduced with two distinct LARG shRNA constructs or a scrambled shRNA control 
construct. Experiment was performed at day 7 (A), day 12 (B), and day 21 (C) post-transduction. Error bars rep-
resent SEM of technical duplicates. Phosphorylation of key signaling proteins in the PI3K/PKB/mTOR pathway 
(PKB/Akt and P70S6K), the MAPK/ERK pathway (ERK and p38), the SAPK/JNK pathway (JNK), NFκB signaling 
(NFκB) or JAK/STAT signaling (STAT3 and STAT5A/B) were not affected by LARG knockdown.
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ABSTRACT
Acute lymphoblastic leukemia (ALL) cells reside in the bone marrow microenvironment 
which nurtures and protects cells from chemotherapeutic drugs. The disruption 
of cell-cell communication within the leukemic niche may offer an important new 
therapeutic strategy. Tunneling nanotubes (TNTs) have been described as a novel 
mode of intercellular communication, but their presence and importance in the 
leukemic niche are currently unknown. Here, we show for the first time that primary 
B-cell precursor ALL cells use TNTs to signal to primary mesenchymal stromal 
cells (MSCs). This signaling results in secretion of pro-survival cytokines, such as 
IP10/CXCL10, IL8 and MCP-1/CCL2. A combination of TNT disrupting conditions 
allows us to analyze the functional importance of TNTs in an ex vivo model. Our 
results indicate that TNT signaling is important for the viability of patient-derived 
B-cell precursor ALL cells and induces stroma-mediated prednisolone resistance. 
Disruption of TNTs significantly inhibits these leukemogenic processes and re-
sensitizes B-cell precursor ALL cells to prednisolone. Our findings establish TNTs as 
a novel communication mechanism by which ALL cells modulate their bone marrow 
microenvironment. The identification of TNT signaling in ALL-MSC communication 
gives insight into the pathobiology of ALL and opens new avenues to develop more 
effective therapies that interfere with the leukemic niche.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) cells reside in the local microenvironment of 
the bone marrow and are able to disrupt normal hematopoietic stem cell niches1. 
The disrupted, so called leukemic, niche is essential in initiating and facilitating 
leukemogenesis2-6. In addition, the leukemic niche protects leukemic cells from 
elimination by immune responses and chemotherapeutic agents, and can facilitate 
the development of drug resistance of leukemic cells7-10. Therefore, the disruption of 
the ALL-leukemic niche interaction offers a promising new therapeutic strategy11-16. 
However, it is still largely unclear how crosstalk occurs within the leukemic niche, 
and how this drives leukemic cell survival and chemotherapy resistance.
Recently, tunneling nanotubes (TNTs), or membrane nanotubes, have been 
described as a novel mode of communication between eukaryotic cells17-21. TNTs are 
thin membrane protrusions consisting of F-actin, that connect cells and facilitate the 
transport of several types of cargo, including organelles, pathogens, calcium fluxes, 
death signals, and membrane bound proteins19,20,22-24. These intercellular membrane 
conduits have been observed in several cell types, like cancer cells, complex tissues 
and organisms20,21,24-29. The pathophysiological importance of TNTs has become 
evident by studies showing that prions and HIV-1 particles use TNTs to promote 
disease spread21,30. However, the presence of TNTs within the leukemic niche and 
hence their role in communication between leukemic cells and the bone marrow 
microenvironment has not yet been addressed. Here, we study the role of TNT 
signaling in communication between primary B-cell precursor ALL (BCP-ALL) cells 
and MSCs and the contribution of TNT signaling to mesenchymal-mediated survival 
and resistance to the chemotherapeutic drug prednisolone.
METHODS
Cell lines
BCP-ALL cell lines, NALM6 (B-Other) and REH (TEL-AML1), were obtained from 
DSMZ (Braunschweig, Germany). Only low cell passages were used, and the identity 
of cell lines was routinely verified by DNA fingerprinting. Immortalized hTERT-
MSCs were a kind gift from Prof. Dr. D. Campana, St. Jude Children’s Hospital, 
Memphis, TN, USA.
Primary patient-derived material
Bone marrow aspirates were obtained from children with newly diagnosed BCP-
ALL prior to treatment. Mononuclear leukemic cells were collected and processed 
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as previously described31. All samples used in this study contained ≥97% leukemic 
blasts (supplementary Figure 7). Mesenchymal stromal cells (MSCs) were isolated 
from bone-marrow aspirates obtained from newly diagnosed BCP-ALL patients 
(before treatment) and healthy controls. MSCs were processed as described 
previously32. Primary MSCs were characterized using positive (CD44/ CD90/ CD105/ 
CD54/ CD73/ CD146/ CD166/ STRO-1) and negative surface markers (CD19/ CD45/ 
CD34) (supplementary Figure 6). Multilineage potential of MSCs was confirmed for 
adipocyte (Oil Red O staining), osteocyte (Alizarin Red S staining), and chondrocyte 
(Col2a/ Thionine/ Alcian Blue staining) differentiation.
Dye transfer experiments
Cells were stained with 1,1’-dioctadecyl-3,3,3’3’-tetramethylindocarbocyanine 
perchlorate (DiI; yellow), 3,3’-dioctadecyloxacarbocyanine (DiO; green), 
1,1’-dioctadecyl-3,3,3’3’-tetramethylindodicarbocyanine perchlorate (DiD; red), or 
Calcein red-orange AM (all from Life Technologies) according to the manufacturer’s 
protocol. Target populations were analyzed before and after co-culture with flow 
cytometry (BD Bioscience, San Jose, CA, USA) or confocal microscopy (see below).
Confocal laser scanning microscopy 
For high resolution images, differentially stained cells were cultured on a glass slide 
coated with 10 μg/mL fibronectin (Sigma) at 37 °C and 5% CO2. Cells were fixated 
as previously described33. Confocal images were acquired with sequential scanning 
of different channels at a resolution of 1024 x 1024 pixels in the x x y plane and 
0.15 μm steps in z-direction (Leica SP5). For time-lapse confocal imaging, cultures 
were maintained at 37°C on a heated stage at 5% CO2 and images were acquired 
with sequential scanning of different channels at a resolution of 512 x 512 pixels in 
the x x y plane and 0.5 μm steps in z-direction. 3D image stacks were acquired by 
optical sectioning using the LAS software provided with the instrument. The system 
was equipped with a 63× plan-apochromat oil 1.4 NA DIC objective. The pinhole 
diameter was set to 1 airy unit (95.5 μm). DiO and DiI were excited with a 488-nm 
Argon laser and a 561-nm Diode-Pumped Solid-State laser, respectively. Phalloidin-
FITC (Sigma) was excited with the 488-nm Argon laser. Image processing was done 
with Fiji software34.
TNT inhibition
TNTs were inhibited using actin inhibition by latrunculin B (125 – 500 nM; Sigma) or 
cytochalasin D (250 nM – 1 μM; Sigma)20, by mechanical disruption via gentle shaking 
of cell cultures (250 rpm)21,35, or by physical separation of leukemic cells (cultured in 
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a 3.0 μm pore-sized insert) and MSCs (cultured in the bottom compartment of a 
transwell system; Corning, NY, USA)21,36. 
Cell viability assays
Primary patient cells (1 x 106 cells) were co-cultured with or without primary MSCs 
(5 x 104) for five days in a 24-well plate at 37 °C and 5% CO2. The percentage of viable 
leukemic cells was determined by staining with Brilliant Violet 421 anti-human CD19 
or CD45 antibody (Biolegend), FITC Annexin V (Biolegend), and Propidium Iodide 
(PI; Sigma), after which the percentage of AnnexinVneg/PIneg/CD19pos/CD45pos cells 
within the MSC negative fraction (see Figure 6A for gating strategy) was determined 
by flow cytometry (BD Biosciences). In supplementary Figure 10, viable leukemic 
cells were counted (PIneg/CD19pos) using a MACSQuant analyzer (Miltenyi Biotec, 
Gladbach, Germany).
Multiplexed fluorescent bead-based immunoassay (Luminex)
Primary leukemic cells and leukemic cell lines were co-cultured with primary MSCs 
with or without TNT inhibition (shaking or transwell condition) for indicated time 
points at 37 °C and 5% CO2. Next, the supernatant was collected and cell viability of 
leukemic cells was assessed as described above. The concentration of 64 cytokines/
chemokines in supernatants of ALL-MSC co-cultures was analyzed using a 
fluorescent bead-based immunoassay (Luminex Human Cytokine/Chemokine Panel 
I and II; Merck Millipore) according to the manufacturer’s protocol. 
Statistical analysis
Student’s t-test was used as a statistical test and a Student’s paired t-test was used 
when applicable (indicated in figure legends). Bar graphs represent the mean of 
biological replicates. Error bars show as standard error of the mean (SEM).
For more details see supplementary methods.
RESULTS
BCP-ALL cells use TNTs to effectively signal to MSCs
TNT formation within the hematopoietic niche was studied by confocal microscopy 
and flow cytometry. TNTs are thin membrane tethers and can be visualized using 
lipophilic carbocyanine dyes20,21. These dyes stain lipophilic structures in the 
entire cell, and exhibit very low cell toxicity, while passive transfer of these dyes is 
negligible. Therefore, these dyes are widely used in live cell tracking experiments1,37. 
Interestingly, it has been shown that organelles and membrane components stained 
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by these dyes can be actively transported via TNTs20. Therefore, these dyes were 
used to visualize intercellular communication via TNTs within the leukemic niche. 
Differential staining of NALM6 BCP-ALL cells (stained with DiI-yellow) and 
mesenchymal stromal cells (hTERT-MSCs; stained with DiO-green) revealed that 
TNTs were formed within 3 hours of co-culture (Figure 1A, supplementary Figure 
1M-P). 3D reconstruction of these images shows that nanotubular structures between 
cells do not connect with the substratum (i.e. the fibronectin-coated glass slide; see 
supplementary Video 1A-B and supplementary Video 2). As expected, staining 
with Phalloidin-FITC shows the presence of F-Actin filaments in these nanotubular 
structures (see supplementary Figure 1Q-R). Importantly, bidirectional transfer of 
lipophilic dyes was observed, indicating active crosstalk within the leukemic niche 
(Figure 1A). Besides formation of TNTs between leukemic cells and MSCs,  TNT 
networks and transfer of lipophilic dye was also observed in mono-cultures of BCP-
ALL cells and MSCs (supplementary Figure 1A-L and supplementary Figure 2).
In order to quantify active crosstalk via TNTs we used flow cytometrical 
analysis of dye transfer from labeled donor cells to unlabeled recipient cells. CD19-
positive BCP-ALL cell lines (NALM6 and REH) were stained with lipophilic dye 
DiI and co-cultured with unstained CD19-negative hTERT-MSCs (supplementary 
Figure 3A-C for gating strategy). After 6 hours of culture, more than 50% of the MSCs 
were positive for DiI. This number increased to >85% after 24 hours, highlighting the 
efficient dye transfer from leukemic cells to MSCs (Figure 1B and supplementary 
Figure 3D). In reciprocal experiments we also observed dye transfer from MSCs to 
BCP-ALL cells, but the magnitude of dye transfer was strikingly less than from ALL 
cells towards MSCs (175-fold, p-value ≤ 0.001) (Figure 1C-D).
Transfer of lipophilic dyes can be mediated by several processes including TNT 
signaling and signaling via extracellular vesicles (ECV). To evaluate the contribution 
of TNT signaling to the observed lipophilic dye transfer between leukemic cells 
and MSCs, we inhibited TNTs using three independent experimental setups: 1) 
reducing TNT formation through actin inhibition20, 2) mechanical disruption of TNT 
connections through gentle shaking of cell cultures21,35, and 3) prevention of TNT 
formation by physically separating leukemic cells (cultured in a 3.0 μm pore-sized 
insert) and MSCs (cultured in the bottom compartment of a transwell system)21,36. 
For inhibition of the polymerized F-actin of which TNTs are composed20, we 
used two classes of F-actin polymerization inhibitors: cytochalasin D and latrunculin 
B. In addition to F-actin elements, TNTs need prolonged cell contact to signal 
efficiently. Gentle shaking of ALL-MSC co-cultures reduces the lifespan of TNTs, 
while direct contact between BCP-ALL cells and MSCs is still possible. However, it is 
well established in literature that flow-derived shear forces (gentle shaking) induce 
integrin-mediated signaling38,39. Therefore, we also physically separate ALL cells and 
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Figure 1. TNT signaling between BCP-ALL cells and MSCs.
(A) Representative confocal images (Z-stack) showing TNT networks (white arrowheads) between BCP-ALL cell 
line REH (DiI, yellow) and hTERT-immortalized MSCs (DiO, green) after co-culture for 3 hours. Bidirectional 
exchange of lipophilic dye via TNTs was observed (green arrow for MSC to ALL, yellow arrow for ALL to MSC). 
Leukemic cells also formed TNT-like structures towards the fibronectin-coated substratum (orange arrowhead).
(B) Graph showing quantification of dye transfer from DiI-stained NALM6 cells towards unstained hTERT-MSCs 
(cultured in 4:1 ratio) in time. Figure shows representative experiment (n = 3).
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MSCs using a transwell system, to exclude the effects of increased integrin signaling. 
We used a 3.0 μm transwell system to investigate the contribution of extracellular 
vesicle signaling to lipophilic dye transfer. In this transwell system leukemic cells are 
physically separated from MSCs, while exchange of extracellular vesicles (30-1000 
nm) is still possible.
Cytochalasin D and latrunculin B both caused a dose-dependent reduction of 
dye transfer after 6 hours of co-culture (p ≤ 0.01; Figure 1E-F and supplementary 
Figure 3E-F). Due to the short half-time of these actin inhibitors40,41, TNT formation 
was restored within 24 hours (supplementary Figure 3E-F). Disruption of TNT 
structures by gentle shaking reduced dye transfer by more than 5-fold (p ≤ 0.01; 
Figure 1E-F and supplementary Figure 3G). Importantly, dye transfer from BCP-
ALL cell lines to MSCs was nearly absent in transwell experiments (p ≤ 0.001), which 
indicates that dye transfer occurs mainly via TNTs and not via extracellular vesicles 
(Figure 1E-F and supplementary Figure 3H). 
The TNT forming capacity was also evaluated in an ex vivo niche model using 
leukemic cells and MSCs that were both freshly obtained from patients with newly 
diagnosed BCP-ALL (Figure 2A, supplementary Figure 4A-J, supplementary Figure 
5A-D, supplementary Figure 6 and supplementary Figure 7).  Ex vivo co-cultures 
revealed that TNTs rapidly (< 3 hours) form between primary BCP-ALL cells and 
primary MSCs, and efficiently transfer lipophilic dye (Figure 2B, supplementary 
Figure 4G-J, supplementary Figure 5). The source of MSC did not affect the efficacy 
of TNT signaling. Dye transfer was similarly efficient from ALL cells towards 10 
different primary MSCs (n = 5 healthy and n = 5 leukemic primary patient-derived 
MSCs; Figure 2C-D and supplementary Figure 8A-C).
The dynamics of TNT formation between BCP-ALL cells and MSCs were 
investigated using time-lapse confocal microscopy. Leukemic cells initiated formation 
of TNTs and transferred lipophilic dye towards MSCs within minutes (Figure 3A; 
supplementary Videos 3 and 4A). Leukemic cells were able to form multiple TNTs 
Figure 1. TNT signaling between BCP-ALL cells and MSCs. (continued)
(C) Graph showing quantification of dye transfer after 24 hours of co-culture (cultured in 1:1 ratio). Left panel 
shows dye transfer from DiI-stained hTERT-MSCs towards unstained NALM6 cells. Right panel shows the re-
ciprocal experiment (also performed in a 1:1 ratio). White and grey histograms represent staining intensity at the 
start of each experiment. (D) Quantification of dye transfer in time of experiment as exemplified in (C), performed 
with two different BCP-ALL cell lines (REH and NALM6). Dye transfer from MSCs towards ALL was compared to 
dye transfer from ALL towards MSCs (n = 4; two-tailed t-test, unpaired). (E) Graph showing quantification of dye 
transfer from DiI-stained NALM6 cells towards unstained hTERT-MSCs with (red histograms) or without (grey 
histograms) TNT inhibition. Cells were co-cultured in 4:1 ratio for 6 hours. Three independent TNT inhibiting 
conditions were used: actin inhibition by cytochalasin D or latrunculin B, physical disruption by gentle shaking, or 
culture in a 3.0 μm transwell system. (F) Quantification of dye transfer experiment exemplified in (E), performed 
with two different BCP-ALL cell lines (REH and NALM6) (n = 4; one-tailed t-test, unpaired). 
Data are means ± SEM; ** p ≤ 0.01, *** p ≤ 0.001. See also supplementary Figures 1 and 3, and supplementary Videos 
1A-B and 2.
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and signal to several MSCs simultaneously (Figure 3B; and supplementary Videos 3 
and 4A-B). TNTs formed between MSCs and leukemic cells were stable for multiple 
hours and could reach several cell diameters in length (Figure 3C, supplementary 
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Figure 2. Primary BCP-ALL cells signal to MSCs via TNTs.
(A) Representative confocal images (Z-stack) showing TNT formation (white arrowhead) between a primary 
CD34-positive cell (DiI, yellow) and a hTERT-immortalized MSC (DiO, green) after co-culture for 3 hours. White 
arrow indicates transfer of dye to recipient cell. (B) Graphs showing quantification of dye transfer in co-cultures 
of BCP-ALL patient cells with primary MSCs (cultured in 4:1 ratio). Inhibition of TNTs was performed by gentle 
shaking of co-cultures, or co-culture in a 3.0 μm transwell system (red histograms). (C) Graphs showing quantifica-
tion of dye transfer from DiI-stained NALM6 cells towards 10 different unstained primary MSCs (cultured in 4:1 
ratio) obtained from leukemia patients (n = 5) and healthy controls (n = 5). (D) Graphs showing quantification of 
dye transfer from DiI-stained NALM6 cells towards 3 different primary MSCs with (red histograms) or without 
(grey histograms) TNT inhibition. 
See also supplementary Figures 4-8.
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Videos 3 and 4A). After 10 hours, the majority of MSCs became DiI-positive 
(supplementary Videos 3 and 4B), as confirmed by flow cytometry (Figure 1B).
TNTs are important players in signaling from BCP-ALL cells to MSCs
The above-mentioned findings suggest that TNT signaling is a highly effective 
communication mechanism between ALL cells and MSCs. This was further illustrated 
by comparing TNT signaling to other intercellular communication mechanisms, 
including gap junctions, integrins and ECV (Figure 4A). Dye transfer from leukemic 
cells towards MSCs was minimal using a 3.0 μm transwell system, in which ECV 
signaling is possible (> 500 fold lower compared to normal co-culture after 24 
hours; p ≤ 0.001; Figure 4B-C). Transfer experiments with the gap junction-specific 
dye Calcein revealed that signaling from leukemic cells towards primary MSCs via 
gap junctions is highly ineffective compared to signaling via TNTs (> 90 fold lower 
after 24 hours; p ≤ 0.001; Figure 4D-E). Integrin signaling has been implicated in the 
induction of TNTs42, raising the question whether TNTs function autonomously or in 
an integrin-dependent manner. To inhibit integrin signaling between BCP-ALL cells 
and MSCs, we used RGDS-peptides, reported to prevent the binding of integrins to 
membranes43. RGDS negatively affected the efficiency of lipophilic dye transfer via 
TNTs whereas the transfer in the presence of negative control peptides (GRADSP) 
remained unaffected (Figure 4F). The reduction in lipophilic dye transfer was limited 
to a maximum of 30% (p ≤ 0.01). Taken together, these data reveal that TNT signaling 
acts independently of other important intercellular communication mechanisms, i.e. 
signaling via extracellular vesicles, gap junctions, and integrins.
BCP-ALL cells use TNTs to drive cytokine release within the microenvironment
The question remains how TNT signaling from leukemic cells affect their 
microenvironment. Since cytokines and chemokines can greatly affect the survival 
of leukemic cells44,45, we considered that the microenvironment responds to TNT 
signaling by secreting supportive soluble factors. Therefore we investigated the 
secreted levels of 64 known cytokines/chemokines in co-cultures of primary 
leukemic cells of two BCP-ALL patients with different sources of primary MSCs. 
Co-culture of these cells induced the secretion of several cytokines. The cytokine 
signature produced within co-cultures suggested that this secretion was leukemia-
driven and independent of the MSC source (Figure 5). IP10/CXCL10 levels increased 
more than 1000-fold when patient ALL#7 cells were co-cultured with MSCs, but 
were undetectable in co-cultures from patient ALL#9 cells (Figure 5A and 5E). 
Likewise, MDC/CCL22 and TARC/CCL17, both undetectable in patient ALL#7 co-
cultures, were induced 6-18 fold when patient ALL#9 cells were co-cultured with 
MSCs (Figure 5C-D and 5G-H). Interleukin-8 (IL8) levels were induced (2-7 fold) 
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Figure 3. Dynamic nature of TNT formation between BCP-ALL cells and MSCs.
(A-C) Time-lapse confocal images (3D image stacks) showing TNT formation (white arrowhead) between NALM6 
cells (DiI, yellow) and  primary MSCs at multiple time points. White arrow indicates transfer of dye to recipient 
cell. Time indicated in the right lower corner is the duration from start of the experiment. Orange Hot look-up table 
(LUT) and transmission overlays were used to illustrate dye transfer towards MSCs. Scale bars represent 10 μm.
(A and C) Depicted images are close-ups of the upper left corner of supplementary Video 3. (B) Depicted images 
are close-ups of supplementary Video 4A.
Data is representative of three independent experiments. See also supplementary Figure 5 and supplementary 
Videos 3 and 4A-B. 
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by primary ALL cells from both patients (Figure 5B and 5F). Cytokines that were 
induced less than 2 fold in co-culture are shown in supplementary Figure 9. Only a 
limited number of cytokines/chemokines were found to be significantly upregulated 
in patients’ ALL-MSC co-cultures compared to mono-cultures of both cell types. Also 
in a proliferative setting (using the BCP-ALL cell line NALM6), a limited number of 
known cytokines were upregulated in co-culture with two different primary MSCs: 
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Figure 4. TNTs are important players in signaling from BCP-ALL cells to MSCs.
(A) Model of crosstalk between leukemic cells and MSCs in the hematopoietic niche. (B) Graphs showing quanti-
fication of dye transfer from DiI-stained NALM6 cells towards unstained hTERT-MSCs. Blue and grey histograms 
represent staining intensity at the start of each experiment. Red histogram represents signaling efficiency via TNTs 
(normal co-culture; left panel) and via extracellular vesicles (ECV) (3.0 μm transwell; right panel).
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IL8 and VEGF levels were on average induced 2 and 3 fold respectively (n=3, p ≤ 0.01, 
Supplementary Figure 9E-H). These MSC-independent and leukemia-consistent 
cytokine signatures suggest that leukemic cells, and not MSCs, are responsible for 
the active modulation of the tumor microenvironment. 
Induction of the observed cytokines was dependent on TNT signaling, as TNT 
inhibition significantly lowered the secreted levels of these factors (Figure 5A-H, 
Supplementary Figure 9E-H). However, TNT inhibition only partly reversed the 
induction of cytokine levels in ALL-MSC co-cultures, suggesting that, next to TNT 
signaling, other intercellular signaling routes contribute to the induction of these 
secretomes. 
Figure 4. TNTs are important players in signaling from BCP-ALL cells to MSCs. (continued)
(C) Bar graphs of experiment shown in (B) after 6 hours (left panel) and 24 hours (right panel) of co-culture (n = 4; 
two-tailed t-test, unpaired). (D) Graphs showing quantification of dye transfer from BCP-ALL cell line NALM6, 
stained with either DiI or calcein, towards primary MSCs after 24 hours of co-culture. Blue and grey histograms 
represent staining intensity at the start of each experiment. Red histogram shows signaling efficiency via TNTs 
(left panel) and via gap junctions (right panel). (E) Bar graphs of experiment shown in (D) after 8 hours (n = 6; left 
panel) and 24 hours (n = 4; right panel) of co-culture (two-tailed t-test, unpaired). (F) Bar graphs representing dye 
transfer from DiI-stained REH cells towards unstained primary MSCs with and without integrin blocking. Integrin 
signaling was blocked by addition of RGDS peptide, and compared to addition of the integrin non-binding peptide 
GRADSP (n = 5; one-tailed t-test, paired).
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Figure 5. BCP-ALL cells use TNTs to drive cytokine release within the microenvironment.
(A) IP10/CXCL10 supernatant levels in co-culture of primary leukemic patient ALL#7 cells with primary MSC#1 
(left panel), MSC#2 (middle panel), or MSC#3 (right panel). TNT signaling was inhibited by gentle shaking or 
culture in a transwell system (one-tailed t-test, unpaired). (B) Same as (A) for IL8 levels. (C) Same as (A) for MDC 
(CCL22) levels. (D) Same as (A) for TARC (CCL17) levels. (E) IP10/CXCL10 supernatant levels in co-culture of pri-
mary leukemic patient ALL#9 cells with primary MSC#4 (left panel), or MSC#5 (right panel). (F) Same as (E) for IL8 
levels. (G) Same as (E) for MDC (CCL22) levels. (H) Same as (E) for TARC (CCL17) levels. 
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01. nd = not detectable (below detection level). 
See also supplementary Figure 9.
TNT signaling is important for the survival of primary BCP-ALL cells
Several studies have shown the importance of the microenvironment for the survival 
of malignant cells, but without elucidating how46. In order to study the effect of TNT 
signaling on leukemic cell viability, we used ex vivo co-cultures of primary BCP-ALL 
cells and primary MSCs (see table S1 for BCP-ALL subtype information, Figure 6A 
for gating strategy). Primary BCP-ALL cell survival significantly increased in 5-day 
co-cultures with primary MSCs compared to mono-cultures. When TNT formation 
was prevented by shaking of co-cultures or by transwell conditions, this increase 
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significantly reduced 3.5- and 3.6-fold, respectively (n = 7, p ≤ 0.001; Figure 6B-D). 
The effect of TNT inhibition was consistent across leukemic cells from multiple 
cytogenetic BCP-ALL subgroups (TEL-AML1, BCR-ABL1-like, and B-Other). 
Inhibition of TNTs sensitizes BCP-ALL cells to prednisolone
We investigated whether inhibition of TNT signaling also affects the response of 
leukemic cells to chemotherapeutic drugs. BCP-ALL patient cells were treated with 
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Figure 6. TNT signaling is important for the survival of primary BCP-ALL cells.
(A) Flow chart and flow cytometrical gating strategy used to study the effect of TNTs on BCP-ALL cell survival. 
Co-cultures of CD19positive leukemic cells and CD19negative MSCs were stained with Brilliant Violet 421™ anti-human 
CD19 antibody, FITC Annexin V, and Propidium Iodide (PI). MSCs were excluded (red gate), and the percentage 
of viable BCP-ALL blasts (AnnexinVneg/PIneg/CD19pos cells) was determined within the MSC-negative fraction. (B) 
Percentage of viable primary leukemic patient cells (n = 3 TEL-AML1, n = 2 B-Other, n = 2 BCR-ABL1-like) in mono-
culture (black bars) or co-culture with patient MSCs (white bars) after 5-day co-culture. (C) The survival benefit 
for primary leukemic patient cells (n = 3 TEL-AML1, n = 2 B-Other, n = 2 BCR-ABL1-like) in co-culture with patient 
MSCs. (D) The mean survival benefit for primary leukemic patient cells in co-culture with patient MSCs (n = 7; 
one-tailed t-test, paired).
Data are means ± SEM; *** p ≤ 0.001.
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the ALL spearhead drug prednisolone for 5 days. Prednisolone was less effective 
in inducing apoptosis of primary BCP-ALL cells in the presence of primary MSCs 
compared to mono-cultures of primary BCP-ALL cells (70% vs 5% reduced viability; 
p ≥ 0.001; Figure 7A), underlining the importance of MSCs in the induction of 
prednisolone resistance (Figure 7A). The protective effect of MSCs was significantly 
reduced by 2-3 fold (n = 4, p ≤ 0.001; Figure 7A) when TNT signaling was inhibited. 
TNT inhibition alone was not sufficient to abrogate all microenvironment-induced 
drug resistance. In shaking and transwell conditions, which allow signaling 
via integrins, soluble factors or ECVs, microenvironment-induced resistance to 
prednisolone was still present (p ≥ 0.01). Since ex vivo cultured leukemic patient cells 
lose their propensity to proliferate, we also addressed the effect of TNT signaling on 
drug resistance in a proliferative setting using the BCP-ALL cell line NALM6. Similar 
to primary BCP-ALL cells, co-culture with MSCs induced prednisolone resistance of 
NALM6 cells (Figure 7B). Inhibition of TNT formation by shaking of co-cultures or 
transwell conditions significantly reduced this effect 4.5- and 8.5- fold, respectively (p 
≤ 0.01; Figure 7B and supplementary Figure 10A-B). These data show that inhibition 
of TNT signaling in co-cultures sensitizes BCP-ALL cells to the anti-leukemic effects 
of prednisolone in both a primary non-proliferative and a proliferative setting.
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Figure 7. Inhibition of TNTs sensitizes BCP-
ALL cells to prednisolone.
(A) Leukemic cell survival of patient ALL#6 cells 
cultured with or without MSCs after 5 days of pred-
nisolone exposure (0.3 μg/mL). All graphs show 
percentage compared to untreated control. TNT 
signaling was inhibited by shaking or transwell con-
ditions (one-tailed t-test, unpaired). Quadruplicates 
represent four different sources of MSCs (MSC#1, 
MSC#2, MSC#6, MSC#7). (B) Leukemic cell survival 
of BCP-ALL cell line NALM6 cultured with or with-
out MSCs after 5 days of prednisolone exposure. 
All graphs show percentage compared to untreated 
control. TNT signaling was inhibited by shaking or 
transwell conditions (one-tailed t-test, unpaired). 
Triplicates represent three different sources of MSCs 
(hTERT, MSC#1, and MSC#2).
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01. See also 
supplementary Figure 10.
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DISCUSSION
The presented study identifies TNT formation as a novel regulator of interaction 
between BCP-ALL cells and their bone marrow niche, which facilitates signaling from 
leukemic cells towards MSCs and affects the release of cytokines and chemokines 
in the microenvironment. Disruption of TNTs inhibits this release, decreases the 
survival benefit that MSCs provide to primary BCP-ALL cells, and sensitizes BCP-
ALL cells to the important anti-leukemic drug prednisolone (Figure 8).
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Figure 8. Model of the TNT-driven leukemic niche.
Model depicting the role of TNT signaling in  leukemic niche formation. Leukemic cells use TNTs to modulate their 
microenvironment by directing non-malignant stromal cells to produce pro-survival cytokines and chemokines. 
This leukemic niche promotes cell survival and drug resistance and can be disrupted by inhibiting TNT signaling.
Relapse of leukemia is caused by a small number of leukemic cells that are able 
to withstand chemotherapy and can cause the complete reconstitution of the 
tumor. Leukemogenic mouse models show the importance of signaling between 
leukemic cells and their bone marrow microenvironment and emphasize the 
pathophysiological relevance of cytokines within the leukemic niche1,47-49. However, 
a major shortcoming in our knowledge about the leukemic niche is the lack of insight 
into the functional mechanism mediating crosstalk between leukemic cells and their 
local niche. Our data adds significant insight into this process and provides an 
opportunity to inhibit the leukemic niche. Importantly, primary BCP-ALL cells use 
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TNTs to modulate their microenvironment, identifying the leukemic cell, and not 
MSCs, as the driver of niche modulation. 
Although less pronounced as seen between ALL cells and MSCs, TNTs are 
also used for communication between leukemic cells. This discovery may reveal 
a new aspect of tumor heterogeneity. In many cancer types, clonal evolution has 
been observed50. A recent study in T-ALL by Blackburn et al. shows that leukemia 
subclones acquire mutations, that can mediate chemotherapy resistance even 
without prior drug exposure51. Leukemic cells might exploit TNTs, which can 
transfer a broad spectrum of molecules and organelles like membrane-associated 
signaling molecules (e.g. H-Ras19), to transfer mutant proteins and subsequently 
chemotherapy resistance between subclones.
Several studies report that the leukemic niche can induce drug resistance for both 
classical chemotherapeutic agents and newly developed targeted therapies9,44-46,52-54. 
The seminal papers by Strausmann et al, and Wilson et al. revealed the widespread 
potential for growth-factor-driven resistance to kinase inhibitors in several tumor 
types. A recent study by Manshouri et al., showed the induction of resistance against 
JAK2 inhibitors by bone marrow stroma-secreted cytokines in JAK2-mutated 
primary hematopoietic cells. BCP-ALL cells use TNTs to induce a pro-inflammatory 
cytokine signature within their microenvironment55. These cytokines have been 
reported to be involved in leukemia survival and resistance to therapy, like IP10/
CXCL1054, IL-856, and MCP-1/CCL257. When TNTs were inhibited, this signature was 
partly reversed and simultaneously leukemic cell survival was decreased. Since these 
cytokines also have a chemoattractive function, it is likely that migration towards the 
stromal compartments of the niche and subsequent induction of contact-dependent 
signaling modules, like integrins and gap junctions, also play a role in this process. 
Further, we observed TNT signaling from MSCs towards leukemic cells, which 
might also influence drug resistance of leukemic cells. For example, TNTs have been 
shown to transport drug-efflux pumps such as P-glycoproteins24, and to transport 
mitochondria preferentially towards cancer cells28. 
Interestingly, we observed leukemia-specific cytokine patterns in MSC-ALL 
co-cultures that were affected by abrogation of TNT signaling. This observation 
opens the discussion how TNT signaling can lead to the upregulation of different 
soluble factors. The broad spectrum of signaling molecules that are transported by 
TNTs potentially allows the ALL to convey specific messages to MSCs in order to 
differentially regulate the secretion of soluble factors by its microenvironment. In 
addition, leukemia is a highly heterogeneous disease consisting of different (cyto)
genetic subtypes that also have individual heterogeneity with regards to their 
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transcriptome and proteome58. These factors are all likely to contribute to leukemia-
unique demands for microenvironmental support.
Targeting TNT-directed communication between leukemic cells and their supportive 
niche may be a promising new approach to kill leukemic cells and prevent drug 
resistance in clinical practice. As of yet, no agents are available that induce specific 
inhibition of TNT signaling, but our data point to the importance to develop such 
agents. TNT signaling can be disrupted through shear stress, applying a physical 
distance between the cells, actin inhibition, and in some cases tubulin inhibition. 
In additional experiments, we observed that tubulin inhibition did not inhibit 
TNT signaling between BCP-ALL cells and MSCs (data not shown). The common 
building block for all TNTs reported in literature is F-actin, making it an obvious 
target for TNT disruption. Actin inhibitors are derived from fungi, plants and 
sponges, which developed these toxins as a defense mechanism. Consequently, 
these compounds inhibit TNT formation (Figure 1E-F) and induce cell death (data 
not shown). Therefore, it is important to develop more specific and less-toxic small 
molecule inhibitors that target elements of the actin cytoskeleton important for TNT 
formation. We propose our primary patient-derived ex vivo model system as a highly 
suitable platform to identify such inhibitors. Once identified, these TNT-specific 
agents will allow us to investigate TNT signaling also in vivo.  
In conclusion, the discovery of TNT signaling between BCP-ALL cells 
and mesenchymal stromal cells adds significant insight into the mechanisms of 
communication in the leukemic niche. BCP-ALL cells use TNT networks to modify 
their healthy microenvironment and hereby create a leukemic niche that induces 
survival and drug resistance. Current chemotherapeutic regimens are primarily 
focused on combating tumor intrinsic properties. Our data provide a new concept 
to develop alternative therapeutic strategies that include targeting of the leukemic 
niche in B-cell acute lymphoblastic leukemia.
Acknowledgements
We thank all members of the research laboratory Pediatric Oncology of the Erasmus 
MC for their help in processing leukemic and mesenchymal stromal cell samples, in 
particular L.C.J. van den Berk, C. van de Ven, and F. Meijers-Stalpers; M. Buitenhuis 
and M. Bierings for critical discussions and reading of the manuscript; D. Geerts 
for scientific input and critical discussions; The Erasmus Optical Imaging Centre for 
providing support of CLSM; The Department of Hematology of the Erasmus MC 
for providing the use of CLSM and Flow Cytometers; The Vlietland Ziekenhuis for 
collecting and providing cord blood. The work described in this paper was funded 
by the KiKa Foundation (Stichting Kinderen Kankervrij – Kika-39), the Dutch 
156 Chapter 5
Cancer Society (UVA 2008; 4265, EMCR 2010; 4687), the Netherlands Organization 
for Scientific Research (NWO – VICI M.L. den Boer) and the Pediatric Oncology 
Foundation Rotterdam.
Author contributions
Co-first authors R. Polak and B. de Rooij contributed equally to the study and are 
listed alphabetically. R. Polak and B. de Rooij designed the study, performed the 
experiments, collected and analyzed all data, and wrote the paper. M.L. den Boer 
designed the study, analyzed data, and wrote the paper. R. Pieters analyzed data 
and wrote the paper. All authors discussed the results and approved the submitted 
manuscript.
Conflict of interest disclosure
the authors declare no competing financial interests.
Tunneling nanotube signaling in the leukemic niche 157
5
REFERENCES
 1. Colmone, A., et al. Leukemic cells create bone marrow niches that disrupt the behavior of 
normal hematopoietic progenitor cells. Science 322, 1861-1865 (2008).
 2. Flynn, C.M. & Kaufman, D.S. Donor cell leukemia: insight into cancer stem cells and the stem 
cell niche. Blood 109, 2688-2692 (2007).
 3. Raaijmakers, M.H., et al. Bone progenitor dysfunction induces myelodysplasia and secondary 
leukaemia. Nature 464, 852-857 (2010).
 4. Walkley, C.R., et al. A microenvironment-induced myeloproliferative syndrome caused by 
retinoic acid receptor gamma deficiency. Cell 129, 1097-1110 (2007).
 5. Walkley, C.R., Shea, J.M., Sims, N.A., Purton, L.E. & Orkin, S.H. Rb regulates interactions 
between hematopoietic stem cells and their bone marrow microenvironment. Cell 129, 1081-
1095 (2007).
 6. Yilmaz, O.H., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-
initiating cells. Nature 441, 475-482 (2006).
 7. Arai, F., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in 
the bone marrow niche. Cell 118, 149-161 (2004).
 8. Fujisaki, J., et al. In vivo imaging of Treg cells providing immune privilege to the 
haematopoietic stem-cell niche. Nature 474, 216-219 (2011).
 9. McMillin, D.W., et al. Tumor cell-specific bioluminescence platform to identify stroma-
induced changes to anticancer drug activity. Nat Med 16, 483-489 (2010).
 10. Nakasone, E.S., et al. Imaging tumor-stroma interactions during chemotherapy reveals 
contributions of the microenvironment to resistance. Cancer Cell 21, 488-503 (2012).
 11. Jin, L., Hope, K.J., Zhai, Q., Smadja-Joffe, F. & Dick, J.E. Targeting of CD44 eradicates human 
acute myeloid leukemic stem cells. Nat Med 12, 1167-1174 (2006).
 12. Matsunaga, T., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a 
decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9, 1158-
1165 (2003).
 13. Nervi, B., et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization 
by the CXCR4 antagonist AMD3100. Blood 113, 6206-6214 (2009).
 14. Sipkins, D.A., et al. In vivo imaging of specialized bone marrow endothelial microdomains 
for tumour engraftment. Nature 435, 969-973 (2005).
 15. Tavor, S., et al. CXCR4 regulates migration and development of human acute myelogenous 
leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64, 2817-2824 (2004).
 16. Zeng, Z., et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes 
resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215-6224 (2009).
 17. Chauveau, A., Aucher, A., Eissmann, P., Vivier, E. & Davis, D.M. Membrane nanotubes 
facilitate long-distance interactions between natural killer cells and target cells. Proc Natl Acad 
Sci U S A 107, 5545-5550 (2010).
 18. Onfelt, B., Nedvetzki, S., Yanagi, K. & Davis, D.M. Cutting edge: Membrane nanotubes 
connect immune cells. J Immunol 173, 1511-1513 (2004).
 19. Rainy, N., et al. H-Ras transfers from B to T cells via tunneling nanotubes. Cell Death Dis 4, 
e726 (2013).
 20. Rustom, A., Saffrich, R., Markovic, I., Walther, P. & Gerdes, H.H. Nanotubular highways for 
intercellular organelle transport. Science 303, 1007-1010 (2004).
158 Chapter 5
 21. Sowinski, S., et al. Membrane nanotubes physically connect T cells over long distances 
presenting a novel route for HIV-1 transmission. Nat Cell Biol 10, 211-219 (2008).
 22. Watkins, S.C. & Salter, R.D. Functional connectivity between immune cells mediated by 
tunneling nanotubules. Immunity 23, 309-318 (2005).
 23. Arkwright, P.D., et al. Fas stimulation of T lymphocytes promotes rapid intercellular exchange 
of death signals via membrane nanotubes. Cell Res 20, 72-88 (2010).
 24. Pasquier, J., et al. Different modalities of intercellular membrane exchanges mediate cell-to-
cell p-glycoprotein transfers in MCF-7 breast cancer cells. J Biol Chem 287, 7374-7387 (2012).
 25. Chinnery, H.R., Pearlman, E. & McMenamin, P.G. Cutting edge: Membrane nanotubes in 
vivo: a feature of MHC class II+ cells in the mouse cornea. J Immunol 180, 5779-5783 (2008).
 26. Marzo, L., Gousset, K. & Zurzolo, C. Multifaceted roles of tunneling nanotubes in intercellular 
communication. Front Physiol 3, 72 (2012).
 27. Seyed-Razavi, Y., Hickey, M.J., Kuffova, L., McMenamin, P.G. & Chinnery, H.R. Membrane 
nanotubes in myeloid cells in the adult mouse cornea represent a novel mode of immune cell 
interaction. Immunol Cell Biol 91, 89-95 (2013).
 28. Pasquier, J., et al. Preferential transfer of mitochondria from endothelial to cancer cells 
through tunneling nanotubes modulates chemoresistance. J Transl Med 11, 94 (2013).
 29. Lou, E., et al. Tunneling nanotubes provide a unique conduit for intercellular transfer of 
cellular contents in human malignant pleural mesothelioma. PLoS One 7, e33093 (2012).
 30. Gousset, K., et al. Prions hijack tunnelling nanotubes for intercellular spread. Nat Cell Biol 11, 
328-336 (2009).
 31. Den Boer, M.L., et al. Patient stratification based on prednisolone-vincristine-asparaginase 
resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 21, 3262-3268 
(2003).
 32. van den Berk, L.C., et al. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute 
lymphoblastic leukaemia. Br J Haematol 166, 240-249 (2014).
 33. Sowinski, S., Alakoskela, J.M., Jolly, C. & Davis, D.M. Optimized methods for imaging 
membrane nanotubes between T cells and trafficking of HIV-1. Methods 53, 27-33 (2011).
 34. Schindelin, J., et al. Fiji: an open-source platform for biological-image analysis. Nat Methods 9, 
676-682 (2012).
 35. Sourisseau, M., Sol-Foulon, N., Porrot, F., Blanchet, F. & Schwartz, O. Inefficient human 
immunodeficiency virus replication in mobile lymphocytes. J Virol 81, 1000-1012 (2007).
 36. Gyorgy, B., et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular 
vesicles. Cellular and molecular life sciences : CMLS 68, 2667-2688 (2011).
 37. Lo Celso, C., et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in 
their niche. Nature 457, 92-96 (2009).
 38. Alon, R. & Dustin, M.L. Force as a facilitator of integrin conformational changes during 
leukocyte arrest on blood vessels and antigen-presenting cells. Immunity 26, 17-27 (2007).
 39. Alon, R. & Ley, K. Cells on the run: shear-regulated integrin activation in leukocyte rolling 
and arrest on endothelial cells. Curr Opin Cell Biol 20, 525-532 (2008).
 40. Huang, F.Y., et al. The antitumour activities induced by pegylated liposomal cytochalasin D 
in murine models. Eur J Cancer 48, 2260-2269 (2012).
 41. Salu, K.J., et al. Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine 
coronary artery model. Cardiovasc Res 69, 536-544 (2006).
 42. Obermajer, N., et al. Cathepsin X-mediated beta2 integrin activation results in nanotube 
outgrowth. Cellular and molecular life sciences : CMLS 66, 1126-1134 (2009).
Tunneling nanotube signaling in the leukemic niche 159
5
 43. Ruoslahti, E. & Pierschbacher, M.D. New perspectives in cell adhesion: RGD and integrins. 
Science 238, 491-497 (1987).
 44. Straussman, R., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors 
through HGF secretion. Nature 487, 500-504 (2012).
 45. Wilson, T.R., et al. Widespread potential for growth-factor-driven resistance to anticancer 
kinase inhibitors. Nature 487, 505-509 (2012).
 46. McMillin, D.W., Negri, J.M. & Mitsiades, C.S. The role of tumour-stromal interactions in 
modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12, 217-228 
(2013).
 47. Medyouf, H., et al. Myelodysplastic Cells in Patients Reprogram Mesenchymal Stromal Cells 
to Establish a Transplantable Stem Cell Niche Disease Unit. Cell Stem Cell (2014).
 48. Schepers, K., et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche 
into a self-reinforcing leukemic niche. Cell Stem Cell 13, 285-299 (2013).
 49. Zhang, B., et al. Altered microenvironmental regulation of leukemic and normal stem cells in 
chronic myelogenous leukemia. Cancer Cell 21, 577-592 (2012).
 50. Greaves, M. & Maley, C.C. Clonal evolution in cancer. Nature 481, 306-313 (2012).
 51. Blackburn, J.S., et al. Clonal Evolution Enhances Leukemia-Propagating Cell Frequency in T 
Cell Acute Lymphoblastic Leukemia through Akt/mTORC1 Pathway Activation. Cancer Cell 
(2014).
 52. Konopleva, M.Y. & Jordan, C.T. Leukemia stem cells and microenvironment: biology and 
therapeutic targeting. J Clin Oncol 29, 591-599 (2011).
 53. Pallasch, C.P., et al. Sensitizing protective tumor microenvironments to antibody-mediated 
therapy. Cell 156, 590-602 (2014).
 54. Manshouri, T., et al. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated 
cells from the effects of a JAK2 inhibitor. Cancer Res 71, 3831-3840 (2011).
 55. Bernardo, M.E. & Fibbe, W.E. Mesenchymal stromal cells: sensors and switchers of 
inflammation. Cell Stem Cell 13, 392-402 (2013).
 56. Francia di Celle, P., et al. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic 
leukemia cells by prolonging survival in an autocrine fashion. Blood 87, 4382-4389 (1996).
 57. Burgess, M., et al. CCL2 and CXCL2 enhance survival of primary chronic lymphocytic 
leukemia cells in vitro. Leuk Lymphoma 53, 1988-1998 (2012).
 58. Roberts, K.G. & Mullighan, C.G. Genomics in acute lymphoblastic leukaemia: insights and 
treatment implications. Nat Rev Clin Oncol 12, 344-357 (2015).
160 Chapter 5
SUPPLEMENTARY DATA 
SUPPLEMENTARY METHODS
Cell lines and reagents
B-cell precursor ALL (BCP-ALL) cell lines, NALM6 (B-Other) and REH (TEL-AML1), 
are obtained from DSMZ (Braunschweig, Germany), are used only at low cell 
passages, and are routinely verified by DNA fingerprinting. Cell lines were cultured 
in RPMI-1640 medium (Invitrogen, Life Technologies, Breda, the Netherlands) 
containing 10% fetal calf serum (FCS; Integro, Zaandam, The Netherlands), 1% 
penicillin-streptomycin at 37 °C and 5% CO2. Immortalized hTERT-MSCs (a kind 
gift from Prof. Dr. D. Campana, St. Jude Children’s Hospital, Memphis, TN, USA) 
were cultured in Dulbecco’s modified Eagle medium (DMEM) low glucose medium 
(Invitrogen), containing 15% FCS, 1% penicillin-streptomycin, 100 μM ascorbic 
acid (Sigma, St Louis, MO, USA) and 1 ng/mL basic fibroblast growth factor (bFGF; 
Serotec, Kidlington, UK) at 37°C and 5% CO2.
Isolation of primary BCP-ALL leukemic blasts from patients
Bone marrow aspirates were obtained from children with newly diagnosed B-cell 
precursor (BCP) ALL prior to treatment. Immunophenotype and genetic subtype 
were determined by local hospital procedures and monitored by the central 
diagnostic laboratory of the Dutch Childhood Oncology Group (DCOG) in The 
Hague. Mononuclear cells were collected using Lymphoprep sucrose-gradient 
centrifugation (1.077 g/mL; Nycomed Pharma, Oslo, Norway). The percentage of 
processed leukemic cells was determined using May-Grünwald-Giemsa staining 
of cytospin preparations. All samples used in this study contained ≥97% leukemic 
blasts. CD19-expression of leukemic blasts was determined for all samples with 
flow cytometry or fluorescence microscopy. Brilliant Violet 421 anti-human CD19 
antibody (Biolegend, San Diego, CA, USA) was used to stain patient cells after which 
flow cytometry was performed. For fluorescence microscopy cells were allowed 
to attach on fibronectin-coated glass slides, fixated with 2% paraformaldehyde 
and stained with monoclonal mouse anti-human CD19 antibody (IQ Products, 
Groningen, The Netherlands) and DyLight-488 goat anti-mouse IgG (Biolegend). 
The cytogenetic subtype was determined by the central diagnostic laboratory and 
is summarized in table S1. Cells were cultured in RPMI Dutch-modified medium 
(Invitrogen) containing 20% FCS, Insulin transferrin sodium selenite (ITS), glutamin, 
and gentamycin at 37 °C and 5% CO2. Bone marrow aspirates were obtained after 
informed consent was signed according to the Declaration of Helsinki. Protocols 
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were approved by the ethics committee of the Erasmus University Medical Center 
in Rotterdam.
Isolation and characterization of healthy and leukemic primary MSCs
Mesenchymal stromal cells (MSCs) were isolated from bone marrow aspirates 
taken during diagnostic procedures as indicated above. Colony-forming MSCs 
were selected by culturing in DMEM medium modified as above at 37 °C and 5% 
CO2. Primary MSCs were characterized using positive (CD44/ CD90/ CD105/ CD54/ 
CD73/ CD146/ CD166/ STRO-1) and negative surface markers (CD19/ CD45/ CD34). 
Expression of surface markers was measured with flow cytometry using the human 
mesenchymal stem cell marker antibody panel (R&D Systems, Minneapolis, MN, 
USA) and CD54-PE, CD73-PE, CD34-PE, IgG1-PE monoclonal antibodies (BD 
Biosciences, San Jose, CA, USA). Multilineage potential of MSCs was confirmed for 
adipocyte (Oil Red O staining), osteocyte (Alizarin Red S staining), and chondrocyte 
(Col2a/ Thionine/ Alcian Blue staining) differentiation.
Confocal laser scanning microscopy 
To assess the formation of TNTs we used confocal scanning microscopy of fixated 
co-cultures as well as time-lapse imaging of co-cultures. In all experiments BCP-
ALL cell lines (REH and NALM6) or primary leukemic cells were co-cultured with 
primary or hTERT-immortalized MSCs in a 4:1 ratio. These conditions represent 
50-60% MSC confluence and normal leukemic cell culture conditions (200.000 cells/
mL). For high resolution images, differentially stained cells were cultured on a glass 
slide coated with 10 μg/mL fibronectin (Sigma) at 37 °C and 5% CO2. Cells were 
fixated after 3 or 24 hours using 1.5% glutaraldehyde, 2% formaldehyde in PBS for 
10 minutes at room temperature, as previously described56. After fixation, slides 
were mounted with ProLong Gold antifade reagent (Life Technologies) and imaged 
using a confocal laser scanning microscopy (Leica SP5). Images were acquired with 
sequential scanning of different channels at a resolution of 1024 x 1024 pixels in the 
x x y plane and 0.15 μm steps in z-direction. For time-lapse imaging, DiO-stained 
MSCs were allowed to attach to a glass slide before start of the experiment. At start 
of experiment, DiI-stained leukemic cells were added and imaged using a confocal 
laser scanning microscope (Leica SP5). Cultures were maintained at 37°C on a heated 
stage and at 5% CO2 and imaged starting roughly 5 minutes after the start of the 
co-culture. Images were acquired every 3.3 minutes for a total duration of 10 hours 
with sequential scanning of different channels at a resolution of 512 x 512 pixels in 
the x x y plane and 0.5 μm steps in z-direction. 
3D image stacks were acquired by optical sectioning using the LAS software 
provided with the instrument. The system was equipped with a 63× plan-
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apochromatic oil 1.4 NA DIC objective. The pinhole diameter was set to 1 airy unit 
(95.5 μm). DiO and DiI were excited with a 488-nm Argon laser and a 561-nm Diode-
Pumped Solid-State laser, respectively. Phalloidin-FITC was excited with the 488-nm 
Argon laser. Transmission images were obtained using the 488-nm Argon laser. 
Image processing was done with Fiji software. Brightness and contrast were 
optimized and applied to the entire image. Z-project using all sides and maximum 
intensity projection was used to analyze 3D image stacks. For 3D projections, 
standard settings with brightest point projection were used.
Flow cytometry
Leukemic cells were co-cultured with MSCs. To quantify TNT signaling from leukemic 
cells to MSCs, leukemic cells were stained with DiI (5 μL per 106 cells, 5 minutes at 37 
°C) and thereafter co-cultured with unstained MSCs for the indicated time periods. 
In dye transfer experiments presented in Figure 1A and 1E-F, Figure 2B-D, Figure 
4B-F, supplementary Figure 3, and supplementary Figure 8, leukemic cells were co-
cultured with MSCs in a 4:1 ratio. To allow a fair comparison between dye transfer 
from leukemic cells to MSCs versus dye transfer from MSCs towards leukemic cells, 
leukemic cells were co-cultured with MSCs in a 1:1 ratio for experiments shown 
in Figure 1C-D. Signaling via gap junctions from leukemic cells towards MSCs 
was quantified in a similar fashion using BCP-ALL cell lines stained with Calcein 
Red-Orange AM (2 μM, 30 minutes at room temperature). DiI-stained MSCs were 
co-cultured with unstained leukemic cells to quantify TNT signaling from MSCs 
towards leukemic cells. After co-cultures, cells were stained with Brilliant Violet 421 
anti-human CD19 antibody (Biolegend). Dye transfer towards the unstained fraction 
was assessed at different time points using flow cytometry (BD Bioscience). 
To quantify interleukemic TNT formation, BCP-ALL cell lines (REH and 
NALM6) were stained with DiO and mixed with an equal amount of cells stained 
with DiD (5 μL per 106 cells, 5 minutes at 37 °C). Double positive cells (DiOpos/DiDpos) 
were quantified after 24 hours as a measure of interleukemic TNT signaling by flow 
cytometry.
We used three independent experimental setups to inhibit TNT formation: 1) Inhibition 
of the actin cytoskeleton with 250 nM – 1 mM cytochalasin D (Sigma) or 125 - 500 nM 
latrunculin B (Sigma).  2) Mechanical disruption of TNTs through gentle shaking (250 rpm) 
of cell cultures. 3) Prevention of TNT formation by applying a physical distance between 
leukemic cells and the MSCs using a 3.0 mm transwell system (Corning, NY, USA). To 
assess the contribution of integrins to TNT signaling, we used 20 - 100 mM Arg-Gly-Asp-Ser 
(RGDS) -peptide (Sigma) to inhibit integrins receptor binding. As a negative control, equal 
concentrations of the non-RGD containing peptide Gly-Arg-Ala-Asp-Ser-Pro (GRADSP; 
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Sigma, St Louis, USA) were used. All flow cytometry data was analyzed using FlowJo V10 
software (Treestar Inc., Ashland, USA).
Cell viability assays
Primary patient cells (1 x 106 cells) were co-cultured with or without primary 
mesenchymal stromal cells (5 x 104) for five days in a 24-well plate at 37 °C and 
5% CO2. Stromal cells were allowed to attach prior to the start of an experiment. 
Cells were cultured either static, with gentle shaking or in a 3.0 μm transwell system 
(leukemic cells in upper compartment, MSCs in bottom compartment). Before the 
start of each experiment, leukemic cells were screened for CD19 positivity (Brilliant 
Violet 421 anti-human CD19 antibody) and CD45 positivity  (Brilliant Violet 421 anti-
human CD45 antibody; Biolegend), which was used to discriminate leukemic cells 
from CD19neg/CD45neg MSCs. The percentage of viable leukemic cells was determined 
after 5 days of culture by staining with Brilliant Violet 421 anti-human CD19 or 
CD45 antibody (Biolegend), FITC Annexin V (Biolegend), and Propidium Iodide (PI; 
Sigma), after which the percentage of AnnexinVneg/PIneg/CD19pos/CD45pos cells within 
the MSC negative fraction (see Figure 6A for gating strategy) was determined by 
flow cytometry (BD Biosciences). 
To establish the effect of TNTs on cellular responsiveness to drugs, primary 
leukemic cells were exposed to prednisolone in a concentration which was lethal 
to 50% of the patient derived leukemic cells (LC50 in μg/mL) or which inhibited 
proliferation of NALM6 cell lines by 50% (GI50 in μg/mL) as determined upfront 
by a 4-day MTT assay41. Viable leukemic cells were counted (PIneg/CD19pos) using a 
MACSQuant analyzer (Miltenyi Biotec, Gladbach, Germany).
Multiplexed fluorescent bead-based immunoassay (Luminex)
Primary leukemic cells  or cell lines were co-cultured with different sources of 
primary MSCs with or without TNT inhibition (shaking or transwell condition) for 5 
days (3 days for cell lines) at 37 °C and 5% CO2. Next, supernatant was collected and 
cell viability of leukemic cells was assessed as described above. The concentration 
of 64 known cytokines/chemokines in these supernatants was analyzed using 
fluorescent bead-based immunoassay (Luminex Human Cytokine/Chemokine Panel 
I and II; Merck Millipore) according to the manufacturer’s protocol. 
164 Chapter 5
SUPPLEMENTARY TABLES
Supplementary Table 1. Characteristics of primary BCP-ALL cells.
Name Subtype Remarks
ALL#1 BCR-ABL1 -
ALL#2 TEL-AML1 -
ALL#3 TEL-AML1 -
ALL#4 TEL-AML1 -
ALL#5 B-Other E2A-rearranged subclone (21%)
ALL#6 B-Other -
ALL#7 BCR-ABL1-like -
ALL#8 BCR-ABL1-like Down syndrome
ALL#9 BCR-ABL1-like -
ALL#10 B-Other ETV6 loss
Supplementary Table 2. Characteristics of primary MSCs.
Name Subtype Remarks
MSC#1 B-Other -
MSC#2 TEL-AML1 -
MSC#3 B-Other -
MSC#4 Remission 1 year after treatment
MSC#5 AML -
MSC#6 Healthy -
MSC#7 Healthy -
MSC#8 Healthy -
MSC#9 Healthy -
MSC#10 Healthy -
MSC#11 B-Other -
MSC#12 TEL-AML1 -
MSC#13 CML -
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Supplementary Table 3. Cytokine secretion in mono and co-cultures of ALL and MSCs.
Cytokine MSCs ALL Co-culture* Cytokine MSCs ALL Co-culture*
6Ckine IL33
BCA-1 IL4
CTACK IL5
EGF x x IL6 x
ENA-78 IL7
Eotaxin x IL8 x x x
Eotaxin-2 IL9
Eotaxin-3 x IP10 x
FGF-2 x LIF
Flt3 Ligand MCP-1 x x
Fractalkine MCP-2
G-CSF MCP-3
GM-CSF x MCP-4
GRO x MDC x
I-309 MIP-1alpha x
IFNalpha2 MIP-1beta x
IFNgamma MIP-1delta
IL10 PDGF-AA x x
IL12 PDGF-BB x
p70 RANTES
IL13 sCD40L
IL15 SCF x
IL16 SDF1-alpha/beta x
IL17A TARC x
IL1alpha TGFalpha
IL1beta TNFalpha x
IL1-ra TNFbeta
IL2 TPO
IL20 TRAIL
IL21 TSLP
IL23 VEGF x x x
IL28a
IL3
*Crosses indicate upregulation of this cytokine in co-culture compared to  monocultures.
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SUPPLEMENTARY FIGURES
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Supplementary Figure 1. TNTs between BCP-ALL cells and MSCs.
(A-H) Interleukemic TNT networks (exemplified by white arrowheads) and exchange of lipophilic dye (exempli-
fied by arrows) between NALM6 (A-D) or REH (E-H) cells (DiI, yellow; DiO, green) were observed after 24 hours of 
co-culture. White arrows indicate transfer of dye to recipient cell. (I-L) TNT networks were formed and dye transfer 
was present between hTERT-immortalized MSCs (DiI, yellow; DiO, green). TNT-like structures also attached to 
the fibronectin-coated substratum (exemplified by orange arrowheads; right panel). Red arrowheads (left panel) 
represent ‘midbodies’. These midbodies look similar to TNTs, but are a short-lasting remainder of cell division. 
(M-P) Co-cultures of hTERT-immortalized MSCs (indicated by MSC) and BCP-ALL cell line NALM6 (indicated by 
LC) showed elaborate TNT networks and dye transfer after 3 hours of co-culture.  (Q-R) Phalloidin-FITC staining 
of F-actin, shows the presence of F-Actin in TNTs between BCP-ALL cells (NALM6) and MSCs (primary MSC#1). 
White arrowheads indicate TNTs. DAPI-staining (blue) was used to stain nuclei. 
Images M-P are 3D image stacks. Scale bars represent 10 μm.
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Supplementary Figure 2. TNT signaling between BCP-ALL cells.
(A) Representative confocal images showing TNT formation (white arrowhead) between two NALM6 cells (DiI, 
yellow; DiO, green) after co-culture for 24 hours. White arrow indicates transfer of dye to recipient cell. (B) DiD-
stained BCP-ALL NALM6 cells were cultured in a 1:1 ratio with DiO-stained BCP-ALL NALM6 cells for 24 hours. 
Double positive cells (DiD+/DiO+) were quantifi ed and used as a measure of interleukemic signaling. Right panel 
represents the start of the experiment. (C) Graphs showing quantifi cation of interleukemic dye transfer between 
NALM6 cells. Gentle shaking reduced interleukemic TNT signaling whereas culture in a 3.0 μm transwell system 
– in which leukemic cells reside in close contact - increased interleukemic TNT signaling.  (D) Bar graphs represent-
ing interleukemic dye transfer in TNT-inhibiting and TNT-inducing conditions, exemplifi ed in (C), compared to 
dye transfer in normal co-culture (n = 4; one-tailed t-test, paired).
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Supplementary Figure 3. Lipophilic dye transfer is caused by TNT signaling.
DiI-stained CD19pos BCP-ALL cells (NALM6 and REH) were co-cultured with unstained CD19neg hTERT-MSCs and 
transfer of DiI staining to hTERT-MSCs was analyzed by fl ow cytometry at the indicated time points. 
(A-C) Gating strategy for analysis of dye transfer from leukemic cells towards MSCs. Panel C represents the start 
of the experiment. (D) Quantifi cation of dye transfer showing effi  cient transfer from DiI-stained REH cells towards 
unstained hTERT-MSCs in time (cultured in 4:1 ratio). Data is representative of three independent experiments. 
(E-H) After 6 hours of co-culture, dye transfer from DiI –stained NALM6 cells towards unstained hTERT-MSCs 
was decreased using three independent TNT inhibiting conditions: actin inhibition (E: cytochalasin D, F: latrun-
culin B), physical disruption by gentle shaking (G), or culture in a 3.0 μm transwell system (H). TNT inhibition by 
gentle shaking, or culture in a 3.0 μm transwell system was continuous, while the inhibition of TNT signaling with 
actin inhibitors (observed after 6 hours of co-culture) was reversed after 24 hours, due to the short half-life of these 
inhibitors. Data is representative of three independent experiments.
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PMT-Trans 561 nm (Yellow) 561 nm (Yellow)
Supplementary Figure 4. TNT networks between primary cells.
(A-B) Culture of BCP-ALL patient cells showed interleukemic TNT formation (arrowhead) after 3 hours.  (C-F) 
Culture of BCP-ALL patient MSCs (c: MSC#1, d-f: MSC#2) showed the formation of intermesenchymal TNT net-
works (arrowheads) which have transferred dye (arrow) after 3 hours.  (G-J) TNT signaling between primary BCP-
ALL cells (DiI; yellow) and primary MSCs (DiO; green) after co-culture for 3 hours showed bidirectional exchange 
of lipophilic dye (arrows) via TNTs (white arrowheads).
Images are 3D image stacks. Data is representative of at least 3 experiments. Scale bars represent 10 μm.
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Supplementary Figure 5. Dynamics of TNT formation between primary cells.
(A) Time-lapse confocal images (3D image stacks) showing TNT formation (white arrowhead) between primary 
BCP-ALL cells (ALL#10; DiI, yellow) and  primary MSCs (pMSC#1; DiO, green) at multiple time points. White ar-
row indicates transfer of dye to recipient cell. Time indicated in the right lower corner is the duration from start of 
the experiment. Orange Hot look-up table (LUT) was used to visualize DiI. Scale bars represent 10 μm. (B-D) Single 
frames of time-lapse confocal microscopy experiments (3D image stacks) showing TNT formation and signaling 
from primary BCP-ALL cells (ALL#10; DiI, yellow) and primary MSCs (pMSC#1; DiO, green).
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Supplementary Figure 6. Surface marker expression of primary human MSCs.
All primary human MSCs were characterized using positive (CD44/ CD90/ CD105/ CD54/ CD73/ CD146/ CD166/ 
STRO-1) and negative surface markers (CD19/ CD45/ CD34). (A-D) Representative graphs showing the expression 
of surface markers on 4 primary MSCs. Blue graphs represent surface marker expression. Gray graphs represent 
expression of isotype controls. 
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Supplementary Figure 7. Characterization of primary leukemic blasts.
(A) The percentage of processed leukemic cells was determined using May-Grünwald-Giemsa staining of cytospin 
preparations. Images show representative cytospin preparation of leukemic blasts of patient ALL#3. Black arrow-
heads indicate lymphocytes. All other cells are scored as leukemic blasts. (B) Table containing blast percentages 
of primary BCP-ALL samples obtained by scoring at least 200 cells per sample. (C) CD19-expression of leukemic 
blasts was determined for all samples with fl ow cytometry or fl uorescence microscopy. Images are representative 
and show CD19 surface marker expression of leukemic blasts of patient ALL#3. Dot plots show CD19 surface 
marker expression of leukemic blasts of patient ALL#3 using fl ow cytometry.
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Supplementary Figure 8. TNT signaling to healthy and leukemic MSCs is similarly eﬃ  cient.
Quantifi cation of dye transfer indicating similarly effi  cient transfer from DiI-stained REH cells towards unstained 
primary healthy and primary leukemic MSCs (cultured in 4:1 ratio) in time.
(A) Dye transfer from DiI –stained NALM6 cells towards unstained primary MSCs of a healthy donor. Three inde-
pendent TNT inhibiting conditions (actin inhibition (cytochalasin D; 1μM, latrunculin B; 500 nM), physical disrup-
tion by gentle shaking, or culture in a 3.0 μm transwell system) decreased dye transfer from leukemic cells towards 
primary MSCs. (B) Same as (A) for transfer towards unstained primary MSCs of a BCP-ALL patient (B-Other). (C) 
Same as (A) for transfer towards unstained primary MSCs of a BCP-ALL patient (TEL-AML1). 
174 Chapter 5
MCP-1 (CCL2)
**
**
**
A Patient ALL#7
GRO 
** **
MCP1 (CCL2)    
****
C Patient ALL#9
Co-cultureCo-culture Co-culture
Co-culture
Co-culture Co-cultureMonoMonoMono
Mono
Mono Mono
Co-cultureMono
Below detection level 
B
Co-cultureMono
Below detection level 
Co-cultureMono
Below detection level 
GRO    D
Co-cultureMono
**
***
ndnd
MSC#5MSC#4MSC#3MSC#2MSC#1
pg
/m
L
pg
/m
L
All experiments combined
MS
C
NA
LM
6
No
rm
al
Sh
ak
ing
Tra
ns
we
ll
0.0
0.5
1.0
C
om
pa
re
d 
to
 N
or
m
al
All experiments combined
MS
C
NA
LM
6
No
rm
al
Sh
ak
ing
Tra
ns
we
ll
0.0
0.5
1.0
C
om
pa
re
d 
to
 N
or
m
al
IL8 
Co-cultureMono Co-cultureMono
pMSC#1 pMSC#2
VEGF 
pMSC#1 pMSC#2
Experiment 1
Experiment 2
Experiment 3
**
*** ***
***
pg
/m
L
Co-cultureMono Co-cultureMono
Co-cultureMono Co-cultureMono
Co-cultureMono Co-cultureMono
Co-cultureMono Co-cultureMono
Co-cultureMono Co-cultureMono
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
pg
/m
L
pg
/m
L
pg
/m
L
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
E
G
F
H
nd nd
NALM6 NALM6
2500
2000
1500
1000
500
0
pg
/m
L
2000
1500
1000
500
0
15000
10000
5000
0
10000
8000
6000
4000
2000
0
15000
10000
500
0
pg
/m
L
pg
/m
L
pg
/m
L
4000
3000
2000
1000
0
1000
800
600
400
200
0
250
200
150
100
50
0
200
150
100
50
0
150
100
50
0
60
40
20
0
60
40
20
0
80
60
40
20
0
2500
2000
1500
1000
500
0
2500
2000
1500
1000
500
0
5000
4000
3000
2000
1000
0
4000
3000
2000
1000
0
4000
3000
2000
1000
0
3000
2000
1000
0
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Tra
ns
we
ll
NA
LM
6
Sh
ak
ing
No
rm
al
MS
C
Supplementary Figure 9. Secretion of cytokines induced by primary BCP-ALL cells.
(A) MCP-1 (CCL2) supernatant levels in co-culture of primary leukemic patient ALL#7 cells with primary MSC#1 
(left panel), MSC#2 (middle panel), or MSC#3 (right panel). TNT signaling was inhibited by gentle shaking or 
culture in a transwell system. *p<0.05, **p<0.01 (one-tailed t-test, unpaired). (B) Same as (A) for GRO levels. (C) 
MCP-1 (CCL2) supernatant levels in co-culture of primary leukemic patient ALL#9 cells with primary MSC#4 (left 
panel), or MSC#5 (right panel).
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Supplementary Figure 9. Secretion of cytokines induced by primary BCP-ALL cells. (continued)
(D) Same as (C) for GRO levels. (E) IL8 supernatant levels in co-culture of BCP-ALL cells (NALM6) with primary 
MSC#1 (left panel) or MSC#2 (right panel). TNT signaling was inhibited by gentle shaking or culture in a transwell 
system. (F) VEGF supernatant levels in co-culture of BCP-ALL cells (NALM6) with primary MSC#1 (left panel) 
or MSC#2 (right panel).  (G) IL8 measurements as seen in (F) relative to the ‘Normal’ condition (one-tailed t-test, 
paired) (H) VEGF measurements as seen in (C) relative to the ‘Normal’ condition (one-tailed t-test, paired)
Data are means ± SEM. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001  (one-tailed t-test, unpaired). nd = not detectable (below 
detection level).
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Supplementary Figure 10. TNTs contribute to drug resistance.
These data represent the same experiment as shown in Figure 7B.
(A) BCP-ALL cell line NALM6 was cultured with (white bars) or without (black bars) MSCs (of three different 
sources) and cultures were exposed to prednisolone. Bars represent the cell count relative to an untreated control. 
(B) The relative survival benefit for NALM6 cells in co-culture with MSCs. Inhibition of TNT signaling (by gentle 
shaking or culture in a 3.0 μm transwell system) re-sensitized to prednisolone (n = 3; one-tailed t-test, unpaired). 
Data are means ± SD. ** p ≤ 0.01 (one-tailed t-test, unpaired).
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SUPPLEMENTARY VIDEOS
Video 1. TNT formation between BCP-ALL cells and MSCs.
TNTs are thin membrane tethers containing F-Actin that do not contact the substratum. These videos show that 
membrane tethers between BCP-ALL cells and MSCs do not touch the substratum.
(A) Video showing all z-stacks of images shown in Figure 1A-D. Video starts at the highest Z-stack and moves to-
wards the fibronectin-coated glass slide. (B) Video showing 3D projections of all z-stacks of images in Figure 1A-D. 
Video 2. TNT connecting a BCP-ALL cell and a MSC.
Video showing a thin membrane tether between a BCP-ALL cell (NALM6; DiI; in red) and a MSC (hTERT-MSC; 
in green) that does not touch the substratum. Dye transfer from the BCP-ALL cell to the MSC is illustrated by the 
presence of red dye in the MSC.
Video 3. Time lapse analysis of TNT formation between BCP-ALL cells and MSCs.
Time-lapse confocal imaging showing TNT formation from NALM6 cells (DiI; yellow) towards primary MSCs 
(DiO; green) in time (red arrows). NALM6 cells were labeled with the fluorescent lipophilic dye DiI, and primary 
MSCs were labeled with the fluorescent lipophilic dye DiO. 
Frames were collected every 3 minutes and 19 seconds and the video runs at 3 frames/second, except between 0:09 
and 0:15 seconds, where the playback speed is increased 1.5 times. All frames are 3D image stacks as described 
in Figure 3 and Supplementary Methods. 3D projections of start and end of experiment are included to show the 
amount of dye transfer and are confocal signals of 561-nm laser overlaid to bright field images. 
Video 4. Time lapse analysis of TNT formation between BCP-ALL cells and MSCs.
(A) Time-lapse confocal imaging showing TNT formation from NALM6 cells (DiI; yellow) towards primary MSCs 
(DiO; green) in time (red arrows). Blue arrow indicates a TNT formed by MSCs. NALM6 cells were labeled with 
the fluorescent lipophilic dye DiI, and primary MSCs were labeled with the fluorescent lipophilic dye DiO. Frames 
were collected every 3 minutes and 19 seconds and the video runs at 3 frames/second. (B) 3D projections of start 
(0 hr) and end (10 hr) of experiment to illustrate the amount of dye transfer. Confocal signals of 561-nm laser are 
overlaid to bright field images. 
These supplementary videos are available online: www.bloodjournal.org/
content/126/21/2404.
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Acute lymphoblastic leukemia cells create a 
leukemic niche without aff ecting the CXCR4/
CXCL12 axis
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ABSTRACT
Acute leukemia cells disrupt the healthy bone marrow microenvironment to create a 
leukemic niche. Several studies have tried to target this leukemic niche by inhibiting 
CXCR4/CXCL12 signaling. Here, we show that B-cell precursor acute lymphoblastic 
leukemia (BCP-ALL) cells modify their niche without affecting the CXCR4/CXCL12 
axis. We used a patient-derived co-culture model in which the leukemic niche was 
represented by BCP-ALL cells and mesenchymal stromal cells (MSCs). Leukemic co-
cultures significantly induced migration of leukemic counterparts, while inhibiting 
migration of healthy CD34+ hematopoietic cells and MSCs. This induction of leukemic 
cell migration was not affected by CXCR4 blockade. Moreover, CXCL12 levels were 
unaltered in co-cultures of primary BCP-ALL cells and primary MSCs. Instead, 
we found the induction of patient-unique secretion patterns affecting alternative 
chemokine pathways, including CCR4, CXCR1/2, and CXCR3 ligands. Also in 
serum of bone marrow aspirates from BCP-ALL patients, we found a significant 
and recurrent increase of CCR4 and CXCR1/2 ligands compared to matched bone 
marrow of the same patients in remission and to healthy controls. These data show 
that BCP-ALL cells modify the migration properties of their niche without altering 
the CXCR4/CXCL12 axis, and identify CCR4 and CXCR1/2 signaling as candidate 
factors for leukemic niche disruption.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) is characterized by an outgrowth of malignant 
lymphoblasts that occupy the bone marrow microenvironment, where they reside 
with mesenchymal stromal cells (MSCs)1. Leukemic cells are able to disrupt the 
healthy microenvironment and create a leukemic niche that shelters malignant cells 
from elimination through cytostatic treatment and immune responses2-7. Disrupting 
intercellular communication in this malignant microenvironment sensitizes leukemic 
cells to chemotherapeutic drugs8. 
Homing of ALL cells toward the bone marrow microenvironment is thought to 
be similar to that of hematopoietic stem cells (HSCs)9,10. Human CD34+ hematopoietic 
cells are attracted by stromal cell-derived factor 1 (SDF-1/CXCL12), a chemoattractant 
actively produced by MSCs in the bone marrow9-11. CXCL12 binds to the CXCR4 
receptor, which is highly expressed on HSCs. Disturbance of the CXCR4/CXCL12 
axis, by treatment with cytokines and/or CXCR4 antagonists, mobilizes HSCs to the 
peripheral blood and is used to harvest HSCs for stem cell transplantation12. Like 
HSCs, ALL cells have high CXCR4 surface expression and disruption of CXCR4/
CXCL12 interaction reduces ALL engraftment in animal models13,14.  However, in 
mice suffering from ALL, CXCR4/CXCL12 inhibition as mono-treatment did not 
reduce the leukemic cell number in the bone marrow13,15. This suggests that ALL cells 
use additional mechanisms to retain a protective microenvironment. In this study, 
we used an ex vivo co-culture model in which we cultured B-cell precursor ALL 
(BCP-ALL) cells with MSCs obtained from patients. Our data reveal that BCP-ALL 
cells create a self-reinforcing leukemic microenvironment that significantly attracts 
malignant cells and repels healthy hematopoietic cells independent of CXCR4/
CXCL12 signaling. This study highlights the need for specific inhibitors other than 
CXCR4 antagonists for the disruption of the leukemic niche in ALL.
METHODS
Cell lines and reagents
B-cell precursor ALL (BCP-ALL) cell lines, NALM6 (B-Other) and REH (TEL-AML1), 
were obtained from DSMZ (Braunschweig, Germany), used at low cell passages, 
and routinely verified by DNA fingerprinting. Cell lines were cultured in RPMI-1640 
medium containing 10% fetal calf serum (FCS), 1% penicillin-streptomycin at 37 °C 
and 5% CO2.
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Isolation of primary BCP-ALL leukemic blasts from patients
Primary BCP-ALL leukemic blasts were isolated from patients as described earlier8. 
In short, mononuclear leukemic cells were collected from bone marrow aspirates 
obtained from children with newly diagnosed BCP-ALL prior to treatment. All 
samples used in this study contained > 95% leukemic blasts.
Isolation and characterization of primary MSCs
Primary MSCs were isolated and characterized using positive (CD44/ CD90/ CD105/ 
CD54/ CD73/ CD146/ CD166/ STRO-1) and negative surface markers (CD19/ CD45/ 
CD34)8. In addition multilineage potential was confirmed as described earlier8.
Isolation of CD34+ cells
CD34+ cells were obtained from umbilical cord blood using the Direct CD34 
Progenitor Cell Isolation kit, human (Miltenyi Biotec, Gladback, Germany). CD34+ 
cells were positively selected by magnetic microbeads using the MACS LS column 
(Miltenyi Biotec) in combination with a MACS separator (Miltenyi Biotec). The purity 
of the isolated cells was confirmed by flow cytometry using the CD34-PE fluorescent 
antibody (BD Pharmingen, San Diego, USA).
Collection of bone marrow aspirates
Serum samples of bone marrow aspirates were collected from children with ALL at 
initial diagnosis and after completion of two courses of chemotherapy according to 
the ALL-10 protocol of the Dutch Childhood Oncology Group (day 79 after start of 
treatment) as previously described11. This study was approved by the Institutional 
Review Board and informed consent was obtained from parents or guardians.
Cell viability assays
Cell viability assays of primary material was performed as earlier described8. In 
short, primary patient cells (1 x 106 cells) were co-cultured with or without primary 
stromal cells (5 x 104) for five days in a 24-well plate at 37 °C and 5% CO2. Stromal 
cells were allowed to attach prior to the start of an experiment. Before the start of 
each experiment, leukemic cells were screened for CD19 positivity (Brilliant Violet 
421 anti-human CD19 antibody), which was used to discriminate leukemic cells 
from CD19neg MSCs. The percentage of viable leukemic cells was determined after 5 
days of culture by staining with Brilliant Violet 421 anti-human CD19 (Biolegend), 
FITC Annexin V (Biolegend), and Propidium Iodide (PI; Sigma), after which the 
percentage of AnnexinVneg/PIneg/CD19pos cells within the MSC negative fraction was 
determined by flow cytometry (BD Biosciences). 
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Multiplexed fluorescent bead-based immunoassay (Luminex)
Primary leukemic cells were co-cultured with different sources of primary MSCs 
for 5 days at 37°C and 5% CO2. Supernatant was collected upon which the viability 
of leukemic cells was assessed as described above. The concentration of 64 known 
cytokines/chemokines in these supernatants was analyzed using fluorescent bead-
based immunoassay (Luminex Human Cytokine/Chemokine Panel I and II; Merck 
Millipore) according to the manufacturer’s protocol.
Serum of bone marrow aspirates of leukemia patients or healthy controls were 
used to determine the concentration of 64 known cytokines/chemokines using the 
same fluorescent bead-based immunoassay (Luminex Human Cytokine/Chemokine 
Panel I and II; Merck Millipore) according to the manufacturer’s protocol
BCP-ALL migration assay
BCP-ALL migration experiments were performed using RPMI 10% FCS at 37°C 
and 5% CO2. 5 x 104 primary MSCs and 2 x 105 BCP-ALL cells were cultured either 
separate or in co-culture in the lower compartment of a transwell in a volume of 750 
μL for 24 hours prior to the start of the experiment. At the start of experiment, 4 x 
105 NALM6-GFP cells in a volume of 250 μL were added to the upper compartment 
of a 6.5 mm diameter transwell system (Corning, NY, USA) with a pore size of 3.0 
μm. Cells were allowed to migrate for 48 hours. At the end of experiment, transwells 
were removed and cells in the bottom compartment were harvested and stained 
with DAPI (Life Technologies). DAPI-/GFP+ cells were used as a measure for cell 
migration and quantified by flow cytometry using a MACSQuant analyzer (Miltenyi 
Biotec, Gladbach, Germany).
CD34+ migration assay
Experiments were performed using either RPMI Dutch Modified 15%FCS or Iscove 
modified Dulbecco medium (Gibco) containing 10% FCS, 50μM β-mercaptoethanol, 1% 
penicillin-streptomycin, 2mM glutamine, stem cell factor (SCF; 50ng/mL; Peprotech) 
and fms-like tyrosine kinase-3 ligand (Flt3L; 50 ng/mL; Peprotech) at 37°C and 5% CO2. 
Primary MSCs (5 x 104) and NALM6-GFP cells (2 x 105) were cultured either separate 
or in co-culture in a volume of 750 μL for 24 hours prior to start of experiment (bottom 
compartment). At the start of experiment, 5 x 105 CD34+ cells in a volume of 250 μL 
were added to the top chamber of a 3.0 μm transwell system (Corning, NY, USA) and 
allowed to migrate for 48 hours at 37°C and 5% CO2. At the end of experiment, transwell 
inserts were removed upon which the cells in the bottom compartment were harvested 
and stained with Propidium Iodide (PI; Sigma) and Brilliant Violet 421 anti-human 
CD45 antibody (Biolegend). PI-/GFP-/CD45+ cells were quantified by flow cytometry 
using a MACSQuant analyzer (Miltenyi Biotec, Gladbach, Germany).
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MSC migration assay
Experiments were performed using DMEM medium containing 5% FCS, 1% penicillin-
streptomycin at 37°C and 5% CO2. REH cells (0.1 – 1.6 x 106) and primary MSCs (5 x 
104) were cultured either separate or in co-culture in a volume of 750 μL for 48 hours 
prior to start of experiment. At the start of experiment, 5 x 104 MSCs were added to the 
top chamber of a 8.0 μm transwell system (Corning) and allowed to migrate through 
the membrane overnight (12-16 hours). Non-migrated cells were removed from the 
upper side of the transwell insert using a cotton swab. Cells that migrated through the 
membrane insert were fixed using 10% Formalin (Sigma) for 10 minutes, washed with 
PBS and stained for 30 minutes with Crystal violet at room temperature. Images were 
captured using a Leica DM IL microscope mounted with a Leica DFC430C camera 
(Leica, Germany). Next, Crystal violet contained by MSCs was dissolved in 150 μL 
methanol, quantified by spectrophotometer using 540-570 nm wavelength settings 
(Versamax, San Francisco) and used as a measure of migration.
Statistical analysis
We used the R2 Genomics Analysis and Visualization Platform (http://r2.amc.nl) 
to visualize gene expression data in Figure 4 and performed one way analysis of 
variance (ANOVA). For other statistics, Student’s t-test was used and a Student’s 
paired t-test was used when applicable. Bar graphs represent the mean of biological 
replicates. Error bars show standard error of the mean (SEM).
RESULTS
ALL-MSC co-cultures induce leukemic cell migration without affecting the 
CXCR4/CXCL12 axis
Several studies have shown that ALL cells home toward the bone marrow 
microenvironment in a CXCR4/CXCL12 dependent manner1,13,14,16. We confirmed 
these findings by assessing the migration of GFP-positive BCP-ALL cells (NALM6) 
toward patient-derived MSCs, using a transwell system. MSCs induced migration of 
BCP-ALL cells by 5-16 fold compared to medium controls (p < 0.05; Figure 1A and 
supplementary Figure 1A-B). The induction of migration correlated with the level of 
CXCL12 produced by the primary MSCs: MSC#3 and MSC#4 secreted lower levels 
of CXCL12, and hence were less effective in attracting leukemic cells compared to 
MSC#1 and MSC#2 (Figure 1B). Inhibition of the CXCR4/CXCL12 axis with AMD3100 
significantly impaired migration of BCP-ALL cells toward MSCs (4.5-fold  reduction, 
p < 0.01; Figure 1C).
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Figure 1. ALL-MSC co-cultures induce leukemic cell migration without affecting the CXCR4/
CXCL12 axis.
(A) Graph showing the fold-change in migration of GFP-positive BCP-ALL cells (NALM6) toward four distinct 
primary bone marrow-derived MSCs compared to background migration toward culture medium after 48 hours 
in a 3.0 μm transwell system (n = 5 for each MSC; one-tailed t-test, unpaired). Migration towards culture medium 
was used to calculate the fold-change migration. (B) Graph showing the secretion of CXCL12 by primary MSCs as 
determined using a fluorescent bead-based immunoassay (n = 6 for each MSC). (C) Graph showing the effect of 
CXCR4 blockade with AMD3100 (10μM) on the migration of NALM6 cells toward primary MSCs after 48 hours in 
a 3.0 μm transwell system (n = 4; one-tailed t-test, paired). Migration towards culture medium was used to calculate 
the fold-change migration. For this experiment we combined the data of four distinct primary MSCs (MSC#1-4).
(D) Schematic overview of the experimental conditions used for experiments shown in  Figure 1E-F. The migration 
of GFP-positive NALM6 cells is measured toward: culture medium (Control), primary MSCs (Normal Niche) or 
GFP-negative ALL-MSC co-cultures (Leukemic Niche). (E) Graph showing the migration of NALM6 cells toward 
MSCs in mono-culture (normal niche, grey bars) or toward ALL-MSC co-cultures (leukemic niche, blue bars), after 
48 hours in a 3.0 μm transwell system (n = 5 for each MSC; one-tailed t-test, paired). 
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We hypothesized that BCP-ALL cells alter the chemoattractive properties of 
their microenvironment once they have homed to the bone marrow via the CXCR4/
CXCL12 axis. To address this hypothesis, GFP-negative BCP-ALL cells (NALM6) 
were cultured with MSCs in the bottom compartment of a transwell system as a 
model of the leukemic niche. Migration of GFP-positive BCP-ALL cells (NALM6) 
from the upper to the bottom compartment was determined (Figure 1D). GFP-positive 
BCP-ALL cells migrated significantly more toward ALL-MSC co-cultures (annotated 
as leukemic niche) than toward MSCs in mono-culture (annotated as normal niche; 
grey bars versus blue bars, p < 0.01; Figure 1E and supplementary Figure 1C-D). 
The leukemic niche induced migration of BCP-ALL cells by 2.2-fold compared to 
the healthy microenvironment (Figure 1F, p < 0.001). Surprisingly, CXCR4 inhibition 
by AMD3100 did not affect the preferential migration of BCP-ALL cells towards the 
leukemic niche (2.2-fold versus 2.5-fold, p = 0.52, Figure 1F and supplementary Figure 
1E). In addition, we compared CXCL12 levels in the supernatant of mono- and co-
cultures of primary BCP-ALL cells derived from 10 different patients representing 
major BCP-ALL subgroups and 4 primary MSCs. CXCL12 levels were high in mono-
cultures of MSCs, and below detection level in mono-cultures of primary BCP-ALL 
cells (supplementary Figure 2A-B). Co-culture of primary BCP-ALL cells and MSCs 
did not increase CXCL12 levels compared to the secreted levels in mono-culture 
(Figure 1G). These results suggest that BCP-ALL cells create a leukemic niche that 
attracts leukemic cells in a CXCR4/CXCL12 independent manner. 
ALL-MSC co-cultures reduce migration of healthy CD34+ HPCs
Since human HSCs migrate almost exclusively toward CXCL1217, we hypothesized 
that healthy HSCs do not have an increased migration toward ALL-MSC co-cultures. 
To this aim, we assessed the migration of healthy CD34+ hematopoietic progenitor 
cells (HPCs) toward primary MSCs cultured with or without BCP-ALL cells. As 
expected, CD34+ HPCs migrated more abundantly toward MSCs than to control 
medium (1.8-fold, p < 0.05; Figure 2). However, migration of CD34+ HPCs toward 
Figure 1. ALL-MSC co-cultures induce leukemic cell migration without affecting the CXCR4/
CXCL12 axis. (continued)
Migration towards culture medium was used to calculate the fold-change migration. Experiments were performed 
with MSCs from four different donors. (F) Graph showing that the leukemic niche affects the migration of BCP-
ALL cells independent of CXCR4/CXCL12 signaling. Migration of NALM6 cells toward N6-MSC co-cultures (leu-
kemic niche, blue bars) is compared to migration toward MSC mono-cultures (normal niche, grey bars) in absence 
or presence of AMD3100 (10 μM) after 48 hours using a 3.0 μm transwell system (n = 4; one-tailed t-test, paired). For 
this experiment we combined the data of four distinct primary MSCs (MSC#1-4). Data is shown as fold induction 
compared to migration towards MSC mono-culture. (G) Plots showing the secreted levels of CXCL12 by  primary 
BCP-ALL cells and MSCs in mono-culture (circles represent the sum of cytokine secretion in mono-culture of 
BCP-ALL and mono-culture of MSC) compared to ALL-MSC co-culture (squares). Data was determined using a 
multiplexed fluorescent bead-based immunoassay. Boxes represent p25-p75 intervals.
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, N6 = NALM6. See also supplementary Figure 1.
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ALL-MSC co-cultures was significantly reduced compared to migration toward 
MSCs in mono-cultures (20% reduction, p < 0.05; Figure 2). This implies that 
ALL-MSC co-cultures produce factors that more specifically attract BCP-ALL cells 
than  healthy CD34+ HPCs.
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Figure 2. ALL-MSC co-cultures 
reduce migration of healthy 
CD34+ HPCs.
Graph showing the migration of um-
bilical cord blood-derived healthy 
CD34+ progenitor cells after 48 hours 
in a 3.0 μm transwell system. Bars rep-
resent migration toward culture me-
dium, NALM6 cells, MSCs and NA-
LM6-MSC cultures (n = 3; one-tailed 
t-test; paired). Migration towards MSC 
mono-culture was used to calculate 
the fold-change migration.
Data are means ± SEM; * p ≤ 0.05, HPC 
= hematopoietic progenitor cell.
BCP-ALL cells recruit MSCs to create a leukemic microenvironment
Much effort is put into understanding the migration of malignant cells. However, 
less is known about the migratory behavior of healthy MSCs. Can leukemic cells 
actively recruit stromal cells toward tumor sites? If so, this would allow leukemic 
cells to create a niche to provide nutrients and survival factors without migrating. 
To address this hypothesis, we performed a transwell migration assay in which 
primary MSCs were allowed to migrate toward BCP-ALL cells or other MSCs in 
the bottom compartment. We observed that MSC migration was induced toward 
other MSCs compared to control medium (p < 0.05; Figure 3A-B). Strikingly, MSCs 
also actively migrated to BCP-ALL cells illustrating that BCP-ALL cells are able to 
recruit MSCs (p < 0.001; Figure 3A-B). However, MSC migration was significantly 
inhibited toward the leukemic niche (ALL-MSC co-cultures) compared to a bottom 
compartment containing only BCP-ALL cells (2-3 fold reduction, p < 0.001, Figure 
3C-E). Interestingly, increasing the amount of ALL cells (up to 16-fold) in ALL-MSC 
co-cultures did not re-induce MSC migration (Figure 3D-E). These results show 
that ALL-MSC co-cultures efficiently attract leukemic cells, but reduce migration of 
MSCs similar to what was observed for healthy CD34+ HPCs (Figure 2 and 3).
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Figure 3. BCP-ALL cells recruit MSCs to create a leukemic microenvironment.
(A) Images of a representative experiment showing MSCs that migrated to the other side of a 8.0 μm transwell 
insert for 16 hours. Cells were fixed and subsequently stained with crystal violet. Images show MSCs migrated 
toward a bottom compartment containing culture medium, MSCs or BCP-ALL cells (REH) (n = 4). (B) Quantifica-
tion of the migration of MSCs toward a bottom compartment containing MSCs or BCP-ALL cells (as exemplified in 
Figure 3A). The amount of migrated cells was measured by spectrophotometry of crystal violet stained cells (n = 4; 
one-tailed t-test; paired). Migration towards MSC mono-culture was used to calculate the fold-change migration.
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Chemokine profiles of primary ALL-MSC co-cultures reveal recurrent induction 
of CCR4 and CXCR1/2 ligands
We hypothesized that the secretion of soluble factors within the leukemic 
microenvironment induces the migratory phenomena described above. To address 
which cytokines/chemokines may be altered in the leukemic niche, we quantified 
the levels of 64 cytokines known to be important in immunology/hematology in the 
supernatant of ex vivo co-cultures of patient-derived BCP-ALL cells (n = 10) and MSCs 
(n = 4) using a multiplexed fluorescent bead-based immunoassay (supplementary 
Table 1). We used primary leukemic cells derived from 10 different patients 
representing major BCP-ALL subgroups. Cytokine/chemokine profiles of primary 
BCP-ALL cells and primary MSCs in mono-culture are depicted in supplementary 
figure 2. Co-cultures of BCP-ALL cells with MSCs revealed the induction of unique 
secretion patterns per patient. These patterns were not affected by changing the 
source of MSC. Instead, each BCP-ALL patient induced the secretion of a specific 
set of factors, suggesting that leukemic cells govern the observed cytokine secretion 
(Figure 4, supplementary Figure 3 and supplementary Table 2). Surprisingly, all 
ALL-MSC co-cultures showed increased levels of CCL2/MCP-1 and/or CCL22/MDC 
(Figure 4A and supplementary Table 2), both ligands for the CCR4 receptor18,19. 
This chemokine receptor is implicated in T cell leukemia and lymphoma, but has 
not been implicated as an important factor for BCP-ALL20. In addition, analysis of 
previously published microarray-based gene expression data showed that CCR4 
expression levels in pediatric ALL cells were significantly higher compared to 
healthy hematopoietic cells (Figure 4B)21,22.
Further, we observed recurrent induction of CXCL8/IL-8 and CXCL1/GRO 
secretion, ligands of the CXCR1 and CXCR2 receptor23. CXCR1/2 ligands were 
induced by BCP-ALL cells from six out of ten patients. BCP-ALL cells from patients 
#1 and #2 induced the secretion of both CXCL8/IL-8 and CXCL1/GRO, while in 
co-cultures of four other patient samples (patient #5, #6, #9, and #10)  the secretion 
of one of these cytokines was induced (Figure 4C). In contrast to CCR4 expression, 
CXCR1 and CXCR2 expression levels were lower in pediatric ALL compared to 
healthy hematopoietic cells (figure 4D). Finally, BCP-ALL cells from two out of ten 
Figure 3. BCP-ALL cells recruit MSCs to create a leukemic microenvironment. (continued)
(C) Schematic overview of experimental conditions used in Figure 2D-E (D) Images of a representative experiment 
showing that MSCs migrate to the other side of a 8.0 μm transwell insert for 16 hours toward an increasing amount 
of BCP-ALL cells (REH) in mono-culture (upper panels) or in co-culture with MSCs (MSC + REH; lower panels). 
(E) Quantification of MSC migration toward REH cells (BCP-ALL, black bars) or REH-MSC co-cultures (leukemic 
niche, blue bars), as exemplified in Figure 3D. Data was obtained by spectrophotometry of crystal violet stained 
cells (n = 4; one-tailed t-test, paired).
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001.
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Figure 4. Chemokine profiles of primary ALL-MSC co-cultures reveal recurrent induction of 
CCR4 and CXCR1/2 ligands.
(A) Plots showing the secretion of CCL2/MCP-1 and CCL22/MDC of primary MSCs and primary BCP-ALL cells 
in mono-culture (circles represent the sum of cytokine secretion in mono-culture of BCP-ALL and mono-culture 
of MSC) compared to ALL-MSC co-cultures (squares). Data was obtained using a multiplexed fluorescent bead-
based immunoassay. Boxes represent p25-p75 intervals. (B) Gene expression levels of the CCR4 receptor in healthy 
hematopoietic cells21 and pediatric ALL cells22. Data was visualized using R2: microarray analysis and visualiza-
tion platform. (C) Same as (A) for CXCL8/IL-8 and CXCL1/GRO secretion. (D) Same as (B) for CXCR1 and CXCR2 
expression.
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patients (patient #1 and #4) upregulated secretion of CXCL10/IP10, which is a ligand 
for the CXCR3 receptor. Gene expression levels of CXCR3 are higher in leukemic 
cells compared to healthy hematopoietic cells (Figure 4F). 
These experiments show that primary BCP-ALL cells induce unique secretion 
patterns in co-culture with MSCs. Importantly, we found that CCR4 ligands CCL2/
MCP-1 and CCL22/MDC were recurrently upregulated in MSC-ALL co-cultures, 
possibly revealing a common target for disruption of the BCP-ALL niche.
Recurrent induction of CCR4 and CXCR1/2 ligands in bone marrow aspirates of 
BCP-ALL patients
We validated the cytokine/chemokine patterns identified in our co-culture model 
using serum derived from bone marrow aspirates from 10 ALL patients at diagnosis. 
We compared the cytokine/chemokine patterns in these samples with serum obtained 
from bone marrow aspirates of the same patients taken at the end of induction 
chemotherapy (day 79 of the Dutch Childhood Oncology Group ALL-10 protocol). 
At this stage of treatment the patients were in remission. Furthermore, we used bone 
marrow aspirates of 7 healthy controls to analyze cytokine/chemokine patterns of 
the healthy niche. All bone marrow aspirates were analyzed using a multiplexed 
fluorescent bead-based immunoassay (supplementary Table 1). Levels of the CCR4 
ligand CCL2/MCP-1 were significantly higher in the bone marrow of untreated, 
newly diagnosed BCP-ALL patients compared to healthy controls (2.0-fold increase, 
p < 0.01; Figure 5A). Interestingly, after induction therapy, the CCL2/MCP-1 levels 
in the bone marrow of ALL patients decreased to levels observed in healthy controls 
(2.2 fold decrease, p < 0.01; Figure 5A). This suggests that the induced CCL2/MCP-
1 levels at diagnosis are causally linked to the presence of leukemic cells. CCL22/
MDC levels were similar between BCP-ALL patients and healthy controls (Figure 
5B). Like CCL2/MCP-1, CXCL1/GRO levels were also increased in the bone marrow 
of BCP-ALL patients (2.3-fold increase, p < 0.05; Figure 5C) and CXCL8/IL8 levels 
showed a trend towards upregulation (2.5-fold, p = 0.052; Figure 5D). Similar to 
CCL2/MCP-1 levels, the secreted levels of these CXCR1/2 ligands were significantly 
reduced after induction chemotherapy (2.3 fold and 3.1-fold respectively, p < 0.05; 
Figure 5C-D), again suggesting causality between the presence of leukemic cells 
and the upregulation of these cytokines. Finally, IP10 levels were similar between 
Figure 4. Chemokine profiles of primary ALL-MSC co-cultures reveal recurrent induction of 
CCR4 and CXCR1/2 ligands. (continued)
(E) Same as (A) for CXCL10/IP10 expression. (F) Same as (B) for CXCR3 expression. Raw data was logarithmically 
transformed to obtain a normal distribution of the data and upregulation of cytokines was tested using a one-tailed 
paired t-test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. See also supplementary Figure 2 and 3 and supplementary Table 
1 and 2.
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Figure 5. Recurrent induction of CCR4 and CXCR1/2 ligands in bone marrow aspirates of 
BCP-ALL patients.
Plots showing the serum levels of cytokines in bone marrow aspirates from healthy controls (n = 7, circles), from 
untreated BCP-ALL patients at diagnosis (n = 10, blue squares) and from BCP-ALL patients after induction treat-
ment (n = 10, triangles; lines indicate paired samples). Data was obtained using a multiplexed fluorescent bead-
based immunoassay in which we measured the levels of 64 cytokines. All cytokines upregulated in leukemic bone 
marrow are shown in Figure 5.
(A) Plot showing the serum levels of CCL2/MCP-1.  (B) Plot showing the serum levels of CCL22/MDC. (C) Plot 
showing the serum levels of GRO/CXCL1. (D) Plot showing the serum levels of  CXCL8/IL-8. (E) Plot showing the 
serum levels of CXCL10/IP10.
Healthy (circles) and leukemic samples (blue squares) were compared using a two-tailed unpaired t-test. Leuke-
mic samples before and after induction therapy (blue squares versus triangles) were compared using a one-tailed 
paired t-test * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001. See also supplementary Table 1.
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ALL patients and healthy controls (Figure 5E). These data implicate that CCR4 and 
CXCR1/2 signaling are affected in the bone marrow of ALL patients.
DISCUSSION
Several studies have tried to target the leukemic niche by inhibiting the most 
important chemokine signal produced by the hematopoietic niche: CXCL1210. 
These studies are mainly focused on acute myeloid leukemia (AML) and decrease 
CXCL12 levels by G-GSF treatment or block CXCR4/CXCL12 interaction with 
antagonists such as AMD3100/Plerixafor. Disruption of the CXCR4/CXCL12 axis 
led to mobilization of leukemic cells, increased sensitivity to therapeutic agents and 
prolonged survival in AML mouse models16,24-31. In addition, Phase 1/2 clinical trials 
have shown the feasibility of using CXCR4 antagonists during chemotherapeutic 
treatment of patients32-35. In ALL however, recent data suggests that blocking 
CXCL12-mediated migration is insufficient to completely disrupt leukemic niches. 
Although administration of CXCR4 antagonists to mice suffering from ALL resulted 
in mobilization of leukemic cells into the peripheral blood, leukemic cell count in 
the bone marrow was unaffected13. In addition, CXCL12 expression was remarkably 
downregulated in murine bone marrow regions of extensive leukemia growth1. 
Likewise, CXCL12 levels in the bone marrow of patients diagnosed with BCP-ALL 
were lower compared to those in the same patients at the time of remission and 
healthy controls11. The data in this study suggests that CXCR4/CXCL12 signaling is 
not driving the leukemic niche in BCP-ALL. Instead of changing CXCL12 production, 
we found that primary leukemic cells induce the release of a unique and patient-
specific secretome in their niche. The induction of these patient-specific chemokines 
suggests that the leukemic cell instructs the stromal microenvironment to produce 
signals that are important for their migration and maintenance, thereby creating a 
self-reinforcing niche. Our study is the first to identify the alternative chemokines 
that might be important for the formation and maintenance of a leukemic niche in 
BCP-ALL. We used a biased approach to identify these pathways by focusing on 
the secretion of 64 cytokines known to be important in immunology/hematology. 
Unbiased approaches, like RNA sequencing and mass-spectrometry could further 
reveal which other molecular pathways are important for the formation of the BCP-
ALL niche. 
The unique cytokine/chemokine profiles for each patient suggests the need for 
patient-specific approaches to disrupt the leukemic niche. However, we also found 
recurrently induced signaling pathways: namely CCR4 and CXCR1/2 signaling. We 
found upregulation of ligands of these cytokine receptors in ex vivo leukemic co-
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cultures, and importantly in bone marrow aspirates of patients with BCP-ALL. This 
suggests that CCR4 or CXCR1/2 inhibition might be an alternative or additional way 
to disrupt the BCP-ALL niche. Clinical trials have been initiated with monoclonal 
antibodies to CCR4 (mogamulizumab) in patients with lymphoma36,37. Unfortunately, 
mogamulizumab requires antibody-dependent cellular cytotoxicity mechanisms 
to eliminate CCR4+ cells which may be less effective at the time of overt leukemia. 
Development of CCR4 antagonists similar to AMD3100 (Plerixafor) would be of 
utmost interest for ALL37. Our data warrant further investigation of the efficiency of 
such agents in disrupting the leukemic niche.
In conclusion, our data indicate that the BCP-ALL niche is highly potent in 
attracting BCP-ALL cells and repelling the influx of healthy hematopoietic cells and 
MSCs in a CXCL12 independent manner (Figure 6). Instead, we show the recurrent 
induction of CCR4 and CXCR1/2 ligands by BCP-ALL cells in the leukemic niche. 
Our data point to CCR4 and CXCR1/2 as valuable future therapeutic targets to 
interfere with the leukemic niche in ALL.
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Figure 6. Model of the self-reinforcing BCP-ALL niche.
Proposed model for the formation of a leukemic niche by BCP-ALL cells. BCP-ALL cells actively migrate toward 
MSCs in a CXCL12 dependent manner. Simultaneously, MSC migration is induced by BCP-ALL cells. When BCP-
ALL cells and MSCs are in close proximity, a leukemic microenvironment is created that specifically attracts other 
BCP-ALL cells and inhibits the migration of MSCs and healthy CD34+ cells. This process is CXCR4/CXCL12 inde-
pendent and is characterized by the secretion of patient-unique cytokines.
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Supplementary Figure 1. ALL-MSC co-cultures induce leukemic cell migration.
(A) Representative microscope images depicting migrated GFP-positive NALM6 cells after 48 hours in a 3.0 μm 
transwell system. GFP-positive NALM6 cells were allowed to migrate toward a bottom compartment containing 
either culture medium, GFP-negative NALM6 cells or primary MSCs (n = 4). (B) Gating strategy for quantifica-
tion of migrated GFP-positive NALM6 cells. (C) Representative flow cytometry plots showing the migration of 
GFP-positive NALM6 cells toward GFP-negative NALM6 cells, MSCs and GFP-negative ALL-MSC co-cultures. 
(D) Representative microscope images showing the migration of GFP-positive NALM6 cells toward GFP-negative 
ALL-MSC co-cultures (right panel) or migration to a bottom compartment containing only MSCs (left panel; n 
= 4). No LCs = no leukemic cells in the bottom compartment. (E) Graph showing the effect of CXCR4 inhibition 
by AMD3100 (10 μM) on migration of NALM6 cells towards MSC mono-cultures (normal niche, grey bars) and 
ALL-MSC co-cultures (leukemic niche, blue bars). Migration towards culture medium is used to calculate the 
fold-change migration. CXCR4 inhibition decreases migration of NALM6 cells towards the healthy and leukemic 
niche in a similar manner. However, the leukemic niche still induces migration of NALM6 cells in the presence of 
AMD3100.
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, N6 = NALM6. See also Figure 1.
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Supplementary Figure 2. Cytokine 
secretion of primary MSCs and BCP-
ALL cells in mono-culture.
(A) Graph showing the cytokine produc-
tion of MSCs from four donors after 5 days 
of mono-culture. (B) Graph showing the 
cytokine production of BCP-ALL cells from 
10 different donors after 5 days of mono-
culture.
Data was obtained using a multiplexed 
fluorescent bead-based immunoassay. Se-
creted levels of 64 cytokines/chemokines 
were analyzed. Cytokines/chemokines that 
were not detected in mesenchymal stromal 
cells or ALL cells were not depicted in this 
figure. nd = not detected
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Supplementary Figure 3. Increased cytokine secretion is not explained by enhanced viability of 
leukemic cells in co-culture.
(A) Graph showing the viability of leukemic cells from patient ALL#4 cultured in absence or in presence of primary 
MSCs. (B) Plots showing the secretion of cytokines by BCP-ALL cells from patient ALL#4 in mono-culture (grey 
circles) and the secretion of cytokines by ALL#4 cells in ALL-MSC co-culture corrected for the secretion of MSCs 
(grey boxes). The dashed boxes indicate significantly upregulated cytokines shown in Figure 4.
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Supplementary Table 1. Cytokine and chemokine screening panel.
Cytokine tested Receptor Cytokine tested Receptor
VEGF VEGFR MIP-1α CCR1
sCD40L C40 and αIIbβ3 and α5β1 MIP-1β CCR1 and CCR5
EGF EGFR PDGF-AA PDGFR
Eotaxin CCR2 and CCR3 and CCR5 PDGF-AB/BB PDGFR
FGF-2 FGFR1 RANTES CCR5
Flt-3 ligand Flt-3 TGF-α EGFR
Fractalkine CX3CR1 TNF-α TNFR1
G-CSF GCSFR TNF-β LTB
GRO CXCR2 TSLP CRLF2 and IL7-R complex
IFNα2 IFNAR 6Ckine CCR7
IFN-γ IFNGR1 and IFNGR2 BCA-1 CXCR5
IL-1α IL1R CTACK CCR10
IL-1β IL1R ENA-78 CXCR2
IL-1ra IL1R Eotaxin-2 CCR3
IL-2 IL2R Eotaxin-3 CCR3
IL-3 IL3R I-309 CCR8
IL-4 IL4R IL-16 CD4
IL-5 IL5R IL-20 IL20R
IL-6 CD 126 and CD130 complex IL-21 IL21R
IL-7 IL7R IL-23 IL23R
IL-8 CXCR1 and CXCR2 IL-28A IL28R
IL-9 IL9R IL-33 IL1RL1
IL-10 IL10R1-IL10R2 complex LIF LIFR
IL12 (p40) IL12R MCP-2 CCR1 and CCR2a and CCR5
IL12 (p70) IL12R MCP-4 CCR2 and CCR3 and CCR5
IL-13 IL13R MIP-1d CCR1 and CCR3
IL-15 IL15RaR SCF c-Kit
IL17A IL17R CXCL12 CXCR4 and CXCR7
IP-10 CXCR3 TARC CCR4
MCP-1 CCR2 and CCR4 TPO CD110
MCP-3 CCR2 TRAIL TRAILR-complex
MDC (CCL22) CCR4
Supplementary Table 2. Overview of cytokines upregulated in BCP-ALL/MSC co-cultures.
ID G-CSF 
CSF3
GM-CSF 
CSF2 
GRO 
CXCL1 
IP10 
CXCL10 
MCP-1 
CCL2 
MCP-3 
CCL8 
MDC 
CCL22 
ENA-78 
CXCL5 
I-309 
CCL1
IL-6 IL-8 
CXCL8 
BCR-ABL1 #1 
#2
#3
ETV6-RUNX1 #4
#5
#6
MLL #7
#8
TCF3-PBX1 #9
#10 
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Supplementary Table 3. Primary mesenchymal stromal cells used in this study.
Name Derived from Subtype
MSC #1 Healthy BM - 
MSC #2 Healthy BM - 
MSC #3 Leukemic BM B-Other
MSC #4 Leukemic BM ETV6-RUNX1

12
3
4
5
6
7
8
9
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This final chapter aims to discuss the work presented in this thesis. We put our 
findings in perspective; discuss the possible implications for leukemia treatment and 
future research, and present future plans derived from our studies. 
TARGETED THERAPY FOR ETV6-RUNX1 POSITIVE 
LEUKEMIA
During the past decades, cancer research has focused on the development of 
more effective and less toxic anti-cancer therapies. A key example of targeted 
anti-cancer drugs are BCR-ABL1 inhibitors. These inhibitors are designed to block 
the constitutive activation of the tyrosine kinase domain of BCR-ABL1, a fusion 
protein resulting from translocation t(9;22), which is present in a subgroup of 
patients with CML and ALL. The addition of BCR-ABL1 inhibitors, such as Imatinib 
or Dasatinib, to treatment protocols significantly increased the survival of patients 
with BCR-ABL1 positive leukemia1-5. Regrettably, such a targeted approach is not 
available for the majority of children suffering from leukemia. In fact, every Dutch 
child with newly diagnosed ALL, except for infants (age < 365 days) and children 
with BCR-ABL1 positive ALL, initially receives the same treatment with classical 
chemotherapeutic agents according to the Dutch Childhood Oncology Group ALL11 
protocol (see Figure 1)6. Subsequent phases of treatment are risk-directed and their 
intensity depends on several clinical features such as disease progression (central 
nervous system or testicular involvement), molecular features (such as the presence 
of the MLL-AF4 fusion gene), and early treatment response (measured by the initial 
response to prednisolone, achievement of cytomorphological complete remission 
after induction treatment, and the level of minimal residual disease)6. These risk-
directed treatment protocols have significantly improved the clinical outcome of 
Figure 1. An overview of the initial treatment phase of ALL patients in the Netherlands
This overview represents the initial treatment phase of ALL patients in the Netherlands according to the Dutch 
Childhood Oncology Group ALL11 protocol6. 
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children with ALL. However, children are treated with intensive chemotherapy 
regimens that induce significant side effects, such as severe infections, and have 
several late adverse effects, such as heart problems, osteonecrosis, psychological 
problems, and secondary tumors3,7-11. 
Fortunately, due to the improvement of molecular screening techniques, 
including gene expression profiling and next generation sequencing, the number 
of genetic drivers and driver mutations found in leukemic cells have increased 
dramatically12-18. This knowledge has led to the initiation of multiple phase I/II 
clinical trials that study the efficacy of drugs targeting these molecular drivers in 
refractory disease (e.g. PI3K/PKB inhibitors discussed in chapter 2). These studies 
have revealed that leukemia is a highly heterogeneous disease that is driven by 
multiple combinations of genetic lesions. Even within one leukemia patient a 
complex clonal diversity occurs, resulting in the presence of multiple subclones18-22. 
Therefore, targeted therapy for leukemia patients should not be directed to secondary 
mutations/hits, since these therapies will not eliminate all subclones effectively. 
Precision therapies directed against the first hit or initial drivers of leukemogenesis 
allow targeting of all leukemic cells and might not affect healthy cells that lack such 
alterations. Hence, these therapies will be more efficient and side effects may be less 
severe. 
Similar to the BCR-ABL1 fusion protein, the ETV6-RUNX1 fusion protein 
might be a perfect candidate for precision therapies, since translocation t(12;21) is 
considered to be a first hit in leukemogenesis. Before leukemia occurs, this early 
genetic lesion is followed by a small number of alterations that are acquired 
independently and without preferential order, thereby generating a dynamic clonal 
architecture18. ETV6-RUNX1 positive leukemic cells are still highly dependent on 
the expression of the fusion protein for their survival23,24. ETV6-RUNX1 positive 
leukemia represents 20% of all children with acute lymphoblastic leukemia and is 
therewith one of the largest subgroups of pediatric leukemia. Despite the fact that 
event-free survival rates of children with ETV6-RUNX1 positive leukemia reach 90-
95% in recent treatment protocols, the absolute number of relapse, death, and (long-
term) side effects is still high among this large group of patients. The primary goal of 
the research described in the first part of this thesis is to identify and subsequently 
target biological drivers of ETV6-RUNX1 positive leukemia.
Model systems to study ETV6-RUNX1 positive ALL
Several laboratories have previously studied ETV6-RUNX1 positive leukemia and 
identified important features of this subtype of ALL. These studies showed the 
importance of the ETV6-RUNX1 fusion protein in cell lines24-29, human progenitor 
cells30-32 and mouse models33-38. 
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The ETV6-RUNX1 fusion gene occurs in the human hematopoietic progenitor 
cell30. The laboratory of Tariq Enver and Mel Greaves for the first time showed that 
ETV6-RUNX1 transduced human cord blood-derived CD34+ progenitors produce 
an abnormal lymphoid progenitor subgroup (CD34+CD38lowCD19+) with enhanced 
survival properties and increased self-renewal potential that is reminiscent of 
pre-leukemic progenitors observed in patients30-32. In addition, preliminary gene 
expression analysis of these cells revealed that ETV6-RUNX1 positive pre-leukemic 
cells display a gene expression signature that contains both hematopoietic stem cell 
(HSC) and pro-B cell associated genes30. However, the small number of replicate 
experiments hampered the authors to further analyze the molecular drivers of this 
phenotype. 
In order to find molecular regulators of ETV6-RUNX1 positive leukemia, the 
laboratory of Renate Panzer-Grümayer performed siRNA silencing experiments in 
which ETV6-RUNX1 expression was abrogated in ETV6-RUNX1 positive human 
cell lines23-26. The silencing of ETV6-RUNX1 induced programmed cell death and 
significantly reduced proliferation of these cells, suggesting that ETV6-RUNX1 
drives a pro-survival and pro-proliferative phenotype23,24. In contrast, the laboratory 
of Jan Trka did not find altered survival or proliferation of ETV6-RUNX1 positive 
cell lines after siRNA mediated knockdown of ETV6-RUNX129. These contradicting 
results could be explained by differences in siRNA design, siRNA biosynthesis, 
or knockdown efficiency. The above-mentioned studies were performed in 
immortalized cancer cell lines. Since cell lines are genetically manipulated and 
cultured over an extended period of time, genotypic and phenotypic variation 
occurs. This raises the question whether these cells are a good representation of a 
primary human (pre-) leukemic cell. Although such studies might give insight in the 
cellular phenotype driven by ETV6-RUNX1, the acquired genetic variation makes 
the analysis of molecular drivers important for human disease challenging and 
possibly incorrect. 
The phenotype of ETV6-RUNX1 expressing progenitors was further elucidated 
using several mice models. For example, the laboratory of Owen Williams 
performed ETV6-RUNX1 overexpression studies in fetal liver-derived murine 
hematopoietic progenitors36,37. These experiments were performed in healthy 
progenitor cells, thereby modeling the effects of the appearance of a ‘first hit’ in such 
a cell population. Similar to the studies performed in human cord blood derived 
hematopoietic progenitors, ETV6-RUNX1 transduced murine progenitors showed 
enhanced self-renewal in vitro and enhanced hematopoietic reconstitution in vivo, 
suggesting activation of pro-proliferative and pro-survival pathways36. In addition, 
expression of ETV6-RUNX1 altered the differentiation of murine progenitors by 
skewing B cell development36. In a study using ETV6-RUNX1 overexpression in 
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bone marrow-derived murine hematopoietic progenitors, a similar increase in early 
B cells was observed. In addition, the authors reported that these cells were unable 
to differentiate beyond the pro-B stage33. These data suggest that ETV6-RUNX1 
also alters differentiation pathways in pre-leukemic progenitors. Furthermore, 
ectopic expression of ETV6-RUNX1 in a murine pro-B cell line changed cytoskeletal 
regulatory genes and altered migration properties38. These experiments performed in 
murine models attempt to recapitulate human disease. However, critical differences 
in phenotype and molecular mechanisms regulating stem cell maintenance and 
lineage differentiation exist between murine and human hematopoiesis39-41. For 
example, the transcription factor Hoxb4 drives hematopoietic differentiation of 
murine embryonic stem cells (ESCs) and induced expansion of murine HSCs by 
nearly 1000 fold42,43, while in contrast HOXB4 did not alter self-renewal properties 
of ESC-derived human HSCs and only moderately induced HSC numbers by 2-4 
fold40,44. Hence, although murine models add significant insight in understanding the 
initiation and evolutionary process of leukemogenesis driven by the ETV6-RUNX1 
fusion protein31,35, it is difficult to translate these findings to human leukemogenesis. 
Murine models are therefore not optimal for studies aiming to find therapeutic 
targets for ETV6-RUNX1 positive leukemia. 
In order to identify targets of the ETV6-RUNX1 fusion protein relevant for 
human leukemia, several laboratories (including our own laboratory) used gene 
expression profiling of leukemic blasts of pediatric ALL patients12,45-48. These studies 
uncovered some promising downstream effectors of the ETV6-RUNX1 fusion 
protein, such as the erythropoietin receptor27,47. However, these studies used gene 
expression analysis of leukemic blasts in which ETV6-RUNX1 expression is already 
coupled to multiple secondary mutations. Therefore, this approach risks to reveal 
molecular targets that are not (directly) driven by the ETV6-RUNX1 fusion protein 
and hence are not important for all subclones within the leukemia. 
To overcome the limitations of previous models, we compared gene expression 
profiling of primary leukemic blasts of 654 ALL patients with gene expression profiling 
of human cord blood-derived CD34-positive HPCs (CB-CD34+) that ectopically 
expressed the ETV6-RUNX1 fusion protein (chapter 3 and 4). This approach allowed 
us to study ETV6-RUNX1 driven target genes that are still important in leukemic 
cells. We analyzed gene expression of ETV6-RUNX1 positive CB-CD34+ cells at 
early time points (20 hours and 40 hours after transduction), since the disadvantage 
of using ectopic expression models is the risk of inducing gene expression levels 
above wild-type levels, not reflecting the normal biological effects. In addition, the 
simultaneous differential expression of genes in leukemic blasts of ETV6-RUNX1 
positive ALL patients makes an overexpression artefact unlikely. Since we used a 
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retroviral vector, we primarily investigated the effects of ETV6-RUNX1 expression 
on dividing but not quiescent CB-CD34+ cells. This population of progenitors is 
likely to be the population of interest since several reports support the hypothesis 
that ETV6-RUNX1 positive ALL originates in the CD34+ lymphoid progenitor 
fraction30,49,50. 
Our studies revealed that ectopic expression of ETV6-RUNX1 in healthy human 
progenitors indeed induced transcriptional networks positively regulating survival, 
proliferation and migration of blood cells (chapter 3 and 4). Some of the molecular 
pathways found to be regulated by ETV6-RUNX1 in human progenitor cells were also 
identified in the above-described cell line and mouse models. For example, several 
genes that are affected by the erythropoietin receptor and by TGFβ signaling were 
induced in our data set. Interestingly, we found a novel network of differentially 
regulated transcription factors that induced autophagy in ETV6-RUNX1 positive 
cells via upregulation of Vps34 expression. This suggests that autophagy maybe a 
target for therapeutic interference. Indeed, we found that inhibition of the autophagy 
pathway affected the viability and proliferation of ETV6-RUNX1 positive leukemic 
cells and sensitized these cells to conventional cytotoxic drugs (chapter 3).
Autophagy: driving proliferation, survival and drug resistance in ETV6-RUNX1 
positive leukemia
Macroautophagy, or shortly autophagy, is a cellular recycling system in which 
unwanted or damaged cellular components are degraded and recycled. All 
mammalian cells use autophagy both in normal and stress conditions. Levels of 
autophagy can rapidly enhance during cellular stress or starvation. During stress, 
autophagy provides the necessary free nucleotides, amino acids, and fatty acids to 
ensure the production of new essential proteins. Although autophagy can sustain cell 
survival during stress conditions, it can also result in cell death due to progressive 
cellular consumption51-53. Whether autophagy generally plays an initiating or 
tumor-suppressive role in cancer is still under debate and is most likely dependent 
on the cellular context54-58. Autophagy can promote survival of cancer cells by 
eliminating damaged mitochondria and other organelles, buffering oxidative stress, 
and thereby preventing apoptosis54,59. In addition, autophagy can cause resistance 
of cancer cells to chemotherapeutic drugs57,60. However, autophagy can also be an 
important tumor-suppressive mechanism that eliminates oncogenic proteins54-57. For 
example, both the PML-RARα fusion protein in acute promyelocytic leukemia61,62 
and the BCR-ABL1 fusion protein in CML63 are degraded by autophagy during 
chemotherapeutic treatment. In this setting, autophagy inhibition would hamper the 
efficacy of treatment, since it decreases the therapy-induced degradation of leukemic 
fusion proteins. However, not all leukemic fusion proteins are degraded in this 
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manner. In RUNX1-RUNX1T1 positive AML, the fusion protein was not degraded 
by autophagy and autophagy inhibition increased the efficacy of therapy64. The 
apparent dual role of autophagy in cancer highlights the importance of investigating 
the context-specific role and the functional role of autophagy in a certain cancer 
before the start of autophagy-based therapeutic interventions. 
In chapter 3 of this thesis, we show that the ETV6-RUNX1 fusion protein 
enhanced levels of autophagy in pre-leukemic and leukemic cells. These enhanced 
levels of autophagy appeared to be an important pro-survival feature and 
encompasses an essential characteristic of ETV6-RUNX1 positive leukemic cells. 
Inhibition of autophagy by hydroxychloroquine (HCQ) induced cell death and 
sensitized ETV6-RUNX1 positive leukemic cells to L-Asparaginase in vitro. These 
experiments were performed in human cell line models and in primary human ALL 
cells. In addition, we showed that these effects were still present in an ex vivo niche 
setting in which we co-cultured primary leukemic cells with primary mesenchymal 
stromal cells. These pre-clinical findings indicate that patients with ETV6-RUNX1 
positive leukemia might benefit from the inclusion of autophagy inhibitors in their 
treatment protocols. The efficacy of autophagy inhibitors during cancer treatment is 
currently examined in phase I/II clinical trials in a heterogeneous group of advanced 
tumors (reviewed in e.g. 57,65). Initial results indicate that autophagy inhibition 
with HCQ is safe, tolerated at high concentrations, and might be effective in some 
patients with advanced solid tumors66-68. In addition, autophagy-independent “off-
target” effects of chloroquines, like HCQ, were reported to enhance response to 
chemotherapy69,70, strengthening the point to use chloroquines in clinical practice. 
However, more specific and more potent autophagy inhibitors are currently 
developed and preclinical studies with these novel inhibitors (e.g. Lys05) show 
promising improved antitumor activity compared to chloroquines71. 
In addition, the recent characterization of the crystal structure of Vps3472 
allowed the development of specific Vps34 inhibitors73-75. Since Vps34 plays an 
essential role in the induction of autophagy in ETV6-RUNX1 positive BCP-ALL, 
these patients may be the perfect candidates for the use of such an inhibitor. 
However, before initiating clinical trials in patients with ETV6-RUNX1 positive 
leukemia, the efficacy and specificity of autophagy inhibition (including Vps34 
inhibitors) should be confirmed in in vivo models. The most widely used in vivo 
model for the validation of the efficacy of human leukemia treatment is the immune 
compromised NOD/SCID/gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; NSG) knockout 
mouse model76-78. In this model, leukemic cell lines and primary leukemic cells 
engraft significantly better than in other immune compromised mouse strains and 
can develop overt leukemia in vivo76. ETV6-RUNX1 positive cell lines engraft in 
NSG mice and can therefore function as a model system to further test the efficacy 
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of autophagy inhibitors. However, as mentioned earlier, cell lines might not be a 
good representation of a primary human leukemic cell. Unfortunately, the use 
of the NSG xenotransplantation model in studies with primary ETV6-RUNX1 
positive leukemic cells is often hampered due to impaired engraftment or low rate 
of leukemia development within the lifespan of a mouse79,80. Further, the leukemic 
microenvironment in the NSG model consists of murine stromal cells, which do 
not represent the human bone marrow microenvironment81. To overcome these 
problems, xenotransplantation approaches are developed in which extramedullary 
human microenvironments are created in scaffolds seeded with human MSCs and 
transplanted in immune-deficient mice82-84. These models allow the engraftment of 
ETV6-RUNX1 positive primary human leukemic cells (van de Ven et al. unpublished 
data) and allow drug testing to be performed in a “humanized” microenvironment. 
Before introducing autophagy inhibitors to clinical protocols, it is recommended to 
perform additional in vivo experiments in such a human bone marrow-like xenograft 
model using primary leukemic cells.
LARG/RhoA signaling: driving migration of ETV6-RUNX1 positive leukemia
Previous gene expression studies in ETV6-RUNX1 positive BCP-ALL cells showed 
significant enrichment of genes involved in the regulation of migration85,86. 
Furthermore, the ETV6-RUNX1 fusion protein induced expression of genes involved 
in cytoskeletal regulation in a murine cell line, and enhanced the migratory capacity 
of murine B cells28. In chapter 4, we revealed the transcriptional program inducing 
the pro-migration phenotype in ETV6-RUNX1 positive CB-CD34+ cells and primary 
leukemic cells, and found that leukemia-associated Rho guanine nucleotide exchange 
factor (LARG)/RhoA signaling is a master regulator of the described pro-migration 
phenotype. 
Targeting the interaction between leukemic cells and their microenvironment 
has been focus for leukemia researchers for years. Several studies use growth factors 
disrupting the CXCR4/CXCL12 axis (G-CSF or GM-CSF) or CXCR4 antagonists to 
target leukemic niches. These studies imply that niche disruption may enhance 
therapy efficiency during leukemia treatment87-97. However, recent data argues that 
leukemia stem cells are not mobilized by CXCR4 inhibition98, suggesting that CXCR4 
inhibition is not sufficient to completely disrupt leukemic niches. Importantly, CXCR4 
inhibition does not only interrupt the leukemic, but also the healthy hematopoietic 
niche99,100. The importance of the leukemic niche for ETV6-RUNX1 positive BCP-ALL 
became apparent in our ex vivo co-culture studies. Primary ETV6-RUNX1 positive 
BCP-ALL cells showed a significant induction of survival and drug resistance when 
co-cultured with primary MSCs (Figure 2). Chapter 4 of this thesis provides the first 
pre-clinical evidence that inhibition of an intracellular signaling route can reduce 
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migration of leukemic cells even in the presence of strong chemokine signals from 
the microenvironment. The discovery of the intracellular signaling pathway driving 
migration in ETV6-RUNX1 positive leukemia, namely the LARG/RhoA signaling 
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Figure 2. Survival analysis of primary ETV6-RUNX1 positive leukemic blast in mono-culture or 
co-culture with primary MSCs 
In these experiments, we used 3 different primary human MSCs isolated from bone marrow (pMSC#1-#3). Black 
bars represent the percentage of annexin-PI negative cells in mono-culture. White bars represent the percentage of 
annexin-PI negative cells in co-culture with MSCs. 
(A) Primary blasts were isolated from 3 ETV6-RUNX1 positive BCP-ALL patients and subsequently cultured for 
3 days in absence or presence of primary MSCs. (B) Primary blasts were isolated from 3 ETV6-RUNX1 positive 
BCP-ALL patients and subsequently cultured for 3 days in absence of presence of primary MSCs during exposure 
to prednisolone. Abreviations: pMSC, primary mesenchymal stromal cell; pE/R+, primary ETV6-RUNX1 positive 
leukemic cells; PRED, prednisolone. 
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pathway, opens the exciting possibility of selectively inhibiting migration of cells 
that express the ETV6-RUNX1 fusion protein. The recent development of small 
molecule inhibitors for LARG and RhoA101-103 allowed us to test this hypothesis. 
Indeed, we show that small molecule inhibition of LARG/RhoA blocks migration of 
ETV6-RUNX1 positive leukemic cells, while the migration of leukemic cells without 
the fusion gene was unaffected by LARG/RhoA inhibition. Therefore, we speculate 
that LARG/RhoA inhibition specifically targets the niche of ETV6-RUNX1 positive 
leukemic cells without affecting healthy hematopoietic niches. This could significantly 
increase effectivity and reduce toxicity of niche-disrupting approaches. However, to 
test this hypothesis and translate these findings to future clinical application, studies 
investigating the effects of small molecule inhibition of LARG/RhoA on both the 
healthy microenvironment and the ETV6-RUNX1 positive leukemic niche in vivo 
are essential. We recommend to perform such in vivo experiments in a humanized 
bone marrow xenograft model using primary leukemic cells. In addition, these 
experiments may reveal whether inhibition of ETV6-RUNX1 positive cell migration 
sensitizes cells to chemotherapy. 
Gene expression analysis of ETV6-RUNX1 driven leukemia
The first part of this thesis has focused on the cellular pathways that are regulated by 
ETV6-RUNX1 in human progenitors and simultaneously are differentially expressed 
in ETV6-RUNX1 positive BCP-ALL. This approach revealed several genes that are 
likely to be important and specific for ETV6-RUNX1 positive leukemia (chapter 
3). Therefore, this gene list provides an important tool for future research on the 
biology of ETV6-RUNX1 positive leukemia and reveals possible additional targets 
for precision therapeutic strategies. 
The ectopic expression studies of ETV6-RUNX1 in CB-CD34+ cells were 
performed simultaneously with ectopic expression studies of RUNX1-RUNX1T1 
(AML1-ETO), allowing us to compare genes driven by two fusion proteins with 
the RUNT DNA binding domain. Both ETV6-RUNX1 and RUNX1-RUNX1T1 are 
known to downregulate RUNX1 target genes104,105. We indeed found several genes 
(32/556 differentially expressed genes) that were regulated both by expression of 
ETV6-RUNX1 and by expression of RUNX1-RUNX1T1 (Figure 3). However, the 
majority of these genes was induced by the fusion proteins. The vast majority of 
differentially expressed genes (524/556 genes) was either differentially regulated in 
RUNX1-RUNX1T1 positive progenitors or in ETV6-RUNX1 positive progenitors, 
suggesting that these fusion proteins not only function as dominant negative 
inhibitors of RUNX1 transcription, but also act as unique transcription factors. This 
is in line with several reports showing that these fusion proteins not only bind to 
RUNX1-bound promoter regions, but also bind to fusion protein specific promoter 
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regions106-108. Interestingly, RUNX1 and activating protein 1 (AP1) were shown to 
play an important role in the formation of an activating or repressing complex by 
the RUNX1-RUNX1T1 fusion protein on these distinct promoter regions109. Whether 
this interplay is also important for the ETV6-RUNX1 fusion protein remains to be 
investigated.
Future perspectives for ETV6-RUNX1 positive BCP-ALL
The first part of this thesis shows that the exploration of genes that are driven by 
a first hit during leukemogenesis and that persist in the leukemic phase, provides 
a promising strategy to find targets for tailored therapy. The interference with 
such downstream targets was shown to effectively reverse important hallmarks of 
cancer110: inhibiting the Vps34/autophagy pathway effectively reduced proliferation 
and induced cell death of ETV6-RUNX1 positive cells in vitro, while targeting the 
LARG/RhoA pathway blocked migration of ETV6-RUNX1 positive cells. The major 
challenge is now to translate this knowledge into precision therapy for leukemia 
patients. In order to make this ultimate step, the results of the experiments in 
chapter 3 and chapter 4 must be reproduced in in vivo models. These models will 
answer a number of key questions that need to be answered before starting clinical 
trials using ETV6-RUNX1 targeted therapy. For example, it will be interesting to 
see whether Vps34/autophagy inhibition will have single agent effectivity in vivo 
and will improve the anti-leukemia effects of chemotherapy (e.g. L-asparaginase) 
without inducing more toxicity. In addition, it is still unclear which autophagy 
inhibitor is best in the setting of ETV6-RUNX1 positive leukemia. Keeping the study 
presented in chapter 3 in mind, Vps34 inhibitors are likely to be the most specific 
agents for this subtype of leukemia. However, the autophagy-independent effects 
of the broadly used chloroquines might boost the efficacy of this group of agents. 
Likewise, it is still unclear whether inhibiting LARG/RhoA signaling in vivo results 
in the disruption of the leukemic niche and will improve the cytotoxic effects of 
32205 287
RUNX1-RUNX1T1
(R/R)
ETV6-RUNX1
(E/R) 
Figure 3. Gene expression analysis of CB-
CD34+ cells ectopically expressing oncogen-
ic fusion proteins
(A) Comparison of differentially expressed genes at 
20 hours and 40 hours after transduction between 
RUNX1-RUNX1T1 and ETV6-RUNX1 positive pro-
genitors revealed that most genes are differentially 
regulated by RUNX1-RUNX1T1 and ETV6-RUNX1. 
(B) 41 probe sets representing 32 genes were simi-
larly regulated by the RUNX1-RUNX1T1 and ETV6-
RUNX1 fusion protein of which the top 25 most 
differentially regulated genes are depicted in this 
heatmap. 
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chemotherapy without inducing more toxicity. In addition, the combination of niche 
disrupting agents might enhance the efficacy of targeted agents, such as autophagy 
inhibitors in ETV6-RUNX1 positive BCP-ALL. Niche disrupting agents might 
also enhance the effectivity of another promising manner to target leukemic cells: 
immunotherapeutics, such as tumor specific monoclonal antibodies (e.g. anti-CD19), 
bi-specific T cell engagers, adoptive cellular therapies (e.g. CAR T cells), and immune 
checkpoint blockade (e.g. PD1/PD-L1 blockade and CTLA4 blockade)111. Although 
the combination of such targeted approaches might be the ideal way to abandon the 
necessity of toxic chemotherapy, their effectivity must first be tested in combination 
with classical chemotherapeutic agents, since jeopardizing the current excellent 
survival rates of patients with ETV6-RUNX1 positive BCP-ALL is unacceptable. 
Once these targeted approaches are shown to be safe, a good first step would be to 
add tailored agents in current treatment protocols and decrease the cumulative dose 
of toxic chemotherapeutic drugs, using innovating patient-centric trial designs112.  
UNDERSTANDING AND TARGETING THE 
LEUKEMIC NICHE
Next to the classical hallmarks of cancer110 that include sustained proliferation, 
evasion of growth suppressors, resistance to cell death and replicative immortality, 
the formation of a tumor microenvironment is now recognized as a key feature of 
cancer113. The leukemic bone marrow microenvironment protects leukemic cells from 
elimination by immune responses and chemotherapeutic agents114,115, and can even 
facilitate the development of drug resistance to both classical chemotherapeutic agents 
and newly developed targeted therapies116-122. Several studies show the importance 
of interaction between leukemic cells and their bone marrow microenvironment 
by convincingly reporting the modulation of the microenvironment by leukemic 
or pre-leukemic cells in murine models123-126. However, the functional mechanisms 
mediating crosstalk between leukemic cells and their local niche remain to be 
investigated. In the second part of this thesis, we aimed to better understand the 
mechanisms by which leukemic cells create a supportive microenvironment. In 
addition, we presented novel strategies aiming to disrupt this leukemic niche.
Cell-to-cell communication within the leukemic niche: the discovery of 
tunneling nanotubes
Cell-to-cell communication in the complex microenvironment of a leukemia can 
take place in multiple ways. Humoral factors, such as secreted growth factors, 
cytokines and chemokines, and extracellular vesicles are important for both normal 
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and leukemic cells127-129. Also direct cell-to-cell contact and subsequent signaling via 
integrins and gap junctions is reported to be an important means of communication 
between leukemic cells and their microenvironment130-137. In chapter 5 of this thesis, we 
describe a novel way of functional connectivity within the leukemic niche: signaling 
via tunneling nanotubes (TNTs). Our study reveals that this type of interaction 
can take place between several cell types in the leukemic niche and is important 
for leukemic cell survival and niche-induced drug resistance. We developed an 
unbiased, quantitative, flow cytometry-based method to quantify TNT signaling by 
which we explored TNT signaling between several cellular counterparts (see chapter 
5). TNT signaling occurred both between leukemic cells and MSCs. However, we 
predominantly observed TNT signaling from leukemic cells towards MSCs. Since 
the bone marrow microenvironment consists of multiple stromal cell types, we also 
explored whether TNT signaling is present between leukemic cells and osteoblast 
or adipocyte progenitors. Indeed, leukemic cells signal to osteoblast progenitors, 
adipocyte progenitors, mature osteoblasts and mature adipocytes (Figure 4). 
In addition, we show that leukemic cells signal equally effective toward bone 
marrow-derived MSCs from leukemia patients as toward MSCs derived from bone 
marrow of healthy volunteers (chapter 5). These data indicate that TNT signaling 
occurs between leukemic cells and a multitude of stromal counterparts in the niche. 
Since leukemic cells use TNTs to communicate with their microenvironment, the 
inhibition of TNTs might be a promising way to disrupt the leukemic niche. Therefore, 
we performed co-culture experiments in which TNT signaling was inhibited. Since 
no TNT specific inhibitors are currently available, we used a combination of two 
rather aspecific controls (chapter 5). TNTs need prolonged cell contact to signal 
efficiently. Therefore, we used gentle shaking of co-cultures to reduce the lifespan 
of TNTs, while allowing direct contact between BCP-ALL cells and MSCs. However, 
flow-derived shear forces (like in gentle shaking conditions) induce integrin-
mediated intracellular signaling138,139. To exclude the effects of increased integrin 
signaling in shaking conditions, we physically separated ALL cells and MSCs using 
a transwell system. This transwell system allowed humoral communication via 
growth factors, cytokines, chemokines and extracellular vesicles (3μm inserts were 
used that allow transfer of extracellular vesicles including exosomes (ranging from 
30nm-100nm) and microvesicles (ranging from 100nm- 1μm)), but inhibited direct 
cell-to-cell communication via TNTs, integrins and gap junctions. The combination 
of these controls allowed us to investigate the role of TNT signaling in co-cultures, 
since their common inhibitory feature is TNT inhibition (Table 1). However, shaking 
and transwell conditions did not exclusively inhibit TNTs while leaving other 
signaling modules unaffected. Evidently, a specific inhibitor of TNTs would be a key 
addition to these studies. 
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One approach to fi nd a TNT specifi c inhibitor is to decipher the molecular 
machinery that regulates TNT formation. Recently, this molecular machinery is 
starting to be unraveled. MSEC, HIV-Nef, and LST1 were reported to induce the 
formation of TNTs140-143. These molecules trigger intracellular signaling pathways, 
such as Rho GTPases and the Ral/exocyst complex, that are known to be important 
for actin remodeling and are associated with fi lopodia/lamelipodia formation. 
Also the PI3K/PKB signaling pathway may be involved in the formation of 
TNTs144,145. Inhibition of the machinery regulating the actin cytoskeleton off ers an 
alternative promising approach to inhibit TNTs. The actin inhibitors cytochalasin 
D and latrunculin B were shown to eff ectively reduce dye transfer from leukemic 
cells toward MSCs (chapter 5 and Figure 5), but were not suitable for functional 
experiments since the observed eff ects were only temporary due to a relatively short 
half-time. In addition, these inhibitors are generally very toxic to cells. To study 
whether actin inhibitors aff ect TNT formation directly or inhibit TNT formation due 
to toxicity, we performed additional dye transfer experiments with another class 
of toxic agents: tubulin inhibitors. In contrast to actin inhibition, tubulin inhibition 
did not aff ect dye transfer from leukemic cells toward MSCs, although tubulin 
inhibitors also signifi cantly induced cell death of leukemic cells (Figure 5). This is 
in concordance with reports showing that TNTs contain F-actin, but do not contain 
microtubule/tubulin structures146. Thus, inhibition of the actin cytoskeleton might 
be a promising approach to inhibit TNT signaling. Several classes of actin inhibitors 
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Figure 4. TNT signaling from leukemic cells toward osteoblast and adipocyte lineages
Primary bone marrow-derived MSCs were diff erentiated toward the adipocyte and osteoblast lineages (see chap-
ter 5 for details) and subsequently co-cultured with DiI-stained BCP-ALL cells (REH cell line). Dye transfer was 
measured 3, 6, and 24 hours after start of co-culture. We assessed dye transfer at three individual time-points dur-
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have been reported, including small molecules that target the actin polymerization 
machinery147. Currently, we are performing experiments with several actin inhibitors 
to find an agent or a combination of agents that offers prolonged and efficient 
inhibition of TNT signaling and simultaneously shows low toxicity in healthy 
hematopoietic and niche cells (de Rooij et al. submitted).
Although the majority of studies on TNTs were performed in vitro, recently 
several studies have visualized the formation of TNTs in vivo148-150. For example, brain 
tumor cells create a functional network of TNT-connected tumor cells in the brain 
that was shown to be important for tissue repair and radioresistance150. However, 
whether TNTs are formed in vivo in the human bone marrow microenvironment 
is still an unanswered question. The laboratory of David Scadden and Charles Lin 
developed a method to track hematopoietic stem cells in a murine bone marrow niche 
by intravital imaging of transplanted HPCs in mouse calvarium bone marrow151-153. 
Since intravital microscopy is a rapidly developing field and imaging quality is 
improving fast, it is possible that in the near future also the formation of TNTs and 
TNT signaling can be visualized in the in vivo bone marrow niche.
Which molecules or organelles are transported via TNTs between leukemic 
cells and MSCs is still unclear. Studies report transfer of organelles, including 
mitochondria146 and lysosomes154, but also oncogenic proteins155-157 and oncogenic 
microRNAs158, and even exosomes and lipid nanoparticles159. For example, TNTs 
have been shown to transport drug-efflux pumps such as P-glycoproteins157. 
Recently, the transfer of mitochondria via TNTs was shown to be important for the 
survival of tumor cells. Tan et al. showed that mitochondrial DNA was transferred 
from the tumor microenvironment to tumor cells depleted of mitochondrial DNA, 
thereby restoring the respiratory function and tumorigenicity of these cells in vivo160. 
Table 1. Effects of TNT inhibiting controls
Shaking Insert
Integrins
Soluble factors
Microvesicles
Exosomes
Tunneling nanotubes
stimulation
inhibition inhibition
inhibition
Table visualizing the effects of gentle 
shaking or culture in a 3 μm tran-
swell system on important intracel-
lular communication mechanisms. 
O = no effect.
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Similarly, the transfer of mitochondria from healthy cells toward cancer cells via 
TNTs was suggested to induce chemoresistance161 and reduce cell death in early 
apoptotic cells162. In our study (chapter 5), we report TNT-dependent induction 
of survival and increase of chemoresistance in BCP-ALL cells in co-culture with 
MSCs. Transfer of mitochondria from MSCs toward leukemic cells might be 
responsible for these eff ects. However, we found a preferential transfer of lipophilic 
dye (labeling organelles and membrane components) from leukemic cells towards 
MSCs. In addition, a pilot experiment (chapter 5) shows that cytokine production in 
co-cultures of BCP-ALL cells and MSCs is driven by the leukemic cell. This suggests 
that leukemic cells use TNTs to direct stromal cells to produce appropriate survival 
factors. However, our study did not uncover the mediators that are transported via 
TNTs. Do leukemic cells use TNTs to send entire organelles, such as mitochondria or 
lysosomes, or (membrane-associated) proteins, nucleic acids or micro-RNAs toward 
MSCs? To answer this question, we initiated a study in which we overexpressed 
fl uorescently tagged proteins that are markers for organelles, cytoskeletal proteins, 
exosomes, or important transmembrane or intracellular signaling molecules (see 
addendum). A more unbiased approach to reveal TNT-transported proteins is the 
use of trans-SILAC. Trans-SILAC was recently developed to study the non-cell-
autonomous proteome exchange among cells of multicellular organisms163 and was 
used to show that melanoma cells transfer Ras oncoproteins to healthy T cells to 
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Figure 5. Tubulin inhibitors do not reduce TNT signaling from leukemic cells toward MSCs
DiI-stained CD19-positive BCP-ALL cells (NALM6) were co-cultured with unstained CD19-negative primary 
MSCs. Transfer of DiI staining to pMSCs was analyzed by fl ow cytometry 16 hours after start of co-culture. Gray 
graphs represent staining of MSCs at start of the experiment. Blue graphs represent dye transfer toward MSCs 
without the addition of an inhibitor. 
(A) Dye transfer from DiI–stained BCP-ALL cells toward unstained MSCs was decreased by inhibition of F-actin 
by Cytochalasin D. (B / C) Dye transfer from DiI–stained BCP-ALL cells toward unstained MSCs was not aff ected 
by microtubule inhibition with Nocodazol (B) or Colchicine (C).
218 Chapter 7
modulate their effector function164. This approach combines stable-isotope labeling 
of amino acids in cell culture (SILAC) with mass spectrometry and high-purity cell 
sorting. These studies did not focus on the intercellular way of protein transport. 
However, since in these studies, the actin inhibitor Latrunculin B was used to exclude 
actin cytoskeleton-dependent transfer163, it is likely that the observed transfer of 
proteins was mediated via TNTs. Alternatively, novel technologies that are able 
to quantify newly synthesized proteins, could be used to study the effects of TNT 
signaling between leukemic cells and MSCs on protein level (Click-iT technology, 
Life Technologies). This approach could also be used to study newly synthesized 
mRNA. These experiments might also provide insight into the molecular pathways 
that are activated within the stromal cells and explain the distinct patient-unique 
cytokine excretion patterns reported in chapter 5 and 6. Mass-spectrometry 
approaches might help in understanding how and why different leukemic cells 
induce distinct secretomes and which molecules are involved in these processes. 
In addition, the further identification of the transported cargo might hold clues for 
druggable targets.
The study presented in chapter 5  focused on TNT formation and signaling 
in the BCP-ALL niche. During these experiments, we wondered whether TNT 
signaling is a unique characteristic of the BCP-ALL niche. Therefore, we performed 
pilot experiments with healthy human hematopoietic cells (isolated from umbilical 
cord blood) and leukemic cells from other acute leukemias. TNT signaling also 
occurred between healthy hematopoietic cells and MSCs (supplementary Figure 1), 
supporting the view that TNT signaling represents a widely used mechanism of cell-
to-cell communication165. However, stromal support differentially affects survival of 
healthy hematopoietic cells from different lineages. Especially CD19-positive B-cells 
are dependent on TNT-driven stromal support ex vivo (supplementary Figure 2). 
Similarly, we observed that the effect of stromal support on leukemic cells depends 
on the phenotypic background (lymphoid or myeloid) and differentiation status of 
the leukemic cell. While primary BCP-ALL cells ex vivo are partially or completely 
dependent on TNT-driven stromal support, only a subgroup of primary T-ALL and 
primary AML cells is supported in such manner. This suggests that TNT inhibition 
will not be beneficial for all patients with acute leukemia (supplementary Figure 3). 
The introduction of TNT inhibitors is far away from clinical practice. As 
discussed above, several important steps should be taken before TNT inhibitors may 
be used in therapy for ALL patients. If a non-toxic specific TNT inhibitor is available, 
in vivo confirmation of the experiments presented in chapter 5 and this discussion 
are essential. These experiments would also allow studying the effects of TNT 
inhibition on normal hematopoiesis. We recommend to perform such experiments 
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in a human bone marrow-like xenograft model using primary leukemic cells with 
different phenotypic and genetic background.
The BCP-ALL niche revised
Several studies have tried to target the leukemic niche by inhibiting the most 
important chemokine signal produced by the hematopoietic niche: CXCL12100. 
Treatment with G-CSF, decreasing CXCL12 levels in the bone marrow, and CXCR4 
antagonists, blocking CXCR4/CXCL12 interaction, led in leukemic mice models 
to mobilization of leukemic cells, increased sensitivity to therapeutic agents, and 
prolonged survival88-97,166. Phase 1/2 clinical trials have shown the feasibility of using 
CXCR4 antagonists during chemotherapeutic treatment167-171. However, recent data 
suggests that blocking CXCL12-mediated migration is insufficient to completely 
disrupt leukemic niches98,172. Furthermore, CXCR4/CXCL12 blockade does not only 
interrupt the leukemic, but also the healthy hematopoietic niche99,100. As discussed 
in paragraph 5.2 of chapter 1, leukemic cells disrupt the healthy bone marrow 
microenvironment in multiple ways. Whether migration and anchorage signals are 
changed in such a leukemic niche is largely unknown, especially in the context of 
BCP-ALL. In chapter 6, we show that BCP-ALL cells indeed affect the migration 
potential of their microenvironment by inducing migration of leukemic counterparts 
and inhibiting migration of healthy hematopoietic cells and mesenchymal stromal 
cells. This process is completely independent of the CXCR4/CXCL12 axis: CXCL12 
levels were not altered, and CXCR4 inhibition did not affect this process. These data 
are in line with earlier reports showing that CXCL12 expression is not up-regulated 
in leukemic niches in vivo. CXCL12 expression was actually downregulated in 
murine bone marrow regions of extensive leukemia growth123. Likewise, CXCL12 
serum levels of patients diagnosed with BCP-ALL were lower compared to healthy 
controls and patients in remission173. Instead of changes in CXCL12 production, we 
found that primary leukemic cells induce a unique and patient-specific secretome 
in co-culture with primary MSCs. This induction was independent of the origin 
of primary MSCs, which suggests that the leukemic cell instructs the stromal 
microenvironment to produce signals that are important for their migration and 
maintenance, thereby creating a self-reinforcing niche. In addition, these data show 
that CXCR4 blockade is not sufficient to disrupt the leukemic niche. Our study is 
the first in which alternative chemokine pathways that might be important for the 
formation and maintenance of a leukemic niche are identified. We used a biased 
approach to identify these pathways by focusing on the secretion of 64 cytokines 
known to be important in immunology/hematology. Unbiased approaches, such 
as RNA sequencing and mass-spectrometry focusing on newly synthesized RNA/
proteins (Click-iT technology, Life Technologies), could further reveal which 
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molecular pathways are important for the formation of a leukemic niche. Our pilot 
study identified unique cytokine secretomes for each patient, suggesting the need 
for patient-specific approaches to disrupt the leukemic niche. However, primary 
cells of 10/10 BCP-ALL patients induced the production of CCR4 ligands (CCL2 and/
or CCL22), suggesting that CCR4 inhibition might be a promising additional way to 
disrupt the BCP-ALL niche. Induction of CCR4 ligands were also found to be higher 
in bone marrow samples of leukemia patients, compared to bone marrow of the same 
patients after induction therapy or healthy controls (chapter 6). Since monoclonal 
antibodies to CCR4 (mogamulizumab) are available174,175, this hypothesis could be 
tested in pre-clinical in vivo models. We recommend to perform such studies in a 
humanized bone marrow xenograft model using primary leukemic cells.
Future perspectives for niche-disrupting therapeutic strategies
The second part of this thesis aimed to better understand the molecular drivers behind 
the leukemic niche in BCP-ALL. The discovery of an important signaling module 
driving this niche (TNT signaling, chapter 5) and the discovery of the migratory 
changes induced by leukemic cells to create a self-reinforcing leukemic niche 
(chapter 6) provides significant insight into the biology of BCP-ALL. In addition, 
these studies revealed novel approaches to disrupt the leukemic niche in BCP-ALL. 
Potentially, niche disruption improves the anti-leukemic effects of chemotherapy, 
targeted therapy, and immunotherapy without inducing more toxicity. However, 
several essential steps have to be taken before the approaches presented in chapter 
5 (TNT inhibition) and chapter 6 (specific disruption of the leukemic niche) can 
be implemented in clinical protocols. First, specific non-toxic inhibitors should 
be developed. Second, proof-of-principal experiments should be conducted in in 
vivo models, using humanized bone marrow niches and primary human leukemic 
cells. In these models, the safety and effectivity of niche-disrupting agents must be 
confirmed. Such agents must be safe as single agent and should enhance the anti-
leukemic effects of chemotherapy, targeted therapy, or immunotherapy without 
inducing more toxicity. Only if these criteria are met, phase I/II trials can be 
conducted to test the safety of niche-disrupting agents. If these trials are successful, 
trials in which such agents are implemented in standard treatment protocols can 
be initialized, aiming to improve overall survival rates and reduce the amount of 
chemotherapeutic drugs administered without affecting outcome negatively.
Although implementation of niche-disrupting strategies in clinical protocols is 
far from reality, a better understanding of the BCP-ALL niche is the first step in this 
process. The second part of this thesis represents a small step in this journey.
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Supplementary Figure 1. TNT signaling from cord blood-derived healthy hematopoietic cells to-
ward primary MSCs
Primary mononuclear cells (CD34 negative MNCs) and CD34+ hematopoietic progenitors (CD34 positive HPCs) 
were isolated from cord blood, stained with DiI and subsequently co-cultured with primary MSCs. Gentle shaking 
and transwell controls were used to inhibit TNT signaling.  
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Supplementary Figure 2. TNT-dependent survival survival of healthy hematopoietic cells in co-
culture with primary MSCs
CD19-positive cells (B-cells), CD3-positive cells (T-cells), CD33-positive cells (myeloid cells), and CD34-positive 
cells (HPCs) were isolated from umbilical cord blood and subsequently cultured for 5 days in absence (black bars) 
or presence (white bars) of primary MSCs. Survival analysis was performed using FACS. Hematopoietic cells were 
distinguished from MSCs by CD45 surface marker expression. Survival was quantifi ed using Annexin V – Prop-
idium Iodide staining. All experiments were performed with or without TNT inhibition. TNTs were inhibited by 
gentle shaking or culture in a 3 μm transwell system. TNT inhibition in this fi gure represents the average of TNT 
inhibiting controls. All experiments were performed at least 3 times with diff erent cord blood donors and with 4 
diff erent primary MSCs. Error bars represent SEM. *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001.
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Supplementary Figure 3. TNT-dependent survival of primary BCP-ALL, T-ALL, and AML cells in 
co-culture with primary MSCs. 
(A) Primary BCP-ALL cells from different cytogenetic subgroups (namely ETV6-RUNX1 (n = 3), BCR-ABL1 (n = 3), 
MLL-rearranged (n = 2), and TCF3-PBX1 (n = 2)) were isolated from bone marrow of pediatric patients. Cells were 
cultured for 5 days in absence (black bars) or presence (white bars) of primary MSCs. All experiments were per-
formed with or without TNT inhibition. TNTs were inhibited by gentle shaking or culture in a 3 μm transwell sys-
tem. TNT inhibition in this figure represents the average of TNT inhibiting controls. Experiments were performed 
with 4 different primary MSCs. A representative experiment was shown for each subgroup. Error bars represent 
SEM. *, p ≤ 0.05, **, p ≤ 0.01, ***, p ≤ 0.001. (B / C) Primary T-ALL (B) and primary AML cells (C) were cultured for 
5 days in absence (black bars) or presence (white bars) of primary MSCs. All experiments were performed with or 
without TNT inhibition. TNTs were inhibited by gentle shaking or culture in a 3 μm transwell system. TNT inhibi-
tion in this figure represents the average of TNT inhibiting controls. Experiments were performed with 4 different 
primary MSCs. Error bars represent SEM. **, p ≤ 0.01.
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Tunneling nanotubes facilitate autophagosome 
transfer in the leukemic niche
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ABSTRACT
Acute lymphoblastic leukemia (ALL) cells create a leukemic niche with mesenchymal 
stromal cells (MSCs). Cytoskeletal structures called tunneling nanotubes (TNTs) 
facilitate communication between ALL cells and MSCs by transporting molecules 
and inducing the secretion of pro-survival cytokines. The identity of the molecules 
driving these malignant processes are currently unknown. Here we investigate 
which structures are transported from ALL cells toward MSCs by quantifying the 
transfer of ectopically expressed fluorescent marker proteins using flow cytometry. 
Our results indicate that actin, endoplasmatic reticulum, ICAM1, autophagosomes, 
mitochondria, and endosomes are contact-dependently transferred from leukemic 
cells toward MSCs. Transfer of mitochondria, adhesion molecule ICAM1, and 
autophagosomes were significantly reduced (≤ 9.6-fold) when TNT signaling was 
inhibited. Autophagosomes and mitochondria are known inducers of cytokine 
signaling and hence their transfer might unveil an important mechanism that ALL 
cells use to affect their microenvironment. Importantly, transfer of autophagosomes 
was 3.0-fold greater than the other molecules tested in ALL-MSC co-cultures, and 
has not been previously associated with TNT signaling. These data provide insight 
into intercellular signaling in the leukemic niche and implicate autophagosomes as 
novel TNT cargo.
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Acute lymphoblastic leukemia (ALL) cells disrupt the healthy bone marrow 
microenvironment to create a leukemic niche that is crucial for facilitating 
leukemogenesis and protects leukemic cells from chemotherapeutic agents and 
immune cells1,2. However, the functional mechanisms that regulate this malignant 
process are largely unknown. Recently, we showed that tunneling nanotubes (TNTs) 
play an important role in the communication between leukemic cells and bone-
marrow derived mesenchymal stromal cells (MSCs)3,4. TNTs are thin membrane 
protrusions that are driven by the actin cytoskeleton5. We recently showed that ALL 
cells use TNTs to signal toward MSCs and subsequently induce the secretion of pro-
survival cytokines, leukemic cell survival and drug resistance4. B-cell precursor ALL 
(BCP-ALL) cells and MSCs exchange lipophilic molecules using TNTs4. However, 
the identity of the transported cargo needs further elucidation. In this study, we 
describe that autophagosomes, mitochondria and the transmembrane protein 
ICAM1 are transferred from B-cell precursor ALL (BCP-ALL) cells toward MSCs in 
a TNT-dependent manner. 
To identify which structures are transferred from leukemic cells to MSCs via 
TNTs, we ectopically (i.e. non-endogenously) expressed fluorescently tagged proteins 
that mark specific cellular structures in BCP-ALL cells (NALM6) using lentiviral 
vectors (Figure 1A and supplementary Figure 1). After lentiviral transduction, we 
obtained stable BCP-ALL cell clones expressing turbo RFP (tRFP)-tagged marker 
proteins. The tRFP-positive BCP-ALL cells were stained with a nucleus specific 
dye (NucBlue), after which specific subcellular localization of fluorescent marker 
proteins was confirmed by confocal microscopy (Figure 1B). For example, CALR, 
which marks the endoplasmatic reticulum (ER), was expressed at the nuclear border 
(Figure 1B second panel from the top). 
Next, we co-cultured tRFP-marker protein expressing BCP-ALL cells with 
tRFP-negative MSCs (Figure 1C) and quantified the transfer of tRFP by flow 
cytometry (Figure 1D). The B-cell marker CD19 was used to distinguish between 
BCP-ALL cells and MSCs (Figure 1D, second panel). Actin, ER, cytoplasm, ICAM1, 
autophagosomes, mitochondria, and early/late/recycle endosomes were transferred 
from BCP-ALL cells to MSCs, since MSCs became increasingly positive for tRFP 
signal after co-culture with tRFP-tagged leukemic clones for 24, 48, and 72 hours 
(Figure 2A). To exclude that tRFP transfer was nonspecific, we plotted the intensity 
of tRFP in BCP-ALL cells, that differed 6.9-fold between the brightest and dimmest 
clone (cytoplasm versus ER; supplementary Figure 2), against the intensity of tRFP 
in MSCs after co-culture for 48 hours (Figure 2B). No correlation was found between 
the amount of transfer and the intensity of the tRFP signal in the leukemic clone from 
which the tRFP-tagged molecule originated (Figure 2B; p = 0.48, Pearson correlation 
test), showing that the observed transfer is not explained by nonspecific leakage 
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Figure 1. Identifying TNT cargo using fl uorescently tagged proteins
(A) Schematic overview of ectopically expressed marker proteins that were used to visualize specifi c cellular struc-
tures in BCP-ALL cells (NALM6). (B) Representative confocal images showing the subcellular localization of tRFP-
positive marker proteins relative to the nucleus in live NALM6 cells. A transmission image is provided to show the 
shape of the leukemic cell (left panel). (C) Experimental setup for visualizing protein transfer from BCP-ALL cells 
toward MSCs. Leukemic clones that express tRFP-positive marker proteins were co-cultured with tRFP-negative 
MSCs and transfer of protein toward was quantifi ed by fl ow cytometry. (D) Gating strategy that was used to 
quantify transfer of tRFP-positive marker protein from leukemic cells toward MSCs by fl ow cytometry. BCP-ALL 
cells and MSCs are gated based on their forward and sideward scatt er (fi rst panel) and separated based on CD19 
expression (second panel). Finally, the median tRFP signal in MSCs was quantifi ed with the PE-channel and used 
as a measure of tRFP-positive marker protein transfer (last panel).
See also supplementary Figure 1.
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of tRFP label. This implies that tRFP transfer from BCP-ALL cells toward MSCs is 
representative for transfer of tagged cellular structures. Autophagosomes appeared 
to be the most highly transported structure from BCP-ALL cells to MSCs (3.0-fold 
more than other proteins after 48 hours; Figure 2C). To assess the contribution of 
TNTs to the transfer of cellular structures, we performed ALL-MSC co-cultures 
in the absence or presence of TNT inhibiting conditions for 48 hours. TNTs were 
inhibited by two established approaches in literature: mechanical disruption of 
TNTs through gentle shaking of cell cultures and physical separation of BCP-ALL 
cells and MSCs using a transwell system (3.0 μm pore size)4,6. While actin inhibitors 
are often used to inhibit TNTs, their short half-time and high cytotoxicity prevented 
their use in these experiments4. Transfer of actin (ACTB), endoplasmatic reticulum 
(CALR), cytoplasmic content (Empty Vector), and endosome markers (RAB family) 
were inhibited by transwell conditions, but not by gentle shaking (Figure 2D). This 
implicates that transfer of these proteins is driven by cell-cell signaling modules 
other than TNTs. For example by gap junctional protein Cx43, which has been 
shown to be involved in transfer of extracellular vesicles7. Interestingly, transfer 
of transmembrane protein ICAM1, autophagosomes (LC3B), and mitochondria 
(PDHA1) were significantly inhibited by both TNT inhibiting conditions (shaking 
and transwell; p < 0.05, Figure 2D). Transmembrane proteins and mitochondria have 
previously been observed to be transferred via TNTs by other cell types8,9. Our data 
show that this is also true for TNT signaling between BCP-ALL cells and MSCs. 
Strikingly, transfer of autophagosomes was 3.0-fold higher than ICAM1 and PDHA1 
transfer (Figure 2C). To our knowledge, this is the first time that autophagosome 
transfer is observed between ALL cells and MSC in a TNT-dependent manner. 
Autophagy is a process that degrades and recycles unwanted or damaged 
cellular components, like proteins and organelles10. This process has been implicated 
as an important regulator of both tumor-initiation and tumor-suppression11. 
Autophagy is driven by double-membraned vesicles known as autophagosomes, 
which are shaped through the actin cytoskeleton12. TNT formation is also dependent 
on actin4,5 and this co-dependence might be important for autophagosome transport 
through the TNT machinery. Interestingly, autophagy induction through starvation 
of cells has been shown to increase the formation of TNTs13, suggesting a correlation 
between these processes. Recently, we observed that TNT signaling induces the 
secretion of pro-survival cytokines4. Autophagy is a known regulator of cytokine 
signaling and this process is influenced by mitochondrial reactive oxygen species 
and/or mitochondrial DNA14.The transfer of mitochondria and autophagosomes 
from leukemic cells toward MSCs might therefore explain the release of supportive 
factors by the tumor microenvironment, as we recently reported elsewhere (Figure 
2E)4. Interestingly, the transcription of ICAM1, a transmembrane protein involved 
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Figure 2. Autophagosomes, mitochondria and ICAM1 are transferred via tunneling nanotubes
(A) BCP-ALL cells expressing tRFP-markers were co-cultured with tRFP-negative MSCs for 24 (black bars), 48 
(dark-grey bars), and 72 hours (light-grey bars). Median intensity of MSCs for tRFP is shown. (B) Graph showing 
the median tRFP intensity of MSCs (X-axis) compared to BCP-ALL tRFP intensity (Y-axis) after co-culture for 48 
hours as depicted in Figure 2A. No correlation was found indicating that transfer of tRFP was protein specifi c (n 
= 3, p = 0.48, Pearson correlation test). (C) Graph showing the transfer of tRFP from BCP-ALL cells toward MSCs 
after 48 hours of co-culture (n = 3). (D) Graph showing the transfer of tRFP from BCP-ALL cells toward MSCs after 
TNT inhibition (grey and black bars), compared to normal co-culture conditions (white bars; n = 3; one-tailed t-test, 
paired). (E) Model of TNT signaling in the leukemic niche:
1: Leukemic cells use TNT signaling to transfer autophagosomes, mitochondria and ICAM1 toward MSCs in their 
microenvironment.
2: Increased reactive oxygen species (ROS) and autophagy in MSCs induces the production of cytokines
3: Supportive and nurturing factors are released into the tumor microenvironment, which induce survival and 
drug resistance in leukemic cells.
Data are means ± SEM; * p ≤ 0.05, ** p ≤ 0.01.  See also supplementary Figure 2.
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in cell-cell adhesion, is known to be upregulated in response to cytokine signaling 
and reactive oxgen species15. Its transport toward MSCs may provide anchorage to 
facilitate TNT function. 
In conclusion, these data show the potential of using fluorescently labeled 
marker proteins to characterize which cellular structures are transported by TNT 
signaling from ALL cells to MSCs. Our study confirmed several known TNT cargo 
(i.e. mitochondria and transmembrane proteins)8,9 and revealed novel structures 
(autophagosomes) that are transported through TNTs. The TNT-dependent transfer 
of autophagosomes and mitochondria from ALL cells toward MSCs might unveil an 
important mechanism that leukemic cells use to affect their microenvironment. Our 
study suggests that instead of upregulating autophagy in an indirect manner, leukemic 
cells transfer autophagosomes to MSCs in order to enhance autophagy-induced 
cytokine secretion. In addition, our study identifies autophagosomes, ICAM1 and 
mitochondria as important structures that are actively transported from leukemic 
cells toward their microenvironment via TNTs.
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SUPPLEMENTARY DATA
METHODS
Cell lines
BCP-ALL cell line NALM6 (B-Other) and human embryonic kidney cell line 
HEK293T were obtained from DSMZ (Braunschweig, Germany), used at low cell 
passages, and routinely verified by DNA fingerprinting. 
Isolation and characterization of MSCs
Mesenchymal stromal cells (MSCs) were isolated from bone-marrow aspirates and 
characterized as previously described1,2. In short, MSCs were confirmed to have 
multilineage potential for adipocyte, osteocyte and chondrocyte differentiation 
and characterized using positive (CD44/ CD90/CD105/CD54/CD73/CD146/CD166/
STRO-1) and negative surface markers (CD19/CD45/CD34).
Leukemic clones containing fluorescent cellular markers
HEK293T cells were transfected with lentiviral vectors coding for tRFP-positive 
marker proteins (Cellpainter™ Organelle Markers; Origene, USA), together with 
the helper plasmids VSVG and pPAX, using X-tremegene 9 (Sigma-Aldrich; Saint 
Louis, USA). Turbo-RFP (tRFP) was added either C- or N-terminally to the marker 
proteins, to minimize its influence on protein structure (supplementary Figure 1). 
Lentiviral particles produced by the HEK293T cells were collected by harvesting 
supernatant for three consecutive days and purified using a 0.45 μm cellulose 
acetate filter (GE Healthcare Life Sciences, Buckinghamshire, United Kingdom) 
and ultra-centrifugation (32.000 rounds per minute (RPM) for 2 hours at room 
temperature).
BCP-ALL cells (NALM6) were transduced with a serial dilution of lentivirus 
to ensure optimal cell viability and virus transduction. Subsequently, BCP-ALL cells 
were centrifuged at 1800 RPM for 45 minutes at room temperature and incubated 
overnight. Afterwards, single cells were plated out and positive leukemic clones were 
selected based on tRFP positivity using a MACSQuant analyzer (Miltenyi Biotec, 
Gladbach Germany). The proliferation capacity of leukemic clones was confirmed to 
be unaffected compared to wildtype cells, by prolonged cell culture.
Confocal laser scanning microscopy 
Leukemic clones expressing tRFP-positive marker proteins were visualized using a 
confocal laser scanning microscope (Leica SP5). The nucleus of leukemic cells was 
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stained using live cell stain “Nucblue”, according to the manufacturer’s protocol (Life 
Technologies, Breda, The Netherlands). Cells were imaged without fixation to retain 
optimal tRFP signal. Confocal images were acquired using sequential scanning of 
different channels at a resolution of 1024 x 1024 pixels in the x x y plane and 0.15 μm 
steps in z-direction. Nucblue and tRFP-positive marker proteins were excited with a 
405-nm ultraviolet laser and a 561-nm Diode-Pumped Solid-State laser, respectively. 
Image processing was done with Fiji software3.
Transfer of tRFP protein markers
tRFP-positive BCP-ALL cells (NALM6) were co-cultured with tRFP-negative MSCs 
in a 4:1 ratio for 24, 48 or 72 hours with and without TNT inhibition. TNTs were 
inhibited by mechanical disruption via gentle shaking of cell cultures (250 RPM), 
or by physical separation of leukemic cells (cultured in a 3.0 μm pore-sized insert) 
and MSCs (cultured in the bottom compartment of a transwell system; Corning, 
New York, USA). BCP-ALL cells and MSCs were separated using Brilliant Violet 421 
labeled anti-human CD19 antibody (Biolegend, San Diego, USA). Median intensity 
of MSCs for the PE-channel was used as a measure of tRFP protein transfer and was 
determined using flow cytometry (BD Biosciences, California, USA; see Figure 1D 
for gating strategy). 
Statistical analysis
Student’s t-test was used as a statistical test and a Student’s paired t-test was used 
when applicable (indicated in figure legends). Pearson correlation testing was used 
to compare the median tRFP intensity of MSCs and BCP-ALL cells after co-culture. 
Error bars show as standard error of the mean (SEM). Sample size and statistical 
test methods are reported in the figure legends. Variance between groups that are 
statistically compared is similar.
Autophagosome transfer via TNTs in the leukemic niche 243
8
SUPPLEMENTARY FIGURES
5’ LTR
CMV promoter 
Kozak
tR
FP
Poly
A
3’ SIN - LTR
O
ri
C
AT
 (C
AM
r )
Insertion protein sequence (C-tRFP tag)
Insertion protein sequence (N-tRFP tag)
7.0 kb
pLenti-tRFP
Marker protein Cellular structure GENENAME Base pairs Tag
Actin, beta Actin filaments ACTB 1852 bp  N-tRFP tag 
Calreticulin Endoplasmatic reticulum CALR 1929 bp  C-tRFP tag 
Empty vector - -  C-tRFP tag 
Intercellular adhesion molecule 1 Integrin signalling ICAM1 3249 bp  C-tRFP tag 
Microtubule-associated protein 1 light chain 3 beta Autophagosomes MAP1LC3B 2304 bp  N-tRFP tag 
Pyruvate dehydrogenase alpha 1 Mitochondria PDHA1 3390 bp  C-tRFP tag 
RAB5A, member RAS oncogene family Early endosome RAB5A 2548 bp  N-tRFP tag 
RAB7A, member RAS oncogene family Late endosome RAB7A 2240 bp   N-tRFP tag 
RAB11A, member RAS oncogene family Recycle endosome RAB11A 4943 bp  N-tRFP tag 
A
B
Supplementary Figure 1. Transduction of leukemic cells with lentiviral vectors encoding for spe-
cific cellular markers
(A) Schematic overview of the lentiviral vector backbone in which specific cellular marker proteins were cloned. 
Two insertion sites were used in order to position the tRFP tag C or N-terminally. (B) Overview of the marker 
proteins depicting which cellular structures they visualize, their gene name, their length in base pairs (bp), and the 
position of the tRFP tag.
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Supplementary Figure 2. tRFP positivity of BCP-ALL clones differs between markers
Graph showing the median tRFP intensity of tRFP-positive BCP-ALL cells for each cellular marker (n = 3). tRFP 
signal differs between clones and therefore transfer of tRFP protein from BCP-ALL cells toward MSCs should be 
corrected for the intensity of leukemic cells.
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Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. 
During the last decades, the overall survival rates of pediatric ALL have improved 
significantly. This is primarily due to optimization of conventional chemotherapeutic 
drug regimens combined with risk-directed stratification. However, to date, still 20% 
of pediatric ALL cases relapse due to resistance to therapy. In addition, short-term 
and long-term treatment-induced side effects remain considerable. New treatment 
regimens increasingly aim to target specific intrinsic characteristics and extrinsic 
signals important for leukemia. This approach has, for example, led to the successful 
development of targeted tyrosine kinase inhibitors that drastically improved the 
outcome of BCR-ABL1 positive leukemia patients. However, the majority of pediatric 
patients with leukemia is treated with non-specific classic chemotherapy regimens. 
This thesis identified leukemia-specific processes that can be used to target leukemic 
cells or the leukemic microenvironment. 
The first part of this thesis focuses on intrinsic cellular processes that are important 
for proliferation, survival and/or drug resistance in ALL. Subsequently, we aimed to 
inhibit these biological processes in order to selectively target leukemic cells.
In chapter 2, we review the PI3K/protein kinase B (PKB/Akt) signaling 
module, an important mediator of cytokine signaling implicated in regulation of 
hematopoiesis. Constitutive activation of this signaling module has been observed 
in a large group of leukemia patients. Because activation of this signaling pathway 
has been demonstrated to be sufficient to induce hematologic malignancies and 
is thought to correlate with poor prognosis and enhanced drug resistance, it is 
considered to be a promising target for therapy. A large number of pharmacologic 
inhibitors directed against either individual or multiple components of this pathway 
have already been developed. Single-specificity inhibitors, targeting individual 
components of the PI3K/PKB signaling module, were shown to affect the survival 
of leukemic cells, but their anti-leukemic effect in patients appears to be modest. 
Compared to such inhibitors, dual-specificity inhibitors targeting the PI3K/PKB 
pathway at multiple levels or the combination of PI3K/PKB pathway inhibitors with 
classic chemotherapeutic regimens appear to have more promising anti-leukemic 
activity and are highly effective in preclinical leukemia models. Further research is 
warranted to examine the safety and efficacy of these regimens in leukemia patients.
In chapter 3 and 4, we study leukemia driven by the translocation t(12;21), 
resulting in the ETV6-RUNX1 fusion protein. This fusion gene, which is present in 25% 
of pediatric patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL), 
is considered a first hit in leukemogenesis. We focused on the biological processes 
that are affected by the ETV6-RUNX1 fusion protein by studying the effect of ectopic 
expression in healthy hematopoietic progenitor cells. This approach revealed a 
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transcriptional network that positively regulates proliferation, survival, migration, 
and cellular homeostasis in ETV6-RUNX1 positive cells. In chapter 3, we report an 
important role for autophagy, a cellular recycling system important for homeostasis 
and proliferation, in ETV6-RUNX1 positive BCP-ALL. Vps34, an important regulator 
of autophagy, was found to be up-regulated in ETV6-RUNX1 positive BCP-ALL 
patient cells. Induction of Vps34 was transcriptionally regulated by ETV6-RUNX1 
and correlated with high levels of autophagy. Inhibition of autophagy reduced cell 
viability in both BCP-ALL cell lines and primary patient-derived BCP-ALL cells 
and selectively sensitized ETV6-RUNX1 positive leukemic cells to L-asparaginase. 
These findings reveal a causal relationship between ETV6-RUNX1 and autophagy, 
and provide the first preclinical evidence for the efficacy of autophagy inhibitors in 
ETV6-RUNX1 driven leukemia.
In chapter 4, we describe the role of Leukemia-Associated Rho Guanine 
nucleotide exchange factor (LARG) in the pro-migratory phenotype induced by the 
ETV6-RUNX1 fusion protein. We revealed that LARG is selectively up-regulated in 
ETV6-RUNX1 positive leukemic cells and induced by ectopic expression of ETV6-
RUNX1 in healthy hematopoietic progenitors. Pharmacological small molecule 
inhibition of LARG and its downstream effector RhoA significantly inhibited the 
migration of ETV6-RUNX1 positive cells toward mesenchymal stromal cells (MSCs) 
and CXCL12, while proliferation and drug resistance remained unaffected. In 
contrast, migration of ETV6-RUNX1 negative cells was not altered by LARG/RhoA 
inhibition. These data show that enhanced LARG/RhoA signaling is important for 
migration of ETV6-RUNX1 positive leukemic cells. The specificity of this process 
for ETV6-RUNX positive cells may enable selective targeting of the leukemic 
microenvironment with small molecule inhibitors. Since leukemic cells are nurtured 
and protected against chemotherapy and immune responses in the leukemic bone 
marrow microenvironment, disruption of this leukemic niche is considered to be a 
promising approach to target leukemia. 
The second part of this thesis aims to better understand and subsequently target 
extrinsic signals from the leukemic microenvironment by studying the crosstalk 
between leukemic cells and their niche. Chapter 5 and 6 focus on the dynamic 
interplay between leukemic cells and MSCs, the best-studied component of the 
leukemic niche, in order to find novel strategies to disrupt leukemic niches. Chapter 
5 describes the discovery of tunneling nanotubes (TNTs) in the leukemic niche. 
TNTs have been described as a novel mode of intercellular communication, but their 
presence and importance in the leukemic microenvironment were so far unknown. 
We showed that primary BCP-ALL cells use TNTs to signal to primary MSCs. This 
signaling resulted in secretion of pro-survival cytokines, such as IP10/CXCL10, 
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IL8/CXCL8 and MCP-1/CCL2. In addition, TNT inhibiting conditions enabled us 
to analyze the functional importance of TNTs in an ex vivo model. TNT signaling 
was found to be important for the viability of patient-derived BCP-ALL cells and 
induction of stroma-mediated prednisolone resistance in leukemic cells. Disruption 
of TNTs significantly inhibited these leukemogenic processes. Our findings establish 
TNTs as a novel communication mechanism by which ALL cells modulate their 
bone marrow microenvironment. The identification of TNT signaling in ALL-MSC 
communication gives insight into the pathobiology of ALL and opens new avenues 
to develop alternative therapies that interfere with the leukemic niche.
Several studies have tried to target the leukemic niche by inhibiting CXCR4/
CXCL12 signaling. However, recent data suggest that blocking CXCL12-mediated 
migration is insufficient to completely disrupt leukemic niches. In chapter 6, 
we aim to identify alternative factors for leukemic niche disruption. We used a 
patient-derived co-culture model in which the leukemic niche was represented by 
BCP-ALL cells and MSCs. Leukemic co-cultures inhibited migration of healthy 
hematopoietic progenitor cells and MSCs, but significantly induced migration of 
leukemic counterparts. This induction of leukemic cell migration was not affected by 
CXCR4 blockade. Moreover, CXCL12 levels were unaltered in co-cultures of primary 
BCP-ALL cells and MSCs, showing that BCP-ALL cells modify their niche without 
affecting the CXCR4/CXCL12 axis. Instead, patient-unique secretion patterns 
affecting alternative chemokine pathways, including CCR4, CXCR1/2, and CXCR3 
ligands, were found  to be induced. Also in serum of bone marrow aspirates from 
BCP-ALL patients, we observed a significant increase of CCR4 and CXCR1/2 ligands 
compared to bone marrow of the same patients in remission and healthy controls. 
These data show that BCP-ALL cells modify the migration properties of their niche 
without altering the CXCR4/CXCL12 axis, and warrant further research on CCR4 
and CXCR1/2 signaling as candidate factors for leukemic niche disruption.
The studies described in this thesis identify both intrinsic characteristics (part 1) 
and extrinsic signals (part 2) driving BCP-ALL in children. Our results contribute 
to a conceptual revision of therapies for BCP-ALL in which besides targeting of 
leukemic cells also targeting of the interaction with the microenvironment needs to 
be considered. In chapter 7, we discuss the promising preclinical results described in 
this thesis and highlight the important next steps that need to be taken to realize our 
dream: a tailored, non-toxic therapy for children with leukemia. 
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NEDERLANDSE SAMENVATTING
Moleculaire determinanten van acute lymfatische leukemie bij kinderen
Op weg naar precisie therapie voor kinderen met acute lymfatische leukemie
Acute lymfatische leukemie (ALL) is de meest voorkomende kanker bij kinderen. 
Zonder behandeling is de ziekte dodelijk. Door de optimalisatie van behandeling 
met chemotherapie is de algehele overleving van kinderen met ALL in de 
afgelopen decennia aanzienlijk verbeterd. Hierbij wordt de intensiteit en duur van 
de therapie aangepast aan de hand van het risico op overlijden. Ondanks deze 
verbeteringen komt bij ongeveer 20% van de kinderen met ALL de leukemie terug 
(recidief). Ook heeft chemotherapie, die alle cellen in het lichaam aanvalt, ernstige 
bijwerkingen bij een aanzienlijk percentage kinderen. Wetenschappers zijn daarom 
op zoek naar nieuwe behandelingen voor leukemie die een recidief voorkomen 
en minder bijwerkingen geven. Deze therapieën zouden gericht moeten zijn tegen 
eigenschappen die uniek zijn voor de leukemiecel. Voor een kleine groep patiënten 
is een dergelijke therapie beschikbaar: kinderen met BCR-ABL1 positieve leukemie. 
Deze soort leukemie wordt veroorzaakt door een genetische fusie van het BCR gen 
en het ABL1 gen. Het extra behandelen van deze kinderen met medicijnen tegen 
het product van dit fusie-gen, het fusie-eiwit BCR-ABL, heeft de overleving van 
deze groep kinderen drastisch verbeterd. Echter, voor de meeste kinderen met 
leukemie is zo’n doelgerichte therapie niet beschikbaar. Zij worden nog altijd alleen 
behandeld met aspecifieke chemotherapie. Dit proefschrift focust zich op het vinden 
van leukemie-specifieke processen die kunnen worden gebruikt om leukemiecellen 
doelgericht te behandelen. 
In het eerste deel van dit proefschrift onderzoeken we moleculaire processen 
binnenin de leukemische cel, die belangrijk zijn voor hun groei, overleving en / of 
resistentie tegen geneesmiddelen. Vervolgens proberen we deze processen in de 
leukemiecel te blokkeren om de leukemiecellen selectief te doden.
Belangrijke processen binnenin een cel, zoals groei en overleving, worden 
aangestuurd door netwerken van eiwitten. Die netwerken worden ook wel 
signaleringsroutes genoemd. In hoofdstuk 2, bespreken we de beschikbare literatuur 
over het belang van de PI3K / proteïne kinase B (PKB / Akt) signaleringsroute in 
leukemie. Deze signaleringsroute is onder andere belangrijk voor het ontstaan van 
gezonde bloedcellen (hematopoiese). Echter, in een grote groep leukemiepatiënten 
is activatie van deze signaleringsroute waargenomen. Voortdurende activatie van 
PI3K / PKB lijkt zelfs voldoende te zijn voor de ontwikkeling van leukemie en 
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lijkt tevens te correleren met een slechte prognose en een verhoogde resistentie 
tegen chemotherapie. Daarom wordt deze signaleringsroute beschouwd als een 
veelbelovend doelwit voor therapie. De eerste stappen in het ontwikkelen van 
medicijnen die deze signaleringsroute remmen zijn genomen. Er zijn al meerdere 
farmacologische remmers ontwikkeld die gericht zijn tegen één of meerdere eiwitten 
in deze signaleringsroute. Vooral farmacologische remmers die de PI3K / PKB route 
op verschillende niveaus aanpakken of een combinatie van PI3K / PKB route remmers 
met chemotherapie zijn zeer effectief gebleken in preklinische leukemiemodellen en 
lijken daarom veelbelovend. Echter, verder onderzoek is nodig om de veiligheid en 
werkzaamheid van deze behandelingen bij leukemiepatiënten te onderzoeken.
In hoofdstuk 3 en 4 gaan we zelf op zoek naar nieuwe aangrijpingspunten 
voor de behandeling van leukemie. In deze hoofdstukken bestuderen we leukemie 
veroorzaakt door het ETV6-RUNX1 (of TEL-AML1) fusie-eiwit. Dit fusie-eiwit 
komt voor bij 25% van de kinderen met voorloper B-cel acute lymfatische leukemie 
(BCP-ALL). Het ontstaan van dit fusie-eiwit wordt gezien als een eerste stap in het 
proces dat van een gezonde cel tot een kankercel maakt (‘first hit’). We weten dat 
dit fusie-eiwit belangrijk is voor de overleving van kankercellen, maar het is nog 
onbekend welke signaleringsroutes in de cel hierbij betrokken zijn. Het begrijpen 
hiervan zou de mogelijkheid bieden om leukemiecellen met het fusie-eiwit specifiek 
aan te vallen. Daarom hebben we de biologische processen die worden aangestuurd 
door het ETV6-RUNX1 fusie-eiwit onderzocht. Dit doen we door het fusie-eiwit 
in te brengen in gezonde stamcellen van het bloed. Het inbrengen van het fusie-
eiwit zorgde voor de activatie van genen die belangrijk zijn voor groei, overleving, 
beweging (migratie) en evenwicht (homeostase) in deze cellen. In hoofdstuk 3, 
beschrijven we dat autofagie een belangrijke rol speelt in ETV6-RUNX1 positieve 
leukemie. Autofagie is het recycling systeem van een cel. Dit systeem is belangrijk 
voor het evenwicht in de cel, maar ook voor overleving en groei van cellen. Vps34, 
een belangrijk eiwit die dit recycling proces aan en uit kan zetten, bleek door het 
ETV6-RUNX1 fusie-eiwit te worden geactiveerd. Hierdoor wordt autofagie in 
leukemiecellen aangezet. Remming van autofagie of Vps34 verminderde dan ook 
de overleving van ETV6-RUNX1 positieve cellen. Daarnaast werden  ETV6-RUNX1 
positieve leukemiecellen gevoeliger voor L-asparaginase, een belangrijk medicijn 
in de behandeling van leukemie. Dit alles was niet het geval voor ETV6-RUNX1 
negatieve leukemiecellen. Deze bevindingen laten een oorzakelijk verband tussen 
ETV6-RUNX1 en autofagie zien, en leveren het eerste preklinische bewijs voor de 
werkzaamheid van autofagie-remmers in deze vorm van leukemie.
Leukemiecellen bevinden zich in patiënten voornamelijk in het beenmerg, 
de bloedfabriek van het lichaam. Deze omgeving beschermt niet alleen gezonde 
bloedcellen; ook leukemiecellen worden hier beschermd, bijvoorbeeld tegen 
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chemotherapie. Wetenschappers proberen dan ook dit micro-milieu (niche) te 
ontwrichten om leukemiecellen gevoeliger te maken voor therapie. In hoofdstuk 
4 laten we zien dat het ETV6-RUNX1 fusie-eiwit genen activeert die belangrijk zijn 
voor migratie (beweging) richting hun micro-milieu. We beschrijven de centrale 
rol van Leukemia-Associated Rho Guanine nucleotide exchange factor (LARG) en 
RhoA in dit proces. LARG zorgt voor activatie van RhoA, een eiwit dat belangrijk is 
voor migratie van cellen. LARG bleek niet alleen geactiveerd te zijn in ETV6-RUNX1 
positieve leukemiecellen, maar werd ook geactiveerd door ETV6-RUNX1 in gezonde 
bloed voorlopercellen te plaatsen. Remming van LARG en RhoA verminderde de 
migratie van ETV6-RUNX1 positieve cellen naar een van de belangrijkste bouwstenen 
van het beenmerg, de mesenchymale stromacel (MSC). Daarnaast weten we dat het 
eiwit CXCL12 belangrijk is voor het behouden van leukemiecellen in het beenmerg. 
In onze studie werd migratie van ETV6-RUNX1 positieve leukemiecellen richting 
CXCL12 significant geremd. Daarentegen werd de migratie van ETV6-RUNX1 
negatieve cellen niet beïnvloed door LARG / RhoA remming. Dit laat zien dat de 
activatie van LARG en RhoA alléén belangrijk is voor de migratie van ETV6-RUNX1 
positieve cellen. De specificiteit van dit proces maakt het hopelijk in de toekomst 
mogelijk om het leukemische micromilieu selectief te remmen. 
In het tweede deel van dit proefschrift bestuderen we de interactie tussen 
leukemiecellen en hun micromilieu in meer detail. We proberen de signalen vanuit 
het micro-milieu beter te begrijpen en proberen uiteindelijk nieuwe strategieën te 
ontwikkelen om dit micro-milieu te verstoren.
Hoofdstuk 5 en 6 bestuderen de dynamische interactie die plaatsvindt tussen 
leukemiecellen en MSCs, de best onderzochte bouwsteen van het leukemische 
micro-milieu. Hoofdstuk 5 beschrijft de ontdekking van tunneling nanotubes 
(TNTs) in de leukemische niche. TNTs zijn zeer dunne verbindingskanaaltjes 
waardoor cellen onderling met elkaar kunnen communiceren. In hoofdstuk 5 laten 
we zien dat BCP-ALL cellen TNTs gebruiken om te communiceren met MSCs. Deze 
interactie zorgde voor de uitscheiding van meerdere belangrijke overlevingsfactoren 
(cytokines) in het micro-milieu (o.a. IP10, IL8 en MCP-1). Ook bleek de interactie 
belangrijk voor de overleving van leukemiecellen en zorgde de communicatie via 
TNTs ervoor dat leukemiecellen resistenter werden tegen chemotherapie (zoals 
Prednison en L-Asparaginase). Het verbreken van TNTs remde deze leukemische 
processen significant. Onze bevindingen laten zien dat TNT-signalering een 
belangrijk communicatiemechanisme is waarmee ALL cellen hun micro-milieu 
reguleren. De ontdekking van het belang van TNT-signalering kan daarom mogelijk 
worden gebruikt om effectievere therapieën te ontwikkelen die interfereren met de 
leukemische niche.
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Zoals al eerder beschreven bestaan er eiwitten die essentieel zijn voor 
het behouden van bloedcellen in het beenmerg. Remming van CXCL12 zorgt 
bijvoorbeeld voor het uittreden van zowel gezonde bloedcellen als leukemiecellen 
uit het beenmerg. Verschillende studies hebben geprobeerd om het leukemische 
micro-milieu te verstoren door het remmen van CXCL12-gestuurde migratie. 
Echter, recente data suggereren dat het blokkeren van CXCL12 onvoldoende is om 
leukemische niches volledig te verbreken. In hoofdstuk 6 zijn we op zoek gegaan 
naar de eiwitten die specifiek belangrijk zijn voor het behouden van leukemiecellen 
in hun micro-milieu. Om een leukemisch micro-milieu te simuleren gebruikten we 
een co-kweek model waarbij de leukemische niche werd vertegenwoordigd door 
BCP-ALL cellen en MSCs. We ontdekten dat deze leukemische niche zorgde voor 
een verhoogde migratie van leukemiecellen richting hun eigen niche en daarentegen 
een verminderde migratie van gezonde bloedcellen en MSCs. Dit proces werd niet 
beïnvloed wanneer CXCL12-gestuurde migratie werd geremd. Bovendien bleef de 
excretie van CXCL12 onveranderd in co-kweken van meerdere leukemie patiënten. 
In plaats daarvan zagen we dat in iedere patiënt een specifieke combinatie van 
migratie-bevorderende eiwitten (chemokines) werd geproduceerd. Opvallend 
was dat in iedere patiënt tenminste één eiwit werd geproduceerd die migratie 
bevorderde via de receptor-eiwitten CCR4 of CXCR1/2. Ook in het beenmerg van 
BCP-ALL patiënten zagen we een aanzienlijke toename van CCR4- en CXCR1/2-
activerende eiwitten vergeleken met het beenmerg van dezelfde patiënten in remissie 
(na behandeling, dus zonder leukemiecellen) en vergeleken met gezonde controles. 
Deze data tonen aan dat BCP-ALL cellen de migratie eigenschappen van hun niche 
veranderen zonder CXCL12 te beïnvloeden, en suggereren dat remming van CCR4 
en CXCR1/2 signalering belangrijke kandidaten kunnen zijn voor het verstoren van 
de leukemische niche.
De studies beschreven in dit proefschrift identificeren zowel intrinsieke kenmerken 
(deel 1) als extrinsieke signalen (deel 2) die belangrijk zijn voor BCP-ALL bij kinderen. 
Onze resultaten dragen bij aan een nieuwe visie op therapie voor BCP-ALL waarin 
therapie specifiek gericht is tegen moleculaire processen in de leukemiecel, maar 
ook tegen de interactie van leukemiecellen met hun micro-milieu. In hoofdstuk 
7, bespreken we de in dit proefschrift beschreven pre-klinische resultaten en de 
belangrijke vervolgstappen die kunnen worden genomen om een op maat gemaakte, 
niet-toxische therapie voor kinderen met leukemie te verwezenlijken.
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DANKWOORD
If you never try you’ll never know
Coldplay
Jaren van onderzoek met passie en inzet van vele mensen hebben geleid tot de inhoud 
van dit schrijven. Het is dan ook met veel trots en plezier dat ik dit proefschrift 
presenteer. En ondanks het feit dat mijn naam op de voorkant staat, zou dit werk er 
nooit geweest zijn zonder de hulp en inzet van anderen. Het is een genoegen jullie 
via deze weg te mogen bedanken. 
Ten eerste wil ik mijn grote dankbaarheid betuigen aan de leukemiepatiënten en 
hun ouders voor het beschikbaar stellen van onderzoeksmateriaal. Gedurende een 
onbeschrijfelijk moeilijke periode in jullie leven, kiezen jullie ervoor wetenschappelijk 
onderzoek te steunen in de hoop toekomstige lotgenoten een betere behandeling te 
gunnen.
Prof.dr. M.L. den Boer, beste Monique, ik weet nog goed dat ik eind 2012 bij jou 
op kantoor zat en je vertrouwen in mij en mijn project voelde. Wat was ik blij dat je 
fiducie zag in mijn plannen en ik mijn promotie in jouw groep heb mogen afmaken. 
Het heeft me een scala aan nieuwe vaardigheden en denkrichtingen opgeleverd. De 
vrijheid die ik als PhD student in jouw groep heb gekregen was bijzonder en heeft 
uiteindelijk tot mooie wetenschappelijke resultaten geleid. Ontzettend bedankt voor 
je vertrouwen, steun en geduld. 
Prof.dr. R. Pieters, beste Rob, jij bent de drijvende kracht achter het leukemie 
onderzoek in Nederland en het is dan ook een eer met je te mogen samenwerken. 
Je scherpte, denkvermogen en visie tijdens onze research meetings waren 
indrukwekkend. En de glinstering in je ogen bij de uitspraak “dit is goud” zal ik 
nooit vergeten (dat vonden wij nou ook). Ik respecteer je hoofdrol in het creëren van 
het Prinses Máxima Centrum voor Kinderoncologie enorm en denk dat je daarmee 
een grote stap hebt gezet in échte vooruitgang voor de patiënt. Bedankt voor de 
mogelijkheid me wetenschappelijk te ontwikkelen onder jouw supervisie.
Dr. M. Buitenhuis, beste Miranda, bij jou begon mijn wetenschappelijke carrière. 
Wat een eer was het om bij die jonge getalenteerde groepsleider in het Erasmus MC 
te mogen beginnen. Ik heb ongelofelijk veel van je geleerd, van de grondbeginselen 
van de moleculaire biologie tot verfijning van moleculaire technieken tot 
wetenschappelijke denken en ethiek, je hebt me als wetenschapper gevormd en ik 
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respecteer je enorm als onderzoeker en als mens. Het is voor mij heel bijzonder dat 
onze samenwerking steeds meer op gelijkwaardig niveau is plaats gaan vinden. 
Dank voor je inzet, vertrouwen, steun en betrokkenheid tot de laatste letter van dit 
proefschrift.
Dr. M.B. Bierings, beste Marc, ook jij bent vanaf het begin belangrijk geweest voor 
mijn onderzoek. Je zette met Miranda de beginselen van mijn project op papier en 
bent ‘along the way’ altijd een essentiële sparring partner geweest. Dank voor je 
scherpe visie, het inbrengen van klinisch perspectief (als we weer eens te moleculair 
afdwaalden), en je aansturing van het project waar dat nodig was. 
Prof.dr. B. Löwenberg, prof.dr. P.J. Coffer en prof.dr. S.S. Sleijfer wil ik van harte 
bedanken voor het deelnemen aan mijn leescommissie en hun kritische blik op het 
finale manuscript. Beste Bob, het was maar al te bijzonder dat ik je voor twee jaar 
“mijn kamergenoot” mocht noemen. Ondanks je ongelofelijke staat van dienst, 
ben je altijd bereikbaar gebleven voor beginnende wetenschappers. Ik heb jouw 
aanwezigheid altijd als grote steun ervaren, zeker toen er lastige keuzes gemaakt 
dienden te worden. Dank dat je er was. Beste Paul, als medisch student mocht ik voor 
het eerst proeven aan de wetenschap in jouw lab. Ik had me geen betere plek kunnen 
bedenken. De goede sfeer, de oprechte interesse in “het waarom” en de gedegenheid 
van je onderzoek zijn nog altijd een voorbeeld voor mij als wetenschapper. Dank 
voor die mooie start! Beste Stefan, dank voor je inzet en deelname aan mijn kleine 
commissie, ik kijk uit naar de verdediging.
Prof.dr. I.P. Touw, prof.dr. J.J. Schuringa en prof.dr. P.M. Hoogerbrugge dank ik 
hartelijk voor het plaatsnemen in mijn corona. Beste Ivo, dank voor je adviezen en 
wetenschappelijk raad tijdens mijn tijd op de afdeling Hematologie. Deze hebben 
mijn onderzoek in de beginfase de nodige richting en realiteitszin gebracht. Beste 
Jan Jacob en Peter, laten we de discussies die op congressen al zijn begonnen op 22 
november continueren, ik kijk er naar uit. 
Mijn onderzoek was niet mogelijk geweest zonder de adequate verzameling en 
sampling van het verkregen patiënten-materiaal. Veel dank gaat dan ook naar de 
kinderoncologen die patiënten uitleggen waarom wetenschappelijk onderzoek zo 
belangrijk is voor de toekomst, maar ook naar de verpleegkundigen, het secretariaat 
van de afdeling kinderoncologie en het hematologisch laboratorium specieel, die 
samen ons onderzoek mogelijk maken. Daarnaast dank ik SKION en de COALL 
studiegroep voor het beschikbaar stellen van materiaal voor onze studies. Het feit 
dat jullie de zaken zo goed voor elkaar hebben legt de grondslag voor veel van ons 
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werk. En dan de toppers van de “patiëntendienst”: Aurelie, Femke, Myrte, Rosanna, 
Jessica, Wilco, Yvette, Pauline, Lonneke, Susan, Patty, Sandrita en Mereltjuh 
(en voorgangers): veel dank voor jullie geweldige werk. Dankzij jullie konden wij 
knallen.
Zoals al eerder gezegd begon mijn PhD periode op de 13e verdieping, afdeling 
Hematologie. De bijzondere en mooie tijd die ik daar gehad heb is te danken aan de 
volgende mensen. 
De “Buitenhuis groep”: we waren maar een klein groepje, maar we waren 
er voor elkaar. Dank voor jullie steun en inzet bij mijn experimenten. Georgi, de 
‘founding father’ van onze clone database, dank voor al je hulp en humor. Aysegül, 
I got to know you as a hard worker with a lot of passion for science. I wish you all the 
best in your future endeavors and with your family. Cindy, jij bent in het bijzonder 
belangrijk geweest om verder te komen met het ETV6-RUNX1 project. Niet alleen 
door al je experimentele werk, maar vooral ook door je kritische blik en waardevolle 
bijdragen aan ons onderzoek. We moeten nog steeds dat potje tennissen trouwens! 
Mijn kamergenoten: Lucia, vanaf het eerste moment dat we elkaar zagen wist ik 
dat we vrienden gingen worden. Je Rotterdamse nuchterheid, directheid en humor 
zijn ongeëvenaard en je bent vooral een fantastische vrouw. Ik ben heel blij dat we 
elkaar blijven zien. Katarzyna, Kasia, you rock girl! We had so much fun in and out 
the lab and it was very special to be there during special and sometimes hard times 
in your life. I am so happy that you found yourself; be proud! Patricia, my Spanish 
tutor, it was nice to dream in Spanish about traveling the world. Enjoy Switzerland. 
Davine en Avinash, wat was het fijn om af en toe de frustraties van ons onderzoek 
met elkaar te kunnen delen, dank daarvoor. 
De andere ‘PhD-warriors’: Farshid, I respect you in so many ways. Good luck 
at the NKI. Marshall, your Halloween parties became “signature-parties” and I 
enjoyed every minute of them. Noemi, your Italian temperament and bright mind 
will get you a long way in science, I’m sure we’ll meet again. Roberto, we had so 
much fun in the lab together, even at the late hours. Thanks for your friendship. Let’s 
keep in touch. Mathijs, zonder jouw expertise in bioinformatica en “out-of-the-box” 
denken was er niets uit onze CD34 data gekomen. Dank voor al je hulp! Eric, mijn 
beste Vroegindewijsneus, door jou hoor ik elke ochtend bij het wakker worden een 
liedje van Dries Roelvink..bedankt man..we gaan jou en Helen zien in Zeist! 
Mijn lab-straatgenoten: Onno, zonder jou waren de ‘deconcolved’ plaatjes in 
het autofagie paper nooit zo mooi geworden. Dank voor je hulp. Je hebt ongelofelijk 
veel talent op veel verschillende vlakken. Marijke, dank voor het tot buikpijn toe 
lachen op werk en tijdens de Roparun. Paulette, onze klik is iets bijzonders. Je was 
mijn steun en toeverlaat in die eerste jaren op het lab. Dank voor je eerlijke, oprechte 
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zelf. Never change! Eric, Bindelsie! Wat had ik zonder jou moeten doen? Het is een 
oprechte vraag en ik weet het antwoord: niets. Dank voor alles Eric, je hulp vóór en 
tijdens experimenten, je onbegrensde expertise, het af en toe gebruik maken van je 
razendsnelle brein. Je bent een bijzonder onzelfzuchtig persoon die ik ontzettend 
waardeer. 
Verder zou de flowcytometrie niet zo soepel draaien zonder de onvermoeibare 
inzet van Elwin en Peter, zou de afdeling niets zijn geweest zonder de planning en 
organisatie van Ans en Leenke en zouden de computers uit elkaar vallen zonder Jan. 
Dank ook aan François, Joyce, Annelieke, Jasper, Nathalie, Isabel, Wendy, Pauline, 
Sonja, Marloes, Chantal, Antoinette, Remco, Rowan, Erdogan, Stefan, Marije, 
Claudia, Renée, Mark, Hansieeeeh, Tomasia, Menno, Anita, Niken, Monica, 
Kerim, Leonie, Yvette, Egied, Si, Jana, Keane en Julia voor alle mooie momenten 
binnen en buiten het lab. 
En natuurlijk dank aan alle groepsleiders, postdocs, PhD studenten en analisten 
die hebben bijgedragen aan de wetenschappelijk discussies tijdens de research 
meetings. In het bijzonder: Jan Cornelissen, Tom Cupedo, Eric Braakman, Bob 
Löwenberg, Ivo Touw, Ruud Delwel, Pieter Sonneveld, Mojca Jongen-Lavrencic, 
Peter Valk, Marc Raaijmakers, Stefan Erkeland en Ferry Cornelissen.
Mijn PhD periode vervolgde twee verdiepingen hoger: afdeling Pediatrische 
Oncologie. De volgende mensen hebben mijn laatste jaren als PhD student geweldig 
gemaakt. 
Ten eerste mijn kamergenoten van (met trots) “the little boys room”: man o 
man wat hebben we gelachen. Mark, jou imitaties en lach doen wonderen op mijn 
lachspieren en humeur en vermoeien nooit, succes met jouw laatste loodjes! Joᾶo, 
you are awesome man, still every time we meet in Rotterdam, we connect so easily. 
It’s been great working with and alongside you and I’ll never forget all the amazing 
lab, soccer and MTB moments. Let there be more! Lieneke, je hebt wat te verdragen 
gehad bij ons op de kamer, maar die zachte gniffel links van me zei gelukkig alles. 
Wat ben ik blij dat je een mooie nieuwe baan gevonden hebt. Succes met het afronden 
van je thesis. Judith, je hebt een bijzondere rol in de groep, maar ook daarbuiten. 
Dank voor je wetenschappelijke en biostatistische adviezen, maar vooral ook voor je 
ongebreidelde enthousiasme op een mountainbike. Alex, achter het roze folie zat jij 
verscholen achter twee beeldschermen te R-en. Dank dat je er was, binnen én buiten 
de groep. Priscilla, mooi hoe jij gegroeid bent vanuit je rol als student tot volwaardig 
PhD student. Dank voor het organiseren van de escape-room uitjes. 
De andere leden van de “B-ALL groep”: Rosanna, je hebt me enorm geholpen 
om het LARG verhaal van de grond te krijgen. Dank voor al je hulp en tijd! Isabel, 
your German gründlichkeit is combined with a nice dose of chaos, I love it, thanks 
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for the great moments in and out the lab. Femke, het was eigenlijk best dapper van je 
om op onze sneltrein te springen, maar je hebt je geweldig staande gehouden. Dank 
voor je inzet en betrokkenheid. Aurelie, ik heb je besmet met het mountainbike virus 
en sindsdien ben je dé drijvende kracht achter onze MTB avonturen, dank voor je 
fijne aanwezigheid in en buiten het lab. Lieke, dank voor je inzet bij het opzetten 
van de MSC database, zonder jou was die niet zo bruikbaar geweest. Ik herinner me 
de goede momenten tijdens het congres in Praag. Myrte, ook jij was een essentiële 
schakel in het opzetten van de MSC databank, hartelijk dank daarvoor én voor je 
Brabantse gezelligheid. Farhad, I still remember the huge bacterial culture flasks you 
used for the microvesicle project and especially the face of Theo when he found out 
about it. Ingrid en Cesca, dank voor jullie opbouwende kritiek tijdens de wekelijke 
research meetings.
Mijn ML I /II lab-maatjes: Rui, we had a great time together in the lab. It was really 
nice to have someone at the same phase of his PhD period, just knowing that you’re 
not alone helps. Thanks for all the fun. Dirk, je bent denk ik de grootste fan van ons 
onderzoek. Wat hebben we veel naast elkaar gezeten tijdens alle mega-experimenten 
die langs zijn gekomen. Je bent een onderzoeker in hart en nieren en hebt een bijzonder 
talent. Veel dank dat we bij tijd en wijlen gebruik mochten maken van je brein en 
met je konden sparren over onze dwaze ideeën. Zoals al eerder benoemd zijn de 
analisten van de oncologie groepen die de “patiëntendienst” runnen een essentieel 
onderdeel van ons lab. Maar dat geldt ook voor de inzet van de andere analisten: 
Ad, Theo (ik kom zeker nog een keer naar die stem van je luisteren), Dicky, Lilian, 
Lisette, Rolien, Sylvia (door jouw aanwezigheid is het lab een stuk veiliger), Ytje, 
Lisette, bedankt! En zonder Marcel en Ram was het lab in elkaar gestort, dank voor 
jullie inzet voor het algemene belang van iedereen in het lab. 
Veel dank ook aan de groepsleiders, postdocs en PhD studenten van het lab 
kindergeneeskunde voor jullie bijdragen aan het wetenschappelijke klimaat en 
de feedback op mijn studies: Eddy, Patricia, Arian, Jasmijn en Daria (mijn ASH 
buddies), Noorie, Askar, Nicole, Celia, Linda, Sharon, Marieke, Léa, Kirsten, 
Yunlei, Patrick, Janneke Samson, Cees Vink en in het bijzonder Maarten Fornerod, 
Michel Zwaan, Marry van den Heuvel-Eibrink, Ronald Stam, en Jules Meijerink. 
Na het doen van al die experimenten en het bouwen van de papers, moet er nog een 
proefschrift tot stand komen. Naast een full time baan als kinderarts in opleiding is 
dat een hele kluif en heb je de steun vanuit de kliniek nodig. Daarom heel veel dank 
aan de arts-assistenten en kinderartsen van het Wilhelmina Kinderziekenhuis, het 
Prinses Máxima Centrum voor Kinderoncologie en het Sint Antonius Ziekenhuis 
die me gesteund hebben gedurende deze periode. In het bijzonder mijn opleiders: 
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Walter Balemans, Maartje ten Berge, Ingrid Lukkassen, Edward Nieuwenhuis en 
Joost Frenkel, veel dank voor jullie altijd aanwezige vertrouwen en steun. 
Vrienden en familie zijn het fundament waar alles op rust. Jullie waardering, liefde 
en zijn maken mij wie ik ben en maken het leven geweldig. 
De America’s, ultieme levensgenieters, onverslaanbaar in goede diners en 
gierende lachen, laten er nog velen komen! De Polakken, een liefdevol en prachtig 
gezelschap met oma als stralend middelpunt. Het is zo jammer dat je dit net gemist 
hebt. En die familiedag, die komt er!
Steefie, mijn oudste en trouwste vriend, ik ken je al sinds de peuterspeelzaal 
en wat is het bijzonder dat ondanks onze totaal andere paden en levens, we zó 
belangrijk voor elkaar zijn. Dank voor je steun door dik en dun. 
Loukie, Jorie, Roos(je) en Birgit, jullie maken ook van jongs af aan deel uit 
van mijn leven. Hoe bijzonder is het dat het bij ons niet uit maakt hoe lang er tussen 
diners zit, of wat er ook gebeurd is, de warmte en vriendschap is er direct en altijd. 
Maarten, Mortimer, en Daniel, we kennen elkaar sinds de brugklas en hebben 
ons sindsdien nooit meer verveeld. Die legendarische fietsvakanties moeten we 
misschien toch nog een keer overwegen? 
Anne-Lieke, we hebben een geweldige tijd gehad samen en je bent heel 
belangrijk geweest tijdens het eerste deel van mijn promotie. Dank voor je steun en 
liefde in die tijd. 
Rolex, mannen van het goede leven, het is een geweldige ervaring jullie als 
vrienden te mogen hebben. Dirk, je out-of-the-box denken is een voorbeeld voor 
velen, zeker voor mij. Gijs, je humor en intense goedheid stralen uit op alles 
wat je doet en iedereen om je heen. Arjan, niet alleen roeiploeggenoot, maar ook 
werkgroepgenoot én huisgenoot; wat hebben we genoten! Paul, jij en Renske hebben 
een bijzondere plek in ons hart. Onze klik is heel speciaal denk ik. We hebben samen 
zoveel meegemaakt en ons Nicaragua avontuur staat ergens bovenaan de mooiste 
momenten van mijn leven. 
Dan mijn paranimfen. Ik ben ontzettend trots dat jullie achter me staan op 22 
november. 
Maarten, vaak groeien goede vrienden van de middelbare school langzaam uit 
elkaar en heel soms gebeurt juist het tegenovergestelde. Sinds dat we elkaar kennen 
zijn we langzaam steeds dichter bij elkaar gekomen en stiekem ook steeds meer op 
elkaar gaan lijken. We denken op soms verbazingwekkend gelijke wijze, en kunnen 
elkaar daardoor op precies de juiste manier en op precies de juiste momenten scherp 
houden. Dank voor je ongelimiteerde vriendschap. 
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Bob, er zijn maar weinig mensen in je leven die wetenschappelijk denkend 
zo op één lijn zitten en die je blindelings vertrouwt in een wereld die niet altijd te 
vertrouwen is. Jij bent die persoon voor mij. Ons wetenschappelijk avontuur heeft 
me laten beseffen dat ik nooit meer zonder die ‘rushes’ wil. Dank voor alle mooie 
momenten, dat onvergetelijke gegrinnik, en vooral dank voor je vriendschap. 
Lieve Ton en Elly, wat een geluk hebben wij met jullie aan onze zijde! Jullie hebben 
een essentiële rol in het functioneren van ons gezin. Het is fantastisch om te zien hoe 
jullie van Max genieten en, vice versa, hoe Max geniet en opfleurt van de oppasdagen 
bij opa Ton en oma Elly. Het is niet te beschrijven hoeveel dat waard is. Dank voor 
alles.
Lieve Annemarie, zussie! je bent een topper en wat ben ik trots op je! Jouw 
doorzettingsvermogen en vertrouwen in wie je bent verdienen een diepe buiging. 
Dank voor je liefde en dank voor het scherphouden van die broer van je.
Lieve pappa en mamma, zonder jullie was ik nooit gekomen waar ik nu ben en 
vooral nooit geweest wíe ik nu ben. Jullie zijn mijn basis, mijn grootste fans. Jullie 
kennen me als geen ander. Ik realiseer me dat mijn manier van leven jullie ook veel 
zorgen oplevert en het doet soms pijn om daar doorheen te walsen. Niet vergeten 
hoeveel ik van jullie hou. Mam, je bent de liefste ‘self-made woman’ die ik ken, op 
alle fronten, en het grappige is dat jij je dat niet eens realiseert. De intensiteit van ons 
gevoel is wat mij betreft een groot cadeau. Pap, je bent mijn grote voorbeeld vanaf 
kleine jongen tot op de dag van vandaag. Wij hebben samen altijd een heel speciale 
band gehad. Onuitgesproken, en dat hoeft ook niet. Een blik of zelfs minder dan dat 
is genoeg om elkaar te begrijpen. Zo bijzonder. Dank voor jullie onvoorwaardelijke 
liefde. 
“Look at the stars, look how they shine for you and everything you do”
Lieve Max, wat een prachtig mooi ventje ben jij, ik ben zo trots op je! Ik geniet met 
volle teugen van jou ‘zijn’. Je maakt het leven geweldig mooi. 
Lieve Merel, mijn droomvrouw en mijn belangrijkste steunpilaar. Het is me 
nog steeds een raadsel waar ik je aan verdien. Je bent lief, je hebt humor, je bent 
getalenteerd en intelligent, je bent prachtig mooi, je bent de beste moeder van de 
wereld. Trots overspoelt me als ik aan je denk. Ik weet niet hoe ik het zonder je had 
moeten doen in de afgelopen jaren. Dank voor je alles betekenende liefde en steun. 
Dankzij jou kan ik zijn wie ik ben. Ik kijk ontzettend uit naar onze toekomst.
